<SEC-DOCUMENT>0001214659-22-011092.txt : 20220913
<SEC-HEADER>0001214659-22-011092.hdr.sgml : 20220913
<ACCEPTANCE-DATETIME>20220913163052
ACCESSION NUMBER:		0001214659-22-011092
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		57
CONFORMED PERIOD OF REPORT:	20220731
FILED AS OF DATE:		20220913
DATE AS OF CHANGE:		20220913

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alzamend Neuro, Inc.
		CENTRAL INDEX KEY:			0001677077
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				811822909
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40483
		FILM NUMBER:		221241117

	BUSINESS ADDRESS:	
		STREET 1:		3500 LENOX RD. NE
		STREET 2:		SUITE 1500
		CITY:			ATLANTA
		STATE:			GA
		ZIP:			30326
		BUSINESS PHONE:		844-722-6333

	MAIL ADDRESS:	
		STREET 1:		3500 LENOX RD. NE
		STREET 2:		SUITE 1500
		CITY:			ATLANTA
		STATE:			GA
		ZIP:			30326
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>p9722010q.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:alxneuro="http://alzamend.com/20220731">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_alxneuro_alzamend.com_20220731 -->
<!-- Field: Set; Name: xdx; ID: xdx_041_20220501_20220731 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001677077 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0wNC0zMA== -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DDocumentFiscalYearFocus_2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_079_XDX_Z%2D%2D\XBRL JOB\2022\2022\Q3\09 September\Securex\IXBRL__ALZAMEND NEURO, INC.__July 31, 2022__Q1(10Q)\In Process\XFR\6\p9722010q.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_064_N_0_Number -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-05-01to2022-07-31" name="dei:EntityCentralIndexKey">0001677077</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-05-01to2022-07-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-05-01to2022-07-31" name="dei:CurrentFiscalYearEndDate">--04-30</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-05-01to2022-07-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-05-01to2022-07-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0015" name="dei:DocumentQuarterlyReport">true</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="AsOf2022-07-31" id="xdx2ixbrl0072" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-07-31" id="xdx2ixbrl0087" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-04-30" id="xdx2ixbrl0088" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-07-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0105" decimals="INF" unitRef="Shares">0</ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-07-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0107" decimals="INF" unitRef="Shares">0</ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-04-30_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0109" decimals="INF" unitRef="Shares">0</ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-04-30_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0111" decimals="INF" unitRef="Shares">0</ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-04-30_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0180" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-04-30_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0187" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="alxneuro:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2022-05-012022-07-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0191" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="alxneuro:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2022-05-012022-07-31_us-gaap_CommonStockMember" id="xdx2ixbrl0192" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="alxneuro:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2022-05-012022-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="xdx2ixbrl0194" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="alxneuro:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2022-05-012022-07-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0195" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-05-012022-07-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0198" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-05-012022-07-31_us-gaap_CommonStockMember" id="xdx2ixbrl0199" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-05-012022-07-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0200" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-05-012022-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="xdx2ixbrl0201" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-07-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0205" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-07-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0212" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="alxneuro:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2021-05-012021-07-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0227" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="alxneuro:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2021-05-012021-07-31_us-gaap_CommonStockMember" id="xdx2ixbrl0228" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="alxneuro:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2021-05-012021-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="xdx2ixbrl0230" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="alxneuro:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2021-05-012021-07-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0231" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="alxneuro:StockIssuedDuringPeriodValueNewIssues2" contextRef="From2021-05-012021-07-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0234" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="alxneuro:StockIssuedDuringPeriodValueNewIssues2" contextRef="From2021-05-012021-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="xdx2ixbrl0237" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="alxneuro:StockIssuedDuringPeriodValueNewIssues2" contextRef="From2021-05-012021-07-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0238" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-05-012021-07-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0243" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-05-012021-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="xdx2ixbrl0246" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-05-012021-07-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0247" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="alxneuro:StockIssuedDuringPeriodValueNewIssues3" contextRef="From2021-05-012021-07-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0252" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="alxneuro:StockIssuedDuringPeriodValueNewIssues3" contextRef="From2021-05-012021-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="xdx2ixbrl0255" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="alxneuro:StockIssuedDuringPeriodValueNewIssues3" contextRef="From2021-05-012021-07-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0256" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="alxneuro:ConversionOfSeriesAConvertibleStock" contextRef="From2021-05-012021-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="alxneuro:ConversionOfSeriesAConvertibleStock" contextRef="From2021-05-012021-07-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="alxneuro:ConversionOfSeriesAConvertibleStock" contextRef="From2021-05-012021-07-31" id="xdx2ixbrl0268" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-05-012021-07-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-05-012021-07-31_us-gaap_CommonStockMember" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-05-012021-07-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-05-012021-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-07-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0281" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-07-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0288" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-05-012021-07-31" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="alxneuro:ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts" contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="alxneuro:FairValueOfWarrantsIssuedInConnectionWithIpo" contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0355" name="alxneuro:FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty" xs:nil="true"></ix:nonNumeric>
  <ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-07-31" id="xdx2ixbrl0366" decimals="0" sign="-" unitRef="USD">32231569</ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0368" decimals="0" sign="-" unitRef="USD">3037074</ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-05-012022-07-31_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0391" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-05-012022-07-31_custom_ConvertibleNotesMember" id="xdx2ixbrl0397" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2019-04-01_custom_AultLifeSciencesFundLLCMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember" id="xdx2ixbrl0415" name="us-gaap:WarrantsAndRightsOutstandingTerm">P5Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2021-07-31" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="alxneuro:PrepaidInsurance1" contextRef="AsOf2022-06-16" id="xdx2ixbrl0437" decimals="0" unitRef="USD">492000</ix:nonFraction>
  <ix:nonNumeric contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0456" name="alxneuro:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1">P6Y1M6D</ix:nonNumeric>
  <ix:nonFraction name="alxneuro:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0460" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0462" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0464" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="alxneuro:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross" contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0466" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0468" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="alxneuro:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited" contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0470" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0482" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">P5Y9M14D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0490" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">P6Y4M9D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0498" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">P5Y11M26D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-05-012022-07-31_srt_MinimumMember_custom_EmployeesAndConsultantsMember" id="xdx2ixbrl0504" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xs:nil="true"></ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-05-012021-07-31_srt_MinimumMember_custom_EmployeesAndConsultantsMember" id="xdx2ixbrl0506" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P2Y6M0D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-05-012021-07-31_srt_MaximumMember_custom_EmployeesAndConsultantsMember" id="xdx2ixbrl0508" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P5Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-05-012022-07-31_custom_EmployeesAndConsultantsMember" id="xdx2ixbrl0510" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-05-012022-07-31_custom_EmployeesAndConsultantsMember" id="xdx2ixbrl0514" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0520" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-05-012022-07-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="xdx2ixbrl0541" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2022-05-012022-07-31_custom_UnamortizedStockBasedCompensationMember" id="xdx2ixbrl0555" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">P2Y2M12D</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2022-07-31_custom_ExercisePrice1Member" id="xdx2ixbrl0565" name="us-gaap:WarrantsAndRightsOutstandingTerm">P1Y7M6D</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2022-07-31_custom_ExercisePrice2Member" id="xdx2ixbrl0577" name="us-gaap:WarrantsAndRightsOutstandingTerm">P2Y3M19D</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2022-07-31_custom_ExercisePriceFiftySixMember" id="xdx2ixbrl0589" name="us-gaap:WarrantsAndRightsOutstandingTerm">P2Y8M12D</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2022-07-31_custom_ExercisePriceFiftySevenMember" id="xdx2ixbrl0601" name="us-gaap:WarrantsAndRightsOutstandingTerm">P3Y10M25D</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2022-07-31" id="xdx2ixbrl0615" name="us-gaap:WarrantsAndRightsOutstandingTerm">P2Y7M6D</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2022-07-31_us-gaap_WarrantMember" id="xdx2ixbrl0625" name="us-gaap:WarrantsAndRightsOutstandingTerm" xs:nil="true"></ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2021-07-31_us-gaap_WarrantMember" id="xdx2ixbrl0626" name="us-gaap:WarrantsAndRightsOutstandingTerm">P5Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember" id="xdx2ixbrl0628" unitRef="N" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember_srt_MinimumMember" id="xdx2ixbrl0632" unitRef="N" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember_srt_MinimumMember" id="xdx2ixbrl0638" unitRef="N" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2019-04-30_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember_us-gaap_WarrantMember" id="xdx2ixbrl0753" name="us-gaap:WarrantsAndRightsOutstandingTerm">P5Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2019-04-30_custom_ALSFMember" id="xdx2ixbrl0759" name="us-gaap:WarrantsAndRightsOutstandingTerm">P12M</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="alxneuro-20220731.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-05-01to2022-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-30_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-30_custom_NoteRecievableForCommonStockRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alxneuro:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-30_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-30_custom_NoteRecievableForCommonStockRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alxneuro:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alxneuro:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-07-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-07-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-07-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alxneuro:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-07-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alxneuro:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alxneuro:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-07-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-07-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_ConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alxneuro:ConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-07-31_custom_ConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alxneuro:ConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-04-30_custom_AultLifeSciencesFundLLCMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxneuro:AultLifeSciencesFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-04-30_custom_AultLifeSciencesFundLLCMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxneuro:AultLifeSciencesFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-01_custom_AultLifeSciencesFundLLCMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxneuro:AultLifeSciencesFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-30_custom_AultLifeSciencesFundLLCMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxneuro:AultLifeSciencesFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_SpartanCapitalSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">alxneuro:SpartanCapitalSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-04-30_custom_StockIncentivePlan2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alxneuro:StockIncentivePlan2016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-012016-04-30_custom_StockIncentivePlan2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alxneuro:StockIncentivePlan2016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-07-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-11-012018-11-30_custom_PerformanceContingentStockOptionsMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxneuro:PerformanceContingentStockOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-11-01</xbrli:startDate>
        <xbrli:endDate>2018-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-252019-11-26_custom_PerformanceContingentStockOptionsMember_custom_KeyEmployeesAndDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxneuro:PerformanceContingentStockOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxneuro:KeyEmployeesAndDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-25</xbrli:startDate>
        <xbrli:endDate>2019-11-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-222021-03-23_custom_PerformanceContingentStockOptionsMember_custom_KeyEmployeesAndDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxneuro:PerformanceContingentStockOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxneuro:KeyEmployeesAndDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-22</xbrli:startDate>
        <xbrli:endDate>2021-03-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_UnamortizedStockBasedCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">alxneuro:UnamortizedStockBasedCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_UnamortizedStockBasedCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">alxneuro:UnamortizedStockBasedCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_srt_MinimumMember_custom_EmployeesAndConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxneuro:EmployeesAndConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-07-31_srt_MinimumMember_custom_EmployeesAndConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxneuro:EmployeesAndConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-07-31_srt_MaximumMember_custom_EmployeesAndConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxneuro:EmployeesAndConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_EmployeesAndConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxneuro:EmployeesAndConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-07-31_custom_EmployeesAndConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxneuro:EmployeesAndConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-07-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-07-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_ExercisePrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alxneuro:ExercisePrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_ExercisePrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alxneuro:ExercisePrice2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_ExercisePrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alxneuro:ExercisePrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_ExercisePriceFiftySixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alxneuro:ExercisePriceFiftySixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_ExercisePrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alxneuro:ExercisePrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_ExercisePriceFiftySevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alxneuro:ExercisePriceFiftySevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_ExercisePrice4Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alxneuro:ExercisePrice4Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_ExercisePrice4Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alxneuro:ExercisePrice4Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementMember_custom_DigitalPowerLendingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxneuro:DigitalPowerLendingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-31</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-082021-03-09_custom_SecuritiesPurchaseAgreementMember_custom_DigitalPowerLendingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxneuro:DigitalPowerLendingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-08</xbrli:startDate>
        <xbrli:endDate>2021-03-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_AL002LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_AL001LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-012020-06-10_custom_AdditionalAL001LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-01</xbrli:startDate>
        <xbrli:endDate>2020-06-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_AL001LicenseMember_custom_PreINDMeetingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:PreINDMeetingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_PreINDMeetingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:PreINDMeetingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_AL001LicenseMember_custom_IndApplicationFilingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:IndApplicationFilingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_IndApplicationFilingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:IndApplicationFilingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_AL001LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFirstDosingOfPatientInClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFirstDosingOfPatientInClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_AL001LicenseMember_custom_UponCompletionOfFirstPatientDosingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponCompletionOfFirstPatientDosingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_UponCompletionOfFirstPatientDosingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponCompletionOfFirstPatientDosingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_AL001LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponCompletionOfFirstClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponCompletionOfFirstClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_AL001LicenseMember_custom_UponFdaApprovalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFdaApprovalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_UponFdaApprovalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFdaApprovalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_AL002LicenseMember_custom_PreINDMeetingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:PreINDMeetingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_PreINDMeetingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:PreINDMeetingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_AL002LicenseMember_custom_IndApplicationFilingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:IndApplicationFilingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_IndApplicationFilingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:IndApplicationFilingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_AL002LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFirstDosingOfPatientInClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFirstDosingOfPatientInClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_AL002LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponCompletionOfFirstClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponCompletionOfFirstClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_AL002LicenseMember_custom_UponFirstPatientTreatedInPhase3ClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFirstPatientTreatedInPhase3ClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_UponFirstPatientTreatedInPhase3ClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFirstPatientTreatedInPhase3ClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_AL002LicenseMember_custom_UponFdaApprovalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFdaApprovalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_UponFdaApprovalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFdaApprovalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_AdditionalAL001LicenseMember_custom_IndApplicationFilingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:IndApplicationFilingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember_custom_IndApplicationFilingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:IndApplicationFilingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFirstDosingOfPatientInClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFirstDosingOfPatientInClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_AdditionalAL001LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponCompletionOfFirstClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponCompletionOfFirstClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFirstPatientTreatedInPhase3ClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFirstPatientTreatedInPhase3ClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFirstPatientTreatedInPhase3ClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFirstPatientTreatedInPhase3ClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFdaApprovalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFdaApprovalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFdaApprovalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFdaApprovalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-302019-04-30_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxneuro:ALSFMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-30</xbrli:startDate>
        <xbrli:endDate>2019-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-302019-04-30_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxneuro:ALSFMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-30</xbrli:startDate>
        <xbrli:endDate>2019-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-30_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxneuro:ALSFMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-30_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxneuro:ALSFMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-30_custom_ALSFMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxneuro:ALSFMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxneuro:ALSFMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-31</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SecuritiesPurchaseAgreementsMember_custom_DigitalPowerLendingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxneuro:DigitalPowerLendingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementsMember_custom_DigitalPowerLendingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxneuro:DigitalPowerLendingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-31</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementsMember_custom_AultGlobalMember_custom_ConvertiblePromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxneuro:AultGlobalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxneuro:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-31</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-012021-03-09_custom_SecuritiesPurchaseAgreementsMember_custom_AultGlobalMember_custom_ConvertiblePromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxneuro:AultGlobalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxneuro:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-01</xbrli:startDate>
        <xbrli:endDate>2021-03-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-262022-04-28_custom_SecuritiesPurchaseAgreementsMember_custom_DigitalPowerLendingMember_custom_FinalTrancheMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001677077</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxneuro:DigitalPowerLendingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">alxneuro:FinalTrancheMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-26</xbrli:startDate>
        <xbrli:endDate>2022-04-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="N">
      <xbrli:measure>alxneuro:Number</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 9pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b>UNITED STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b>SECURITIES AND
EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>Washington, DC
20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 18pt"><b>FORM&#160;<span id="xdx_901_edei--DocumentType_c20220501__20220731_zHRT325XLyk9"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1%; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_90D_edei--DocumentQuarterlyReport_dxL_c20220501__20220731_ziGokgl1su69" title="::XDX::true"><span style="-sec-ix-hidden: xdx2ixbrl0015">&#254;</span></span></span></td>
    <td style="width: 99%; font-size: 10pt"><b>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the quarterly period ended&#160;<span id="xdx_900_edei--DocumentPeriodEndDate_dd_c20220501__20220731_zFTWHc06BcUj"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">July 31,
2022</ix:nonNumeric></span></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OR</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 1%; font-size: 10pt; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_edei--DocumentTransitionReport_c20220501__20220731_zaF2I9rv2aM7"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: left; width: 99%; font-size: 10pt; vertical-align: bottom"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Commission File Number:&#160;<span id="xdx_90F_edei--EntityFileNumber_c20220501__20220731_z9BzanLZt5se"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" name="dei:EntityFileNumber">001-40483</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt; text-align: center; color: #231F20"><span style="font-size: 24pt"><b><span id="xdx_907_edei--EntityRegistrantName_c20220501__20220731_zdvOqRmzDXE1"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" name="dei:EntityRegistrantName">ALZAMEND
NEURO, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 52%; font-size: 10pt; text-align: center"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20220501__20220731_zeLz1XecXZ29"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="width: 48%; font-size: 10pt; text-align: center"><b><span id="xdx_90A_edei--EntityTaxIdentificationNumber_c20220501__20220731_zpfrgpcKzXzb"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" name="dei:EntityTaxIdentificationNumber">81-1822909</ix:nonNumeric></span></b></td></tr>
  <tr>
    <td style="font-size: 10pt; text-align: center">(State or other jurisdiction of incorporation or organization)</td>
    <td style="font-size: 10pt; text-align: center">&#160;(I.R.S. Employer Identification Number)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 43%; text-align: center">&#160;<b><span id="xdx_909_edei--EntityAddressAddressLine1_c20220501__20220731_zaaDLXU6LjTb"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" name="dei:EntityAddressAddressLine1">3500 Lenox Rd NE</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressAddressLine2_c20220501__20220731_zwhVA9j4pKN6"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" name="dei:EntityAddressAddressLine2">Suite 1500</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressCityOrTown_c20220501__20220731_z2ijVILjbps9"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" name="dei:EntityAddressCityOrTown">Atlanta</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressStateOrProvince_c20220501__20220731_zy39ioKxRU9k"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" name="dei:EntityAddressStateOrProvince">GA</ix:nonNumeric></span></b></td>
    <td style="width: 18%; text-align: center"><b><span id="xdx_90D_edei--EntityAddressPostalZipCode_c20220501__20220731_zZyP6ADhtLs6"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" name="dei:EntityAddressPostalZipCode">30326</ix:nonNumeric></span></b></td>
    <td style="width: 39%; text-align: center"><b>(<span id="xdx_90A_edei--CityAreaCode_c20220501__20220731_zEkVbUAkSL86"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" name="dei:CityAreaCode">844</ix:nonNumeric></span>) <span id="xdx_907_edei--LocalPhoneNumber_c20220501__20220731_zQlTZlztVGFc"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" name="dei:LocalPhoneNumber">722-6303</ix:nonNumeric></span></b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">(Address of principal executive offices)</td>
    <td style="text-align: center">(Zip Code)</td>
    <td style="text-align: center">(Registrant&#8217;s telephone number, including area code)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered under Section 12(b) of the
Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 42%; text-align: center"><b>Title of Each Class</b></td>
    <td style="vertical-align: top; width: 20%; text-align: center"><b>Trading Symbol</b></td>
    <td style="width: 38%; text-align: center"><b>Name of each exchange on which registered</b></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center"><span id="xdx_908_edei--Security12bTitle_c20220501__20220731_zKBwzZNrSONd"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" name="dei:Security12bTitle">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_903_edei--TradingSymbol_c20220501__20220731_zonv1ww6V5oj"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" name="dei:TradingSymbol">ALZN</ix:nonNumeric></span></td>
    <td style="text-align: center"><span id="xdx_901_edei--SecurityExchangeName_c20220501__20220731_zjmzkqRRQG6c"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Capital Market</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered under Section 12(g) of the
Act:&#160;&#160;&#160;&#160;&#160;&#160;None</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.&#160;<span id="xdx_909_edei--EntityCurrentReportingStatus_c20220501__20220731_zEi7zpE4se74"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif; background-color: white">&#9746;</span>&#160;No&#160;<span style="font-family: Times New Roman, Times, Serif; background-color: white">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding
12 months (or for such shorter period that the registrant was required to submit such files).&#160;<span id="xdx_906_edei--EntityInteractiveDataCurrent_c20220501__20220731_zdQOI7XN7HY6"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif; background-color: white">&#9746;</span>&#160;No&#160;<span style="font-family: Times New Roman, Times, Serif; background-color: white">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 25%">Large accelerated filer</td>
    <td style="white-space: nowrap; width: 35%"><span style="font-family: Times New Roman, Times, Serif; background-color: white">&#9744;</span></td>
    <td style="white-space: nowrap; width: 40%; text-align: right">Accelerated filer <span style="font-family: Times New Roman, Times, Serif; background-color: white">&#9744;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span id="xdx_90C_edei--EntityFilerCategory_c20220501__20220731_zXFT4Li2AOk7"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; background-color: white">&#9746;</span></td>
    <td style="white-space: nowrap; text-align: right">Smaller reporting company <span style="font-family: Times New Roman, Times, Serif; background-color: white"><span id="xdx_906_edei--EntitySmallBusiness_c20220501__20220731_zoD4u2QHrPx6"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">Emerging growth company</td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; background-color: white"><span id="xdx_903_edei--EntityEmergingGrowthCompany_c20220501__20220731_zN84CrW3pRE6"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td>
    <td style="text-align: right; white-space: nowrap">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family: Times New Roman, Times, Serif; background-color: white"><span id="xdx_905_edei--EntityExTransitionPeriod_c20220501__20220731_zd5gcjwGek3g"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;<span style="font-family: Times New Roman, Times, Serif; background-color: white">&#9744;</span>&#160;<span id="xdx_908_edei--EntityShellCompany_c20220501__20220731_zkifMYGHsyt"><ix:nonNumeric contextRef="From2022-05-01to2022-07-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif; background-color: white">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 13, 2022 there were&#160;<span id="xdx_90D_edei--EntityCommonStockSharesOutstanding_iI_pid_uShares_c20220913_zJKLMML01Ofe" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2022-09-13" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95,481,790</ix:nonFraction></span>&#160;shares
of registrant&#8217;s common stock, $0.0001 par value per share, outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">&#160;</td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Table of Contents</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: center"><b>Page</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; width: 7%"><b>PART I.</b></td>
    <td style="white-space: nowrap; width: 87%"><b><span style="text-decoration: underline">FINANCIAL INFORMATION</span></b></td>
    <td style="white-space: nowrap; width: 6%; text-align: center">3</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">Item 1.</td>
    <td style="white-space: nowrap">Financial Statements (unaudited)</td>
    <td style="white-space: nowrap; text-align: center">3</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">Condensed Balance Sheets</td>
    <td style="white-space: nowrap; text-align: center">3</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">Condensed Statements of Operations</td>
    <td style="white-space: nowrap; text-align: center">4</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">Condensed Statements of Stockholders&#8217; Equity</td>
    <td style="white-space: nowrap; text-align: center">5</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">Condensed Statements of Cash Flows</td>
    <td style="white-space: nowrap; text-align: center">7</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">Notes to Condensed Financial Statements</td>
    <td style="white-space: nowrap; text-align: center">8</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">Item 2.</td>
    <td style="white-space: nowrap">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</td>
    <td style="white-space: nowrap; text-align: center">18</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">Item 3.</td>
    <td style="white-space: nowrap">Quantitative and Qualitative Disclosures About Market Risk</td>
    <td style="white-space: nowrap; text-align: center">26</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">Item 4.</td>
    <td style="white-space: nowrap">Controls and Procedures</td>
    <td style="white-space: nowrap; text-align: center">27</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap"><b>PART II</b></td>
    <td style="white-space: nowrap"><b><span style="text-decoration: underline">OTHER INFORMATION</span></b></td>
    <td style="white-space: nowrap; text-align: center">29</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">Item 1.</td>
    <td style="white-space: nowrap">Legal Proceedings</td>
    <td style="white-space: nowrap; text-align: center">29</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">Item 1A.</td>
    <td style="white-space: nowrap">Risk Factors</td>
    <td style="white-space: nowrap; text-align: center">29</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">Item 2.</td>
    <td style="white-space: nowrap">Unregistered Sales of Equity Securities and Use of Proceeds</td>
    <td style="white-space: nowrap; text-align: center">29</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">Item 3.</td>
    <td style="white-space: nowrap">Defaults Upon Senior Securities</td>
    <td style="white-space: nowrap; text-align: center">29</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">Item 4.</td>
    <td style="white-space: nowrap">Mine Safety Disclosures</td>
    <td style="white-space: nowrap; text-align: center">29</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">Item 5. </td>
    <td style="white-space: nowrap">Other Information</td>
    <td style="white-space: nowrap; text-align: center">29</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">Item 6.</td>
    <td style="white-space: nowrap">Exhibits</td>
    <td style="white-space: nowrap; text-align: center">29</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">Signatures</td>
    <td style="white-space: nowrap; text-align: center">30</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 2; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I &#8211; FINANCIAL INFORMATION&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.75in"><b>ITEM 1.</b></td><td style="text-align: justify"><b>FINANCIAL STATEMENTS</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Alzamend Neuro, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Balance Sheets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_111_z6k4JNP2ZWq1" summary="xdx: Statement - Condensed Balance Sheets (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20220731_zH0sQVyuIRf8" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">July 31, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220430_znBt56POtzv1" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsAbstract_iB_zy0ECq6G7XX6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsCurrentAbstract_i01B_zfQSLKYw8dm5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">&#160;CURRENT ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzA9v_zj3lC29d0Iy9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">&#160;Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,527,121</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,063,811</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACzA9v_zTgFEoukLlfl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">587,542</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">349,723</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrent_i02TI_mtACzA9v_maAzI0v_zmF5UTPZTT5e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">&#160;TOTAL CURRENT ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,114,663</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,413,534</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_i02I_maAzI0v_zLVIeWQ60D26" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;Property, plant and equipment, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,812</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,909</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Assets_i01TI_mtAzI0v_zfWejDIoBzhe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,210,475</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,516,443</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zIIRycnl2ak8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">&#160;LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesCurrentAbstract_i01B_zo4mooqODc94" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">&#160;CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableCurrent_i02I_maLCzCaz_zxneLaIe4Y4e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;Accounts payable and accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,028,700</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,162,850</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DueToRelatedPartiesCurrent_i02I_maLCzCaz_z4NIR1HajDD6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">&#160;Related party payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0072">-</span></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,082</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzCaz_maLzWWb_z4vr8kEI6Ru7" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">&#160;TOTAL CURRENT LIABILITIES</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,028,700</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,164,932</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Liabilities_i02TI_mtLzWWb_maLASEzTfV_zSKFwY2gwPm4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">&#160;TOTAL LIABILITIES</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,028,700</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,164,932</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CommitmentsAndContingencies_i01I_zD2OcneIzolj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">&#160;COMMITMENTS AND CONTINGENCIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockholdersEquityAbstract_i01B_zE5555hs5eH9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">&#160;STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PreferredStockValue_i02I_pid_maSEzuad_z5OTqtx97OLa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
  <td>&#160;Convertible Preferred stock, $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20220731_zTGrYSLPufGl" title="Preferred stock, par value (in dollars per share)"><span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20220430_zTUKxXFTAAuj" title="Preferred stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value: <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20220731_zzLpEPa353qg" title="Preferred stock, shares authorized"><span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20220430_zOe33LNUPts" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized;<br />
&#160;Series A Convertible Preferred Stock, $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20220731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zdvA6yB3Vg6a" title="Preferred stock, par value (in dollars per share)"><span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20220430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zaE2OICecvT7" title="Preferred stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-07-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-04-30_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> stated value per share, <span id="xdx_903_ecustom--PreferredStockSharesDesignated_iI_uShares_c20220731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zs2tYreGEtuf" title="Preferred stock shares designated"><span id="xdx_900_ecustom--PreferredStockSharesDesignated_iI_uShares_c20220430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zYlCnwQr46hb"><ix:nonFraction name="alxneuro:PreferredStockSharesDesignated" contextRef="AsOf2022-07-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="alxneuro:PreferredStockSharesDesignated" contextRef="AsOf2022-04-30_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,360,000</ix:nonFraction></ix:nonFraction></span></span> shares designated;<br /> &#160;<span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_pid_dxL_uShares_c20220731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ztzHSXSgmPjd" title="Preferred stock, shares issued::XDX::0"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dxL_uShares_c20220731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zpKbfFW8PEc" title="Preferred stock, shares outstanding::XDX::0"><span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_pid_dxL_uShares_c20220430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zQVzCOBEMFOb" title="Preferred stock, shares issued::XDX::0"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dxL_uShares_c20220430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zFBHuj9DKff" title="Preferred stock, shares outstanding::XDX::0"><span style="-sec-ix-hidden: xdx2ixbrl0105"><span style="-sec-ix-hidden: xdx2ixbrl0107"><span style="-sec-ix-hidden: xdx2ixbrl0109"><span style="-sec-ix-hidden: xdx2ixbrl0111">nil</span></span></span></span></span></span></span></span> issued and outstanding as of July 31, 2022 and April 30, 2022</td>
  <td>&#160;<br />
&#160;<br /> &#160;</td>
  <td style="text-align: left">&#160;<br />
&#160;<br /> &#160;</td>
  <td style="text-align: right">&#160;<br />
&#160;<br /> <span style="-sec-ix-hidden: xdx2ixbrl0087">-</span></td>
  <td style="white-space: nowrap; text-align: left">&#160;<br />
&#160;<br /> &#160;</td>
  <td>&#160;<br />
&#160;<br /> &#160;</td>
  <td style="text-align: left">&#160;<br />
&#160;<br /> &#160;</td>
  <td style="text-align: right">&#160;<br />
&#160;<br /> <span style="-sec-ix-hidden: xdx2ixbrl0088">-</span></td>
  <td style="white-space: nowrap; text-align: left">&#160;<br />
&#160;<br /> &#160;</td>
</tr>
<tr id="xdx_40D_eus-gaap--CommonStockValue_i02I_maSEzuad_zWIpyjm2jBgk" style="vertical-align: bottom; background-color: White">
  <td>&#160;Common stock, $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20220731_zjwysxVtp473" title="Common stock, par value (in dollars per share)"><span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20220430_zkytVvADjvwe" title="Common stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value: <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20220731_zfTqB8xjOwsg" title="Common stock, shares authorized"><span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20220430_zQRhAYg3I791" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20220731_zJuvbKQzdnM5" title="Common stock, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_uShares_c20220731_zdBBuDVFoXJ" title="Common stock, shares outstanding"><span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20220430_zm3NS2G9oIJ3" title="Common stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_pid_uShares_c20220430_zPF3c59Y2DWa" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95,481,790</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span><br />
&#160;shares issued and outstanding as of July 31, 2022 and April 30, 2022</td>
  <td>&#160;<br />
&#160;</td>
  <td style="text-align: left">&#160;<br />
&#160;</td>
  <td style="text-align: right">&#160;<br />
<ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,548</ix:nonFraction></td>
  <td style="white-space: nowrap; text-align: left">&#160;<br />
&#160;</td>
  <td>&#160;<br />
&#160;</td>
  <td style="text-align: left">&#160;<br />
&#160;</td>
  <td style="text-align: right">&#160;<br />
<ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,548</ix:nonFraction></td>
  <td style="white-space: nowrap; text-align: left">&#160;<br />
&#160;</td>
</tr>
<tr id="xdx_403_eus-gaap--AdditionalPaidInCapital_i02I_maSEzuad_zxJa0TQKS895" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,287,091</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,419,753</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--NoteReceivableForCommonStockRelatedParty_i02I_maSEzuad_zNISpIzsPOF7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;Note receivable for common stock &#8211; related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="alxneuro:NoteReceivableForCommonStockRelatedParty" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,883,295</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="alxneuro:NoteReceivableForCommonStockRelatedParty" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,883,295</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzuad_zGT2eDO93W3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">&#160;Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">32,231,569</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">29,194,495</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--StockholdersEquity_i02TI_mtSEzuad_maLASEzTfV_zmEqItG8Cwo7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">&#160;TOTAL STOCKHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,181,775</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,351,511</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzTfV_zVZy0xXPUXA2" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,210,475</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,516,443</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these unaudited condensed financial statements.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Alzamend Neuro, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Statements of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_113_zikZeWOyN0M5" summary="xdx: Statement - Condensed Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_49E_20220501__20220731_z6ArbpKsK7S7" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_491_20210501__20210731_z0Y53uR8iDgh" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CostsAndExpensesAbstract_iB_zz2KCB0JIbW9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">&#160;OPERATING EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_i01_maCAEzeUk_zvjpTRPczskl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: 10pt">&#160;Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-05-01to2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,375,953</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">916,408</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_i01_maCAEzeUk_zhqbiVDXfLob" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt">&#160;General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-05-01to2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,659,589</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,389,831</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CostsAndExpenses_i01T_mtCAEzeUk_msOILzafZ_zlqMF9Ljeq81" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 20pt">&#160;Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2022-05-01to2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,035,542</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,306,239</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingIncomeLoss_iT_mtOILzafZ_maNILzl2Z_zHX4E1Gjn3Lb" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">&#160;Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-05-01to2022-07-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,035,542</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,306,239</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zuSSmiGDibxa" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">&#160;OTHER EXPENSE, NET</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InterestExpense_iN_di_msNIEzNid_zgGXP3DNWta6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">&#160;Interest expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-05-01to2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,532</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,628</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NonoperatingIncomeExpense_iT_mtNIEzNid_maNILzl2Z_znTUCa0jeBU1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: 10.05pt">&#160;Total other expense, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-05-01to2022-07-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,532</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,628</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_iT_mtNILzl2Z_z397EwAM1gj7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;NET LOSS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-05-01to2022-07-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,037,074</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,319,867</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--EarningsPerShareBasic_pid_uUSDPShares_zgdnq9tw8val" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;Basic and diluted net loss per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-05-01to2022-07-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.03</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.03</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_uShares_zLMYFcyvhCeg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;Basic and diluted weighted average common shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-05-01to2022-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,481,790</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">84,588,492</ix:nonFraction></p></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these unaudited condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Alzamend Neuro, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Statements of Stockholders&#8217;
Equity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Three Months Ended July 31, 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_114_zgZ7mdn84Td5" summary="xdx: Statement - Condensed Statements of Stockholders&apos; Equity (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesAPreferredStockMember_z77eJrQrBJja" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zQ5EIB8Th6nj" style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zCrD5ycskU44" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_custom--NoteRecievableForCommonStockRelatedPartyMember_zwWCTUHOvwWe" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zHGBvOwpoLyf" style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" id="xdx_4B4_zM1UtwCTtTQ3" style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">Series A Convertible</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Additional</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Note Receivable <br />
for</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Preferred Stock</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Common Stock</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Paid-In</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Common Stock -</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Accumulated</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Capital</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Related Party</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Deficit</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43D_c20220501__20220731_eus-gaap--StockholdersEquity_iS_zh8DiB82lz2i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">BALANCES, April 30, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_uShares_c20220501__20220731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zeucnlc3Et9e" title="Beginning balance (in shares)" style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0187">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0180">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_uShares_c20220501__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zG8XSJdP5edl" title="Beginning balance (in shares)" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-04-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95,481,790</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-04-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,548</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-04-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,419,753</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-04-30_custom_NoteRecievableForCommonStockRelatedPartyMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,883,295</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-04-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">29,194,495</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,351,511</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_43F_c20220501__20220731_ecustom--StockbasedCompensationToEmployeesAndConsultants_zsd4r8CKOSKg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation to employees and consultants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0191">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0192">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alxneuro:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2022-05-012022-07-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">867,338</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0194">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0195">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alxneuro:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2022-05-01to2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">867,338</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_436_c20220501__20220731_eus-gaap--NetIncomeLoss_zRbsS0iLUumi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0198">-</span></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0199">-</span></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0200">-</span></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0201">-</span></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-05-012022-07-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,037,074</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-05-01to2022-07-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,037,074</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_433_c20220501__20220731_eus-gaap--StockholdersEquity_iE_zOiX7adGLSSh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">BALANCES, July 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_uShares_c20220501__20220731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zFvE1gxIOPMd" title="Ending balance (in shares)" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0212">-</span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0205">-</span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_uShares_c20220501__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zezGWmVPyZsd" title="Ending balance (in shares)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-07-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95,481,790</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-07-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,548</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-07-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,287,091</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,883,295</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-07-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">32,231,569</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,181,775</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these unaudited condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Alzamend Neuro, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Statements of Stockholders&#8217;
Equity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Three Months Ended July 31, 2021</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_4B8_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesAPreferredStockMember_zhfYxfcuNHZ5" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zZ4dNssduGr7" style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zgoAGCKnvVWh" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_custom--NoteRecievableForCommonStockRelatedPartyMember_zpVVjQcirNW3" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zE5O77efuFna" style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" id="xdx_4B4_zBrlK5OsPnv4" style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">Series A Convertible</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Additional</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Note Receivable <br />
for</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Preferred Stock</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Common Stock</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Paid-In</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Common Stock -</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Accumulated</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Capital</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Related Party</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Deficit</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_438_c20210501__20210731_eus-gaap--StockholdersEquity_iS_zx1yixYTriJ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">BALANCES, April 30, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_uShares_c20210501__20210731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zz4GXmmvTD24" title="Beginning balance (in shares)" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-04-30_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">750,000</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-04-30_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_uShares_c20210501__20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7cgunR4hxvl" title="Beginning balance (in shares)" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-04-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">67,429,525</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-04-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,743</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-04-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,721,859</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-04-30_custom_NoteRecievableForCommonStockRelatedPartyMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,883,295</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-04-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,832,437</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-04-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,012,945</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_43C_c20210501__20210731_ecustom--StockbasedCompensationToEmployeesAndConsultants_zY6lgJWKZBGk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation to employees and consultants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0227">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0228">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alxneuro:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2021-05-012021-07-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">739,622</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0230">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0231">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alxneuro:StockbasedCompensationToEmployeesAndConsultants" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">739,622</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_43A_c20210501__20210731_ecustom--StockIssuedDuringPeriodValueNewIssues2_z0ifPhmpvF" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from sale of common stocks and warrants-related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0234">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--StockIssuedDuringPeriodSharesNewIssues2_pid_uShares_c20210501__20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYo7MEZmaC72" title="Proceeds from sale of common stocks and warrants-related party (in shares)" style="text-align: right"><ix:nonFraction name="alxneuro:StockIssuedDuringPeriodSharesNewIssues2" contextRef="From2021-05-012021-07-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,333,333</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alxneuro:StockIssuedDuringPeriodValueNewIssues2" contextRef="From2021-05-012021-07-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alxneuro:StockIssuedDuringPeriodValueNewIssues2" contextRef="From2021-05-012021-07-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,999,867</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0237">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0238">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alxneuro:StockIssuedDuringPeriodValueNewIssues2" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_436_c20210501__20210731_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_z8xGqTxddVf9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from stock option exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0243">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20210501__20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z79AXIDrjnbc" title="Proceeds from stock option exercise (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-05-012021-07-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-05-012021-07-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-05-012021-07-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0246">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0247">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20210501__20210731_ecustom--StockIssuedDuringPeriodValueNewIssues3_z1RmvgXMUp01" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from initial public offering, net of underwriters' discounts and commissions and issuance costs of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_dm_c20210501__20210731_z6rjQZXeEO3e" title="Proceeds from Issuance Initial Public Offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">1.5</ix:nonFraction> million</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0252">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--StockIssuedDuringPeriodSharesNewIssues3_pid_uShares_c20210501__20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKQPx1o19f56" title="Proceeds from initial public offering, net of underwriters&apos; discounts and commissions and issuance costs of $1.5 million (in shares)" style="text-align: right"><ix:nonFraction name="alxneuro:StockIssuedDuringPeriodSharesNewIssues3" contextRef="From2021-05-012021-07-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,875,000</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alxneuro:StockIssuedDuringPeriodValueNewIssues3" contextRef="From2021-05-012021-07-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">288</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alxneuro:StockIssuedDuringPeriodValueNewIssues3" contextRef="From2021-05-012021-07-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,911,168</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0255">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0256">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alxneuro:StockIssuedDuringPeriodValueNewIssues3" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,911,456</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20210501__20210731_ecustom--ConversionOfSeriesAConvertibleStock_zoIuxJ1f3poc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Conversion of Series A convertible stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_uShares_c20210501__20210731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zhDgzv8fwn46" title="Conversion of Series A convertible stock (in shares)" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2021-05-012021-07-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">750,000</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="alxneuro:ConversionOfSeriesAConvertibleStock" contextRef="From2021-05-012021-07-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">75</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_uShares_c20210501__20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoxzhd8WKPm7" title="Conversion of Series A convertible stock (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2021-05-012021-07-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000,000</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="alxneuro:ConversionOfSeriesAConvertibleStock" contextRef="From2021-05-012021-07-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="alxneuro:ConversionOfSeriesAConvertibleStock" contextRef="From2021-05-012021-07-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,425</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0266">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0268">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_43D_c20210501__20210731_eus-gaap--NetIncomeLoss_zgNWF5lI3rLi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">&#160;Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0274">-</span></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0275">-</span></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0276">-</span></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0277">-</span></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-05-012021-07-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,319,867</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,319,867</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_439_c20210501__20210731_eus-gaap--StockholdersEquity_iE_zr4NLklIgRSl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;BALANCES, July 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_uShares_c20210501__20210731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zeF3fRnvrt66" title="Ending balance (in shares)" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0288">-</span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0281">-</span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pid_uShares_c20210501__20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziJMwmv5T4Ka" title="Ending balance (in shares)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-07-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">86,887,858</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-07-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,689</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-07-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,371,166</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,883,295</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-07-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,152,304</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,344,256</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these unaudited condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Alzamend Neuro, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Statements of Cash Flows</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_112_znbQv2Ehz7gh" summary="xdx: Statement - Condensed Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_49E_20220501__20220731_zbhiuoJS4uGd" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_49E_20210501__20210731_zxpxnnxiu0Yg" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zst2XWidsHjd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_i01_maNCPBUzPJM_zDIrpv0mKoR" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: 10pt">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-05-01to2022-07-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,037,074</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,319,867</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zKQ7DJSTTXOh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Depreciation_i02_maNCPBUzPJM_zyDG9s6h8rXd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt">Depreciation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-05-01to2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,097</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0302">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AmortizationOfDebtDiscountPremium_i02_maNCPBUzPJM_zBvkKkUis46l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt">Interest expense - debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0304">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,795</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensation_i02_maNCPBUzPJM_zUXhhuruA5Y5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt">Stock-based compensation to employees and consultants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-05-01to2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">867,338</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">739,622</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zA2JeRx8wy06" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 20pt">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUzPJM_ze6ISvjut4Ee" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 30pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-05-01to2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">237,819</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">216,169</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccountsPayableTrade_i03_maNCPBUzPJM_zOp34zIwld0i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 30pt">Accounts payable and accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2022-05-01to2022-07-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">136,232</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">568,955</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzPJM_maCCERCzHRr_zHeoOwIuTmbb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 30pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-05-01to2022-07-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,536,690</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,222,664</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zN3qKu0SAhgh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUz29O_zrDThSrG6lj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt">Proceeds from the issuance of common stock and warrants - related party, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0325">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromStockOptionsExercised_i01_maNCPBUz29O_z5GwosEozUCd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt">Proceeds from stock option exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0328">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts_i01_maNCPBUz29O_zFZO1cZTY71c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -6.8pt; padding-left: 16.8pt">Proceeds from initial public offering, net of underwriters&#8217; discounts and commissions and issuance costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0331">-</span></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="alxneuro:ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,911,456</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUz29O_maCCERCzHRr_zwq9FAl8FdJb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 30pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">-</span></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,911,556</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_i01T_mtCCERCzHRr_zi6IfOUc6Vck" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net (decrease) increase in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2022-05-01to2022-07-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,536,690</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,688,892</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iS_zMrxCI0xaD8d" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Cash at beginning of period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,063,811</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-04-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,929,270</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iE_zAMYFA1rgsLb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Cash at end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,527,121</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,618,162</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zrN5VCUKYZ21" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Supplemental disclosures of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_i01B_zvsOkuvEQBDj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-cash financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--FairValueOfWarrantsIssuedInConnectionWithIpo_i02_zoJyYBhNHFJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt">Fair value of warrants issued in connection with initial public offering</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="alxneuro:FairValueOfWarrantsIssuedInConnectionWithIpo" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">461,877</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty_i02_zYAL94uw95U2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-align: left; text-indent: 0pt">Fair value of warrants issued in connection with March 2021 securities purchase agreement, related party</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0355">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonNumeric contextRef="From2021-05-012021-07-31" name="alxneuro:FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty">4,799,742</ix:nonNumeric></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these unaudited condensed financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Alzamend Neuro, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Unaudited Condensed Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_806_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zAYDEQTG8lal" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><b>1.</b></td><td style="text-align: justify"><b><span id="xdx_82A_zUe5PEn8xtX">DESCRIPTION OF BUSINESS</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Organization</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Alzamend Neuro, Inc. (the
&#8220;Company&#8221; or &#8220;Alzamend&#8221;), is an early clinical-stage biopharmaceutical company focused on developing novel products
for the treatment of neurodegenerative diseases and psychiatric disorders. The Company&#8217;s primary focus is Alzheimer&#8217;s disease.
With two current and future product candidates, Alzamend aims to bring treatments or cures to market at a reasonable cost as quickly as
possible. The Company&#8217;s current pipeline consists of two novel therapeutic drug candidates (collectively, the &#8220;Technology&#8221;):
(i) a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001, through
two royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., as licensor (the &#8220;Licensor&#8221;);
and (ii) a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability
of a patient&#8217;s immunological system to combat Alzheimer&#8217;s, known as AL002 or CA022W, through a royalty-bearing exclusive worldwide
license from the same Licensor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is devoting substantially
all its efforts towards research and development of its Technology and raising capital. The Company has not generated any product revenue
to date. The Company has financed its operations to date primarily through debt financings and through the sale of its common stock, par
value $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20220731_zAc6sOZXZyOd" title="Common stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share (&#8220;Common Stock&#8221;). The Company expects to continue to incur net losses in the foreseeable future.</p>

</ix:nonNumeric><p id="xdx_815_zuWOdkiXsqn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_80E_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zeVPtDNzUBhd" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><b>2.</b></td><td style="text-align: justify"><b><span id="xdx_825_zbf7sF9xh414">LIQUIDITY AND GOING CONCERN</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying condensed
financial statements have been prepared on the basis that the Company will continue as a going concern. As of July 31, 2022, the Company
had cash of $<span id="xdx_90B_eus-gaap--Cash_iI_dm_c20220731_zhy80yRdKLec" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">11.5</ix:nonFraction> million</span> and an accumulated deficit of $<span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_dxL_c20220731_zGUbxu4sGi0h" title="Accumulated deficit::XDX::-32231569"><span style="-sec-ix-hidden: xdx2ixbrl0366">32.2</span></span> million. The Company incurred losses for the three months ended July 31,
2022 totaling $<span id="xdx_908_eus-gaap--NetIncomeLoss_dxL_c20220501__20220731_zdYObLJwvjU3" title="Net loss::XDX::-3037074"><span style="-sec-ix-hidden: xdx2ixbrl0368">3.0</span></span> million. Historically, the Company has financed its operations principally through issuances of equity and debt instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company expects to continue to incur losses for the foreseeable
future and needs to raise additional capital until it is able to generate revenues from operations sufficient to fund its development
and commercial operations. However, based on the Company&#8217;s current business plan, management believes that the Company&#8217;s cash
at July 31, 2022 is sufficient to meet the Company&#8217;s anticipated cash requirements during the twelve-month period subsequent to
the issuance of the financial statements included in this Quarterly Report.</p>

</ix:nonNumeric><p id="xdx_814_z591jLONa3i9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zEnl1wQwZMM9" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><b>3.</b></td><td style="text-align: justify"><b><span id="xdx_82A_zqNueUgRrBh4">SIGNIFICANT ACCOUNTING POLICIES</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zfwkyg0j68g6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_86D_zvEVSkVnw5ea">Basis of Presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying condensed
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#8220;U.S. GAAP&#8221;) and the rules of the Securities and Exchange Commission (&#8220;SEC&#8221;) applicable to interim
reports of companies filing as a smaller reporting company. These financial statements should be read in conjunction with the audited
financial statements and notes thereto contained in the Company&#8217;s Report on Form 10-K for the year ended April 30, 2022, filed with
the SEC on July 19, 2022. In the opinion of management, the accompanying condensed interim financial statements include all adjustments
necessary in order to make the financial statements not misleading. The results of operations for interim periods are not necessarily
indicative of the results to be expected for the full year or any other future period. Certain notes to the financial statements that
would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal year as reported
in the Company&#8217;s Report on Form 10-K have been omitted. The accompanying condensed balance sheet at April 30, 2022 has been derived
from the audited balance sheet at April 30, 2022 contained in such Form 10-K.</p>

</ix:nonNumeric><p id="xdx_85A_zqRVQUf3MaE1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_84C_eus-gaap--UseOfEstimates_zPjUqfNQfl64" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_86D_zuEq5qo7PVub">Accounting Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial
statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
expenses during the reporting period. The Company&#8217;s critical accounting policies that involve significant judgment and estimates
include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.</p>

</ix:nonNumeric><p id="xdx_854_zfVl8rBifcLk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z4s9nr151g07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_866_zzzEfTX9Y3R6">Cash and Cash Equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company considers all
highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of July 31, 2022
and April&#160;30, 2022, the Company had no cash equivalents.</p>

</ix:nonNumeric><p id="xdx_85F_zwAf77t1wJ8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zlFyaG6tVih4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_86A_zGVYruX2f5Qd">Fair Value of Financial
Instruments</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial Accounting Standards
Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820, <i>Fair Value Measurement</i>, defines fair value
as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques
used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy
is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last
is considered unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 1: Quoted prices in
active markets for identical assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 2: Inputs other than
Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in
markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the
full term of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 3 assumptions: Unobservable
inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including
liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of warrants
are determined using the Black-Scholes valuation model, a &#8220;Level 3&#8221; fair value measurement, based on the estimated fair value
of Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market
capitalization of such other entities, the expected life based on the remaining contractual term of the conversion option and warrants
and the risk free interest rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrants&#8217;
contractual life.</p>

</ix:nonNumeric><p id="xdx_858_z271fxl84CI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zZeFFfq2tm7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_862_zhRjIvqlH04l">Property and Equipment,
Net</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property and equipment are
stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life
of five years. Significant additions and improvements are capitalized, while repairs and maintenance are charged to expense as incurred.</p>

</ix:nonNumeric><p id="xdx_856_zXvaF1VSmu08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zXwRPdI1Zt27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_867_zFKQr73uXiSc">Research and Development
Expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development costs
are expensed as incurred. Research and development costs consist of scientific consulting fees and lab supplies, as well as fees paid
to other entities that conduct certain research and development activities on behalf of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has acquired and
may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire
license, products or rights, as well as any future milestone payments, are immediately recognized as research and development expense
provided that there is no alternative future use of the rights in other research and development projects.</p>

</ix:nonNumeric><p id="xdx_855_zDeOFLHJZkrg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_842_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z0ek2XiKgVIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_861_z8UkG0bAKQ4b">Stock-Based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognizes stock-based
compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they
occur. The Company&#8217;s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes
option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management
evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance
conditions as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p>

<ix:exclude><!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognizes stock-based
compensation expense for restricted stocks on a straight-line basis over the requisite service period and account for forfeitures as they
occur. The Company&#8217;s stock-based compensation for restricted stocks is based upon the estimated fair value of the Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Black-Scholes option pricing
model utilizes inputs which are highly subjective assumptions and generally require significant judgment. Certain of such assumptions
involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the
Company uses significantly different assumptions or estimates, the Company&#8217;s stock-based compensation could be materially different.</p>

</ix:nonNumeric><p id="xdx_854_zV3YTiex39p4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="alxneuro:WarrantsPolicyTextBlock"><p id="xdx_84A_ecustom--WarrantsPolicyTextBlock_zVILuVRGwGv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_86E_zTSh4yZKGKB9">Warrants</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts for stock
warrants as either equity instruments, derivative liabilities, or liabilities in accordance with ASC 480,&#160;<i>Distinguishing Liabilities
from Equity </i>(&#8220;ASC 480&#8221;)&#160;and ASC 815,&#160;<i>Derivatives and Hedging </i>(&#8220;ASC 815&#8221;)<i>,</i>&#160;depending
on the specific terms of the warrant agreement.</p>

</ix:nonNumeric><p id="xdx_854_zj2S6EKuo1Dg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z3ZnSefRZT7l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86C_zPJ5LMJzaIAf">Loss per Common Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company utilizes FASB
ASC 260,&#160;<i>Earnings per Share</i>. Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average
number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is
increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued
and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible
preferred stock, options and warrants were to be exercised or converted or otherwise resulted in the issuance of Common Stock that then
shared in the earnings of the entity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since the effects of outstanding
options, warrants, convertible preferred stock and convertible notes are anti-dilutive in the periods presented, shares of Common Stock
underlying these instruments have been excluded from the computation of loss per common share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zqAqwlq1ti7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_z2EGMMfrV5E3">The following sets forth the
number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have
been excluded from the computation of loss per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Series A convertible preferred stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuPhXO7Xn5k8" style="width: 15%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0391">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_d0_c20210501__20210731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zpZbSI0DZ5l4" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-05-012021-07-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000,000</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock options <sup id="xdx_F47_z7VLZN3QiKJ3">(1)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zDEFTaorQYA8" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-05-012022-07-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,600,000</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210501__20210731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zP8r5yrCJpR4" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-05-012021-07-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,500,000</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zXEgdLKzy3Ul" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-05-012022-07-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,149,788</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210501__20210731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zBUP2jHaWtD4" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-05-012021-07-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,830,785</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Convertible notes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_z7SL48dtsmcb" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">-</span></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210501__20210731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zdWVJZRS6Aqk" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-05-012021-07-31_custom_ConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">232,049</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731_zfMhB8hOwJgl" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-05-01to2022-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,749,788</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210501__20210731_zJlIX9UaCm7j" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">41,562,834</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_F06_zYnJiBoeeez5" style="font-size: 10pt">(1)
</span><span id="xdx_F19_zbxSgU7evvoa" style="font-size: 10pt"><ix:footnote id="Footnote000401" xml:lang="en-US">The Company has excluded
</ix:footnote></span><span id="xdx_903_ecustom--NumberOfStockExcluded_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zLBewUqX7Aoi" style="font-size: 10pt"><ix:nonFraction name="alxneuro:NumberOfStockExcluded" contextRef="From2022-05-012022-07-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction>
</span><span style="font-size: 10pt">stock options, with
an exercise price of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zMhijAxjDH57"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-05-012022-07-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0004</ix:nonFraction></span></span><span style="font-size: 10pt">,
from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares
issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14.</span></p>

</ix:nonNumeric><p id="xdx_8A8_zZHtbKUQHxol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_858_z1hrQlFg4g2e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zUdrSdjZia24" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;<b><span id="xdx_86F_zVXO0adZ8wAe">Recent Accounting Standards</span></b></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, new accounting
pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact
of recently issued standards that are not yet effective are not expected to have a material impact on the Company&#8217;s financial position
or results of operations upon adoption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has considered
all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on its
financial statements.</p>

</ix:nonNumeric><p id="xdx_852_zBKb6h1xHcq2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

</ix:nonNumeric><p id="xdx_819_zlNamZi0qfYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="alxneuro:MortgageNoteReceivableFromRelatedPartyTextBlock"><p id="xdx_80E_ecustom--MortgageNoteReceivableFromRelatedPartyTextBlock_zkdm7ezppFV3" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><b>4.</b></td><td style="text-align: justify"><b><span id="xdx_828_zx98wDGcdROf">NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 30, 2019, the Company
and Ault Life Sciences Fund, LLC (&#8220;ALSF&#8221;) entered into a securities purchase agreement for the purchase of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20190401__20190430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AultLifeSciencesFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z3nI7JwidrEa" title="Number of shares purchase (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-04-012019-04-30_custom_AultLifeSciencesFundLLCMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span> shares
of Common Stock for a total purchase price of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20190401__20190430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AultLifeSciencesFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zPL1TiCoRA85" title="Number of shares purchase"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-04-012019-04-30_custom_AultLifeSciencesFundLLCMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000,000</ix:nonFraction></span>, or $1.50 per share with <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_uShares_c20190401__20190430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AultLifeSciencesFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z60erB5NwzY9" title="Number of warrants granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2019-04-012019-04-30_custom_AultLifeSciencesFundLLCMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span> warrants with a <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20190401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AultLifeSciencesFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zy6UYJWv04fg" title="Warrant terms::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0415">5</span></span>-year life and an exercise
price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20190430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AultLifeSciencesFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zjsIZXTWgDoa" title="Exercise price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-04-30_custom_AultLifeSciencesFundLLCMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></span> per share and vesting upon issuance. The total purchase price of $15,000,000 was in the form of a non-interest bearing
note receivable with a 12-month term from ALSF, a related party. In November 2019, the term of the note receivable was extended to December
31, 2021, and in May 2021, the term of the note receivable was extended to December 31, 2023. The note is secured by a pledge of the purchased
shares. As the note receivable from ALSF is related to the issuance of Common Stock, it is recorded as an offset to additional paid-in
capital. At July 31, 2022 and April 30, 2022, the outstanding balance of the note receivable was $<span id="xdx_903_ecustom--LongTermDebtAverageAmountOfOutstanding_iI_pid_uShares_c20220430_zbZk62Up5Awc" title="Outstanding receivable amount"><ix:nonFraction name="alxneuro:LongTermDebtAverageAmountOfOutstanding" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,883,295</ix:nonFraction></span>. ALSF is wholly owned by
Ault Life Sciences, Inc. (&#8220;ALSI&#8221;). ALSI is majority owned by Ault &amp; Company, Inc. (&#8220;Ault &amp; Co.&#8221;). Messrs.
Horne and Nisser, directors of the Company, are also directors of Ault &amp; Co.</p>

</ix:nonNumeric><p id="xdx_814_zLeHkMYgKCHg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p>

<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p>
<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock"><p id="xdx_809_eus-gaap--OtherCurrentAssetsTextBlock_z13daPvwsyI1" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt; text-align: right"><b>5.</b></td><td style="width: 9pt"></td><td style="text-align: justify"><b><span id="xdx_821_zyAIsiFeEDwb">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="alxneuro:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"><p id="xdx_89A_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zn2OLOQrCH2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B4_z51KuO4CVQqd">Prepaid expenses and other
current assets are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220731_zEEriKc63i12" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">July 31, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20210731_zRUzSlvEWXv9" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Prepaid consulting fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">116,667</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">186,667</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PrepaidInsurance_iI_zFyZnmAz1kL" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">451,885</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">155,880</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherPrepaidExpenseCurrent_iI_zv2YIVkopYw2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,577</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,176</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherReceivables_iI_zxv0Z4sdhiRi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other receivables</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,413</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0432">-</span></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssets_iTI_z51oCsa0bG91" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">587,542</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="AsOf2021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">349,723</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zS4qW0Pp78z9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 16, 2022, the
Company purchased D&amp;O insurance for 12 months in the amount of $<span id="xdx_902_ecustom--PrepaidInsurance1_iI_c20220616_zSGd7ckJK2jg" title="Purchase D&amp;O Insurance"><span style="-sec-ix-hidden: xdx2ixbrl0437">492,000.</span></span> Prepaid insurance at July 31, 2022 represented the unamortized
portion of annual premium paid for this policy of $<span id="xdx_901_ecustom--UnamortizedPrepaidExpense_iI_c20220731_zpQqgYHremza" title="Unamortized prepaid expense"><ix:nonFraction name="alxneuro:UnamortizedPrepaidExpense" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">452,000</ix:nonFraction></span>. At July 31, 2022, prepaid consulting fees of $<span id="xdx_905_ecustom--PrepaidConsultingFees_iI_c20220731__us-gaap--RelatedPartyTransactionAxis__custom--SpartanCapitalSecuritiesMember_zo4Ndd27ZBfg" title="Prepaid consulting fees"><ix:nonFraction name="alxneuro:PrepaidConsultingFees" contextRef="AsOf2022-07-31_custom_SpartanCapitalSecuritiesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,000</ix:nonFraction></span> consisted of payments
to Spartan Capital Securities, LLC (&#8220;Spartan Capital&#8221;).</p>

</ix:nonNumeric><p id="xdx_819_zuyRMxt29Yqe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_802_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zt9vFm3kLFja" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><b>6.</b></td><td style="text-align: justify"><b><span id="xdx_824_z1xyv6iqIWkd">STOCK-BASED COMPENSATION</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>2016 Stock Incentive
Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 30, 2016, the Company&#8217;s
stockholders approved the Company&#8217;s 2016 Stock Incentive Plan (the &#8220;Plan&#8221;). The Plan provides for the issuance of a
maximum of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_uShares_c20160430__us-gaap--PlanNameAxis__custom--StockIncentivePlan2016Member_z5YhwQ8NDZ5" title="Number of shares authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2016-04-30_custom_StockIncentivePlan2016Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,500,000</ix:nonFraction></span> shares of Common Stock to be offered to the Company&#8217;s directors, officers, employees, and consultants. On
March 1, 2019, the Company&#8217;s stockholders approved an additional <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pid_uShares_c20160401__20160430__us-gaap--PlanNameAxis__custom--StockIncentivePlan2016Member_zzHsGB9bGQkf" title="Additional number of shares available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2016-04-012016-04-30_custom_StockIncentivePlan2016Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,500,000</ix:nonFraction></span> shares to be available for issuance under the Plan. Options
granted under the Plan have an exercise price equal to or greater than the fair value of the underlying Common Stock at the date of grant
and become exercisable based on a vesting schedule determined at the date of grant. The options expire between five and 10 years from
the date of grant. Restricted stock awards granted under the Plan are subject to a vesting period determined at the date of grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>2021 Stock Incentive
Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2021, the Company&#8217;s
board of directors (the &#8220;Board&#8221;) adopted, and the stockholders approved, the Alzamend Neuro, Inc. 2021 Stock Incentive Plan
(the &#8220;2021 Plan&#8221;). The 2021 Plan authorizes the grant to eligible individuals of (1) stock options (incentive and non-statutory),
(2) restricted stock, (3) stock appreciation rights, or SARs, (4) restricted stock units, and (5) other stock-based compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Stock Subject to the 2021
Plan.</i>&#160;The maximum number of shares of Common Stock that may be issued under the 2021 Plan is 10,000,000 shares, which number
will be increased to the extent that compensation granted under the 2021 Plan is forfeited, expires or is settled for cash (except as
otherwise provided in the 2021 Plan). Substitute awards (awards made or shares issued by the Company in assumption of, or in substitution
or exchange for, awards previously granted, or the right or obligation to make future awards, in each case by a company that the Company
acquires or any subsidiary of the Company or with which the Company or any subsidiary combines) will not reduce the shares authorized
for grant under the 2021 Plan, nor will shares subject to a substitute award be added to the shares available for issuance or transfer
under the 2021 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All options that the Company
grants are granted at the per share fair value on the grant date. Vesting of options differs based on the terms of each option. The Company
has valued the options at their date of grant utilizing the Black-Scholes option pricing model. As of the date of issuance of these options,
there was not an active public market for the Company&#8217;s shares. Accordingly, the fair value of the underlying options was determined
based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other
entities. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an
equivalent term approximating the expected life of the options as calculated using the simplified method. The expected life of the options
used was based on the contractual life of the option granted. Stock-based compensation is a non-cash expense because the Company settles
these obligations by issuing shares of Common Stock from its authorized shares instead of settling such obligations with cash payments.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zIIE8c15LYH3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zFzbIN2U4gFd">A summary of stock option
activity for the three months ended July 31, 2022 is presented below:</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>Outstanding Options</b></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: center; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>Shares <br /> Available <br /> for Grant</b></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>Number of <br /> Shares</b></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>Weighted <br /> Average <br /> Exercise <br /> Price</b></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>Weighted <br /> Average <br /> Remaining <br /> Contractual <br /> Life (years)</b></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>Aggregate Intrinsic <br /> Value</b></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%">Balance at April 30, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pid_uShares_c20220501__20220731_z3FeV4uK1WI9" title="Balance at begining (in shares)" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,800,000</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220501__20220731_zYgncrLDXxs8" title="Balance at begining (in shares)" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,700,000</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220501__20220731_zyGkfNf3PXil" title="Balance at begining" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.20</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dxL_c20220501__20220731_zj0Rm6QuAx0b" title="::XDX::P6Y1M6D" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0456">6.10</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220501__20220731_zGV3ZNgGvpY8" title="Balance at begining" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-04-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,219,700</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted_pid_uShares_c20220501__20220731_zNjyqkCRWKNa" title="Options granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0460">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220501__20220731_zbvDvTrPGwV8" title="Options granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220501__20220731_zj3TQqDY0wm6" title="Options granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0464">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross_pid_uShares_c20220501__20220731_zvsY4c4MmtHd" title="Options exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0466">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220501__20220731_z6Cqz8rAzwr7" title="Options exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0468">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Options expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited_pid_uShares_c20220501__20220731_zgkev0eedOL" title="Options expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0470">-</span></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_uShares_c20220501__20220731_z9YvBOi4Kgj1" title="Options expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-05-01to2022-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,100,000</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">)&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_pid_uUSDPShares_c20220501__20220731_zt1uBEgaOpS8" title="Options expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="From2022-05-01to2022-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at July 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_uShares_c20220501__20220731_z1iv2MSPzCb7" title="Balance at end (in shares)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,800,000</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20220501__20220731_z1IU0bYZqDef" title="Balance at end (in shares)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,600,000</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220501__20220731_zOhuHg3c1BHa" title="Balance at end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.22</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220501__20220731_zeFbb0VWsFX2" title="Balance at end (in shares)::XDX::P5Y9M14D" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0482">5.79</span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20220501__20220731_zb8XrzbhPg66" title="Balance at end" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,777,200</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="4" style="text-align: left; padding-bottom: 2.5pt">Options vested and expected to vest at July 31, 2022</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_uShares_c20220731_zQqUROTgawa5" title="Options vested and expected to vest" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,700,000</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731_zJNA2VD2ZIh3" title="Options vested and expected to vest at end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.23</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dxL_c20220501__20220731_zXZhGTWgVcad" title="Options vested and expected to vest at end::XDX::P6Y4M9D" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0490">6.36</span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20220731_zqSBBt5xFNj9" title="Options vested and expected to vest at end" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,777,200</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options exercisable at July 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20220731_zawlo43xFvTa" title="Options exercisable at end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,514,479</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731_zBlOVfebEIWj" title="Options exercisable at end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.07</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dxL_c20220501__20220731_zBmnJxnHzWhi" title="Options exercisable at end::XDX::P5Y11M26D" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0498">6.03</span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20220731_zRiEnO41IPKa" title="Options exercisable at end" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,777,200</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zcuaMwm16CP1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate intrinsic value
in the table above represents the total pretax intrinsic value (i.e., the difference between the estimated fair value on the respective
date and the exercise price, times the number of shares) that would have been received by the option holders had all option holders exercised
their options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in"><b><i>Stock Options Granted to Employees and Consultants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="alxneuro:ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock"><p id="xdx_892_ecustom--ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock_zY2YBlIAQC3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BF_zWYKRkfgDPY4">The estimated fair value of
stock options granted to employees and consultants during the three months ended July 31, 2021 were calculated using the Black-Scholes
option-pricing model using the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="4" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected term (in years)</td><td>&#160;</td>
    <td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c20220501__20220731__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zYlsYmHJjAuk" title="Expected Term (in years)" style="text-align: center"><span style="-sec-ix-hidden: xdx2ixbrl0504">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210501__20210731__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zeKpX0C9ilbl" title="Expected Term (in years)::XDX::P2Y6M0D"><span style="-sec-ix-hidden: xdx2ixbrl0506">2.50</span></span> &#8211; <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210501__20210731__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zLqA0imhsFR7" title="Expected Term (in years)::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0508">5.00</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 65%">Volatility</td><td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220501__20220731__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zNI3hfZY152" title="Volatility"><span style="-sec-ix-hidden: xdx2ixbrl0510">-</span></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 17%; text-align: center"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210501__20210731__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zWyYbNOLSX1a" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-05-012021-07-31_custom_EmployeesAndConsultantsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">86.31</ix:nonFraction></span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220501__20220731__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zhWUcM51a0F9" title="Risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl0514">-</span></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210501__20210731__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_z4J6dY1Rvf57" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-05-012021-07-31_srt_MinimumMember_custom_EmployeesAndConsultantsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.01</ix:nonFraction></span>%-<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210501__20210731__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zzdRAbMMziB8" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-05-012021-07-31_srt_MaximumMember_custom_EmployeesAndConsultantsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.07</ix:nonFraction></span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220501__20220731_zsUBZBVJvcMd" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0520">-</span></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210501__20210731_zKZGgQaEGZsf" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></span>%</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A2_z5NzlPecmGG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Expected Term:</i>&#160;The
expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method
(based on the mid-point between the vesting date and the end of the contractual term).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Expected Volatility:</i>&#160;The
Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry
that were deemed to be representative of future stock price trends as the Company did not have sufficient trading history for its Common
Stock at July 31, 2022. The Company will continue to apply this process until a sufficient amount of historical information regarding
the volatility of its own stock price becomes available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Risk-Free Interest Rate:</i>&#160;The
Company based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities
with similar maturities as of the date of the grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Expected Dividend:</i>&#160;The
Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock-based compensation to
employees and consultants from stock option grants for the three months ended July 31, 2022 and 2021 were $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20220501__20220731__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvtpRE4ZYyD3" title="Stock-based compensation to employees"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-05-012022-07-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">867,000</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_c20210501__20210731__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAilxE5KcZlk"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-05-012021-07-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">740,000</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Performance Contingent
Stock Options Granted to Employee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2018, the Board
granted <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20181101__20181130__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_z1Mc7egcDj71" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2018-11-012018-11-30_custom_PerformanceContingentStockOptionsMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span> performance-contingent options under the Plan to the Chief Executive Officer. These options have an exercise price of
$<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20181101__20181130__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zsJWUEY6oUfi" title="Exercise price (in dollars per share)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2018-11-012018-11-30_custom_PerformanceContingentStockOptionsMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These options have two separate
performance triggers for vesting based upon the therapies achieving certain Food and Drug Administration (&#8220;FDA&#8221;) approval
milestones within a specified timeframe. By definition, the performance condition in these options can only be achieved after the performance
condition of FDA approval has been achieved. As such, the requisite service period is based on the estimated period over which the market
condition can be achieved. When a performance goal is deemed to be probable of achievement, time-based vesting and recognition of stock-based
compensation expense commences. In the event any of the milestones are not achieved by the specified timelines, such vesting award will
terminate and no longer be exercisable with respect to that portion of the shares. The maximum potential expense associated with the performance-contingent
awards is $<span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_dm_c20220501__20220731__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zoiYgmGmWsK2" title="Maximum potential expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-05-012022-07-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">1.2</ix:nonFraction> million</span> of general and administrative expense if all of the performance conditions are achieved as stated in the option
agreement. Due to the significant risks and uncertainties associated with FDA approvals, as of July 31, 2022, the Company believes that
the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for
these awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 26, 2019, the
Board granted <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20191125__20191126__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KeyEmployeesAndDirectorMember_zEbE1pnPO9pi" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2019-11-252019-11-26_custom_PerformanceContingentStockOptionsMember_custom_KeyEmployeesAndDirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,250,000</ix:nonFraction></span> performance- and market-contingent awards to certain key employees and a director. These grants were made outside
of the Plan. These awards have an exercise price of $1.50 per share. These awards have multiple separate market triggers for vesting based
upon either (i) the successful achievement of stepped target closing prices on a national securities exchange for 90 consecutive trading
days later than 180 days after the Company&#8217;s initial public offering (&#8220;IPO&#8221;) for its Common Stock, or (ii) stepped target
prices for a change in control transaction. The target prices range from $15 per share to $40 per share. <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20191125__20191126__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KeyEmployeesAndDirectorMember_zHkKdCfjVF4c" title="Terms of warrent"><ix:nonNumeric contextRef="From2019-11-252019-11-26_custom_PerformanceContingentStockOptionsMember_custom_KeyEmployeesAndDirectorMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">In the event any of the stock
price milestones are not achieved within three years</ix:nonNumeric></span>, the unvested portion of the performance options will be reduced by 25%. Due to the
significant risks and uncertainties associated with achieving the market-contingent awards, as of July 31, 2022, the Company believes
that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized
for these awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Performance Contingent
Stock Options Granted to TAMM Net</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 23, 2021, the Company
issued performance-based stock options to the certain team members at TAMM Net, Inc. to purchase an aggregate of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20210322__20210323__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KeyEmployeesAndDirectorMember_zZGlKkR32XV2" title="Options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-03-222021-03-23_custom_PerformanceContingentStockOptionsMember_custom_KeyEmployeesAndDirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">450,000</ix:nonFraction></span> shares of Common
Stock at a per share exercise price of $1.50 per share, of which 50% vest upon the completion of Phase I of AL001 by March 31, 2022, and
the remaining 50% vest upon completion of Phase I of AL002 by December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The performance goal of completing
Phase I of AL001 was achieved on March 22, 2022, and the Company recognized stock compensation related to the completion of Phase I of
AL001 over the implied service period to complete this milestone. Due to the significant risks and uncertainties associated with achieving
the completion of Phase I for AL002, as of July 31, 2022, the Company believes that the achievement of the requisite performance conditions
is not probable and, as a result, no compensation cost has been recognized for these awards related to AL002.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Performance Contingent
Stock Options Granted to Consultants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 14, 2021, the Company
issued performance-based stock options to two consultants to purchase an aggregate of 200,000 shares of Common Stock with an exercise
price of $2.42 per share, of which 50,000 vest upon completion of each of the Phase II clinical trials of AL001 for a Bipolar indication,
AL001 for a PTSD indication, AL001 for a depression indication and AL002 for an Alzheimer&#8217;s indication.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of July 31, 2022, the Company
believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been
recognized for these awards related to Phase II of AL001 and AL002.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Stock-Based Compensation
Expense</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_z6eY9f1bMvgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B9_zf1t9hqjOdX4">The Company&#8217;s results
of operations include expenses relating to stock-based compensation for three months ended July 31, 2022 and 2021, that were comprised
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">&#160;Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20220501__20220731__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z9BR1zngADYj" title="Research and development" style="width: 15%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0541">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20210501__20210731__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zbo04MID9r19" title="Research and development" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-05-012021-07-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">141,917</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20220501__20220731__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_znkayglINsj3" title="General and administrative" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-05-012022-07-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">867,338</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20210501__20210731__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z7UFSlnxxObj" title="General and administrative" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-05-012021-07-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">597,705</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: 10pt">&#160;Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220501__20220731_zXJ0mGBJlso6" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-05-01to2022-07-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">867,338</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210501__20210731_zHSrLAD7s2Mi" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-05-012021-07-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">739,622</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zjzUxngSvDy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of July 31, 2022, total
unamortized stock-based compensation expense related to unvested employee and non-employee awards that are expected to vest was $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_dm_uShares_c20220731__us-gaap--IncomeStatementLocationAxis__custom--UnamortizedStockBasedCompensationMember_zjNQbjnzepF2" title="Options vested and expected to vest"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2022-07-31_custom_UnamortizedStockBasedCompensationMember" format="ixt:numdotdecimal" decimals="INF" scale="6" unitRef="Shares">3.7</ix:nonFraction> million</span>.
The weighted-average period over which such stock-based compensation expense will be recognized is approximately <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtxL_c20220501__20220731__us-gaap--IncomeStatementLocationAxis__custom--UnamortizedStockBasedCompensationMember_zOfBUEh8k5B9" title="Weighted-average period vested and expected to vest at end::XDX::P2Y2M12D"><span style="-sec-ix-hidden: xdx2ixbrl0555">2.2</span></span> years.</p>

</ix:nonNumeric><p id="xdx_810_zeK8Aro8brW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b></b></p>
<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="alxneuro:WarrantsDisclosureTextBlock"><p id="xdx_805_ecustom--WarrantsDisclosureTextBlock_zX5kpIKJxDm4" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><b>7.</b></td><td style="text-align: justify"><b><span id="xdx_823_zGhtQHLZgSKe">WARRANTS</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zA8s07XDXMkl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BF_z1dJr0F8R55d">The following table summarizes
information about Common Stock warrants outstanding and exercisable at July 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="14" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Outstanding</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Exercisable</b></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Weighted</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Average</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Weighted</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Weighted</b></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Remaining</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Average</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Average</b></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Exercise</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Number</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Contractual</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Exercise</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Number</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Exercise</b></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Price</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Outstanding</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Life (years)</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Price</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Exercisable</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Price</b></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%">$</td>
    <td style="width: 14%; text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z6c3hqhOSxka" title="Exercse price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-07-31_custom_ExercisePrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zMfm1H51mBX" title="Number warrant outstanding" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-07-31_custom_ExercisePrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z2K7DPB0wuea" title="Weighted average remaining contractual life (years)::XDX::P1Y7M6D" style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0565">1.6</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_98D_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_znMpTRBDE3bk" title="Warrant outstanding, weighted average exercise price (in dollars per share)" style="width: 14%; text-align: right"><ix:nonFraction name="alxneuro:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" contextRef="AsOf2022-07-31_custom_ExercisePrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_986_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_znyZMA6Qwlf" title="Number of warrant exercisable" style="width: 14%; text-align: right"><ix:nonFraction name="alxneuro:ClassOfWarrantOrRightExercisable" contextRef="AsOf2022-07-31_custom_ExercisePrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_988_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zIsqCau88ok3" title="Warrant exercisable, weighted average exercise price (in dollars per share)" style="width: 13%; text-align: right"><ix:nonFraction name="alxneuro:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-07-31_custom_ExercisePrice1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>$</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zJI72zHlPMvi" title="Exercse price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-07-31_custom_ExercisePrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.75</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zx0FfbvTHgX7" title="Number warrant outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-07-31_custom_ExercisePrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">161,342</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zGawpNPyjy78" title="Weighted average remaining contractual life (years)::XDX::P2Y3M19D" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0577">2.3</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zGsLhEt5oFp2" title="Warrant outstanding, weighted average exercise price (in dollars per share)" style="text-align: right"><ix:nonFraction name="alxneuro:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" contextRef="AsOf2022-07-31_custom_ExercisePrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.75</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zERqgRVJ4Od" title="Number of warrant exercisable" style="text-align: right"><ix:nonFraction name="alxneuro:ClassOfWarrantOrRightExercisable" contextRef="AsOf2022-07-31_custom_ExercisePrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">161,342</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98D_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_z0gwdL3UTfW3" title="Warrant exercisable, weighted average exercise price (in dollars per share)" style="text-align: right"><ix:nonFraction name="alxneuro:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-07-31_custom_ExercisePrice2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.75</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_zqvmMztnnAHh" title="Exercse price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-07-31_custom_ExercisePrice3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_z0ekQeMOm1he" title="Number warrant outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-07-31_custom_ExercisePriceFiftySixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,427,196</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_z4djd98mNtwk" title="Weighted average remaining contractual life (years)::XDX::P2Y8M12D" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0589">2.7</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_zCkGHj1FHXRc" title="Warrant outstanding, weighted average exercise price (in dollars per share)" style="text-align: right"><ix:nonFraction name="alxneuro:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" contextRef="AsOf2022-07-31_custom_ExercisePriceFiftySixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_zsXrtR6EzwH4" title="Number of warrant exercisable" style="text-align: right"><ix:nonFraction name="alxneuro:ClassOfWarrantOrRightExercisable" contextRef="AsOf2022-07-31_custom_ExercisePriceFiftySixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,427,196</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_zz1f9yFngWXe" title="Warrant exercisable, weighted average exercise price (in dollars per share)" style="text-align: right"><ix:nonFraction name="alxneuro:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-07-31_custom_ExercisePriceFiftySixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_zE4Tpmn5pHWd" title="Exercse price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-07-31_custom_ExercisePrice4Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.25</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zQxgUdMpQly8" title="Number warrant outstanding" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-07-31_custom_ExercisePriceFiftySevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">61,250</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zSJmIUBqhkce" title="Weighted average remaining contractual life (years)::XDX::P3Y10M25D" style="border-bottom: black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0601">3.9</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td id="xdx_984_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zOyd1700VTk7" title="Warrant outstanding, weighted average exercise price (in dollars per share)" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="alxneuro:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" contextRef="AsOf2022-07-31_custom_ExercisePriceFiftySevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.25</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_982_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zrOSbnjyCzu6" title="Number of warrant exercisable" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="alxneuro:ClassOfWarrantOrRightExercisable" contextRef="AsOf2022-07-31_custom_ExercisePriceFiftySevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">61,250</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td id="xdx_981_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zjWEFKDoFzYf" title="Warrant exercisable, weighted average exercise price (in dollars per share)" style="border-bottom: black 1pt solid; text-align: right"><ix:nonFraction name="alxneuro:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-07-31_custom_ExercisePriceFiftySevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.25</ix:nonFraction></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">$<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member__srt--RangeAxis__srt--MinimumMember_zMW0WoWiKWWf" title="Exercse price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-07-31_custom_ExercisePrice4Member_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> - $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member__srt--RangeAxis__srt--MaximumMember_zm0S1G3iyfg6" title="Exercse price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-07-31_custom_ExercisePrice4Member_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.25</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731_zTmFv0DmSME1" title="Number warrant outstanding" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,149,788</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731_zhvPLCA1MJRl" title="Weighted average remaining contractual life (years)::XDX::P2Y7M6D" style="border-bottom: black 2.25pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0615">2.6</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_989_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731_zOQkaHdYgMna" title="Warrant outstanding, weighted average exercise price (in dollars per share)" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="alxneuro:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.90</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_987_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731_zQcLHY4ZUaF5" title="Number of warrant exercisable" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="alxneuro:ClassOfWarrantOrRightExercisable" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,149,788</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_981_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731_zh0MolRQFQgj" title="Warrant exercisable, weighted average exercise price (in dollars per share)" style="border-bottom: black 2.25pt double; text-align: right"><ix:nonFraction name="alxneuro:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.90</ix:nonFraction></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_zaXr8cONK36c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="alxneuro:ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock"><p id="xdx_89D_ecustom--ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock_zbbMtIAfu7d1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span id="xdx_8B3_zuejyHMYX3s5">The estimated fair value of warrants granted during
the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Expected term (in years)</td><td style="width: 1%">&#160;</td>
    <td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQImOIzcjzd2" title="Expected term (in years)" style="width: 17%; text-align: center"><span style="-sec-ix-hidden: xdx2ixbrl0625">-</span></td><td style="width: 1%">&#160;</td>
    <td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwjO06Eurs6c" title="::XDX::P5Y" style="width: 17%; text-align: center"><span style="-sec-ix-hidden: xdx2ixbrl0626">5.00</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&#160;</td>
    <td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zypgzgImH01k" title="Warrants measurement input" style="text-align: center"><span style="-sec-ix-hidden: xdx2ixbrl0628">-</span></td><td>&#160;</td>
    <td id="xdx_987_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zhiVY4h4qVjg" title="Warrants measurement input" style="text-align: center"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember" format="ixt:numunitdecimalin" decimals="INF" unitRef="N">103.70</ix:nonFraction>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zbAoT8ln8IM4" title="Warrants measurement input" style="text-align: center"><span style="-sec-ix-hidden: xdx2ixbrl0632">-</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zV3jQ2XvrIh8" title="Warrants measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="N">0.27</ix:nonFraction></span>% - <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_ziPVDHLdtEvf" title="Warrants measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="N">0.28</ix:nonFraction></span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zIGdub23qDb3" title="Warrants measurement input" style="text-align: center"><span style="-sec-ix-hidden: xdx2ixbrl0638">-</span></td><td>&#160;</td>
    <td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--MinimumMember_zxnTvqD9M2Bf" title="Warrants measurement input" style="text-align: center"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember_srt_MinimumMember" format="ixt:numunitdecimalin" decimals="INF" unitRef="N">0.0</ix:nonFraction>%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zrYzGKYkc0bd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Expected Term:</i>&#160;The
expected term represents the period that the warrants granted are expected to be outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Expected Volatility:</i>&#160;The
Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry
that were deemed to be representative of future stock price trends as the Company did not have sufficient trading history for its Common
Stock at July 31, 2021. The Company will continue to apply this process until a sufficient amount of historical information regarding
the volatility of its own stock price becomes available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Risk-Free Interest Rate:</i>&#160;The
Company based the risk-free interest rate over the expected term of the warrants based on the constant maturity rate of U.S. Treasury
securities with similar maturities as of the date of the grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Expected Dividend:</i>&#160;The
Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.</p>

</ix:nonNumeric><p id="xdx_814_zlK5FJtFzEdd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zeJtmtZyoMob" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><b>8.</b></td><td style="text-align: justify"><b><span id="xdx_821_ziQTb3OuL0la">OTHER RELATED PARTY TRANSACTIONS</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2021, the Company
entered into a securities purchase agreement with Digital Power Lending, LLC (&#8220;DPL&#8221;) pursuant to which the Company sold an
aggregate of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesOther_uShares_c20210331__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DigitalPowerLendingMember_z0rDBIwJc2nk" title="Number of shares sold (in shares)"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementMember_custom_DigitalPowerLendingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,666,667</ix:nonFraction></span> shares of Common Stock for an aggregate of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueOther_pn6n6_c20210331__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DigitalPowerLendingMember_zKBJrKyqdRNe" title="Number of shares sold"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementMember_custom_DigitalPowerLendingMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">10</ix:nonFraction></span> million, or $1.50 per share, which sales were made in tranches.
On March 9, 2021, <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesOther_uShares_c20210308__20210309__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DigitalPowerLendingMember_zP7D71hzyXg6" title="Description of related party transaction">DPL paid $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2021-03-082021-03-09_custom_SecuritiesPurchaseAgreementMember_custom_DigitalPowerLendingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4</ix:nonFraction> million, less the $1.8 million in prior advances and <span id="xdx_90E_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20210308__20210309__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DigitalPowerLendingMember_zNyOV3iXDwA8" title="Description of related party transaction"><ix:nonNumeric contextRef="From2021-03-082021-03-09_custom_SecuritiesPurchaseAgreementMember_custom_DigitalPowerLendingMember" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">the surrender for cancellation of a $50,000 convertible
promissory note held by BitNile Holdings, Inc. (&#8220;BitNile&#8221;), the parent company of DPL, for an aggregate of 2,666,667 shares
of Common Stock. Under the terms of the securities purchase agreement, DPL (i) purchased an additional 1,333,333 shares of Common Stock
upon approval of the IND for Phase IA clinical trials for AL001 for a purchase price of $2 million, and (ii) purchased 2,666,667 shares
of Common Stock upon the completion of Phase IA clinical trials for AL001 for a purchase price of $4 million.</ix:nonNumeric></span></span> <span id="xdx_90D_eus-gaap--LongTermPurchaseCommitmentMilestones_c20210308__20210309__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DigitalPowerLendingMember_zdE6HV9yJ3Of" title="Description of milestones"><ix:nonNumeric contextRef="From2021-03-082021-03-09_custom_SecuritiesPurchaseAgreementMember_custom_DigitalPowerLendingMember" name="us-gaap:LongTermPurchaseCommitmentMilestones">The Company issued to DPL
warrants to purchase 3,333,333 shares of Common Stock at an exercise price of $3.00 per share. Finally, the Company agreed that for a
period of 18 months following the date of the payment of the final tranche of $4 million, DPL will have the right to invest an additional
$10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million as of
the date of this Quarterly Report.</ix:nonNumeric></span></p>

</ix:nonNumeric><p id="xdx_816_zdZimaK9IAT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b></b></p>
<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zkanNUh1xAQj" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><b>9.</b></td><td style="text-align: justify"><b><span id="xdx_820_zZ51ZDSEGj0a">COMMITMENTS AND CONTINGENCIES</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Contractual Obligations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 1, 2016, the Company
entered into a Standard Exclusive License Agreement for AL002 with Sublicensing Terms with Licensor, pursuant to which Licensor granted
the Company a royalty bearing exclusive worldwide license limited to the field of Alzheimer&#8217;s Immunotherapy and Diagnostics, under
United States Patent No. 8,188,046, entitled &#8220;Amyloid Beta Peptides and Methods of Use,&#8221; filed April&#160;7, 2009 and granted
May 29, 2012.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">There
are certain initial license fees and milestone payments required to be paid by the Company to the Licensor pursuant to the terms of license
agreements. The license agreements for AL002 require the Company to pay royalty payments of&#160;<span id="xdx_908_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._pid_dp_uPure_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember_zuYYu2jVdjH3" title="Percentage of royalty payments on net sales of product"><ix:nonFraction name="alxneuro:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct." contextRef="From2022-05-012022-07-31_custom_AL002LicenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4</ix:nonFraction></span>% on net sales of products developed
from the licensed technology for AL002 while the license agreements for AL001 require that the Company pay combined royalty payments of&#160;<span id="xdx_90D_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._pid_dp_uPure_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zswzgyVAZn3c"><ix:nonFraction name="alxneuro:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct." contextRef="From2022-05-012022-07-31_custom_AL001LicenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.5</ix:nonFraction></span>%
on net sales of products developed from the licensed technology for AL001.&#160;<span id="xdx_904_ecustom--DescriptionOfLicensesAgreements_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zJdrqzHoMiTb" title="Description of licenses agreements"><ix:nonNumeric contextRef="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember" name="alxneuro:DescriptionOfLicensesAgreements">The Company has already paid an initial license fee of
$200,000 for AL002 and an initial license fee of $200,000 for AL001. As an additional licensing fee for the license of AL002, the Licensor
received 3,601,809 shares of common stock. As an additional licensing fee for the license of the AL001 technologies, the Licensor received
2,227,923 shares of common stock. Minimum royalties for AL001 are $25,000 in 2023, $45,000 in 2024 and $70,000 in 2025 and every year
thereafter, for the life of the agreement. Minimum royalties for AL002 are $20,000 in 2022, $40,000 in 2023 and $50,000 in 2024 and every
year thereafter, for the life of the respective agreement.</ix:nonNumeric></span>&#160;Additionally, the Company is required to pay milestone payments on the
due dates to the Licensor for the license of the AL001 technologies and for the AL002 technology, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock"><p id="xdx_895_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zC4M9bZ7vk2f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><span id="xdx_8B9_zGw8l6J7Ii23">Original
AL001 License:</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid"><b>Payment</b></td>
    <td style="text-align: left; white-space: nowrap; vertical-align: middle"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><b>&#160;Due Date</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="border-bottom: black 1pt solid"><b>&#160;Event</b></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 1%">$</td>
    <td id="xdx_98F_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--PreINDMeetingMember_zjPksGXDXy2l" title="Payment" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2022-07-31_custom_AL001LicenseMember_custom_PreINDMeetingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></td>
    <td style="vertical-align: middle; width: 1%; text-align: left"><span id="xdx_F2F_zbSOF11wVTUd" style="font-size: 10pt">*</span></td>
    <td id="xdx_985_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--PreINDMeetingMember_zY1jktkhGQaj" title="Due Date" style="width: 46%"><ix:nonNumeric contextRef="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_PreINDMeetingMember" name="us-gaap:OtherCommitmentsDescription">&#160;Completed September 2019</ix:nonNumeric></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 40%">&#160;Pre-IND meeting</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: middle; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_982_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zjJkpJxz5mze" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2022-07-31_custom_AL001LicenseMember_custom_IndApplicationFilingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">65,000</ix:nonFraction></td>
    <td style="vertical-align: middle; text-align: left"><span id="xdx_F2A_z7X0v1jlCYQb" style="font-size: 10pt">*</span></td>
    <td id="xdx_984_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_znf58gBDm5Gi" title="Due Date"><ix:nonNumeric contextRef="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_IndApplicationFilingMember" name="us-gaap:OtherCommitmentsDescription">&#160;Completed June 2021</ix:nonNumeric></td>
    <td>&#160;</td>
    <td>&#160;IND application filing</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: middle; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_98B_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zroqmNPrjqsj" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2022-07-31_custom_AL001LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">190,000</ix:nonFraction></td>
    <td style="vertical-align: middle; text-align: left"><span id="xdx_F21_za1ODzHwTgW2" style="font-size: 10pt">*</span></td>
    <td id="xdx_985_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zzCLYgSWciN" title="Due Date"><ix:nonNumeric contextRef="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember" name="us-gaap:OtherCommitmentsDescription">&#160;Completed December 2021</ix:nonNumeric></td>
    <td>&#160;</td>
    <td>&#160;Upon first dosing of patient in a clinical trial</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: middle; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_98B_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPatientDosingMember_z0KUOaSBO4o" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2022-07-31_custom_AL001LicenseMember_custom_UponCompletionOfFirstPatientDosingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></td>
    <td style="vertical-align: middle; text-align: left"><span id="xdx_F26_zxJOWjomOu2c" style="font-size: 10pt">*</span></td>
    <td id="xdx_98B_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPatientDosingMember_zrBkyfasuBsi" title="Due Date"><ix:nonNumeric contextRef="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_UponCompletionOfFirstPatientDosingMember" name="us-gaap:OtherCommitmentsDescription">&#160;Completed March 2022</ix:nonNumeric></td>
    <td>&#160;</td>
    <td>&#160;Upon Completion of first clinical trial</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; vertical-align: middle"><span style="font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_988_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_zCKSqqyXl998" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2022-07-31_custom_AL001LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,250,000</ix:nonFraction></td>
    <td style="text-align: left; vertical-align: middle"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_zF44zw4wFwuh" title="Due Date"><ix:nonNumeric contextRef="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember" name="us-gaap:OtherCommitmentsDescription">&#160;12 months from completion of the first Phase II clinical trial</ix:nonNumeric></td>
    <td>&#160;</td>
    <td>&#160;Upon first patient treated in a Phase III clinical trial</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; vertical-align: middle"><span style="font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_986_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_z6Sh2hKlwVx" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2022-07-31_custom_AL001LicenseMember_custom_UponFdaApprovalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,000,000</ix:nonFraction></td>
    <td style="text-align: left; vertical-align: middle"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_z3CnLJGH3Dyh" title="Due Date"><ix:nonNumeric contextRef="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_UponFdaApprovalMember" name="us-gaap:OtherCommitmentsDescription">&#160;8 years from the effective date of the agreement</ix:nonNumeric></td>
    <td>&#160;</td>
    <td>&#160;Upon FDA approval</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td id="xdx_F02_zTGwSVr03vB3" style="width: 47px; text-align: right">*</td>
    <td style="width: 7px">&#160;</td>
    <td id="xdx_F19_zqQop9x9Ve8i" style="text-align: justify"><ix:footnote id="Footnote000686" xml:lang="en-US">Milestone met and completed</ix:footnote></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>&#160;AL002
License:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"><b>Payment</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Due Date</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Event</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%">$</td>
    <td id="xdx_982_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--PreINDMeetingMember_zGzDlXyVxJ34" title="Payment" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2022-07-31_custom_AL002LicenseMember_custom_PreINDMeetingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></td>
    <td style="vertical-align: top; white-space: nowrap; width: 1%; text-align: left">*</td>
    <td id="xdx_98D_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--PreINDMeetingMember_zX6BlkE1pDaa" title="Due Date" style="width: 46%"><ix:nonNumeric contextRef="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_PreINDMeetingMember" name="us-gaap:OtherCommitmentsDescription">Completed January 2022</ix:nonNumeric></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 40%; text-align: justify">&#160;Upon IND application filing</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_987_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zdltbFvp3WWh" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2022-07-31_custom_AL002LicenseMember_custom_IndApplicationFilingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_988_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zTXfq8ACZeWj" title="Due Date"><ix:nonNumeric contextRef="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_IndApplicationFilingMember" name="us-gaap:OtherCommitmentsDescription">12 months from IND application filing date</ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;Upon first dosing of patient in first Phase I clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_981_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zDILv2k8DQLf" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2022-07-31_custom_AL002LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">175,000</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_98C_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zUfFSGpxKuL2" title="Due Date"><ix:nonNumeric contextRef="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember" name="us-gaap:OtherCommitmentsDescription">12 months from first patient dosed in Phase I</ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;Upon completion of first Phase I clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_982_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_zYjuxneHWsic" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2022-07-31_custom_AL002LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_98C_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_z8A6Aqu6xTXe" title="Due Date"><ix:nonNumeric contextRef="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember" name="us-gaap:OtherCommitmentsDescription">24 months from completion of first Phase I clinical trial</ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;Upon completion of first Phase II clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_98C_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember_zkQDPeV7Vuu2" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2022-07-31_custom_AL002LicenseMember_custom_UponFirstPatientTreatedInPhase3ClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,000,000</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_98F_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember_zhQzIoEWxNte" title="Due Date"><ix:nonNumeric contextRef="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_UponFirstPatientTreatedInPhase3ClinicalTrialMember" name="us-gaap:OtherCommitmentsDescription">12 months from completion of the first Phase II clinical trial</ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;Upon first patient treated in a Phase III clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_989_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_zmbtq9N8w5Gf" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2022-07-31_custom_AL002LicenseMember_custom_UponFdaApprovalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,000,000</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_989_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_zIwoWHKEmIU9" title="Due Date"><ix:nonNumeric contextRef="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_UponFdaApprovalMember" name="us-gaap:OtherCommitmentsDescription">7 years from the effective date of the agreement</ix:nonNumeric></td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;Upon FDA BLA approval</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
Company has met the pre-IND meeting, IND application filing, and successfully completed the Phase I clinical trial milestones encompassing
AL001. If the Company fails to meet a milestone by its specified date, the Licensor may terminate the license agreement.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Licensor
was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by the Company
while Licensor remains the owner of any equity securities of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
June&#160;10, 2020, the Company obtained two (2) additional royalty-bearing exclusive worldwide licenses from the Licensor to a therapy
named AL001. One of the additional licenses is for the treatment of neurodegenerative diseases excluding Alzheimer&#8217;s and the other
license is for the treatment of psychiatric diseases and disorders. There are certain license fees and milestone payments required to
be paid pursuant to the terms of the Standard Exclusive License Agreements with Sublicensing Terms, both dated June&#160;10, 2020 and
effective&#160;as of November&#160;1, 2019, with the Licensor and the University of South Florida (the &#8220;June AL001 License Agreements&#8221;).
Under each of the June AL001 License Agreements, a royalty payment of&#160;<span id="xdx_902_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._pid_dp_uPure_c20200501__20200610__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zNNbAyQf2r5f" title="Percentage of royalty payments on net sales of product"><ix:nonFraction name="alxneuro:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct." contextRef="From2020-05-012020-06-10_custom_AdditionalAL001LicenseMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></span>% is required on net sales of products developed from the
licensed technology. For the two (2) additional AL001 licenses, in the aggregate, the Company has paid initial license fees of $<span id="xdx_907_ecustom--InitialLicenseFees_c20200501__20200610__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zC2q1CTKa5Xf" title="Initial license fees"><ix:nonFraction name="alxneuro:InitialLicenseFees" contextRef="From2020-05-012020-06-10_custom_AdditionalAL001LicenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000</ix:nonFraction></span>.
Additionally, under each of the June AL001 License Agreements, the Company is required to pay milestone payments on the due dates to the
Licensor for the license of the technology, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Additional
AL001 Licenses:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"><b>Payment</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Due Date</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Event</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%">$</td>
    <td id="xdx_98E_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zSyt8NPBi1l8" title="Payment" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2022-07-31_custom_AdditionalAL001LicenseMember_custom_IndApplicationFilingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td id="xdx_98E_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zPJNTq6CZuA" title="Due Date" style="width: 47%"><ix:nonNumeric contextRef="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember_custom_IndApplicationFilingMember" name="us-gaap:OtherCommitmentsDescription">Upon IND application filing</ix:nonNumeric></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 38%">&#160;IND application filing</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_98A_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zl1CyYvjPSY8" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,000</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_98D_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zcl1aoueDhsf" title="Due Date"><ix:nonNumeric contextRef="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember" name="us-gaap:OtherCommitmentsDescription">12 months from IND filing date</ix:nonNumeric></td>
    <td>&#160;</td>
    <td>&#160;Upon first dosing of patient in a clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_980_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_z7zMeNxDQmzc" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2022-07-31_custom_AdditionalAL001LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">400,000</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_981_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_zIO8W0mRuTy6" title="Due Date"><ix:nonNumeric contextRef="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember" name="us-gaap:OtherCommitmentsDescription">12 months from first patient dosing</ix:nonNumeric></td>
    <td>&#160;</td>
    <td>&#160;Upon Completion of first clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_985_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember_zOj7P1GfKvdf" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFirstPatientTreatedInPhase3ClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,000,000</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_980_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember_zxE8buiCBtYi" title="Due Date"><ix:nonNumeric contextRef="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFirstPatientTreatedInPhase3ClinicalTrialMember" name="us-gaap:OtherCommitmentsDescription">36 months from completion of the first Phase II clinical trial</ix:nonNumeric></td>
    <td>&#160;</td>
    <td>&#160;Upon first patient treated in a Phase III clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_988_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_zqTtiPVGzRv8" title="Payment" style="text-align: right"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFdaApprovalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,000,000</ix:nonFraction></td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_984_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_zcQ256EItc9g" title="Due Date"><ix:nonNumeric contextRef="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFdaApprovalMember" name="us-gaap:OtherCommitmentsDescription">8 years from the effective date of the agreement</ix:nonNumeric></td>
    <td>&#160;</td>
    <td>&#160;First commercial sale</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AA_zpzXhmb8lA62" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

</ix:nonNumeric><p id="xdx_81B_zQ5mEP2cIROi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zK5UYkg4Cesc" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><b>10.</b></td><td style="text-align: justify"><b><span id="xdx_827_zbILYSsVVV0f">EQUITY TRANSACTIONS</span></b></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company is authorized to issue <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20220131_zb98q96lTl8f" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-01-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span> shares of Preferred Stock $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20220731_zdH8s9cCurY2" title="Preferred stock, par or stated value per share"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-07-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value. The Board has designated <span id="xdx_90C_ecustom--PreferredStockSharesDesignated_iI_pid_uShares_c20220731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z4qJm3OkDB2f" title="Preferred stock shares designated"><ix:nonFraction name="alxneuro:PreferredStockSharesDesignated" contextRef="AsOf2022-07-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,360,000</ix:nonFraction></span> shares as the
Series A Preferred Shares. The rights, preferences, privileges and restrictions on the remaining authorized <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20220731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zicgMKvJeCRg" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-07-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,640,000</ix:nonFraction></span> shares of Preferred
Stock have not been determined. The Board is authorized to create a new series of preferred shares and determine the number of shares,
as well as the rights, preferences, privileges and restrictions granted to or imposed upon any series of preferred shares.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Series A Preferred Shares</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of July 31, 2022, there
were no Series A Preferred Shares or any other shares of Preferred Stock issued or outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 30, 2019, the Company
and ALSF entered into a SPA for the purchase of <span id="xdx_90B_ecustom--NumberOfSharesPurchase_pid_uShares_c20190430__20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_zUM4Aea5YzNb"><ix:nonFraction name="alxneuro:NumberOfSharesPurchase" contextRef="From2019-04-302019-04-30_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span> shares of Common Stock for a total purchase price of $<span id="xdx_906_ecustom--SharesPurchasePrice_c20190430__20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_zwdHAmVT4Hfi" title="Shares purchase price"><ix:nonFraction name="alxneuro:SharesPurchasePrice" contextRef="From2019-04-302019-04-30_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000,000</ix:nonFraction></span>, or $<span id="xdx_90B_ecustom--SharesPurchasePricePerShares_pid_uUSDPShares_c20190430__20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_z9DDDN572Xsg" title="Shares purchase price (in dollars per share)"><ix:nonFraction name="alxneuro:SharesPurchasePricePerShares" contextRef="From2019-04-302019-04-30_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.50</ix:nonFraction></span>
per share with <span id="xdx_90E_ecustom--NumberOfSharesPurchase_pid_uShares_c20190430__20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVVz7zw2rOH7" title="Number of shares purchase"><ix:nonFraction name="alxneuro:NumberOfSharesPurchase" contextRef="From2019-04-302019-04-30_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span> warrants with a <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlNqWrKjQWqi" title="Warrents terms::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0753">5</span></span>-year life and an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_zX1nN7yM4G64" title="Exercise price (in dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-04-30_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></span> per share and vesting upon issuance. The total purchase
price of $<span id="xdx_903_ecustom--SharesPurchasePrice_c20190430__20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_zAZlUunKjwe5" title="Shares purchase price"><ix:nonFraction name="alxneuro:SharesPurchasePrice" contextRef="From2019-04-302019-04-30_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000,000</ix:nonFraction></span> was in the form of a non-interest bearing note receivable with a <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20190430__dei--LegalEntityAxis__custom--ALSFMember_z18T6MJg4wF7" title="Warrant terms::XDX::P12M"><span style="-sec-ix-hidden: xdx2ixbrl0759">12</span></span>-month term from ALSF, a related party. The note
is secured by a pledge of the purchased shares. Pursuant to the SPA, ALSF is entitled to full ratchet anti-dilution protection, most-favored
nation status, denying the Company the right to enter into a variable rate transaction absent its consent, a right to participate in any
future financing the Company may consummate and to have all the shares of Common Stock to which it is entitled under the SPA registered
under the Securities Act within 180 days of the final closing of the IPO. In May 2021, the term of the note receivable was extended to
December 31, 2023. The note is secured by a pledge of the purchased shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2021, the Company
entered into a securities purchase agreement with DPL pursuant to which the Company agreed to sell an aggregate of <span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesNewIssuesOne_pid_uShares_c20210331__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_zy5DFZSu1ao7" title="Number of shares issued"><ix:nonFraction name="alxneuro:StockIssuedDuringPeriodSharesNewIssuesOne" contextRef="From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,666,667</ix:nonFraction></span> shares of
Common Stock for an aggregate of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20210331__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_zNFKWj6VCPC5" title="Proceeds from sale of equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">10</ix:nonFraction></span> million, or $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember_zCaXsWfxZ8oi" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-03-31_custom_SecuritiesPurchaseAgreementsMember_custom_DigitalPowerLendingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.50</ix:nonFraction></span> per share, which sales will be made in tranches. On March 9, 2021, DPL paid $<span id="xdx_905_eus-gaap--ProceedsFromRelatedPartyDebt_pn6n6_c20210331__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember_z2aXmUMZrc0d" title="Proceeds from related party"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementsMember_custom_DigitalPowerLendingMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">4</ix:nonFraction></span>
million, less the $<span id="xdx_905_ecustom--AdvanceFromRelatedParties_dm_c20210331__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember_zkteMakRiUf6" title="Advance from related parties"><ix:nonFraction name="alxneuro:AdvanceFromRelatedParties" contextRef="From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementsMember_custom_DigitalPowerLendingMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">1.8</ix:nonFraction> million</span> in prior advances and the surrender for cancellation of a $<span id="xdx_902_ecustom--SharesValueSurrenderForCancellation_c20210331__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--AultGlobalMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zGMITcUFeNcd" title="Shares value surrender for cancellation"><ix:nonFraction name="alxneuro:SharesValueSurrenderForCancellation" contextRef="From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementsMember_custom_AultGlobalMember_custom_ConvertiblePromissoryNoteMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> convertible promissory note held by BitNile,
for an aggregate of <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesNewIssuesOne_pid_uShares_c20210301__20210309__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--AultGlobalMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zlfqwtjRc5w7" title="Number of shares issued"><ix:nonFraction name="alxneuro:StockIssuedDuringPeriodSharesNewIssuesOne" contextRef="From2021-03-012021-03-09_custom_SecuritiesPurchaseAgreementsMember_custom_AultGlobalMember_custom_ConvertiblePromissoryNoteMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,666,667</ix:nonFraction></span> shares of Common Stock. Under the terms of the securities purchase agreement, <span id="xdx_907_ecustom--DescriptionOfPurchaseAgreementTerms_uShares_c20210301__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember_znJPG0EBILh6" title="Description of purchase agreement terms">DPL (i) purchased an additional
1,333,333 shares of Common Stock upon approval by the FDA of the Company&#8217;s IND for its Phase IA clinical trials for AL001 for a
purchase price of $2 million, and (ii) purchased 2,666,667 shares of Common Stock upon the completion of these Phase IA clinical trials
for AL001 for a purchase price of $4 million. The Company further agreed to issue to DPL warrants to purchase 3,333,333 shares of Common
Stock at an exercise price of $3.00 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finally, the Company
agreed that for a period of 18 months following the date of the payment of the final tranche of $4 million, on April 28, 2022, DPL
will have the right to invest an additional $<span id="xdx_903_ecustom--AdditionalRightToInvest_pn6n6_c20220426__20220428__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember__us-gaap--VestingAxis__custom--FinalTrancheMember_zipEB0892X61" title="Additional right to invest"><ix:nonFraction name="alxneuro:AdditionalRightToInvest" contextRef="From2022-04-262022-04-28_custom_SecuritiesPurchaseAgreementsMember_custom_DigitalPowerLendingMember_custom_FinalTrancheMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">10</ix:nonFraction></span>
million on the same terms, except that no specific milestones have been determined with respect to the additional $<span id="xdx_903_ecustom--AdditionalRightToInvest_pn6n6_c20220426__20220428__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember__us-gaap--VestingAxis__custom--FinalTrancheMember_zMfUOG0sp2i8" title="Additional right to invest"><ix:nonFraction name="alxneuro:AdditionalRightToInvest" contextRef="From2022-04-262022-04-28_custom_SecuritiesPurchaseAgreementsMember_custom_DigitalPowerLendingMember_custom_FinalTrancheMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">10</ix:nonFraction></span>
million as of the date of this Quarterly Report.</p>

</ix:nonNumeric><p id="xdx_813_zO7KWsTMJ4Ef" style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0"></p>

<p style="margin: 0"></p>
<ix:nonNumeric contextRef="From2022-05-01to2022-07-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zoyC9SVl1CS1" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><b>11.</b></td><td style="text-align: justify"><b><span id="xdx_82B_zPkfDZBlRNDi">SUBSEQUENT EVENTS</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has evaluated
subsequent events through the date the financial statements were issued. The Company has determined that there are no such events that
warrant disclosure or recognition in the condensed financial statements presented herein.&#160;</p>

</ix:nonNumeric><p id="xdx_816_z9LGc3NPZKtb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>You should read the following management&#8217;s
discussion and analysis of financial condition and results of operations in conjunction with our unaudited condensed financial statements
and notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q and with our audited financial statements and related
notes thereto and Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report
on Form 10-K, filed with the Securities and Exchange Commission, or the SEC, on July 19, 2022.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTE ABOUT FORWARD-LOOKING STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Quarterly Report on Form 10-Q contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as
amended (the &#8220;Exchange Act&#8221;). This section should be read in conjunction with our unaudited condensed financial statements
and related notes included in Part I, Item 1 of this report. The statements contained in this report that are not purely historical are
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange
Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These statements relate to future events or our
future financial performance. We have attempted to identify forward-looking statements by terminology including &#8220;anticipates,&#8221;
&#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221;
&#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221;
&#8220;should&#8221; or &#8220;will&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions;
uncertainties and other factors may cause our actual results, levels of activity, performance or achievements to be materially different
from any future results, levels or activity, performance or achievements expressed or implied by these forward-looking statements. Although
we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels
of activity, performance or achievements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In this Quarterly Report,
unless the context requires otherwise, references to the &#8220;Company,&#8221; &#8220;Alzamend,&#8221; &#8220;we,&#8221; &#8220;our company&#8221;
and &#8220;us&#8221; refer to Alzamend Neuro, Inc., a Delaware corporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated on February
26, 2016, as Alzamend Neuro, Inc. under the laws of the State of Delaware. We were formed to acquire and commercialize patented intellectual
property and know-how to prevent, treat and potentially cure the crippling and deadly Alzheimer&#8217;s. Existing Alzheimer&#8217;s treatments
only temporarily relieve symptoms but do not slow or halt the underlying worsening of the disease. We have developed a novel approach
in an attempt to combat Alzheimer&#8217;s through immunotherapy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Accounting Policies and Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Research and Development
Expenses</i>.&#160;</b>Research and development costs are expensed as incurred. Research and development costs consist of scientific consulting
fees and lab supplies, as well as fees paid to other entities that conduct certain research and development activities on behalf of our
company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acquired and may continue
to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license,
product or rights, as well as any future milestone payments, are immediately recognized as research and development expense provided that
there is no alternative future use of the rights in other research and development projects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Stock-Based Compensation.&#160;</i></b>We
maintain a stock-based compensation plan as a long-term incentive for employees, non-employee directors and consultants. The plan allows
for the issuance of incentive stock options, non-qualified stock options, restricted stock units, and other forms of equity awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognize stock-based compensation
expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they occur. Our stock-based
compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the
extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement
of any such performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Black-Scholes option pricing
model utilizes inputs which are highly subjective assumptions and generally require significant judgment. These assumptions include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><b><i>Fair Value of Common Stock.</i></b>&#160;See the subsection titled &#8220;Common Stock Valuations&#8221;
below.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><b><i>Risk-Free Interest Rate.</i></b>&#160;The risk-free interest rate is based on the U.S. Treasury
zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><b><i>Expected Volatility.</i></b>&#160;Because we do not have a sufficient trading history for our common
stock (&#8220;Common Stock&#8221;), the expected volatility was estimated based on the average volatility for comparable publicly traded
life sciences companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based
on the similar size, stage in life cycle or area of specialty. We will continue to apply this process until a sufficient amount of historical
information regarding the volatility of our own stock price becomes available.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><b><i>Expected Term.</i></b>&#160;The expected term represents the period that the stock-based awards
are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the
end of the contractual term), as we do not have sufficient historical data to use any other method to estimate expected term.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify"><b><i>Expected Dividend Yield.</i></b>&#160;We have never paid dividends on our Common Stock and have
no plans to pay dividends on our Common Stock. Therefore, we used an expected dividend yield of zero.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of such assumptions
involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and we
use significantly different assumptions or estimates, our stock-based compensation could be materially different.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Common Stock Valuations.&#160;</i></b>Prior
to our initial public offering (&#8220;IPO&#8221;) in June 2021, there was no public market for our Common Stock, and, as a result, the
fair value of the shares of Common Stock underlying our stock-based awards was estimated on each grant date by our Board. To determine
the fair value of our Common Stock underlying option grants, our Board considered, among other things, input from management, and our
Board&#8217;s assessment of additional objective and subjective factors that it believed were relevant, and factors that may have changed
from the date of the most recent valuation through the date of the grant. These factors included, but were not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">our results of operations and financial position, including our levels of available capital resources;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">our stage of development and material risks related to our business;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">progress of our research and development activities;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">our business conditions and projections;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as
recently completed mergers and acquisitions of peer companies;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the lack of marketability of our Common Stock as a private company;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the prices at which we sold shares of our Common Stock to outside investors in arms-length transactions;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the likelihood of achieving a liquidity event for our security holders, such as an IPO or a sale of our
company, given prevailing market conditions;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">trends and developments in our industry; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">external market conditions affecting the life sciences and biotechnology industry sectors.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the closing of our
IPO, our Board determined the fair market value of our Common Stock based on the closing price of our Common Stock as reported on the
date of grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Plan of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
plan of operations is currently focused on the development of both our therapeutic candidates which are at different stages of development.
We submitted an Investigational New Drug (&#8220;IND&#8221;) application for AL001 to the FDA on June 30, 2021. On July 28, 2021, we announced
receipt of FDA &#8220;Study May Proceed&#8221; letter for a Phase I study under our IND application for AL001, a lithium-based ionic cocrystal
oral therapy for patients with dementia related to mild, moderate, and severe cognitive impairment associated with Alzheimer&#8217;s.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On August 17, 2021, we
announced that we have contracted Altasciences Clinical Kansas (&#8220;Altasciences&#8221;) to conduct a six-month Phase I relative bioavailability
study for AL001 for dementia related to Alzheimer&#8217;s beginning in September 2021. The Phase I first-in-human study is for the purpose
of determining potential clinically safe and appropriate dosing for AL001 in future studies. The Phase I study will investigate the pharmacokinetics
(the movement of drug through the body) of lithium following a single dose of AL001 (the &#8220;study drug&#8221;) compared to a typical
single dose of a marketed 300 mg immediate-release lithium carbonate capsule (the &#8220;comparator&#8221; &#8211; currently indicated
to treat mood disorders) in healthy male and female subjects. The lithium and salicylate components of AL001 will be given within the
amounts already approved for use in patients. The purpose of the research study is to test the safety, tolerability, and bioavailability
(how much and when drug gets in the body) of the study drug, AL001, compared to the currently marketed formulation of the comparator,
lithium carbonate. This is expected to ascertain what AL001 doses should be given, and how often, in subsequent Phase 2 safety and efficacy
trials involving Alzheimer&#8217;s patients. At least 24 healthy male and female human subjects will complete the Phase I trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
September 13, 2021, we announced that the first group of healthy participants have been dosed in a six-month Phase I relative bioavailability
study for AL001 for dementia related to Alzheimer&#8217;s. A full report of the Phase I first-in-human study was completed in March 2022.
The Phase I study is for the purpose of determining potential clinically safe and appropriate dosing for AL001 in a planned Phase 2 multiple
ascending dose study. AL001 is a lithium-delivering ionic cocrystal under development as an oral treatment for patients with dementia
related to mild, moderate, and severe cognitive impairment associated with Alzheimer&#8217;s.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We have an additional preclinical
candidate for Alzheimer&#8217;s, AL002, which has transitioned from early-stage development to an extensive program of preclinical study
and evaluation, which was completed on May 31, 2021, and was followed by a comprehensive report prepared by Charles River Laboratories,
Inc., an independent preclinical service provider, received on July 23, 2021. Our preclinical program included a toxicologic evaluation,
histopathology study and brain beta amyloid analysis and was expanded to include an immunoglobulin analysis and biodistribution study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 30, 2021, we announced
that we submitted a pre-IND meeting request for AL002 and supporting briefing documents to the Center for Biological Evaluation and Research
of the FDA. On September 30, 2021, we announced that we have received a written response to our meeting request relating to our Type B
Pre-IND application from the FDA providing a path for our planned clinical development of AL002. AL002 is a patented method using a mutant-peptide
sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient&#8217;s immunological system to combat
Alzheimer&#8217;s. Preclinical work supports AL002 being associated with a positive anti-inflammatory response and a decrease in brain
amyloid contents. Based on AL002&#8217;s positive toxicology results, the biologic nature of this product and the urgent need to deliver
treatments for Alzheimer&#8217;s to patients, we proposed, and the FDA agreed, to conduct a combined Phase I/II study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recently announced
that the FDA&#8217;s agreement to us conducting a combined Phase I/II study, together with our process to identify the right manufacturing
partner to provide our study drug materials for the Phase I/II study, has extended the timeline for when we anticipate filing the IND,
which is now expected to be done in the third calendar quarter of 2022, and we plan to initiate the clinical trial of AL002 as soon as
possible after the approval of the IND by the FDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During Phase I first-in-human
trial, participants received a single dose of AL001 containing lithium in an amount equivalent to 150 mg lithium carbonate; this is the
dose proposed by the inventors as likely appropriate for Alzheimer&#8217;s treatment when given three times daily (&#8220;TID&#8221;).
Currently, marketed immediate-release lithium carbonate 300 mg are given TID; for example, lithium carbonate 300 mg TID is a dose commonly
used for bipolar affective disorders. It can be difficult to set the appropriate dose of lithium carbonate and other lithium products
due to the small margin between effective and toxic blood levels and to avoid side effects or inadequate treatment outcomes. We see the
possibility of providing the benefits from lithium at up to 50% of the currently approved lithium carbonate dosage, with the potential
for better outcomes and with elimination of the need for lithium therapeutic drug monitoring. Moreover, the data confirms AL001&#8217;s
potential as a replacement of the current lithium-based treatments and may provide a treatment for over 40 million Americans suffering
from Alzheimer&#8217;s and other neurodegenerative diseases and psychiatric disorders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Such findings may allow us
to design a development program that will potentially reduce the amount of new data generated to support approval. Bioequivalence may
have utility for AL001 when seeking approval for the indications of currently marketed lithium products, and for new indications as a
benchmark for safety. Given the systemic pharmacokinetic similarity to marketed immediate-release lithium carbonate products, AL001 may
be dosed TID in the planned Phase II study, a multiple ascending dose safety study in Alzheimer&#8217;s patients. In addition, we are
pursuing investigational new drug applications with the FDA for bipolar disorder, MDD, and PTSD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 4, 2022, we announced
the appointment of Dr. Terri Hunter, Ph.D., a Technology Transfer Specialist, to our Scientific Advisory Board. During her tenure at the
University of South Florida, Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend&#8217;s two product
candidates, AL001 and AL002.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 11, 2022, we announced
that we have contracted with Altasciences and iResearch Atlanta, LLC (&#8220;iResearch&#8221;) to manage and conduct, respectively, our
Phase IIA multiple ascending dose (&#8220;MAD&#8221;) study in patients with mild to moderate Alzheimer&#8217;s. The Phase IIA study,
which commenced enrollment in May 2022, is for the purposes of evaluating the safety and tolerability of AL001 under multiple dose, steady-state
conditions, and to determine the maximum tolerated dose in patients with mild to moderate Alzheimer&#8217;s.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 28, 2022, we announced
that Digital Power Lending, LLC (&#8220;DPL&#8221;) has made an additional investment in our company. On March 28, 2022, we announced
receipt of the full data set from Phase I clinical trial for AL001. Based on the achievement of this milestone, under the March 12, 2021,
securities purchase agreement, we sold an additional 2,666,667 shares of Common Stock to DPL for $4 million, or $1.50 per share, and issued
to DPL warrants to acquire 1,333,333 shares of Common Stock with an exercise price of $3.00 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 5, 2022, we announced
that the first patient with mild to moderate Alzheimer&#8217;s has been dosed in a 12-month Phase IIA MAD study for dementia related to
Alzheimer&#8217;s. The Phase IIA study will evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions
and determine the maximum tolerated dose in patients diagnosed with mild to moderate Alzheimer&#8217;s. Lithium has been well characterized
for safety and is approved/marketed in multiple formulations for bipolar affective disorders. Lithium dosing for the MAD cohorts is based
on a fraction of the usual dose for treatment of bipolar affective disorder (i.e., AL001 lithium content at a lithium carbonate equivalent
of 300 mg TID, daily total of 900 mg), with the target dose for Alzheimer&#8217;s treatment at half of that lithium carbonate equivalent
value (150 mg TID, daily total of 450 mg). In each cohort, consisting of six active and two placebo patients (as per randomization), multiple
ascending doses will be administered TID for 14 days under fasted conditions (at least 1 hour before or 4 hours after meals) up to tolerability/safety
limits. The lithium and salicylate components of AL001 will be given within the amounts already approved for use in patients. Up to 40
subjects will complete the Phase IIA trial. The maximum tolerated dose will then be used for further studies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 17, 2022, we announced
that we have submitted a Pre-IND meeting request for AL001 and supporting briefing documents to the FDA for the treatment of bipolar disorder,
MDD and PTSD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The continuation of our current
plan of operations with respect to completing our IND application and beginning the series of human clinical trials for each of our therapeutics
requires us to raise additional capital to fund our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because our working capital
requirements depend upon numerous factors, including the progress of our preclinical and clinical testing, timing and cost of obtaining
regulatory approvals, changes in levels of resources that we devote to the development of manufacturing and marketing capabilities, competitive
and technological advances, status of competitors, and our ability to establish collaborative arrangements with other organizations, we
will require additional financing to fund future operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span style="text-decoration: underline">Results of Operations for the Three Months Ended July 31,
2022 and 2021</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
the results of our operations for the three months ended July 31, 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">$ Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font-weight: bold; text-align: left">&#160;OPERATING EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; width: 40%; text-align: left">&#160;Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,375,953</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">916,408</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">459,545</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">50</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: left; padding-bottom: 1pt">&#160;General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,659,589</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,389,831</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">269,758</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">19</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; text-align: left; padding-bottom: 1pt; text-indent: 10pt">&#160;Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,035,542</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,306,239</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">729,303</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">32</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font-weight: bold; text-align: left">&#160;Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,035,542</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,306,239</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(729,303</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font-weight: bold; text-align: left">&#160;OTHER EXPENSE, NET</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; text-align: left; padding-bottom: 1pt">&#160;Interest expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,532</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(13,628</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">12,096</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">-89</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font-weight: bold; text-align: left; padding-bottom: 1pt">&#160;Total other expense, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,532</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(13,628</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">12,096</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">-89</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;NET LOSS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,037,074</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,319,867</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(717,207</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">31</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;Basic and diluted net loss per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.03</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.03</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.00</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">*</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;Basic and diluted weighted average common&#160;shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">97,481,790</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">77,338,492</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">*</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: left">&#160;* Not meaningful</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenue</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were formed on February 26, 2016, to acquire and commercialize patented
intellectual property and know-how to prevent, treat and cure the crippling and deadly disease, Alzheimer&#8217;s. We currently have only
two product candidates, AL001 and AL002. These products are in the early clinical stage of development and will require extensive clinical
study, review and evaluation, regulatory review and approval, significant marketing efforts and substantial investment before either or
both of them, or any respective successors, will provide us with any revenue. We did not generate any revenues during the three months
ended July 31, 2022 and 2021, and we do not anticipate that we will generate revenue for the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General and Administrative Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative expenses for the three months ended July
31, 2022 and 2021 were $1.7 million and $1.4 million, respectively. As reflected in the table below, general and administrative expenses
primarily consisted of the following expense categories: stock-based compensation expense; professional fees; insurance; as well as salaries
and benefits. For the three months ended July 31, 2022 and 2021, the remaining general and administrative expenses of $83,000 and $232,000,
respectively, primarily consisted of payments for filing fees, transfer agent fees, license fees, travel, and other office expenses, none
of which is significant individually.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">$ Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">&#160;Stock-based compensation expense</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">867,338</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">597,705</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">269,633</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">45</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">243,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,122</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(56,722</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-19</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">196,427</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">124,994</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;Salary and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">223,777</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">188,809</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,968</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;Licenses and fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,461</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,461</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;Board of director fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">&#160;Other general and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">82,686</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">231,762</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(149,076</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">-64</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 20pt">Total general and administrative expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,659,589</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,389,831</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">269,758</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">19</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">*Not meaningful</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock-Based Compensation Expense</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
July 31, 2022 and 2021, we incurred general and administrative stock-based compensation expense of $867,000 and $598,000, respectively, related
to stock option grants to executives, employees and consultants as well as shares issued for services to Spartan Capital Securities, LLC
(&#8220;Spartan Capital&#8221;). All option grants are granted at the per share fair value on the grant date. Vesting of options differs
based on the terms of each option. We valued the options at their date of grant utilizing the Black-Scholes option pricing model. We valued
the shares issued for services at their intrinsic value on the date of issuance. Stock-based compensation is a non-cash expense because
we settle these obligations by issuing shares of Common Stock from authorized shares instead of settling such obligations with cash payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Professional Fees</i>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The second largest component
of our general and administrative expenses is professional fees. During the three months ended July 31, 2022 and 2021, we reported professional
fees of $243,000 and $300,000, respectively, which were principally comprised of the following items:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Three Months Ended July 31, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36pt"></td><td style="width: 22.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">In June 2017, we entered into a five-year consulting agreement with Spartan Capital pursuant to which
Spartan Capital agreed to provide consulting services with respect to general corporate matters. In December 2017, we paid to Spartan
Capital a consulting fee of $1.4&#160;million for the services to be rendered over the 60-month term of this consulting agreement. During
the three months ended July 31, 2022, we recorded an expense of $70,000 as a result of this consulting agreement.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36pt"></td><td style="width: 22.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">During the three months ended July 31, 2022, we incurred $80,000 in audit fees, $24,000 in tax preparation
fees, $23,000 in Sarbanes-Oxley compliance fees and $13,000 in related party consulting.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Three Months Ended July 31, 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36pt"></td><td style="width: 22.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">During the three months ended July 31, 2021, we recorded an expense of $70,000 in connection with the
five-year consulting agreement with Spartan Capital.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36pt"></td><td style="width: 22.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">During the three months ended July 31, 2021, we incurred $29,000 in legal fees.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36pt"></td><td style="width: 22.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">During the three months ended July 31, 2021, we incurred $79,000 in audit fees.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Salaries and Benefits</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
July 31, 2022 and 2021, we incurred $224,000 and $189,000, respectively, in employee-related expenses. As of July 31, 2022, we had four
full-time and four part-time employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Henry
C.W. Nisser, our Executive Vice President and General Counsel, Kenneth S. Cragun, our Senior Vice President of Finance, and David J. Katzoff,
our Chief Financial Officer, work for us on a part-time basis. Mr. Katzoff, as a result of his recent appointment as our Chief Financial
Officer, will spend no less than an average of 28 hours per week on our company&#8217;s business. Mr. Nisser spends no less than an average
of 8 hours per week on our company&#8217;s business and Mr. Cragun spends no less than an average of 10 hours per week on our company&#8217;s
business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses for the three months ended July 31,
2022 and 2021 were $1.4 million and $916,000, respectively. As reflected in the table below, research and development expenses primarily
consisted of professional fees, licenses and fees, as well as stock-based compensation expense.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">$ Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">&#160;Professional fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,216,672</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">704,692</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">511,980</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">73</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;Licenses and fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,542</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(61,788</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-95</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">141,914</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(141,917</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;Other research and development expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">155,739</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,472</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">151,270</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">3,383</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 20pt">&#160;Total research and development expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,375,953</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">916,408</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">459,545</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">50</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">*Not meaningful</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Professional Fees</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
July 31, 2022 and 2021, we reported professional fees of $1.2 million and $705,000, respectively, which were principally comprised of
professional fees attributed to various types of scientific services, including FDA consulting services. The increase relates to professional
fees incurred related to Phase IIA clinical trial monitoring AL001 and IND preparation for AL002.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Licenses and Fees</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are certain initial
license fees and milestone payments required to be paid to the University of South Florida and the Licensor, for the licenses of the technologies,
pursuant to the terms of the License Agreement with Sublicensing Terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Stock-Based Compensation Expense</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
July 31, 2022 and 2021, we incurred zero and $142,000, respectively, in research and development stock compensation expense related to
stock option grants to consultants. All option grants are granted at the per share fair value on the grant date. Vesting of options differs
based on the terms of each option. We valued the options at their date of grant utilizing the Black-Scholes option pricing model. Stock-based
compensation is a non-cash expense because we settle these obligations by issuing shares of Common Stock from authorized shares instead
of settling such obligations with cash payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Expense, Net</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Interest Expense</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interest expense was $2,000
for the three months ended July 31, 2022, primarily related to financing of D&amp;O insurance.<i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying financial
statements have been prepared on the basis that our company will continue as a going concern. As of July 31, 2022, we had cash of $11.5
million and an accumulated deficit of $32.2 million. We have incurred recurring losses and reported losses for the three months ended
July 31, 2022 totaling $3.0 million. In the past, we have financed our operations principally through issuances of promissory notes and
equity securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March of 2021, we entered
into a securities purchase agreement with DPL, pursuant to which we sold an aggregate of 6,666,667 shares of Common Stock for an aggregate
of $10 million, or $1.50 per share, which sales were made in tranches. On March 9, 2021, DPL paid $4 million, less the $1.8 million in
prior advances and the surrender for cancellation of the $50,000 convertible promissory note, previously issued to BitNile Holdings, Inc.,
the parent company of DPL, for an aggregate of 2,666,667 shares of Common Stock. Under the terms of the securities purchase agreement,
DPL (i) purchased, in July 2021, an additional 1,333,333 shares of Common Stock upon FDA approval of our IND for our Phase IA clinical
trials for AL001 for a purchase price of $2 million, and (ii) purchased, in April 2022, 2,666,667 shares of Common Stock upon completion
of our Phase IA clinical trials for AL001 for a purchase price of $4 million. We issued DPL warrants to purchase 3,333,333 shares of Common
Stock at an exercise price of $3.00 per share. Finally, we agreed that for a period of eighteen months following the date of the payment
of the final tranche of $4 million, DPL will have the right to invest an additional $10 million on the same terms, except that no specific
milestones have been determined with respect to the additional $10 million as of the date of this Quarterly Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will need to obtain substantial
additional funding in the future for our clinical development activities and continuing operations. If we are unable to raise capital
when needed or on favorable terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization
efforts. Our future capital requirements will depend on many factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">successful enrollment in, and completion of, clinical trials;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">our ability to establish agreements with third-party manufacturers for clinical supply for our clinical
trials and, if our product candidates are approved, commercial manufacturing;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">our ability to maintain our current research and development programs and establish new research and development
programs;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">addition and retention of key research and development personnel;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">our efforts to enhance operational, financial, and information management systems, and hire additional
personnel, including personnel to support development of our product candidates;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter
and performing our obligations in such collaborations;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the timing and amount of milestone and other payments we may receive under our collaboration arrangements;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">our eventual commercialization plans for our product candidates;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the costs involved in prosecuting, defending, and enforcing patent claims and other intellectual property
claims; and</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the costs and timing of regulatory approvals.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A change in the outcome of
any of these or other variables with respect to the development of any of our product candidates could significantly change the costs
and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we
may need additional funds to meet operational needs and capital requirements associated with such operating plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to continue to incur losses for the foreseeable future and
need to raise additional capital until we are able to generate revenues from operations sufficient to fund our development and commercial
operations. However, based on our current business plan, we believe that our cash at July 31, 2022, is sufficient to meet our anticipated
cash requirements during the twelve-month period subsequent to the issuance of the financial statements included in this Quarterly Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cash Flows</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes our cash flows for
the three months ended July 31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash provided by (used in):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; width: 64%; text-align: left">Operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(2,536,690</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(1,222,664</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9pt; text-align: left; padding-bottom: 1pt">Financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">14,911,556</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net increase (decrease) in cash </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,536,690</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,688,892</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Operating Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended July 31, 2022, net cash used in operating
activities was $2.5 million. This consisted primarily of a net loss of $3.0 million and a decrease in our net operating assets and liabilities
of $374,000, partially offset by non-cash charges of $874,000. The non-cash charges primarily consisted of stock-based compensation expense.
The decrease in our net operating assets and liabilities were due to a decrease in accounts payable and accrued liabilities and an increase
in prepaid expenses and other current assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Investing Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no investing activities
for the three months ended July 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Financing Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There were no financing activities for the three
months ended July 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Contractual Obligations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
May 1, 2016, we entered into a Standard Exclusive License Agreement for AL002 with Sublicensing Terms with the University of South Florida
Research Foundation, Inc., as licensor (the &#8220;Licensor&#8221;), pursuant to which the Licensor granted us a royalty bearing exclusive
worldwide license limited to the field of Alzheimer&#8217;s Immunotherapy and Diagnostics, under United States Patent No. 8,188,046, entitled
&#8220;Amyloid Beta Peptides and Methods of Use,&#8221; filed April&#160;7, 2009 and granted May 29, 2012.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">There
are certain initial license fees and milestone payments required to be paid by us to the Licensor, pursuant to the terms of license agreements
we have entered into with the Licensor. The license agreements for AL002 require us to pay royalty payments of 4% on net sales of products
developed from the licensed technology for AL002 while the license agreements for AL001 require that we pay combined royalty payments
of 4.5% on net sales of products developed from the licensed technology for AL001. We have already paid an initial license fee of $200,000
for AL002 and an initial license fee of $200,000 for AL001. As an additional licensing fee for the license of AL002, the Licensor received
3,601,809 shares of our common stock. As an additional licensing fee for the license of the AL001 technologies, the Licensor received
2,227,923 shares of our common stock. Minimum royalties for AL001 are $25,000 in 2023, $45,000 in 2024 and $70,000 in 2025 and every year
thereafter, for the life of the agreement. Minimum royalties for AL002 are $20,000 in 2022, $40,000 in 2023 and $50,000 in 2024 and every
year thereafter, for the life of the respective agreement. Additionally, we are required to pay milestone payments on the due dates to
the Licensor for the license of the AL001 technologies and for the AL002 technology, as follows:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Original AL001
License:</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid"><b>Payment</b></td>
    <td style="text-align: left; white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid"><b>&#160;Due Date</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="border-bottom: black 1pt solid"><b>&#160;Event</b></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 1%">$</td>
    <td style="width: 12%; text-align: right">50,000</td>
    <td style="vertical-align: top; width: 1%; text-align: left">*</td>
    <td style="width: 47%">Completed September 2019</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 38%">Pre-IND meeting</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>$</td>
    <td style="text-align: right">65,000</td>
    <td style="vertical-align: top; text-align: left">*</td>
    <td>Completed June 2021</td>
    <td>&#160;</td>
    <td>&#160;ND application filing</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>$</td>
    <td style="text-align: right">190,000</td>
    <td style="vertical-align: top; text-align: left">*</td>
    <td>Completed December 2021</td>
    <td>&#160;</td>
    <td>Upon first dosing of patient in a clinical trial</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>$</td>
    <td style="text-align: right">500,000</td>
    <td style="vertical-align: top; text-align: left">*</td>
    <td>Completed March 2022</td>
    <td>&#160;</td>
    <td>Upon Completion of first clinical trial</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>$</td>
    <td style="text-align: right">1,250,000</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>12 months from completion of the first Phase II clinical trial</td>
    <td>&#160;</td>
    <td>Upon first patient treated in a Phase III clinical trial</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>$</td>
    <td style="text-align: right">10,000,000</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>8 years from the effective date of the agreement</td>
    <td>&#160;</td>
    <td>Upon FDA approval</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">*Milestone met and completed&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>AL002 License:</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"><b>Payment</b></td>
    <td style="text-align: left; white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Due Date</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Event</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; width: 1%">$</td>
    <td style="white-space: nowrap; width: 12%; text-align: right">50,000</td>
    <td style="vertical-align: top; width: 1%; text-align: left">*</td>
    <td style="width: 45%">Upon IND application filing</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 40%">&#160;Upon IND application filing</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">$</td>
    <td style="white-space: nowrap; text-align: right">50,000</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>12 months from IND application filing date</td>
    <td>&#160;</td>
    <td>&#160;Upon first dosing of patient in first Phase I clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">$</td>
    <td style="white-space: nowrap; text-align: right">175,000</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>12 months from first patient dosed in Phase I</td>
    <td>&#160;</td>
    <td>&#160;Upon completion of first Phase I clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">$</td>
    <td style="white-space: nowrap; text-align: right">500,000</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>24 months from completion of first Phase I clinical trial</td>
    <td>&#160;</td>
    <td>&#160;Upon completion of first Phase II clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">$</td>
    <td style="white-space: nowrap; text-align: right">1,000,000</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>12 months from completion of the first Phase II clinical trial</td>
    <td>&#160;</td>
    <td>&#160;Upon first patient treated in a Phase III clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: right">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">$</td>
    <td style="white-space: nowrap; text-align: right">10,000,000</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>7 years from the effective date of the agreement</td>
    <td>&#160;</td>
    <td>&#160;Upon FDA BLA approval</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">*Milestone met and completed&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have met the pre-IND meeting, IND application filing, and successfully completed the Phase I clinical trial milestones encompassing AL001.
If we fail to meet a milestone by its specified date, Licensor may terminate the license agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Licensor was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by
us while the Licensor remains the owner of any equity securities of our company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">On
June&#160;10, 2020, we obtained two (2) additional royalty-bearing exclusive worldwide licenses from the Licensor to a therapy named AL001.
One of the additional licenses is for the treatment of neurodegenerative diseases excluding Alzheimer&#8217;s and the other license is
for the treatment of psychiatric diseases and disorders. There are certain license fees and milestone payments required to be paid pursuant
to the terms of the Standard Exclusive License Agreements with Sublicensing Terms, both dated June&#160;10, 2020 and effective&#160;as
of November&#160;1, 2019, with the Licensor and the University of South Florida (the &#8220;June AL001 License Agreements&#8221;). Under
each of the June AL001 License Agreements, a royalty payment of&#160;3% is required on net sales of products developed from the licensed
technology. For the two (2) additional AL001 licenses, in the aggregate, we have paid initial license fees of $20,000. Additionally, under
each of the June AL001 License Agreements, we are required to pay milestone payments on the due dates to the Licensor for the license
of the technology, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Additional AL001
Licenses:</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"><b>Payment</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Due Date</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Event</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%">$</td>
    <td style="width: 12%; text-align: right">50,000</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 47%">&#160;Upon IND application filing</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 38%">&#160;IND application filing</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$</td>
    <td style="text-align: right">150,000</td>
    <td>&#160;</td>
    <td>&#160;12 months from IND filing date</td>
    <td>&#160;</td>
    <td>&#160;Upon first dosing of patient in a clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$</td>
    <td style="text-align: right">400,000</td>
    <td>&#160;</td>
    <td>&#160;12 months from first patient dosing</td>
    <td>&#160;</td>
    <td>&#160;Upon Completion of first clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$</td>
    <td style="text-align: right">1,000,000</td>
    <td>&#160;</td>
    <td>&#160;36 months from completion of the first Phase II clinical trial</td>
    <td>&#160;</td>
    <td>&#160;Upon first patient treated in a Phase III clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$</td>
    <td style="text-align: right">8,000,000</td>
    <td>&#160;</td>
    <td>&#160;8 years from the effective date of the agreement</td>
    <td>&#160;</td>
    <td>&#160;First commercial sale</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have any off-balance
sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial
condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Accounting Standards</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For information about recent
accounting pronouncements that may impact our financial statements, please refer to Note 3 of the Notes to Unaudited Condensed Financial
Statements under the heading &#8220;Recent Accounting Standards.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.75in"><b>ITEM 3.</b></td><td style="text-align: justify"><b>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Because
we are a smaller reporting company, this section is not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.75in"><b>ITEM 4.</b></td><td style="text-align: justify"><b>CONTROLS AND PROCEDURES</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Evaluation of Disclosure
Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have established disclosure controls and procedures designed to ensure that information required to be disclosed in the reports that we
file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules
and forms and is accumulated and communicated to management, including the principal executive officer and principal financial officer,
to allow timely decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
principal executive officer and principal financial officer, with the assistance of other members of the Company&#8217;s management, have
evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e)
and 15d-15(e) under the Exchange Act) as of the end of the period covered by this quarterly report. Based upon our evaluation, each of
our principal executive officer and principal financial officer has concluded that the Company&#8217;s internal control over financial
reporting was not effective as of the end of the period covered by this Quarterly Report on Form 10-Q because the Company has not yet
completed its remediation of the material weakness previously identified and disclosed in the Company&#8217;s Annual Report on Form 10-K
for the year ended April 30, 2022, the end of its most recent fiscal year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Specifically,
management has <span style="background-color: white">identified the following material weaknesses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">1.</td><td style="text-align: justify">we do not have sufficient resources in our accounting function, <span style="background-color: white">which
restricts our ability to perform sufficient reviews and approval of manual journal entries posted to the general ledger and to consistently
execute review procedures over general ledger account reconciliations, financial statement preparation and accounting for non-routine
transactions</span>; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">2.</td><td style="text-align: justify">our <span style="background-color: white">primary user access controls (i.e., provisioning, de-provisioning,
privileged access and user access reviews) to ensure appropriate authorization and segregation of duties that would adequately restrict
user and privileged access to the financially relevant systems and data to appropriate personnel were not designed and/or implemented
effectively. We did not design and/or implement sufficient controls for program change management to certain financially relevant systems
affecting our processes</span>.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">A
material weakness is a control deficiency or combination of control deficiencies that result in more than a remote likelihood that a material
misstatement of the annual or interim financial statements will not be prevented or detected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Planned Remediation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
are implementing measures designed to improve our internal control over financial reporting to remediate material weaknesses, including
the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Formalizing our internal control documentation and strengthening supervisory reviews by our management;
and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Adding additional accounting personnel and segregating duties amongst accounting personnel.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Management
continues to work to improve its controls related to our material weaknesses, specifically relating to user access and change management
surrounding our information technology systems and applications. Management will continue to implement measures to remediate material
weaknesses, such that these controls are designed, implemented, and operating effectively. The remediation actions include: (i) enhancing
design and documentation related to both user access and change management processes and control activities; and (ii) developing and communicating
additional policies and procedures to govern the area of information technology change management. In order to achieve the timely implementation
of the above, management has commenced the following actions and will continue to assess additional opportunities for remediation on an
ongoing basis:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Engaging a third-party <span style="background-color: white">specialist</span> to assist management with
improving the Company&#8217;s overall control environment, focusing on change management and access controls; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Implementing new applications and <span style="background-color: white">systems</span> that are aligned
with management&#8217;s focus on creating strong internal controls.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
are currently working to improve and simplify our internal processes and implement enhanced controls, as discussed above, to address the
material weaknesses in our internal control over financial reporting and to remedy the ineffectiveness of our disclosure controls and
procedures. These material weaknesses will not be considered to be remediated until the applicable remediated controls are operating for
a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Despite the existence of these material weaknesses, we believe that
the condensed financial statements included in the period covered by this Quarterly Report on Form 10-Q fairly present, in all material
respects, our financial condition, results of operations and cash flows for the periods presented in conformity with U.S. generally accepted
accounting principles.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Changes in Internal Control</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as detailed above,
during the quarter ended July 31, 2022, there was no change in our internal control over financial reporting that materially affected,
or is reasonably likely to materially affect, our internal control over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II &#8212; OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.75in"><b>ITEM 1.</b></td><td style="text-align: justify"><b>LEGAL PROCEEDINGS</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or
in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of outcome, litigation
can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>ITEM 1A.</b></td><td style="text-align: justify"><b>RISK FACTORS</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: justify; text-indent: 0.5in">The risks described
in Part I, Item&#160;1A, &#8220;Risk Factors,&#8221; in our 2022 Annual Report on Form 10-K, could materially and adversely affect our
business, financial condition and results of operations, and the trading price of our Common Stock could decline. These risk factors do
not identify all risks that we face - our operations could also be affected by factors that are not presently known to us or that we currently
consider to be immaterial to our operations. Due to risks and uncertainties, known and unknown, our past financial results may not be
a reliable indicator of future performance and historical trends should not be used to anticipate results or trends in future periods.
The Risk Factors section of our&#160;2022&#160;Annual Report on Form 10-K remains current in all material respects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.75in"><b>ITEM 2.</b></td><td style="text-align: justify"><b>UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.75in"><b>ITEM 3.</b></td><td style="text-align: justify"><b>DEFAULTS UPON SENIOR SECURITIES</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.75in"><b>ITEM 4.</b></td><td style="text-align: justify"><b>MINE SAFETY DISCLOSURES</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-indent: 0.5in">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>ITEM 5.</b></td><td style="text-align: justify"><b>OTHER INFORMATION</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.75in"><b>ITEM 6.</b></td><td style="text-align: justify"><b>EXHIBITS</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 7%"><b>Exhibit No.</b></td>
    <td style="border-bottom: white 1pt solid; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 92%"><b>Exhibit&#160;Description</b></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 5pt; white-space: nowrap; text-align: justify">3.1</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1677077/000161577416006901/filename3.htm">Certificate of Incorporation (incorporated by reference to Exhibit&#160;2.1 of Form DOS filed with the SEC on August&#160;19, 2016).</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-left: 5pt; white-space: nowrap; text-align: justify">3.2</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1677077/000110465921063812/tm2039434d6_ex3-2.htm">Amended and Restated Bylaws.</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 5pt; white-space: nowrap; text-align: justify">3.3</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1677077/000121465920000853/ex1a-2a_3.htm">Certificate of Designation of Alzamend Neuro, Inc. Series&#160;A Convertible Preferred Stock, dated May&#160;30, 2016 (incorporated by reference to Exhibit&#160;2.3 of Form 1-A/A filed with the SEC on February&#160;4, 2020).</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap; text-align: justify">31.1*</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ex31_1.htm">Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a)</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; text-align: justify">31.2*</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ex31_2.htm">Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a)</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap; text-align: justify">32.1**</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ex32_1.htm">Certification of Chief Executive and Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">101.INS*</td>
    <td>&#160;</td>
    <td>XBRL Instance Document. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap">101.SCH*</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Schema Document.</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">101.CAL*</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Calculation Linkbase Document.</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap">101.DEF*</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Definition Linkbase Document.</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">101.LAB*</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Label Linkbase Document.</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap">101.PRE*</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Presentation Linkbase Document.</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap">104</td>
    <td>&#160;</td>
    <td>Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">*Filed herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">** This certification will not be deemed &#8220;filed&#8221;
for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be
deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the
extent specifically incorporated by reference into such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 2px solid; margin-top: 8pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: left; width: 100%"><span style="font-size: 8pt">&#160;</span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="3" style="text-align: justify"><b>ALZAMEND NEURO, INC.</b></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 55%; text-align: justify">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 43%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">Date: September&#160;13, 2022</td>
    <td style="text-align: justify">By:</td>
    <td style="text-align: justify">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">/s/ Stephan Jackman</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;Stephan Jackman<br />
    Chief Executive Officer (principal executive officer)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 55%; text-align: justify">Date: September&#160;13, 2022</td>
    <td style="width: 1%; text-align: justify">By:</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 43%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">/s/ David J. Katzoff</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David J. Katzoff<br />
    Chief Financial Officer (principal financial and accounting officer)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">30</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2px solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>



<p style="margin: 0"></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31_1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>


</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXHIBIT 31.1 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CERTIFICATION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Stephan Jackman, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">1.&nbsp;&nbsp;I have reviewed
this quarterly report on Form 10-Q of Alzamend Neuro, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">2.&nbsp;&nbsp;Based on my
knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.&nbsp;&nbsp;Based on my
knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">4.&nbsp;&nbsp;The registrant&rsquo;s
other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Designed such internal
control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) Evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) Disclosed in this report
any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">5.&nbsp;&nbsp;The registrant&rsquo;s
other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to
the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent
functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Any fraud, whether or
not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over
financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated:&nbsp;&nbsp;September 13, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: justify">/s/ Stephan Jackman</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 13pt; white-space: nowrap; width: 25%; text-align: justify">Name: Stephan Jackman</TD>
    <TD STYLE="width: 75%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 13pt; white-space: nowrap; text-align: justify">Title: Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 13pt; white-space: nowrap; text-align: justify">(Principal Executive Officer)</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31_2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>


</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXHIBIT 31.2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CERTIFICATION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, David J. Katzoff, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">1.&nbsp;&nbsp;I have reviewed
this quarterly report on Form 10-Q of Alzamend Neuro, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">2.&nbsp;&nbsp;Based on my
knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.&nbsp;&nbsp;Based on my
knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">4.&nbsp;&nbsp;The registrant&rsquo;s
other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Designed such internal
control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) Evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) Disclosed in this report
any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">5.&nbsp;&nbsp;The registrant&rsquo;s
other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to
the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent
functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Any fraud, whether or
not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over
financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated:&nbsp;&nbsp;September 13, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid">/s/ David J. Katzoff</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 13pt; white-space: nowrap; text-align: justify; width: 30%">Name: David J. Katzoff</TD>
    <TD STYLE="width: 70%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 13pt; white-space: nowrap; text-align: justify">Title: Chief Financial Officer</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 13pt; white-space: nowrap; text-align: justify">(Principal Financial and Accounting Officer)</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="border-top: Black 2px solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex32_1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>


</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXHIBIT 32.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT
TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the quarterly
report of Alzamend Neuro, Inc. (the&nbsp;&ldquo;Company&rdquo;) on Form 10-Q for the period ended July&nbsp;31, 2022, as filed with the
Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned&nbsp;certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) the Report fully complies
with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) the information contained
in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: September 13,
    2022</FONT></TD>
    <TD COLSPAN="2">

    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: /s/ Stephan Jackman</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 5%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Stephan Jackman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: September 13, 2022</FONT> </FONT></TD>
    <TD COLSPAN="2">

    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: /s/ David J. Katzoff</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 5%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: David J. Katzoff</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>alxneuro-20220731.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 9aM5s7xRiXhun8uCaHNMOa2I+bPtxpd9KelBvm17bTmKjysjWnAlwiXURZqGkYsP -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:alxneuro="http://alzamend.com/20220731" elementFormDefault="qualified" targetNamespace="http://alzamend.com/20220731">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://alzamend.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Balance Sheets (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Condensed Statements of Operations (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
	  <link:definition>00000005 - Statement - Condensed Statements of Stockholders' Equity (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/StatementsOfStockholdersEquityParenthetical" id="StatementsOfStockholdersEquityParenthetical">
	  <link:definition>00000006 - Statement - Condensed Statements of Stockholders' Equity (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000007 - Statement - Condensed Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/DescriptionOfBusiness" id="DescriptionOfBusiness">
	  <link:definition>00000008 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/LiquidityAndGoingConcern" id="LiquidityAndGoingConcern">
	  <link:definition>00000009 - Disclosure - LIQUIDITY AND GOING CONCERN</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
	  <link:definition>00000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/NoteReceivableForCommonStockRelatedParty" id="NoteReceivableForCommonStockRelatedParty">
	  <link:definition>00000011 - Disclosure - NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
	  <link:definition>00000012 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
	  <link:definition>00000013 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/Warrants" id="Warrants">
	  <link:definition>00000014 - Disclosure - WARRANTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/OtherRelatedPartyTransactions" id="OtherRelatedPartyTransactions">
	  <link:definition>00000015 - Disclosure - OTHER RELATED PARTY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/EquityTransactions" id="EquityTransactions">
	  <link:definition>00000017 - Disclosure - EQUITY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000018 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
	  <link:definition>00000019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
	  <link:definition>00000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
	  <link:definition>00000021 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
	  <link:definition>00000022 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/WarrantsTables" id="WarrantsTables">
	  <link:definition>00000023 - Disclosure - WARRANTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000024 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/DescriptionOfBusinessDetailsNarrative" id="DescriptionOfBusinessDetailsNarrative">
	  <link:definition>00000025 - Disclosure - DESCRIPTION OF BUSINESS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative" id="LiquidityAndGoingConcernDetailsNarrative">
	  <link:definition>00000026 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails" id="FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails">
	  <link:definition>00000027 - Disclosure - The following sets forth the number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have been excluded from the computation of loss per common share: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/SignificantAccountingPoliciesDetailsNarrative" id="SignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative" id="NoteReceivableForCommonStockRelatedPartyDetailsNarrative">
	  <link:definition>00000029 - Disclosure - NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsAreAsFollowsDetails" id="PrepaidExpensesAndOtherCurrentAssetsAreAsFollowsDetails">
	  <link:definition>00000030 - Disclosure - Prepaid expenses and other current assets are as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative" id="PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative">
	  <link:definition>00000031 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails" id="SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails">
	  <link:definition>00000032 - Disclosure - A summary of stock option activity for the three months ended July 31, 2022 is presented below: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails" id="EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails">
	  <link:definition>00000033 - Disclosure - The estimated fair value of stock options granted to employees and consultants during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/CompanysResultsOfOperationsIncludeExpensesRelatingToStock-basedCompensationForThreeMonthsEndedJuly312022And2021ThatWereComprisedAsFollowsDetails" id="CompanysResultsOfOperationsIncludeExpensesRelatingToStock-basedCompensationForThreeMonthsEndedJuly312022And2021ThatWereComprisedAsFollowsDetails">
	  <link:definition>00000034 - Disclosure - The Company&#8217;s results of operations include expenses relating to stock-based compensation for three months ended July 31, 2022 and 2021, that were comprised as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
	  <link:definition>00000035 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details" id="FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details">
	  <link:definition>00000036 - Disclosure - The following table summarizes information about Common Stock warrants outstanding and exercisable at July 31, 2022: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails" id="EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails">
	  <link:definition>00000037 - Disclosure - The estimated fair value of warrants granted during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative" id="OtherRelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000038 - Disclosure - OTHER RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/OriginalAl001LicenseDetails" id="OriginalAl001LicenseDetails">
	  <link:definition>00000039 - Disclosure - Original AL001 License: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://alzamend.com/role/EquityTransactionsDetailsNarrative" id="EquityTransactionsDetailsNarrative">
	  <link:definition>00000041 - Disclosure - EQUITY TRANSACTIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="alxneuro-20220731_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="alxneuro-20220731_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="alxneuro-20220731_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="alxneuro-20220731_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="alxneuro_NoteRecievableForCommonStockRelatedPartyMember" name="NoteRecievableForCommonStockRelatedPartyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_ConvertibleNotesMember" name="ConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_AultLifeSciencesFundLLCMember" name="AultLifeSciencesFundLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_SpartanCapitalSecuritiesMember" name="SpartanCapitalSecuritiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_StockIncentivePlan2016Member" name="StockIncentivePlan2016Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_PerformanceContingentStockOptionsMember" name="PerformanceContingentStockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_KeyEmployeesAndDirectorMember" name="KeyEmployeesAndDirectorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_UnamortizedStockBasedCompensationMember" name="UnamortizedStockBasedCompensationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_EmployeesAndConsultantsMember" name="EmployeesAndConsultantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_ExercisePrice1Member" name="ExercisePrice1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_ExercisePrice2Member" name="ExercisePrice2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_ExercisePrice3Member" name="ExercisePrice3Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_ExercisePriceFiftySixMember" name="ExercisePriceFiftySixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_ExercisePrice4Member" name="ExercisePrice4Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_ExercisePriceFiftySevenMember" name="ExercisePriceFiftySevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_DigitalPowerLendingMember" name="DigitalPowerLendingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_AL002LicenseMember" name="AL002LicenseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_AL001LicenseMember" name="AL001LicenseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_AdditionalAL001LicenseMember" name="AdditionalAL001LicenseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_PreINDMeetingMember" name="PreINDMeetingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_IndApplicationFilingMember" name="IndApplicationFilingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_UponFirstDosingOfPatientInClinicalTrialMember" name="UponFirstDosingOfPatientInClinicalTrialMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_UponCompletionOfFirstPatientDosingMember" name="UponCompletionOfFirstPatientDosingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_UponCompletionOfFirstClinicalTrialMember" name="UponCompletionOfFirstClinicalTrialMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_UponFdaApprovalMember" name="UponFdaApprovalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_UponFirstPatientTreatedInPhase3ClinicalTrialMember" name="UponFirstPatientTreatedInPhase3ClinicalTrialMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_SecuritiesPurchaseAgreementsMember" name="SecuritiesPurchaseAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_ALSFMember" name="ALSFMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_AultGlobalMember" name="AultGlobalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_ConvertiblePromissoryNoteMember" name="ConvertiblePromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_FinalTrancheMember" name="FinalTrancheMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_NoteReceivableForCommonStockRelatedParty" name="NoteReceivableForCommonStockRelatedParty" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_PreferredStockSharesDesignated" name="PreferredStockSharesDesignated" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_StockbasedCompensationToEmployeesAndConsultants" name="StockbasedCompensationToEmployeesAndConsultants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_StockIssuedDuringPeriodValueNewIssues2" name="StockIssuedDuringPeriodValueNewIssues2" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_StockIssuedDuringPeriodSharesNewIssues2" name="StockIssuedDuringPeriodSharesNewIssues2" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_StockIssuedDuringPeriodValueNewIssues3" name="StockIssuedDuringPeriodValueNewIssues3" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_StockIssuedDuringPeriodSharesNewIssues3" name="StockIssuedDuringPeriodSharesNewIssues3" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_ConversionOfSeriesAConvertibleStock" name="ConversionOfSeriesAConvertibleStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts" name="ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_FairValueOfWarrantsIssuedInConnectionWithIpo" name="FairValueOfWarrantsIssuedInConnectionWithIpo" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty" name="FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_DisclosureNoteReceivableForCommonStockRelatedPartyAbstract" name="DisclosureNoteReceivableForCommonStockRelatedPartyAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_MortgageNoteReceivableFromRelatedPartyTextBlock" name="MortgageNoteReceivableFromRelatedPartyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_DisclosureWarrantsAbstract" name="DisclosureWarrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_WarrantsDisclosureTextBlock" name="WarrantsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_WarrantsPolicyTextBlock" name="WarrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock" name="ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock" name="ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_NumberOfStockExcluded" name="NumberOfStockExcluded" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_LongTermDebtAverageAmountOfOutstanding" name="LongTermDebtAverageAmountOfOutstanding" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_PrepaidInsurance1" name="PrepaidInsurance1" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_UnamortizedPrepaidExpense" name="UnamortizedPrepaidExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_PrepaidConsultingFees" name="PrepaidConsultingFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_ClassOfWarrantOrRightExercisable" name="ClassOfWarrantOrRightExercisable" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" name="ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_LicenseEventsAxis" name="LicenseEventsAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="alxneuro_LicenseEventsDomain" name="LicenseEventsDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_PercentageOfRoyaltyPaymentsOnNetSalesOfProduct." name="PercentageOfRoyaltyPaymentsOnNetSalesOfProduct." nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_DescriptionOfLicensesAgreements" name="DescriptionOfLicensesAgreements" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_InitialLicenseFees" name="InitialLicenseFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_NumberOfSharesPurchase" name="NumberOfSharesPurchase" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_SharesPurchasePrice" name="SharesPurchasePrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_SharesPurchasePricePerShares" name="SharesPurchasePricePerShares" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_StockIssuedDuringPeriodSharesNewIssuesOne" name="StockIssuedDuringPeriodSharesNewIssuesOne" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_AdvanceFromRelatedParties" name="AdvanceFromRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_SharesValueSurrenderForCancellation" name="SharesValueSurrenderForCancellation" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_DescriptionOfPurchaseAgreementTerms" name="DescriptionOfPurchaseAgreementTerms" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_AdditionalRightToInvest" name="AdditionalRightToInvest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="alxneuro_ConversionOfSeriesAConvertibleStockShares" name="ConversionOfSeriesAConvertibleStockShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>alxneuro-20220731_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://alzamend.com/role/Cover" xlink:href="alxneuro-20220731.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/BalanceSheets" xlink:href="alxneuro-20220731.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/BalanceSheetsParenthetical" xlink:href="alxneuro-20220731.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/StatementsOfOperations" xlink:href="alxneuro-20220731.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/StatementsOfStockholdersEquity" xlink:href="alxneuro-20220731.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/StatementsOfStockholdersEquityParenthetical" xlink:href="alxneuro-20220731.xsd#StatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/StatementsOfCashFlows" xlink:href="alxneuro-20220731.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/DescriptionOfBusiness" xlink:href="alxneuro-20220731.xsd#DescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/LiquidityAndGoingConcern" xlink:href="alxneuro-20220731.xsd#LiquidityAndGoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/SignificantAccountingPolicies" xlink:href="alxneuro-20220731.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/NoteReceivableForCommonStockRelatedParty" xlink:href="alxneuro-20220731.xsd#NoteReceivableForCommonStockRelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="alxneuro-20220731.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/Stock-basedCompensation" xlink:href="alxneuro-20220731.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/Warrants" xlink:href="alxneuro-20220731.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/OtherRelatedPartyTransactions" xlink:href="alxneuro-20220731.xsd#OtherRelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/CommitmentsAndContingencies" xlink:href="alxneuro-20220731.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/EquityTransactions" xlink:href="alxneuro-20220731.xsd#EquityTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/SubsequentEvents" xlink:href="alxneuro-20220731.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/SignificantAccountingPoliciesPolicies" xlink:href="alxneuro-20220731.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/SignificantAccountingPoliciesTables" xlink:href="alxneuro-20220731.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="alxneuro-20220731.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/Stock-basedCompensationTables" xlink:href="alxneuro-20220731.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/WarrantsTables" xlink:href="alxneuro-20220731.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/CommitmentsAndContingenciesTables" xlink:href="alxneuro-20220731.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/DescriptionOfBusinessDetailsNarrative" xlink:href="alxneuro-20220731.xsd#DescriptionOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:href="alxneuro-20220731.xsd#LiquidityAndGoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails" xlink:href="alxneuro-20220731.xsd#FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="alxneuro-20220731.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative" xlink:href="alxneuro-20220731.xsd#NoteReceivableForCommonStockRelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsAreAsFollowsDetails" xlink:href="alxneuro-20220731.xsd#PrepaidExpensesAndOtherCurrentAssetsAreAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative" xlink:href="alxneuro-20220731.xsd#PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails" xlink:href="alxneuro-20220731.xsd#SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails" xlink:href="alxneuro-20220731.xsd#EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/CompanysResultsOfOperationsIncludeExpensesRelatingToStock-basedCompensationForThreeMonthsEndedJuly312022And2021ThatWereComprisedAsFollowsDetails" xlink:href="alxneuro-20220731.xsd#CompanysResultsOfOperationsIncludeExpensesRelatingToStock-basedCompensationForThreeMonthsEndedJuly312022And2021ThatWereComprisedAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="alxneuro-20220731.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details" xlink:href="alxneuro-20220731.xsd#FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails" xlink:href="alxneuro-20220731.xsd#EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative" xlink:href="alxneuro-20220731.xsd#OtherRelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/OriginalAl001LicenseDetails" xlink:href="alxneuro-20220731.xsd#OriginalAl001LicenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="alxneuro-20220731.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/EquityTransactionsDetailsNarrative" xlink:href="alxneuro-20220731.xsd#EquityTransactionsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_NoteReceivableForCommonStockRelatedParty" xlink:label="loc_alxneuroNoteReceivableForCommonStockRelatedParty" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_alxneuroNoteReceivableForCommonStockRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Statements of Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/StatementsOfStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Condensed Statements of Stockholders&apos; Equity (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts" xlink:label="loc_alxneuroProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_alxneuroProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/DescriptionOfBusiness" xlink:title="00000008 - Disclosure - DESCRIPTION OF BUSINESS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/LiquidityAndGoingConcern" xlink:title="00000009 - Disclosure - LIQUIDITY AND GOING CONCERN" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/SignificantAccountingPolicies" xlink:title="00000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/NoteReceivableForCommonStockRelatedParty" xlink:title="00000011 - Disclosure - NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000012 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/Stock-basedCompensation" xlink:title="00000013 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/Warrants" xlink:title="00000014 - Disclosure - WARRANTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/OtherRelatedPartyTransactions" xlink:title="00000015 - Disclosure - OTHER RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/EquityTransactions" xlink:title="00000017 - Disclosure - EQUITY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/SignificantAccountingPoliciesTables" xlink:title="00000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000021 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/Stock-basedCompensationTables" xlink:title="00000022 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/WarrantsTables" xlink:title="00000023 - Disclosure - WARRANTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/CommitmentsAndContingenciesTables" xlink:title="00000024 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/DescriptionOfBusinessDetailsNarrative" xlink:title="00000025 - Disclosure - DESCRIPTION OF BUSINESS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:title="00000026 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails" xlink:title="00000027 - Disclosure - The following sets forth the number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have been excluded from the computation of loss per common share: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative" xlink:title="00000029 - Disclosure - NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsAreAsFollowsDetails" xlink:title="00000030 - Disclosure - Prepaid expenses and other current assets are as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative" xlink:title="00000031 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails" xlink:title="00000032 - Disclosure - A summary of stock option activity for the three months ended July 31, 2022 is presented below: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails" xlink:title="00000033 - Disclosure - The estimated fair value of stock options granted to employees and consultants during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/CompanysResultsOfOperationsIncludeExpensesRelatingToStock-basedCompensationForThreeMonthsEndedJuly312022And2021ThatWereComprisedAsFollowsDetails" xlink:title="00000034 - Disclosure - The Company&#8217;s results of operations include expenses relating to stock-based compensation for three months ended July 31, 2022 and 2021, that were comprised as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000035 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details" xlink:title="00000036 - Disclosure - The following table summarizes information about Common Stock warrants outstanding and exercisable at July 31, 2022: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails" xlink:title="00000037 - Disclosure - The estimated fair value of warrants granted during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative" xlink:title="00000038 - Disclosure - OTHER RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/OriginalAl001LicenseDetails" xlink:title="00000039 - Disclosure - Original AL001 License: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://alzamend.com/role/EquityTransactionsDetailsNarrative" xlink:title="00000041 - Disclosure - EQUITY TRANSACTIONS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>alxneuro-20220731_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://alzamend.com/role/Cover" xlink:href="alxneuro-20220731.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/BalanceSheets" xlink:href="alxneuro-20220731.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/BalanceSheetsParenthetical" xlink:href="alxneuro-20220731.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/StatementsOfOperations" xlink:href="alxneuro-20220731.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/StatementsOfStockholdersEquity" xlink:href="alxneuro-20220731.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/StatementsOfStockholdersEquityParenthetical" xlink:href="alxneuro-20220731.xsd#StatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/StatementsOfCashFlows" xlink:href="alxneuro-20220731.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/DescriptionOfBusiness" xlink:href="alxneuro-20220731.xsd#DescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/LiquidityAndGoingConcern" xlink:href="alxneuro-20220731.xsd#LiquidityAndGoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/SignificantAccountingPolicies" xlink:href="alxneuro-20220731.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/NoteReceivableForCommonStockRelatedParty" xlink:href="alxneuro-20220731.xsd#NoteReceivableForCommonStockRelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="alxneuro-20220731.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/Stock-basedCompensation" xlink:href="alxneuro-20220731.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/Warrants" xlink:href="alxneuro-20220731.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/OtherRelatedPartyTransactions" xlink:href="alxneuro-20220731.xsd#OtherRelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/CommitmentsAndContingencies" xlink:href="alxneuro-20220731.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/EquityTransactions" xlink:href="alxneuro-20220731.xsd#EquityTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/SubsequentEvents" xlink:href="alxneuro-20220731.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/SignificantAccountingPoliciesPolicies" xlink:href="alxneuro-20220731.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/SignificantAccountingPoliciesTables" xlink:href="alxneuro-20220731.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="alxneuro-20220731.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/Stock-basedCompensationTables" xlink:href="alxneuro-20220731.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/WarrantsTables" xlink:href="alxneuro-20220731.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/CommitmentsAndContingenciesTables" xlink:href="alxneuro-20220731.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/DescriptionOfBusinessDetailsNarrative" xlink:href="alxneuro-20220731.xsd#DescriptionOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:href="alxneuro-20220731.xsd#LiquidityAndGoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails" xlink:href="alxneuro-20220731.xsd#FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="alxneuro-20220731.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative" xlink:href="alxneuro-20220731.xsd#NoteReceivableForCommonStockRelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsAreAsFollowsDetails" xlink:href="alxneuro-20220731.xsd#PrepaidExpensesAndOtherCurrentAssetsAreAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative" xlink:href="alxneuro-20220731.xsd#PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails" xlink:href="alxneuro-20220731.xsd#SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails" xlink:href="alxneuro-20220731.xsd#EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/CompanysResultsOfOperationsIncludeExpensesRelatingToStock-basedCompensationForThreeMonthsEndedJuly312022And2021ThatWereComprisedAsFollowsDetails" xlink:href="alxneuro-20220731.xsd#CompanysResultsOfOperationsIncludeExpensesRelatingToStock-basedCompensationForThreeMonthsEndedJuly312022And2021ThatWereComprisedAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="alxneuro-20220731.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details" xlink:href="alxneuro-20220731.xsd#FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails" xlink:href="alxneuro-20220731.xsd#EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative" xlink:href="alxneuro-20220731.xsd#OtherRelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/OriginalAl001LicenseDetails" xlink:href="alxneuro-20220731.xsd#OriginalAl001LicenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="alxneuro-20220731.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/EquityTransactionsDetailsNarrative" xlink:href="alxneuro-20220731.xsd#EquityTransactionsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_PreferredStockSharesDesignated" xlink:label="loc_alxneuroPreferredStockSharesDesignated_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_alxneuroPreferredStockSharesDesignated_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Statements of Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_NoteRecievableForCommonStockRelatedPartyMember" xlink:label="loc_alxneuroNoteRecievableForCommonStockRelatedPartyMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_alxneuroNoteRecievableForCommonStockRelatedPartyMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_StockbasedCompensationToEmployeesAndConsultants" xlink:label="loc_alxneuroStockbasedCompensationToEmployeesAndConsultants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_alxneuroStockbasedCompensationToEmployeesAndConsultants_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_StockIssuedDuringPeriodValueNewIssues2" xlink:label="loc_alxneuroStockIssuedDuringPeriodValueNewIssues2_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_alxneuroStockIssuedDuringPeriodValueNewIssues2_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_StockIssuedDuringPeriodSharesNewIssues2" xlink:label="loc_alxneuroStockIssuedDuringPeriodSharesNewIssues2_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_alxneuroStockIssuedDuringPeriodSharesNewIssues2_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_alxneuroStockIssuedDuringPeriodValueNewIssues3_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_alxneuroStockIssuedDuringPeriodValueNewIssues3_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_alxneuroStockIssuedDuringPeriodSharesNewIssues3_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_alxneuroStockIssuedDuringPeriodSharesNewIssues3_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ConversionOfSeriesAConvertibleStock" xlink:label="loc_alxneuroConversionOfSeriesAConvertibleStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_alxneuroConversionOfSeriesAConvertibleStock_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/StatementsOfStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Condensed Statements of Stockholders&apos; Equity (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/DescriptionOfBusiness" xlink:title="00000008 - Disclosure - DESCRIPTION OF BUSINESS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/LiquidityAndGoingConcern" xlink:title="00000009 - Disclosure - LIQUIDITY AND GOING CONCERN" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/SignificantAccountingPolicies" xlink:title="00000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/NoteReceivableForCommonStockRelatedParty" xlink:title="00000011 - Disclosure - NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000012 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/Stock-basedCompensation" xlink:title="00000013 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/Warrants" xlink:title="00000014 - Disclosure - WARRANTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/OtherRelatedPartyTransactions" xlink:title="00000015 - Disclosure - OTHER RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/EquityTransactions" xlink:title="00000017 - Disclosure - EQUITY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/SignificantAccountingPoliciesTables" xlink:title="00000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000021 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/Stock-basedCompensationTables" xlink:title="00000022 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/WarrantsTables" xlink:title="00000023 - Disclosure - WARRANTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/CommitmentsAndContingenciesTables" xlink:title="00000024 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/DescriptionOfBusinessDetailsNarrative" xlink:title="00000025 - Disclosure - DESCRIPTION OF BUSINESS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:title="00000026 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails" xlink:title="00000027 - Disclosure - The following sets forth the number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have been excluded from the computation of loss per common share: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ConvertibleNotesMember" xlink:label="loc_alxneuroConvertibleNotesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_alxneuroConvertibleNotesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_NumberOfStockExcluded" xlink:label="loc_alxneuroNumberOfStockExcluded_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_alxneuroNumberOfStockExcluded_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_20" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative" xlink:title="00000029 - Disclosure - NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AultLifeSciencesFundLLCMember" xlink:label="loc_alxneuroAultLifeSciencesFundLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_alxneuroAultLifeSciencesFundLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_SecuritiesPurchaseAgreementMember" xlink:label="loc_alxneuroSecuritiesPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_alxneuroSecuritiesPurchaseAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_LongTermDebtAverageAmountOfOutstanding" xlink:label="loc_alxneuroLongTermDebtAverageAmountOfOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_alxneuroLongTermDebtAverageAmountOfOutstanding_60" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsAreAsFollowsDetails" xlink:title="00000030 - Disclosure - Prepaid expenses and other current assets are as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative" xlink:title="00000031 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_SpartanCapitalSecuritiesMember" xlink:label="loc_alxneuroSpartanCapitalSecuritiesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_alxneuroSpartanCapitalSecuritiesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_PrepaidInsurance1" xlink:label="loc_alxneuroPrepaidInsurance1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_alxneuroPrepaidInsurance1_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_UnamortizedPrepaidExpense" xlink:label="loc_alxneuroUnamortizedPrepaidExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_alxneuroUnamortizedPrepaidExpense_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_PrepaidConsultingFees" xlink:label="loc_alxneuroPrepaidConsultingFees_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_alxneuroPrepaidConsultingFees_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails" xlink:title="00000032 - Disclosure - A summary of stock option activity for the three months ended July 31, 2022 is presented below: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails" xlink:title="00000033 - Disclosure - The estimated fair value of stock options granted to employees and consultants during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_EmployeesAndConsultantsMember" xlink:label="loc_alxneuroEmployeesAndConsultantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_alxneuroEmployeesAndConsultantsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_80" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/CompanysResultsOfOperationsIncludeExpensesRelatingToStock-basedCompensationForThreeMonthsEndedJuly312022And2021ThatWereComprisedAsFollowsDetails" xlink:title="00000034 - Disclosure - The Company&#8217;s results of operations include expenses relating to stock-based compensation for three months ended July 31, 2022 and 2021, that were comprised as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000035 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_StockIncentivePlan2016Member" xlink:label="loc_alxneuroStockIncentivePlan2016Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_alxneuroStockIncentivePlan2016Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_PerformanceContingentStockOptionsMember" xlink:label="loc_alxneuroPerformanceContingentStockOptionsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_alxneuroPerformanceContingentStockOptionsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_KeyEmployeesAndDirectorMember" xlink:label="loc_alxneuroKeyEmployeesAndDirectorMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_alxneuroKeyEmployeesAndDirectorMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_UnamortizedStockBasedCompensationMember" xlink:label="loc_alxneuroUnamortizedStockBasedCompensationMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_alxneuroUnamortizedStockBasedCompensationMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_110" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details" xlink:title="00000036 - Disclosure - The following table summarizes information about Common Stock warrants outstanding and exercisable at July 31, 2022: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ExercisePrice1Member" xlink:label="loc_alxneuroExercisePrice1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_alxneuroExercisePrice1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ExercisePrice2Member" xlink:label="loc_alxneuroExercisePrice2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_alxneuroExercisePrice2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ExercisePrice3Member" xlink:label="loc_alxneuroExercisePrice3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_alxneuroExercisePrice3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ExercisePriceFiftySixMember" xlink:label="loc_alxneuroExercisePriceFiftySixMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_alxneuroExercisePriceFiftySixMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ExercisePrice4Member" xlink:label="loc_alxneuroExercisePrice4Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_alxneuroExercisePrice4Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ExercisePriceFiftySevenMember" xlink:label="loc_alxneuroExercisePriceFiftySevenMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_alxneuroExercisePriceFiftySevenMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:label="loc_alxneuroClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_alxneuroClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ClassOfWarrantOrRightExercisable" xlink:label="loc_alxneuroClassOfWarrantOrRightExercisable_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_alxneuroClassOfWarrantOrRightExercisable_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:label="loc_alxneuroClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_alxneuroClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_100" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails" xlink:title="00000037 - Disclosure - The estimated fair value of warrants granted during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative" xlink:title="00000038 - Disclosure - OTHER RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_SecuritiesPurchaseAgreementMember" xlink:label="loc_alxneuroSecuritiesPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_alxneuroSecuritiesPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_DigitalPowerLendingMember" xlink:label="loc_alxneuroDigitalPowerLendingMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_alxneuroDigitalPowerLendingMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionDescriptionOfTransaction_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionDescriptionOfTransaction_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentMilestones" xlink:label="loc_us-gaapLongTermPurchaseCommitmentMilestones_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLongTermPurchaseCommitmentMilestones_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/OriginalAl001LicenseDetails" xlink:title="00000039 - Disclosure - Original AL001 License: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaapProductLiabilityContingencyLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaapProductLiabilityContingencyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapProductLiabilityContingencyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AL001LicenseMember" xlink:label="loc_alxneuroAL001LicenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_alxneuroAL001LicenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AL002LicenseMember" xlink:label="loc_alxneuroAL002LicenseMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_alxneuroAL002LicenseMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AdditionalAL001LicenseMember" xlink:label="loc_alxneuroAdditionalAL001LicenseMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_alxneuroAdditionalAL001LicenseMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_LicenseEventsAxis" xlink:label="loc_alxneuroLicenseEventsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_alxneuroLicenseEventsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_LicenseEventsDomain" xlink:label="loc_alxneuroLicenseEventsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_alxneuroLicenseEventsAxis" xlink:to="loc_alxneuroLicenseEventsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_LicenseEventsDomain" xlink:label="loc_alxneuroLicenseEventsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_alxneuroLicenseEventsAxis" xlink:to="loc_alxneuroLicenseEventsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_PreINDMeetingMember" xlink:label="loc_alxneuroPreINDMeetingMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alxneuroLicenseEventsDomain" xlink:to="loc_alxneuroPreINDMeetingMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_IndApplicationFilingMember" xlink:label="loc_alxneuroIndApplicationFilingMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alxneuroLicenseEventsDomain" xlink:to="loc_alxneuroIndApplicationFilingMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_UponFirstDosingOfPatientInClinicalTrialMember" xlink:label="loc_alxneuroUponFirstDosingOfPatientInClinicalTrialMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alxneuroLicenseEventsDomain" xlink:to="loc_alxneuroUponFirstDosingOfPatientInClinicalTrialMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_UponCompletionOfFirstPatientDosingMember" xlink:label="loc_alxneuroUponCompletionOfFirstPatientDosingMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alxneuroLicenseEventsDomain" xlink:to="loc_alxneuroUponCompletionOfFirstPatientDosingMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_UponCompletionOfFirstClinicalTrialMember" xlink:label="loc_alxneuroUponCompletionOfFirstClinicalTrialMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alxneuroLicenseEventsDomain" xlink:to="loc_alxneuroUponCompletionOfFirstClinicalTrialMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_UponFdaApprovalMember" xlink:label="loc_alxneuroUponFdaApprovalMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alxneuroLicenseEventsDomain" xlink:to="loc_alxneuroUponFdaApprovalMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_UponFirstPatientTreatedInPhase3ClinicalTrialMember" xlink:label="loc_alxneuroUponFirstPatientTreatedInPhase3ClinicalTrialMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alxneuroLicenseEventsDomain" xlink:to="loc_alxneuroUponFirstPatientTreatedInPhase3ClinicalTrialMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapContractualObligation_350" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaapOtherCommitmentsDescription_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapOtherCommitmentsDescription_350" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaapProductLiabilityContingencyLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaapProductLiabilityContingencyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapProductLiabilityContingencyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AL002LicenseMember" xlink:label="loc_alxneuroAL002LicenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_alxneuroAL002LicenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AL001LicenseMember" xlink:label="loc_alxneuroAL001LicenseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_alxneuroAL001LicenseMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AdditionalAL001LicenseMember" xlink:label="loc_alxneuroAdditionalAL001LicenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_alxneuroAdditionalAL001LicenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_PercentageOfRoyaltyPaymentsOnNetSalesOfProduct." xlink:label="loc_alxneuroPercentageOfRoyaltyPaymentsOnNetSalesOfProduct._50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_alxneuroPercentageOfRoyaltyPaymentsOnNetSalesOfProduct._50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_DescriptionOfLicensesAgreements" xlink:label="loc_alxneuroDescriptionOfLicensesAgreements_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_alxneuroDescriptionOfLicensesAgreements_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_InitialLicenseFees" xlink:label="loc_alxneuroInitialLicenseFees_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_alxneuroInitialLicenseFees_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://alzamend.com/role/EquityTransactionsDetailsNarrative" xlink:title="00000041 - Disclosure - EQUITY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_SecuritiesPurchaseAgreementsMember" xlink:label="loc_alxneuroSecuritiesPurchaseAgreementsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_alxneuroSecuritiesPurchaseAgreementsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ALSFMember" xlink:label="loc_alxneuroALSFMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_alxneuroALSFMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_DigitalPowerLendingMember" xlink:label="loc_alxneuroDigitalPowerLendingMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_alxneuroDigitalPowerLendingMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AultGlobalMember" xlink:label="loc_alxneuroAultGlobalMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_alxneuroAultGlobalMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ConvertiblePromissoryNoteMember" xlink:label="loc_alxneuroConvertiblePromissoryNoteMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_alxneuroConvertiblePromissoryNoteMember_110" xlink:type="arc" order="113" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_FinalTrancheMember" xlink:label="loc_alxneuroFinalTrancheMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_alxneuroFinalTrancheMember_140" xlink:type="arc" order="143" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_PreferredStockSharesDesignated" xlink:label="loc_alxneuroPreferredStockSharesDesignated_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_alxneuroPreferredStockSharesDesignated_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_NumberOfSharesPurchase" xlink:label="loc_alxneuroNumberOfSharesPurchase_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_alxneuroNumberOfSharesPurchase_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_SharesPurchasePrice" xlink:label="loc_alxneuroSharesPurchasePrice_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_alxneuroSharesPurchasePrice_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_SharesPurchasePricePerShares" xlink:label="loc_alxneuroSharesPurchasePricePerShares_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_alxneuroSharesPurchasePricePerShares_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_160" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:label="loc_alxneuroStockIssuedDuringPeriodSharesNewIssuesOne_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_alxneuroStockIssuedDuringPeriodSharesNewIssuesOne_160" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_160" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_160" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt_160" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AdvanceFromRelatedParties" xlink:label="loc_alxneuroAdvanceFromRelatedParties_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_alxneuroAdvanceFromRelatedParties_160" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_SharesValueSurrenderForCancellation" xlink:label="loc_alxneuroSharesValueSurrenderForCancellation_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_alxneuroSharesValueSurrenderForCancellation_160" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_DescriptionOfPurchaseAgreementTerms" xlink:label="loc_alxneuroDescriptionOfPurchaseAgreementTerms_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_alxneuroDescriptionOfPurchaseAgreementTerms_160" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AdditionalRightToInvest" xlink:label="loc_alxneuroAdditionalRightToInvest_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_alxneuroAdditionalRightToInvest_160" xlink:type="arc" order="15" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>alxneuro-20220731_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_NoteRecievableForCommonStockRelatedPartyMember" xlink:label="alxneuro_NoteRecievableForCommonStockRelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_NoteRecievableForCommonStockRelatedPartyMember" xlink:to="alxneuro_NoteRecievableForCommonStockRelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_NoteRecievableForCommonStockRelatedPartyMember_lbl" xml:lang="en-US">Note Recievable For Common Stock Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ConvertibleNotesMember" xlink:label="alxneuro_ConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ConvertibleNotesMember" xlink:to="alxneuro_ConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_ConvertibleNotesMember_lbl" xml:lang="en-US">Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AultLifeSciencesFundLLCMember" xlink:label="alxneuro_AultLifeSciencesFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_AultLifeSciencesFundLLCMember" xlink:to="alxneuro_AultLifeSciencesFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_AultLifeSciencesFundLLCMember_lbl" xml:lang="en-US">Ault Life Sciences Fund L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_SecuritiesPurchaseAgreementMember" xlink:label="alxneuro_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_SecuritiesPurchaseAgreementMember" xlink:to="alxneuro_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_SpartanCapitalSecuritiesMember" xlink:label="alxneuro_SpartanCapitalSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_SpartanCapitalSecuritiesMember" xlink:to="alxneuro_SpartanCapitalSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_SpartanCapitalSecuritiesMember_lbl" xml:lang="en-US">Spartan Capital Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_StockIncentivePlan2016Member" xlink:label="alxneuro_StockIncentivePlan2016Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_StockIncentivePlan2016Member" xlink:to="alxneuro_StockIncentivePlan2016Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_StockIncentivePlan2016Member_lbl" xml:lang="en-US">Stock Incentive Plan2016 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_PerformanceContingentStockOptionsMember" xlink:label="alxneuro_PerformanceContingentStockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_PerformanceContingentStockOptionsMember" xlink:to="alxneuro_PerformanceContingentStockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_PerformanceContingentStockOptionsMember_lbl" xml:lang="en-US">Performance Contingent Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_KeyEmployeesAndDirectorMember" xlink:label="alxneuro_KeyEmployeesAndDirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_KeyEmployeesAndDirectorMember" xlink:to="alxneuro_KeyEmployeesAndDirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_KeyEmployeesAndDirectorMember_lbl" xml:lang="en-US">Key Employees and Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_UnamortizedStockBasedCompensationMember" xlink:label="alxneuro_UnamortizedStockBasedCompensationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_UnamortizedStockBasedCompensationMember" xlink:to="alxneuro_UnamortizedStockBasedCompensationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_UnamortizedStockBasedCompensationMember_lbl" xml:lang="en-US">Unamortized Stock Based Compensation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_EmployeesAndConsultantsMember" xlink:label="alxneuro_EmployeesAndConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_EmployeesAndConsultantsMember" xlink:to="alxneuro_EmployeesAndConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_EmployeesAndConsultantsMember_lbl" xml:lang="en-US">Employees and Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ExercisePrice1Member" xlink:label="alxneuro_ExercisePrice1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ExercisePrice1Member" xlink:to="alxneuro_ExercisePrice1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_ExercisePrice1Member_lbl" xml:lang="en-US">Exercise Price1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ExercisePrice2Member" xlink:label="alxneuro_ExercisePrice2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ExercisePrice2Member" xlink:to="alxneuro_ExercisePrice2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_ExercisePrice2Member_lbl" xml:lang="en-US">Exercise Price 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ExercisePrice3Member" xlink:label="alxneuro_ExercisePrice3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ExercisePrice3Member" xlink:to="alxneuro_ExercisePrice3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_ExercisePrice3Member_lbl" xml:lang="en-US">Exercise Price 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ExercisePriceFiftySixMember" xlink:label="alxneuro_ExercisePriceFiftySixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ExercisePriceFiftySixMember" xlink:to="alxneuro_ExercisePriceFiftySixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_ExercisePriceFiftySixMember_lbl" xml:lang="en-US">Exercise Price Fifty Six [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ExercisePrice4Member" xlink:label="alxneuro_ExercisePrice4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ExercisePrice4Member" xlink:to="alxneuro_ExercisePrice4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_ExercisePrice4Member_lbl" xml:lang="en-US">Exercise Price 4 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ExercisePriceFiftySevenMember" xlink:label="alxneuro_ExercisePriceFiftySevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ExercisePriceFiftySevenMember" xlink:to="alxneuro_ExercisePriceFiftySevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_ExercisePriceFiftySevenMember_lbl" xml:lang="en-US">Exercise Price Fifty Seven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Option Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_DigitalPowerLendingMember" xlink:label="alxneuro_DigitalPowerLendingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_DigitalPowerLendingMember" xlink:to="alxneuro_DigitalPowerLendingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_DigitalPowerLendingMember_lbl" xml:lang="en-US">Digital Power Lending [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AL002LicenseMember" xlink:label="alxneuro_AL002LicenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_AL002LicenseMember" xlink:to="alxneuro_AL002LicenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_AL002LicenseMember_lbl" xml:lang="en-US">A L002 License [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AL001LicenseMember" xlink:label="alxneuro_AL001LicenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_AL001LicenseMember" xlink:to="alxneuro_AL001LicenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_AL001LicenseMember_lbl" xml:lang="en-US">A L001 License [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AdditionalAL001LicenseMember" xlink:label="alxneuro_AdditionalAL001LicenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_AdditionalAL001LicenseMember" xlink:to="alxneuro_AdditionalAL001LicenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_AdditionalAL001LicenseMember_lbl" xml:lang="en-US">Additional A L001 License [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_LicenseEventsAxis" xlink:label="alxneuro_LicenseEventsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_LicenseEventsAxis" xlink:to="alxneuro_LicenseEventsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_LicenseEventsAxis_lbl" xml:lang="en-US">License Events [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_PreINDMeetingMember" xlink:label="alxneuro_PreINDMeetingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_PreINDMeetingMember" xlink:to="alxneuro_PreINDMeetingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_PreINDMeetingMember_lbl" xml:lang="en-US">Pre I N D Meeting [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_IndApplicationFilingMember" xlink:label="alxneuro_IndApplicationFilingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_IndApplicationFilingMember" xlink:to="alxneuro_IndApplicationFilingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_IndApplicationFilingMember_lbl" xml:lang="en-US">Ind Application Filing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_UponFirstDosingOfPatientInClinicalTrialMember" xlink:label="alxneuro_UponFirstDosingOfPatientInClinicalTrialMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_UponFirstDosingOfPatientInClinicalTrialMember" xlink:to="alxneuro_UponFirstDosingOfPatientInClinicalTrialMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_UponFirstDosingOfPatientInClinicalTrialMember_lbl" xml:lang="en-US">Upon First Dosing of Patient in Clinical Trial [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_UponCompletionOfFirstPatientDosingMember" xlink:label="alxneuro_UponCompletionOfFirstPatientDosingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_UponCompletionOfFirstPatientDosingMember" xlink:to="alxneuro_UponCompletionOfFirstPatientDosingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_UponCompletionOfFirstPatientDosingMember_lbl" xml:lang="en-US">Upon Completion of First Patient Dosing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_UponCompletionOfFirstClinicalTrialMember" xlink:label="alxneuro_UponCompletionOfFirstClinicalTrialMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_UponCompletionOfFirstClinicalTrialMember" xlink:to="alxneuro_UponCompletionOfFirstClinicalTrialMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_UponCompletionOfFirstClinicalTrialMember_lbl" xml:lang="en-US">Upon Completion of First Clinical Trial [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_UponFdaApprovalMember" xlink:label="alxneuro_UponFdaApprovalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_UponFdaApprovalMember" xlink:to="alxneuro_UponFdaApprovalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_UponFdaApprovalMember_lbl" xml:lang="en-US">Upon Fda Approval [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_UponFirstPatientTreatedInPhase3ClinicalTrialMember" xlink:label="alxneuro_UponFirstPatientTreatedInPhase3ClinicalTrialMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_UponFirstPatientTreatedInPhase3ClinicalTrialMember" xlink:to="alxneuro_UponFirstPatientTreatedInPhase3ClinicalTrialMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_UponFirstPatientTreatedInPhase3ClinicalTrialMember_lbl" xml:lang="en-US">Upon First Patient Treated In Phase3 Clinical Trial [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_SecuritiesPurchaseAgreementsMember" xlink:label="alxneuro_SecuritiesPurchaseAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_SecuritiesPurchaseAgreementsMember" xlink:to="alxneuro_SecuritiesPurchaseAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_SecuritiesPurchaseAgreementsMember_lbl" xml:lang="en-US">Securities Purchase Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ALSFMember" xlink:label="alxneuro_ALSFMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ALSFMember" xlink:to="alxneuro_ALSFMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_ALSFMember_lbl" xml:lang="en-US">A L S F [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AultGlobalMember" xlink:label="alxneuro_AultGlobalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_AultGlobalMember" xlink:to="alxneuro_AultGlobalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_AultGlobalMember_lbl" xml:lang="en-US">Ault Global [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ConvertiblePromissoryNoteMember" xlink:label="alxneuro_ConvertiblePromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ConvertiblePromissoryNoteMember" xlink:to="alxneuro_ConvertiblePromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_ConvertiblePromissoryNoteMember_lbl" xml:lang="en-US">Convertible Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_FinalTrancheMember" xlink:label="alxneuro_FinalTrancheMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_FinalTrancheMember" xlink:to="alxneuro_FinalTrancheMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_FinalTrancheMember_lbl" xml:lang="en-US">Final Tranche [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">&#160;ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">&#160;CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">&#160;Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">&#160;Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">&#160;TOTAL CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">&#160;Property, plant and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">&#160;TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">&#160;LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">&#160;CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">&#160;Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">&#160;Related party payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">&#160;TOTAL CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">&#160;TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">&#160;COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">&#160;STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">&#160;Convertible Preferred stock, $0.0001 par value: 10,000,000 shares authorized; &#160;Series A Convertible Preferred Stock, $0.0001 stated value per share, 1,360,000 shares designated; &#160;nil issued and outstanding as of July 31, 2022 and April 30, 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">&#160;Common stock, $0.0001 par value: 300,000,000 shares authorized; 95,481,790 &#160;shares issued and outstanding as of July 31, 2022 and April 30, 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">&#160;Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_NoteReceivableForCommonStockRelatedParty" xlink:label="alxneuro_NoteReceivableForCommonStockRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_NoteReceivableForCommonStockRelatedParty" xlink:to="alxneuro_NoteReceivableForCommonStockRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_NoteReceivableForCommonStockRelatedParty_lbl" xml:lang="en-US">&#160;Note receivable for common stock &#8211; related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">&#160;Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">&#160;TOTAL STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">&#160;TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_PreferredStockSharesDesignated" xlink:label="alxneuro_PreferredStockSharesDesignated" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_PreferredStockSharesDesignated" xlink:to="alxneuro_PreferredStockSharesDesignated_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_PreferredStockSharesDesignated_lbl" xml:lang="en-US">Preferred stock shares designated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">&#160;OPERATING EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">&#160;Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">&#160;General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">&#160;Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">&#160;Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">&#160;OTHER EXPENSE, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">&#160;Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">&#160;Total other expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">&#160;NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">&#160;Basic and diluted net loss per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">&#160;Basic and diluted weighted average common shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_StockbasedCompensationToEmployeesAndConsultants" xlink:label="alxneuro_StockbasedCompensationToEmployeesAndConsultants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_StockbasedCompensationToEmployeesAndConsultants" xlink:to="alxneuro_StockbasedCompensationToEmployeesAndConsultants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_StockbasedCompensationToEmployeesAndConsultants_lbl" xml:lang="en-US">Stock-based compensation to employees and consultants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">&#160;Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_StockIssuedDuringPeriodValueNewIssues2" xlink:label="alxneuro_StockIssuedDuringPeriodValueNewIssues2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_StockIssuedDuringPeriodValueNewIssues2" xlink:to="alxneuro_StockIssuedDuringPeriodValueNewIssues2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_StockIssuedDuringPeriodValueNewIssues2_lbl" xml:lang="en-US">Proceeds from sale of common stocks and warrants-related party</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_StockIssuedDuringPeriodSharesNewIssues2" xlink:label="alxneuro_StockIssuedDuringPeriodSharesNewIssues2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_StockIssuedDuringPeriodSharesNewIssues2" xlink:to="alxneuro_StockIssuedDuringPeriodSharesNewIssues2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_StockIssuedDuringPeriodSharesNewIssues2_lbl" xml:lang="en-US">Proceeds from sale of common stocks and warrants-related party (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from stock option exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from stock option exercise (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_StockIssuedDuringPeriodValueNewIssues3" xlink:label="alxneuro_StockIssuedDuringPeriodValueNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_StockIssuedDuringPeriodValueNewIssues3" xlink:to="alxneuro_StockIssuedDuringPeriodValueNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_StockIssuedDuringPeriodValueNewIssues3_lbl" xml:lang="en-US">Proceeds from initial public offering, net of underwriters' discounts and commissions and issuance costs of $1.5 million</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="alxneuro_StockIssuedDuringPeriodSharesNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="alxneuro_StockIssuedDuringPeriodSharesNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_StockIssuedDuringPeriodSharesNewIssues3_lbl" xml:lang="en-US">Proceeds from initial public offering, net of underwriters' discounts and commissions and issuance costs of $1.5 million (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ConversionOfSeriesAConvertibleStock" xlink:label="alxneuro_ConversionOfSeriesAConvertibleStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ConversionOfSeriesAConvertibleStock" xlink:to="alxneuro_ConversionOfSeriesAConvertibleStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_ConversionOfSeriesAConvertibleStock_lbl" xml:lang="en-US">Conversion of Series A convertible stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of Series A convertible stock (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Interest expense - debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation to employees and consultants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from the issuance of common stock and warrants - related party, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from stock option exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts" xlink:label="alxneuro_ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts" xlink:to="alxneuro_ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts_lbl" xml:lang="en-US">Proceeds from initial public offering, net of underwriters&#8217; discounts and commissions and issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net (decrease) increase in cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">Cash at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-cash financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_FairValueOfWarrantsIssuedInConnectionWithIpo" xlink:label="alxneuro_FairValueOfWarrantsIssuedInConnectionWithIpo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_FairValueOfWarrantsIssuedInConnectionWithIpo" xlink:to="alxneuro_FairValueOfWarrantsIssuedInConnectionWithIpo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_FairValueOfWarrantsIssuedInConnectionWithIpo_lbl" xml:lang="en-US">Fair value of warrants issued in connection with initial public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty" xlink:label="alxneuro_FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty" xlink:to="alxneuro_FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty_lbl" xml:lang="en-US">Fair value of warrants issued in connection with March 2021 securities purchase agreement, related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">LIQUIDITY AND GOING CONCERN</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_DisclosureNoteReceivableForCommonStockRelatedPartyAbstract" xlink:label="alxneuro_DisclosureNoteReceivableForCommonStockRelatedPartyAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_DisclosureNoteReceivableForCommonStockRelatedPartyAbstract" xlink:to="alxneuro_DisclosureNoteReceivableForCommonStockRelatedPartyAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_DisclosureNoteReceivableForCommonStockRelatedPartyAbstract_lbl" xml:lang="en-US">Note Receivable For Common Stock Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_MortgageNoteReceivableFromRelatedPartyTextBlock" xlink:label="alxneuro_MortgageNoteReceivableFromRelatedPartyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_MortgageNoteReceivableFromRelatedPartyTextBlock" xlink:to="alxneuro_MortgageNoteReceivableFromRelatedPartyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_MortgageNoteReceivableFromRelatedPartyTextBlock_lbl" xml:lang="en-US">NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_DisclosureWarrantsAbstract" xlink:label="alxneuro_DisclosureWarrantsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_DisclosureWarrantsAbstract" xlink:to="alxneuro_DisclosureWarrantsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_DisclosureWarrantsAbstract_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_WarrantsDisclosureTextBlock" xlink:label="alxneuro_WarrantsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_WarrantsDisclosureTextBlock" xlink:to="alxneuro_WarrantsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_WarrantsDisclosureTextBlock_lbl" xml:lang="en-US">WARRANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">OTHER RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">EQUITY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Accounting Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_WarrantsPolicyTextBlock" xlink:label="alxneuro_WarrantsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_WarrantsPolicyTextBlock" xlink:to="alxneuro_WarrantsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alxneuro_WarrantsPolicyTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Standards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">The following sets forth the number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have been excluded from the computation of loss per common share:</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="alxneuro_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="alxneuro_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Prepaid expenses and other current assets are as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">A summary of stock option activity for the three months ended July 31, 2022 is presented below:</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock" xlink:label="alxneuro_ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock" xlink:to="alxneuro_ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock_lbl" xml:lang="en-US">The estimated fair value of stock options granted to employees and consultants during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US">The Company&#8217;s results of operations include expenses relating to stock-based compensation for three months ended July 31, 2022 and 2021, that were comprised as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xml:lang="en-US">The following table summarizes information about Common Stock warrants outstanding and exercisable at July 31, 2022:</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock" xlink:label="alxneuro_ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock" xlink:to="alxneuro_ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock_lbl" xml:lang="en-US">The estimated fair value of warrants granted during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US">Original AL001 License:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_NumberOfStockExcluded" xlink:label="alxneuro_NumberOfStockExcluded" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_NumberOfStockExcluded" xlink:to="alxneuro_NumberOfStockExcluded_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_NumberOfStockExcluded_lbl" xml:lang="en-US">Number Of Stock Excluded</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares purchase (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Number of shares purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrant terms</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_LongTermDebtAverageAmountOfOutstanding" xlink:label="alxneuro_LongTermDebtAverageAmountOfOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_LongTermDebtAverageAmountOfOutstanding" xlink:to="alxneuro_LongTermDebtAverageAmountOfOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_LongTermDebtAverageAmountOfOutstanding_lbl" xml:lang="en-US">Outstanding receivable amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_PrepaidInsurance1" xlink:label="alxneuro_PrepaidInsurance1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_PrepaidInsurance1" xlink:to="alxneuro_PrepaidInsurance1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_PrepaidInsurance1_lbl" xml:lang="en-US">Purchase D&amp;O Insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_UnamortizedPrepaidExpense" xlink:label="alxneuro_UnamortizedPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_UnamortizedPrepaidExpense" xlink:to="alxneuro_UnamortizedPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_UnamortizedPrepaidExpense_lbl" xml:lang="en-US">Unamortized prepaid expense</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_PrepaidConsultingFees" xlink:label="alxneuro_PrepaidConsultingFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_PrepaidConsultingFees" xlink:to="alxneuro_PrepaidConsultingFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_PrepaidConsultingFees_lbl" xml:lang="en-US">Prepaid consulting fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Balance at begining (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Balance at begining (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Balance at begining</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="alxneuro_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="alxneuro_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Balance at begining</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" xlink:label="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" xlink:to="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted_lbl" xml:lang="en-US">Options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross" xlink:label="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross" xlink:to="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross_lbl" xml:lang="en-US">Options exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited" xlink:label="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited" xlink:to="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited_lbl" xml:lang="en-US">Options expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2_lbl" xml:lang="en-US">Balance at end (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Balance at end (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Balance at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Balance at end (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Balance at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Options vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options vested and expected to vest at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Options vested and expected to vest at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Options vested and expected to vest at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options exercisable at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options exercisable at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Options exercisable at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Options exercisable at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected Term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares authorized for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional number of shares available for issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Maximum potential expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xml:lang="en-US">Terms of warrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_2_lbl" xml:lang="en-US">Weighted-average period vested and expected to vest at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercse price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number warrant outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Weighted average remaining contractual life (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:label="alxneuro_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:to="alxneuro_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US">Warrant outstanding, weighted average exercise price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ClassOfWarrantOrRightExercisable" xlink:label="alxneuro_ClassOfWarrantOrRightExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ClassOfWarrantOrRightExercisable" xlink:to="alxneuro_ClassOfWarrantOrRightExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_ClassOfWarrantOrRightExercisable_lbl" xml:lang="en-US">Number of warrant exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:label="alxneuro_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:to="alxneuro_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Warrant exercisable, weighted average exercise price (in dollars per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_3_lbl" xml:lang="en-US">Expected term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Description of related party transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Number of shares sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xml:lang="en-US">Description of related party transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentMilestones" xlink:label="us-gaap_LongTermPurchaseCommitmentMilestones" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentMilestones" xlink:to="us-gaap_LongTermPurchaseCommitmentMilestones_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentMilestones_lbl" xml:lang="en-US">Description of milestones</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="us-gaap_ProductLiabilityContingencyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityContingencyTable" xlink:to="us-gaap_ProductLiabilityContingencyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductLiabilityContingencyTable_lbl" xml:lang="en-US">Product Liability Contingency [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="us-gaap_ProductLiabilityContingencyLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityContingencyLineItems" xlink:to="us-gaap_ProductLiabilityContingencyLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductLiabilityContingencyLineItems_lbl" xml:lang="en-US">Product Liability Contingency [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="us-gaap_OtherCommitmentsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDescription" xlink:to="us-gaap_OtherCommitmentsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDescription_lbl" xml:lang="en-US">Due Date</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_PercentageOfRoyaltyPaymentsOnNetSalesOfProduct." xlink:label="alxneuro_PercentageOfRoyaltyPaymentsOnNetSalesOfProduct." />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_PercentageOfRoyaltyPaymentsOnNetSalesOfProduct." xlink:to="alxneuro_PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._lbl" xml:lang="en-US">Percentage of royalty payments on net sales of product</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_DescriptionOfLicensesAgreements" xlink:label="alxneuro_DescriptionOfLicensesAgreements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_DescriptionOfLicensesAgreements" xlink:to="alxneuro_DescriptionOfLicensesAgreements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_DescriptionOfLicensesAgreements_lbl" xml:lang="en-US">Description of licenses agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_InitialLicenseFees" xlink:label="alxneuro_InitialLicenseFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_InitialLicenseFees" xlink:to="alxneuro_InitialLicenseFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_InitialLicenseFees_lbl" xml:lang="en-US">Initial license fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Preferred stock, par or stated value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_NumberOfSharesPurchase" xlink:label="alxneuro_NumberOfSharesPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_NumberOfSharesPurchase" xlink:to="alxneuro_NumberOfSharesPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alxneuro_NumberOfSharesPurchase_lbl" xml:lang="en-US">Number of shares purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_SharesPurchasePrice" xlink:label="alxneuro_SharesPurchasePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_SharesPurchasePrice" xlink:to="alxneuro_SharesPurchasePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_SharesPurchasePrice_lbl" xml:lang="en-US">Shares purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_SharesPurchasePricePerShares" xlink:label="alxneuro_SharesPurchasePricePerShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_SharesPurchasePricePerShares" xlink:to="alxneuro_SharesPurchasePricePerShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_SharesPurchasePricePerShares_lbl" xml:lang="en-US">Shares purchase price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:label="alxneuro_StockIssuedDuringPeriodSharesNewIssuesOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:to="alxneuro_StockIssuedDuringPeriodSharesNewIssuesOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_StockIssuedDuringPeriodSharesNewIssuesOne_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from sale of equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AdvanceFromRelatedParties" xlink:label="alxneuro_AdvanceFromRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_AdvanceFromRelatedParties" xlink:to="alxneuro_AdvanceFromRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_AdvanceFromRelatedParties_lbl" xml:lang="en-US">Advance from related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_SharesValueSurrenderForCancellation" xlink:label="alxneuro_SharesValueSurrenderForCancellation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_SharesValueSurrenderForCancellation" xlink:to="alxneuro_SharesValueSurrenderForCancellation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_SharesValueSurrenderForCancellation_lbl" xml:lang="en-US">Shares value surrender for cancellation</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_DescriptionOfPurchaseAgreementTerms" xlink:label="alxneuro_DescriptionOfPurchaseAgreementTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_DescriptionOfPurchaseAgreementTerms" xlink:to="alxneuro_DescriptionOfPurchaseAgreementTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_DescriptionOfPurchaseAgreementTerms_lbl" xml:lang="en-US">Description of purchase agreement terms</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AdditionalRightToInvest" xlink:label="alxneuro_AdditionalRightToInvest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_AdditionalRightToInvest" xlink:to="alxneuro_AdditionalRightToInvest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_AdditionalRightToInvest_lbl" xml:lang="en-US">Additional right to invest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_NoteReceivableForCommonStockRelatedParty" xlink:to="alxneuro_NoteReceivableForCommonStockRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_NoteReceivableForCommonStockRelatedParty_doc" xml:lang="en-US">The element represents note receivable for common stock related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_PreferredStockSharesDesignated" xlink:to="alxneuro_PreferredStockSharesDesignated_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_PreferredStockSharesDesignated_doc" xml:lang="en-US">The element represents preferred stock shares designated.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_MortgageNoteReceivableFromRelatedPartyTextBlock" xlink:to="alxneuro_MortgageNoteReceivableFromRelatedPartyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_MortgageNoteReceivableFromRelatedPartyTextBlock_doc" xml:lang="en-US">The element represents mortgage note receivable from related party text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="alxneuro_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_doc" xml:lang="en-US">The element represents schedule of prepaid expenses and other current assets table text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock" xlink:to="alxneuro_ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock_doc" xml:lang="en-US">The element represents schedule of stock options granted to employees and consultants table text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_WarrantsDisclosureTextBlock" xlink:to="alxneuro_WarrantsDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_WarrantsDisclosureTextBlock_doc" xml:lang="en-US">The element represents warrants disclosure text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts" xlink:to="alxneuro_ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts_doc" xml:lang="en-US">The element represents proceeds from initial public offering net of underwriters discounts and commissions and issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock" xlink:to="alxneuro_ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock_doc" xml:lang="en-US">The element represents schedule of estimated fair value of warrants granted table text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty" xlink:to="alxneuro_FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty_doc" xml:lang="en-US">The element represents fair value of warrants issued in connection with march2021 securities purchase agreement related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_NoteRecievableForCommonStockRelatedPartyMember" xlink:to="alxneuro_NoteRecievableForCommonStockRelatedPartyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_NoteRecievableForCommonStockRelatedPartyMember_doc" xml:lang="en-US">The element represents note recievable for common stock related party member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_StockIssuedDuringPeriodValueNewIssues2" xlink:to="alxneuro_StockIssuedDuringPeriodValueNewIssues2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_StockIssuedDuringPeriodValueNewIssues2_doc" xml:lang="en-US">The element represents stock issued during period value new issues2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_StockIssuedDuringPeriodValueNewIssues3" xlink:to="alxneuro_StockIssuedDuringPeriodValueNewIssues3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_StockIssuedDuringPeriodValueNewIssues3_doc" xml:lang="en-US">The element represents stock issued during period value new issues3.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ConversionOfSeriesAConvertibleStock" xlink:to="alxneuro_ConversionOfSeriesAConvertibleStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_ConversionOfSeriesAConvertibleStock_doc" xml:lang="en-US">The element represents conversion of series a convertible stock.</link:label>
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ConversionOfSeriesAConvertibleStockShares" xlink:label="alxneuro_ConversionOfSeriesAConvertibleStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ConversionOfSeriesAConvertibleStockShares" xlink:to="alxneuro_ConversionOfSeriesAConvertibleStockShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_ConversionOfSeriesAConvertibleStockShares_doc" xml:lang="en-US">The element represents conversion of series a convertible stock shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_StockIssuedDuringPeriodSharesNewIssues2" xlink:to="alxneuro_StockIssuedDuringPeriodSharesNewIssues2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_StockIssuedDuringPeriodSharesNewIssues2_doc" xml:lang="en-US">The element represents stock issued during period shares new issues2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="alxneuro_StockIssuedDuringPeriodSharesNewIssues3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_StockIssuedDuringPeriodSharesNewIssues3_doc" xml:lang="en-US">The element represents stock issued during period shares new issues3.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_NumberOfStockExcluded" xlink:to="alxneuro_NumberOfStockExcluded_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_NumberOfStockExcluded_doc" xml:lang="en-US">The element represents number of stock excluded.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_NumberOfSharesPurchase" xlink:to="alxneuro_NumberOfSharesPurchase_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_NumberOfSharesPurchase_doc" xml:lang="en-US">The element represents number of shares purchase.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_SecuritiesPurchaseAgreementsMember" xlink:to="alxneuro_SecuritiesPurchaseAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_SecuritiesPurchaseAgreementsMember_doc" xml:lang="en-US">The element represents securities purchase agreements member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ALSFMember" xlink:to="alxneuro_ALSFMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_ALSFMember_doc" xml:lang="en-US">The element represents a l s f member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_SharesPurchasePrice" xlink:to="alxneuro_SharesPurchasePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_SharesPurchasePrice_doc" xml:lang="en-US">The element represents shares purchase price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_SecuritiesPurchaseAgreementMember" xlink:to="alxneuro_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">The element represents securities purchase agreement member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_SharesPurchasePricePerShares" xlink:to="alxneuro_SharesPurchasePricePerShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_SharesPurchasePricePerShares_doc" xml:lang="en-US">The element represents shares purchase price per shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:to="alxneuro_StockIssuedDuringPeriodSharesNewIssuesOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_StockIssuedDuringPeriodSharesNewIssuesOne_doc" xml:lang="en-US">The element represents stock issued during period shares new issues one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_DigitalPowerLendingMember" xlink:to="alxneuro_DigitalPowerLendingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_DigitalPowerLendingMember_doc" xml:lang="en-US">The element represents digital power lending member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_AdvanceFromRelatedParties" xlink:to="alxneuro_AdvanceFromRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_AdvanceFromRelatedParties_doc" xml:lang="en-US">The element represents advance from related parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_SharesValueSurrenderForCancellation" xlink:to="alxneuro_SharesValueSurrenderForCancellation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_SharesValueSurrenderForCancellation_doc" xml:lang="en-US">The element represents shares value surrender for cancellation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_AultGlobalMember" xlink:to="alxneuro_AultGlobalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_AultGlobalMember_doc" xml:lang="en-US">The element represents ault global member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ConvertiblePromissoryNoteMember" xlink:to="alxneuro_ConvertiblePromissoryNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_ConvertiblePromissoryNoteMember_doc" xml:lang="en-US">The element represents convertible promissory note member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_DescriptionOfPurchaseAgreementTerms" xlink:to="alxneuro_DescriptionOfPurchaseAgreementTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_DescriptionOfPurchaseAgreementTerms_doc" xml:lang="en-US">The element represents description of purchase agreement terms.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_AdditionalRightToInvest" xlink:to="alxneuro_AdditionalRightToInvest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_AdditionalRightToInvest_doc" xml:lang="en-US">The element represents additional right to invest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_FinalTrancheMember" xlink:to="alxneuro_FinalTrancheMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_FinalTrancheMember_doc" xml:lang="en-US">The element represents final tranche member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_PercentageOfRoyaltyPaymentsOnNetSalesOfProduct." xlink:to="alxneuro_PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._doc" xml:lang="en-US">The element represents percentage of royalty payments on net sales of product..</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_AL002LicenseMember" xlink:to="alxneuro_AL002LicenseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_AL002LicenseMember_doc" xml:lang="en-US">The element represents a l002 license member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_AL001LicenseMember" xlink:to="alxneuro_AL001LicenseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_AL001LicenseMember_doc" xml:lang="en-US">The element represents a l001 license member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_DescriptionOfLicensesAgreements" xlink:to="alxneuro_DescriptionOfLicensesAgreements_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_DescriptionOfLicensesAgreements_doc" xml:lang="en-US">The element represents description of licenses agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_AdditionalAL001LicenseMember" xlink:to="alxneuro_AdditionalAL001LicenseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_AdditionalAL001LicenseMember_doc" xml:lang="en-US">The element represents additional a l001 license member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_LicenseEventsAxis" xlink:to="alxneuro_LicenseEventsAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_LicenseEventsAxis_doc" xml:lang="en-US">The element represents license events axis.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_PreINDMeetingMember" xlink:to="alxneuro_PreINDMeetingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_PreINDMeetingMember_doc" xml:lang="en-US">The element represents pre i n d meeting member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_IndApplicationFilingMember" xlink:to="alxneuro_IndApplicationFilingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_IndApplicationFilingMember_doc" xml:lang="en-US">The element represents ind application filing member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_UponFirstDosingOfPatientInClinicalTrialMember" xlink:to="alxneuro_UponFirstDosingOfPatientInClinicalTrialMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_UponFirstDosingOfPatientInClinicalTrialMember_doc" xml:lang="en-US">The element represents upon first dosing of patient in clinical trial member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_UponCompletionOfFirstPatientDosingMember" xlink:to="alxneuro_UponCompletionOfFirstPatientDosingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_UponCompletionOfFirstPatientDosingMember_doc" xml:lang="en-US">The element represents upon completion of first patient dosing member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_UponCompletionOfFirstClinicalTrialMember" xlink:to="alxneuro_UponCompletionOfFirstClinicalTrialMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_UponCompletionOfFirstClinicalTrialMember_doc" xml:lang="en-US">The element represents upon completion of first clinical trial member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_UponFdaApprovalMember" xlink:to="alxneuro_UponFdaApprovalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_UponFdaApprovalMember_doc" xml:lang="en-US">The element represents upon fda approval member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_LongTermDebtAverageAmountOfOutstanding" xlink:to="alxneuro_LongTermDebtAverageAmountOfOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_LongTermDebtAverageAmountOfOutstanding_doc" xml:lang="en-US">The element represents long term debt average amount of outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_PrepaidInsurance1" xlink:to="alxneuro_PrepaidInsurance1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_PrepaidInsurance1_doc" xml:lang="en-US">The element represents prepaid insurance1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_UponFirstPatientTreatedInPhase3ClinicalTrialMember" xlink:to="alxneuro_UponFirstPatientTreatedInPhase3ClinicalTrialMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_UponFirstPatientTreatedInPhase3ClinicalTrialMember_doc" xml:lang="en-US">The element represents upon first patient treated in phase3 clinical trial member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_StockIncentivePlan2016Member" xlink:to="alxneuro_StockIncentivePlan2016Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_StockIncentivePlan2016Member_doc" xml:lang="en-US">The element represents stock incentive plan2016 member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_InitialLicenseFees" xlink:to="alxneuro_InitialLicenseFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_InitialLicenseFees_doc" xml:lang="en-US">The element represents initial license fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ExercisePrice1Member" xlink:to="alxneuro_ExercisePrice1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_ExercisePrice1Member_doc" xml:lang="en-US">The element represents exercise price1 member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ExercisePrice2Member" xlink:to="alxneuro_ExercisePrice2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_ExercisePrice2Member_doc" xml:lang="en-US">The element represents exercise price2 member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ExercisePrice3Member" xlink:to="alxneuro_ExercisePrice3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_ExercisePrice3Member_doc" xml:lang="en-US">The element represents exercise price3 member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ExercisePrice4Member" xlink:to="alxneuro_ExercisePrice4Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_ExercisePrice4Member_doc" xml:lang="en-US">The element represents exercise price4 member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ExercisePriceFiftySixMember" xlink:to="alxneuro_ExercisePriceFiftySixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_ExercisePriceFiftySixMember_doc" xml:lang="en-US">The element represents exercise price fifty six member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ExercisePriceFiftySevenMember" xlink:to="alxneuro_ExercisePriceFiftySevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_ExercisePriceFiftySevenMember_doc" xml:lang="en-US">The element represents exercise price fifty seven member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:to="alxneuro_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_doc" xml:lang="en-US">The element represents class of warrant or right weighted average exercise price of warrants or rights.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ClassOfWarrantOrRightExercisable" xlink:to="alxneuro_ClassOfWarrantOrRightExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_ClassOfWarrantOrRightExercisable_doc" xml:lang="en-US">The element represents class of warrant or right exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:to="alxneuro_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">The element represents class of warrant or right exercisable weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" xlink:to="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award number of shares available for grant options granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited" xlink:to="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award number of shares available for grant options cancelled or forfeited.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross" xlink:to="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross_doc" xml:lang="en-US">The element represents share based compensation arrangement by share based payment award options exercised in period gross.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_EmployeesAndConsultantsMember" xlink:to="alxneuro_EmployeesAndConsultantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_EmployeesAndConsultantsMember_doc" xml:lang="en-US">The element represents employees and consultants member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_PerformanceContingentStockOptionsMember" xlink:to="alxneuro_PerformanceContingentStockOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_PerformanceContingentStockOptionsMember_doc" xml:lang="en-US">The element represents performance contingent stock options member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_KeyEmployeesAndDirectorMember" xlink:to="alxneuro_KeyEmployeesAndDirectorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_KeyEmployeesAndDirectorMember_doc" xml:lang="en-US">The element represents key employees and director member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_UnamortizedStockBasedCompensationMember" xlink:to="alxneuro_UnamortizedStockBasedCompensationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_UnamortizedStockBasedCompensationMember_doc" xml:lang="en-US">The element represents unamortized stock based compensation member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_WarrantsPolicyTextBlock" xlink:to="alxneuro_WarrantsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_WarrantsPolicyTextBlock_doc" xml:lang="en-US">The element represents warrants policy text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_ConvertibleNotesMember" xlink:to="alxneuro_ConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_ConvertibleNotesMember_doc" xml:lang="en-US">The element represents convertible notes member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_UnamortizedPrepaidExpense" xlink:to="alxneuro_UnamortizedPrepaidExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_UnamortizedPrepaidExpense_doc" xml:lang="en-US">The element represents unamortized prepaid expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_PrepaidConsultingFees" xlink:to="alxneuro_PrepaidConsultingFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_PrepaidConsultingFees_doc" xml:lang="en-US">The element represents prepaid consulting fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_SpartanCapitalSecuritiesMember" xlink:to="alxneuro_SpartanCapitalSecuritiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_SpartanCapitalSecuritiesMember_doc" xml:lang="en-US">The element represents spartan capital securities member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="alxneuro_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">The element represents sharebased compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_StockbasedCompensationToEmployeesAndConsultants" xlink:to="alxneuro_StockbasedCompensationToEmployeesAndConsultants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_StockbasedCompensationToEmployeesAndConsultants_doc" xml:lang="en-US">The element represents stockbased compensation to employees and consultants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_FairValueOfWarrantsIssuedInConnectionWithIpo" xlink:to="alxneuro_FairValueOfWarrantsIssuedInConnectionWithIpo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alxneuro_FairValueOfWarrantsIssuedInConnectionWithIpo_doc" xml:lang="en-US">The element represents fair value of warrants issued in connection with ipo.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_2_lbl" xml:lang="en-US">Costs and Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_2_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_WarrantsPolicyTextBlock" xlink:to="alxneuro_WarrantsPolicyTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_WarrantsPolicyTextBlock_3_lbl" xml:lang="en-US">Warrants Policy [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_2_lbl" xml:lang="en-US">Related Party Transaction, Description of Transaction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxneuro_NumberOfSharesPurchase" xlink:to="alxneuro_NumberOfSharesPurchase_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alxneuro_NumberOfSharesPurchase_3_lbl" xml:lang="en-US">Number Of Shares Purchase</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>alxneuro-20220731_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://alzamend.com/role/Cover" xlink:href="alxneuro-20220731.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/BalanceSheets" xlink:href="alxneuro-20220731.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/BalanceSheetsParenthetical" xlink:href="alxneuro-20220731.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/StatementsOfOperations" xlink:href="alxneuro-20220731.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/StatementsOfStockholdersEquity" xlink:href="alxneuro-20220731.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/StatementsOfStockholdersEquityParenthetical" xlink:href="alxneuro-20220731.xsd#StatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/StatementsOfCashFlows" xlink:href="alxneuro-20220731.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/DescriptionOfBusiness" xlink:href="alxneuro-20220731.xsd#DescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/LiquidityAndGoingConcern" xlink:href="alxneuro-20220731.xsd#LiquidityAndGoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/SignificantAccountingPolicies" xlink:href="alxneuro-20220731.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/NoteReceivableForCommonStockRelatedParty" xlink:href="alxneuro-20220731.xsd#NoteReceivableForCommonStockRelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="alxneuro-20220731.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/Stock-basedCompensation" xlink:href="alxneuro-20220731.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/Warrants" xlink:href="alxneuro-20220731.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/OtherRelatedPartyTransactions" xlink:href="alxneuro-20220731.xsd#OtherRelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/CommitmentsAndContingencies" xlink:href="alxneuro-20220731.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/EquityTransactions" xlink:href="alxneuro-20220731.xsd#EquityTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/SubsequentEvents" xlink:href="alxneuro-20220731.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/SignificantAccountingPoliciesPolicies" xlink:href="alxneuro-20220731.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/SignificantAccountingPoliciesTables" xlink:href="alxneuro-20220731.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="alxneuro-20220731.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/Stock-basedCompensationTables" xlink:href="alxneuro-20220731.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/WarrantsTables" xlink:href="alxneuro-20220731.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/CommitmentsAndContingenciesTables" xlink:href="alxneuro-20220731.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/DescriptionOfBusinessDetailsNarrative" xlink:href="alxneuro-20220731.xsd#DescriptionOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:href="alxneuro-20220731.xsd#LiquidityAndGoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails" xlink:href="alxneuro-20220731.xsd#FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="alxneuro-20220731.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative" xlink:href="alxneuro-20220731.xsd#NoteReceivableForCommonStockRelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsAreAsFollowsDetails" xlink:href="alxneuro-20220731.xsd#PrepaidExpensesAndOtherCurrentAssetsAreAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative" xlink:href="alxneuro-20220731.xsd#PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails" xlink:href="alxneuro-20220731.xsd#SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails" xlink:href="alxneuro-20220731.xsd#EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/CompanysResultsOfOperationsIncludeExpensesRelatingToStock-basedCompensationForThreeMonthsEndedJuly312022And2021ThatWereComprisedAsFollowsDetails" xlink:href="alxneuro-20220731.xsd#CompanysResultsOfOperationsIncludeExpensesRelatingToStock-basedCompensationForThreeMonthsEndedJuly312022And2021ThatWereComprisedAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="alxneuro-20220731.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details" xlink:href="alxneuro-20220731.xsd#FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails" xlink:href="alxneuro-20220731.xsd#EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative" xlink:href="alxneuro-20220731.xsd#OtherRelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/OriginalAl001LicenseDetails" xlink:href="alxneuro-20220731.xsd#OriginalAl001LicenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="alxneuro-20220731.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://alzamend.com/role/EquityTransactionsDetailsNarrative" xlink:href="alxneuro-20220731.xsd#EquityTransactionsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_NoteReceivableForCommonStockRelatedParty" xlink:label="loc_alxneuroNoteReceivableForCommonStockRelatedParty" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_alxneuroNoteReceivableForCommonStockRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_PreferredStockSharesDesignated" xlink:label="loc_alxneuroPreferredStockSharesDesignated" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_alxneuroPreferredStockSharesDesignated" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaapCostsAndExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostsAndExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Statements of Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_NoteRecievableForCommonStockRelatedPartyMember" xlink:label="loc_alxneuroNoteRecievableForCommonStockRelatedPartyMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_alxneuroNoteRecievableForCommonStockRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_StockbasedCompensationToEmployeesAndConsultants" xlink:label="loc_alxneuroStockbasedCompensationToEmployeesAndConsultants" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_alxneuroStockbasedCompensationToEmployeesAndConsultants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_StockIssuedDuringPeriodValueNewIssues2" xlink:label="loc_alxneuroStockIssuedDuringPeriodValueNewIssues2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_alxneuroStockIssuedDuringPeriodValueNewIssues2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_StockIssuedDuringPeriodSharesNewIssues2" xlink:label="loc_alxneuroStockIssuedDuringPeriodSharesNewIssues2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_alxneuroStockIssuedDuringPeriodSharesNewIssues2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_alxneuroStockIssuedDuringPeriodValueNewIssues3" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_alxneuroStockIssuedDuringPeriodValueNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_alxneuroStockIssuedDuringPeriodSharesNewIssues3" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_alxneuroStockIssuedDuringPeriodSharesNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ConversionOfSeriesAConvertibleStock" xlink:label="loc_alxneuroConversionOfSeriesAConvertibleStock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_alxneuroConversionOfSeriesAConvertibleStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/StatementsOfStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Condensed Statements of Stockholders&apos; Equity (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts" xlink:label="loc_alxneuroProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_alxneuroProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_FairValueOfWarrantsIssuedInConnectionWithIpo" xlink:label="loc_alxneuroFairValueOfWarrantsIssuedInConnectionWithIpo" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_alxneuroFairValueOfWarrantsIssuedInConnectionWithIpo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty" xlink:label="loc_alxneuroFairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_alxneuroFairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/DescriptionOfBusiness" xlink:title="00000008 - Disclosure - DESCRIPTION OF BUSINESS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/LiquidityAndGoingConcern" xlink:title="00000009 - Disclosure - LIQUIDITY AND GOING CONCERN">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/SignificantAccountingPolicies" xlink:title="00000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/NoteReceivableForCommonStockRelatedParty" xlink:title="00000011 - Disclosure - NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY">
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_DisclosureNoteReceivableForCommonStockRelatedPartyAbstract" xlink:label="loc_alxneuroDisclosureNoteReceivableForCommonStockRelatedPartyAbstract" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_MortgageNoteReceivableFromRelatedPartyTextBlock" xlink:label="loc_alxneuroMortgageNoteReceivableFromRelatedPartyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alxneuroDisclosureNoteReceivableForCommonStockRelatedPartyAbstract" xlink:to="loc_alxneuroMortgageNoteReceivableFromRelatedPartyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000012 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/Stock-basedCompensation" xlink:title="00000013 - Disclosure - STOCK-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/Warrants" xlink:title="00000014 - Disclosure - WARRANTS">
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_DisclosureWarrantsAbstract" xlink:label="loc_alxneuroDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_WarrantsDisclosureTextBlock" xlink:label="loc_alxneuroWarrantsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alxneuroDisclosureWarrantsAbstract" xlink:to="loc_alxneuroWarrantsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/OtherRelatedPartyTransactions" xlink:title="00000015 - Disclosure - OTHER RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/EquityTransactions" xlink:title="00000017 - Disclosure - EQUITY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_WarrantsPolicyTextBlock" xlink:label="loc_alxneuroWarrantsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_alxneuroWarrantsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/SignificantAccountingPoliciesTables" xlink:title="00000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000021 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="loc_alxneuroScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_alxneuroScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/Stock-basedCompensationTables" xlink:title="00000022 - Disclosure - STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock" xlink:label="loc_alxneuroScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_alxneuroScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/WarrantsTables" xlink:title="00000023 - Disclosure - WARRANTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_DisclosureWarrantsAbstract" xlink:label="loc_alxneuroDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfCommonStockOutstandingRollForwardTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alxneuroDisclosureWarrantsAbstract" xlink:to="loc_us-gaapScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock" xlink:label="loc_alxneuroScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alxneuroDisclosureWarrantsAbstract" xlink:to="loc_alxneuroScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/CommitmentsAndContingenciesTables" xlink:title="00000024 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="loc_srtContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_srtContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/DescriptionOfBusinessDetailsNarrative" xlink:title="00000025 - Disclosure - DESCRIPTION OF BUSINESS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:title="00000026 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails" xlink:title="00000027 - Disclosure - The following sets forth the number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have been excluded from the computation of loss per common share: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ConvertibleNotesMember" xlink:label="loc_alxneuroConvertibleNotesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_alxneuroConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_NumberOfStockExcluded" xlink:label="loc_alxneuroNumberOfStockExcluded" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_alxneuroNumberOfStockExcluded" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative" xlink:title="00000029 - Disclosure - NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_DisclosureNoteReceivableForCommonStockRelatedPartyAbstract" xlink:label="loc_alxneuroDisclosureNoteReceivableForCommonStockRelatedPartyAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alxneuroDisclosureNoteReceivableForCommonStockRelatedPartyAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AultLifeSciencesFundLLCMember" xlink:label="loc_alxneuroAultLifeSciencesFundLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_alxneuroAultLifeSciencesFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_SecuritiesPurchaseAgreementMember" xlink:label="loc_alxneuroSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_alxneuroSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_LongTermDebtAverageAmountOfOutstanding" xlink:label="loc_alxneuroLongTermDebtAverageAmountOfOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_alxneuroLongTermDebtAverageAmountOfOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsAreAsFollowsDetails" xlink:title="00000030 - Disclosure - Prepaid expenses and other current assets are as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative" xlink:title="00000031 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_SpartanCapitalSecuritiesMember" xlink:label="loc_alxneuroSpartanCapitalSecuritiesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_alxneuroSpartanCapitalSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_PrepaidInsurance1" xlink:label="loc_alxneuroPrepaidInsurance1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_alxneuroPrepaidInsurance1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_UnamortizedPrepaidExpense" xlink:label="loc_alxneuroUnamortizedPrepaidExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_alxneuroUnamortizedPrepaidExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_PrepaidConsultingFees" xlink:label="loc_alxneuroPrepaidConsultingFees" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_alxneuroPrepaidConsultingFees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails" xlink:title="00000032 - Disclosure - A summary of stock option activity for the three months ended July 31, 2022 is presented below: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_alxneuroSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_alxneuroSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" xlink:label="loc_alxneuroShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_alxneuroShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross" xlink:label="loc_alxneuroShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_alxneuroShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited" xlink:label="loc_alxneuroShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_alxneuroShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails" xlink:title="00000033 - Disclosure - The estimated fair value of stock options granted to employees and consultants during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_EmployeesAndConsultantsMember" xlink:label="loc_alxneuroEmployeesAndConsultantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_alxneuroEmployeesAndConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/CompanysResultsOfOperationsIncludeExpensesRelatingToStock-basedCompensationForThreeMonthsEndedJuly312022And2021ThatWereComprisedAsFollowsDetails" xlink:title="00000034 - Disclosure - The Company&#8217;s results of operations include expenses relating to stock-based compensation for three months ended July 31, 2022 and 2021, that were comprised as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000035 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_StockIncentivePlan2016Member" xlink:label="loc_alxneuroStockIncentivePlan2016Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_alxneuroStockIncentivePlan2016Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_PerformanceContingentStockOptionsMember" xlink:label="loc_alxneuroPerformanceContingentStockOptionsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_alxneuroPerformanceContingentStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_KeyEmployeesAndDirectorMember" xlink:label="loc_alxneuroKeyEmployeesAndDirectorMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_alxneuroKeyEmployeesAndDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_UnamortizedStockBasedCompensationMember" xlink:label="loc_alxneuroUnamortizedStockBasedCompensationMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_alxneuroUnamortizedStockBasedCompensationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details" xlink:title="00000036 - Disclosure - The following table summarizes information about Common Stock warrants outstanding and exercisable at July 31, 2022: (Details)">
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_DisclosureWarrantsAbstract" xlink:label="loc_alxneuroDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alxneuroDisclosureWarrantsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ExercisePrice1Member" xlink:label="loc_alxneuroExercisePrice1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_alxneuroExercisePrice1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ExercisePrice2Member" xlink:label="loc_alxneuroExercisePrice2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_alxneuroExercisePrice2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ExercisePrice3Member" xlink:label="loc_alxneuroExercisePrice3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_alxneuroExercisePrice3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ExercisePriceFiftySixMember" xlink:label="loc_alxneuroExercisePriceFiftySixMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_alxneuroExercisePriceFiftySixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ExercisePrice4Member" xlink:label="loc_alxneuroExercisePrice4Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_alxneuroExercisePrice4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ExercisePriceFiftySevenMember" xlink:label="loc_alxneuroExercisePriceFiftySevenMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_alxneuroExercisePriceFiftySevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:label="loc_alxneuroClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_alxneuroClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ClassOfWarrantOrRightExercisable" xlink:label="loc_alxneuroClassOfWarrantOrRightExercisable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_alxneuroClassOfWarrantOrRightExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:label="loc_alxneuroClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_alxneuroClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails" xlink:title="00000037 - Disclosure - The estimated fair value of warrants granted during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions: (Details)">
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_DisclosureWarrantsAbstract" xlink:label="loc_alxneuroDisclosureWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alxneuroDisclosureWarrantsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative" xlink:title="00000038 - Disclosure - OTHER RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_SecuritiesPurchaseAgreementMember" xlink:label="loc_alxneuroSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_alxneuroSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_DigitalPowerLendingMember" xlink:label="loc_alxneuroDigitalPowerLendingMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_alxneuroDigitalPowerLendingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionDescriptionOfTransaction" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionDescriptionOfTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentMilestones" xlink:label="loc_us-gaapLongTermPurchaseCommitmentMilestones" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLongTermPurchaseCommitmentMilestones" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/OriginalAl001LicenseDetails" xlink:title="00000039 - Disclosure - Original AL001 License: (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaapProductLiabilityContingencyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapProductLiabilityContingencyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaapProductLiabilityContingencyLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapProductLiabilityContingencyLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AL001LicenseMember" xlink:label="loc_alxneuroAL001LicenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_alxneuroAL001LicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AL002LicenseMember" xlink:label="loc_alxneuroAL002LicenseMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_alxneuroAL002LicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AdditionalAL001LicenseMember" xlink:label="loc_alxneuroAdditionalAL001LicenseMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_alxneuroAdditionalAL001LicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_LicenseEventsAxis" xlink:label="loc_alxneuroLicenseEventsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_alxneuroLicenseEventsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_LicenseEventsDomain" xlink:label="loc_alxneuroLicenseEventsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alxneuroLicenseEventsAxis" xlink:to="loc_alxneuroLicenseEventsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_PreINDMeetingMember" xlink:label="loc_alxneuroPreINDMeetingMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alxneuroLicenseEventsDomain" xlink:to="loc_alxneuroPreINDMeetingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_IndApplicationFilingMember" xlink:label="loc_alxneuroIndApplicationFilingMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alxneuroLicenseEventsDomain" xlink:to="loc_alxneuroIndApplicationFilingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_UponFirstDosingOfPatientInClinicalTrialMember" xlink:label="loc_alxneuroUponFirstDosingOfPatientInClinicalTrialMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alxneuroLicenseEventsDomain" xlink:to="loc_alxneuroUponFirstDosingOfPatientInClinicalTrialMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_UponCompletionOfFirstPatientDosingMember" xlink:label="loc_alxneuroUponCompletionOfFirstPatientDosingMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alxneuroLicenseEventsDomain" xlink:to="loc_alxneuroUponCompletionOfFirstPatientDosingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_UponCompletionOfFirstClinicalTrialMember" xlink:label="loc_alxneuroUponCompletionOfFirstClinicalTrialMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alxneuroLicenseEventsDomain" xlink:to="loc_alxneuroUponCompletionOfFirstClinicalTrialMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_UponFdaApprovalMember" xlink:label="loc_alxneuroUponFdaApprovalMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alxneuroLicenseEventsDomain" xlink:to="loc_alxneuroUponFdaApprovalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_UponFirstPatientTreatedInPhase3ClinicalTrialMember" xlink:label="loc_alxneuroUponFirstPatientTreatedInPhase3ClinicalTrialMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alxneuroLicenseEventsDomain" xlink:to="loc_alxneuroUponFirstPatientTreatedInPhase3ClinicalTrialMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapContractualObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaapOtherCommitmentsDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_us-gaapOtherCommitmentsDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaapProductLiabilityContingencyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapProductLiabilityContingencyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaapProductLiabilityContingencyLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_us-gaapProductLiabilityContingencyLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AL002LicenseMember" xlink:label="loc_alxneuroAL002LicenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_alxneuroAL002LicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AL001LicenseMember" xlink:label="loc_alxneuroAL001LicenseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_alxneuroAL001LicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AdditionalAL001LicenseMember" xlink:label="loc_alxneuroAdditionalAL001LicenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_alxneuroAdditionalAL001LicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_PercentageOfRoyaltyPaymentsOnNetSalesOfProduct." xlink:label="loc_alxneuroPercentageOfRoyaltyPaymentsOnNetSalesOfProduct." />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_alxneuroPercentageOfRoyaltyPaymentsOnNetSalesOfProduct." xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_DescriptionOfLicensesAgreements" xlink:label="loc_alxneuroDescriptionOfLicensesAgreements" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_alxneuroDescriptionOfLicensesAgreements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_InitialLicenseFees" xlink:label="loc_alxneuroInitialLicenseFees" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductLiabilityContingencyLineItems" xlink:to="loc_alxneuroInitialLicenseFees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://alzamend.com/role/EquityTransactionsDetailsNarrative" xlink:title="00000041 - Disclosure - EQUITY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_SecuritiesPurchaseAgreementsMember" xlink:label="loc_alxneuroSecuritiesPurchaseAgreementsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_alxneuroSecuritiesPurchaseAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ALSFMember" xlink:label="loc_alxneuroALSFMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_alxneuroALSFMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_DigitalPowerLendingMember" xlink:label="loc_alxneuroDigitalPowerLendingMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_alxneuroDigitalPowerLendingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AultGlobalMember" xlink:label="loc_alxneuroAultGlobalMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_alxneuroAultGlobalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_ConvertiblePromissoryNoteMember" xlink:label="loc_alxneuroConvertiblePromissoryNoteMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_alxneuroConvertiblePromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapVestingAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_FinalTrancheMember" xlink:label="loc_alxneuroFinalTrancheMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_alxneuroFinalTrancheMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_PreferredStockSharesDesignated" xlink:label="loc_alxneuroPreferredStockSharesDesignated" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_alxneuroPreferredStockSharesDesignated" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_NumberOfSharesPurchase" xlink:label="loc_alxneuroNumberOfSharesPurchase" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_alxneuroNumberOfSharesPurchase" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_SharesPurchasePrice" xlink:label="loc_alxneuroSharesPurchasePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_alxneuroSharesPurchasePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_SharesPurchasePricePerShares" xlink:label="loc_alxneuroSharesPurchasePricePerShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_alxneuroSharesPurchasePricePerShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:label="loc_alxneuroStockIssuedDuringPeriodSharesNewIssuesOne" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_alxneuroStockIssuedDuringPeriodSharesNewIssuesOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AdvanceFromRelatedParties" xlink:label="loc_alxneuroAdvanceFromRelatedParties" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_alxneuroAdvanceFromRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_SharesValueSurrenderForCancellation" xlink:label="loc_alxneuroSharesValueSurrenderForCancellation" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_alxneuroSharesValueSurrenderForCancellation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_DescriptionOfPurchaseAgreementTerms" xlink:label="loc_alxneuroDescriptionOfPurchaseAgreementTerms" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_alxneuroDescriptionOfPurchaseAgreementTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="alxneuro-20220731.xsd#alxneuro_AdditionalRightToInvest" xlink:label="loc_alxneuroAdditionalRightToInvest" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_alxneuroAdditionalRightToInvest" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146024356416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Sep. 13, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--04-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ALZAMEND
NEURO, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001677077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-1822909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3500 Lenox Rd NE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Atlanta<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">GA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">30326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">722-6303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALZN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,481,790<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146024626656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>&#160;CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">&#160;Cash</a></td>
<td class="nump">$ 11,527,121<span></span>
</td>
<td class="nump">$ 14,063,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">&#160;Prepaid expenses and other current assets</a></td>
<td class="nump">587,542<span></span>
</td>
<td class="nump">349,723<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">&#160;TOTAL CURRENT ASSETS</a></td>
<td class="nump">12,114,663<span></span>
</td>
<td class="nump">14,413,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">&#160;Property, plant and equipment, net</a></td>
<td class="nump">95,812<span></span>
</td>
<td class="nump">102,909<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">&#160;TOTAL ASSETS</a></td>
<td class="nump">12,210,475<span></span>
</td>
<td class="nump">14,516,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>&#160;CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">&#160;Accounts payable and accrued liabilities</a></td>
<td class="nump">1,028,700<span></span>
</td>
<td class="nump">1,162,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">&#160;Related party payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,082<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">&#160;TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">1,028,700<span></span>
</td>
<td class="nump">1,164,932<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">&#160;TOTAL LIABILITIES</a></td>
<td class="nump">1,028,700<span></span>
</td>
<td class="nump">1,164,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>&#160;STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">&#160;Convertible Preferred stock, $0.0001 par value: 10,000,000 shares authorized; &#160;Series A Convertible Preferred Stock, $0.0001 stated value per share, 1,360,000 shares designated; &#160;nil issued and outstanding as of July 31, 2022 and April 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">&#160;Common stock, $0.0001 par value: 300,000,000 shares authorized; 95,481,790 &#160;shares issued and outstanding as of July 31, 2022 and April 30, 2022</a></td>
<td class="nump">9,548<span></span>
</td>
<td class="nump">9,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">&#160;Additional paid-in capital</a></td>
<td class="nump">58,287,091<span></span>
</td>
<td class="nump">57,419,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_NoteReceivableForCommonStockRelatedParty', window );">&#160;Note receivable for common stock &#8211; related party</a></td>
<td class="num">(14,883,295)<span></span>
</td>
<td class="num">(14,883,295)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">&#160;Accumulated deficit</a></td>
<td class="num">(32,231,569)<span></span>
</td>
<td class="num">(29,194,495)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">&#160;TOTAL STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">11,181,775<span></span>
</td>
<td class="nump">13,351,511<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">&#160;TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 12,210,475<span></span>
</td>
<td class="nump">$ 14,516,443<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_NoteReceivableForCommonStockRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents note receivable for common stock related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_NoteReceivableForCommonStockRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146024295696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">95,481,790<span></span>
</td>
<td class="nump">95,481,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">95,481,790<span></span>
</td>
<td class="nump">95,481,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">8,640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_PreferredStockSharesDesignated', window );">Preferred stock shares designated</a></td>
<td class="nump">1,360,000<span></span>
</td>
<td class="nump">1,360,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_PreferredStockSharesDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents preferred stock shares designated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_PreferredStockSharesDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146024168816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>&#160;OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">&#160;Research and development</a></td>
<td class="nump">$ 1,375,953<span></span>
</td>
<td class="nump">$ 916,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">&#160;General and administrative</a></td>
<td class="nump">1,659,589<span></span>
</td>
<td class="nump">1,389,831<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">&#160;Total operating expenses</a></td>
<td class="nump">3,035,542<span></span>
</td>
<td class="nump">2,306,239<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">&#160;Loss from operations</a></td>
<td class="num">(3,035,542)<span></span>
</td>
<td class="num">(2,306,239)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>&#160;OTHER EXPENSE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">&#160;Interest expense</a></td>
<td class="num">(1,532)<span></span>
</td>
<td class="num">(13,628)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">&#160;Total other expense, net</a></td>
<td class="num">(1,532)<span></span>
</td>
<td class="num">(13,628)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">&#160;NET LOSS</a></td>
<td class="num">$ (3,037,074)<span></span>
</td>
<td class="num">$ (2,319,867)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">&#160;Basic and diluted net loss per common share</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">&#160;Basic and diluted weighted average common shares outstanding</a></td>
<td class="nump">97,481,790<span></span>
</td>
<td class="nump">84,588,492<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146026949536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Series A Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Note Recievable For Common Stock Related Party [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Apr. 30, 2021</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 6,743<span></span>
</td>
<td class="nump">$ 33,721,859<span></span>
</td>
<td class="num">$ (14,883,295)<span></span>
</td>
<td class="num">$ (16,832,437)<span></span>
</td>
<td class="nump">$ 2,012,945<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Apr. 30, 2021</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="nump">67,429,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_StockbasedCompensationToEmployeesAndConsultants', window );">Stock-based compensation to employees and consultants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">739,622<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">739,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">&#160;Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,319,867)<span></span>
</td>
<td class="num">(2,319,867)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_StockIssuedDuringPeriodValueNewIssues2', window );">Proceeds from sale of common stocks and warrants-related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">1,999,867<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_StockIssuedDuringPeriodSharesNewIssues2', window );">Proceeds from sale of common stocks and warrants-related party (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from stock option exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from stock option exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_StockIssuedDuringPeriodValueNewIssues3', window );">Proceeds from initial public offering, net of underwriters' discounts and commissions and issuance costs of $1.5 million</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 288<span></span>
</td>
<td class="nump">12,911,168<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,911,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_StockIssuedDuringPeriodSharesNewIssues3', window );">Proceeds from initial public offering, net of underwriters' discounts and commissions and issuance costs of $1.5 million (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_ConversionOfSeriesAConvertibleStock', window );">Conversion of Series A convertible stock</a></td>
<td class="num">$ (75)<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="num">(1,425)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A convertible stock (in shares)</a></td>
<td class="num">(750,000)<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jul. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,689<span></span>
</td>
<td class="nump">49,371,166<span></span>
</td>
<td class="num">(14,883,295)<span></span>
</td>
<td class="num">(19,152,304)<span></span>
</td>
<td class="nump">15,344,256<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jul. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">86,887,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Apr. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,548<span></span>
</td>
<td class="nump">57,419,753<span></span>
</td>
<td class="num">(14,883,295)<span></span>
</td>
<td class="num">(29,194,495)<span></span>
</td>
<td class="nump">13,351,511<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Apr. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">95,481,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_StockbasedCompensationToEmployeesAndConsultants', window );">Stock-based compensation to employees and consultants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">867,338<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">867,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">&#160;Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,037,074)<span></span>
</td>
<td class="num">(3,037,074)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jul. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,548<span></span>
</td>
<td class="nump">$ 58,287,091<span></span>
</td>
<td class="num">$ (14,883,295)<span></span>
</td>
<td class="num">$ (32,231,569)<span></span>
</td>
<td class="nump">$ 11,181,775<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jul. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">95,481,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_ConversionOfSeriesAConvertibleStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents conversion of series a convertible stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_ConversionOfSeriesAConvertibleStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_StockIssuedDuringPeriodSharesNewIssues2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents stock issued during period shares new issues2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_StockIssuedDuringPeriodSharesNewIssues2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_StockIssuedDuringPeriodSharesNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents stock issued during period shares new issues3.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_StockIssuedDuringPeriodSharesNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_StockIssuedDuringPeriodValueNewIssues2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents stock issued during period value new issues2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_StockIssuedDuringPeriodValueNewIssues2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_StockIssuedDuringPeriodValueNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents stock issued during period value new issues3.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_StockIssuedDuringPeriodValueNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_StockbasedCompensationToEmployeesAndConsultants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents stockbased compensation to employees and consultants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_StockbasedCompensationToEmployeesAndConsultants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146025553664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Stockholders' Equity (Unaudited) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146026927824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,037,074)<span></span>
</td>
<td class="num">$ (2,319,867)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">7,097<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Interest expense - debt discount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation to employees and consultants</a></td>
<td class="nump">867,338<span></span>
</td>
<td class="nump">739,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(237,819)<span></span>
</td>
<td class="num">(216,169)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(136,232)<span></span>
</td>
<td class="nump">568,955<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,536,690)<span></span>
</td>
<td class="num">(1,222,664)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and warrants - related party, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts', window );">Proceeds from initial public offering, net of underwriters&#8217; discounts and commissions and issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">12,911,456<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">14,911,556<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net (decrease) increase in cash</a></td>
<td class="num">(2,536,690)<span></span>
</td>
<td class="nump">13,688,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at beginning of period</a></td>
<td class="nump">14,063,811<span></span>
</td>
<td class="nump">1,929,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at end of period</a></td>
<td class="nump">11,527,121<span></span>
</td>
<td class="nump">15,618,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_FairValueOfWarrantsIssuedInConnectionWithIpo', window );">Fair value of warrants issued in connection with initial public offering</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 461,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty', window );">Fair value of warrants issued in connection with March 2021 securities purchase agreement, related party</a></td>
<td class="text"> <span></span>
</td>
<td class="text">4,799,742<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_FairValueOfWarrantsIssuedInConnectionWithIpo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents fair value of warrants issued in connection with ipo.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_FairValueOfWarrantsIssuedInConnectionWithIpo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents fair value of warrants issued in connection with march2021 securities purchase agreement related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents proceeds from initial public offering net of underwriters discounts and commissions and issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146107960032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text"><p id="xdx_806_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zAYDEQTG8lal" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>1.</b></td><td style="text-align: justify"><b><span id="xdx_82A_zUe5PEn8xtX">DESCRIPTION OF BUSINESS</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Organization</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Alzamend Neuro, Inc. (the
&#8220;Company&#8221; or &#8220;Alzamend&#8221;), is an early clinical-stage biopharmaceutical company focused on developing novel products
for the treatment of neurodegenerative diseases and psychiatric disorders. The Company&#8217;s primary focus is Alzheimer&#8217;s disease.
With two current and future product candidates, Alzamend aims to bring treatments or cures to market at a reasonable cost as quickly as
possible. The Company&#8217;s current pipeline consists of two novel therapeutic drug candidates (collectively, the &#8220;Technology&#8221;):
(i) a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001, through
two royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., as licensor (the &#8220;Licensor&#8221;);
and (ii) a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability
of a patient&#8217;s immunological system to combat Alzheimer&#8217;s, known as AL002 or CA022W, through a royalty-bearing exclusive worldwide
license from the same Licensor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is devoting substantially
all its efforts towards research and development of its Technology and raising capital. The Company has not generated any product revenue
to date. The Company has financed its operations to date primarily through debt financings and through the sale of its common stock, par
value $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20220731_zAc6sOZXZyOd" title="Common stock, par value (in dollars per share)">0.0001</span> per share (&#8220;Common Stock&#8221;). The Company expects to continue to incur net losses in the foreseeable future.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146025567408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY AND GOING CONCERN<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">LIQUIDITY AND GOING CONCERN</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zeVPtDNzUBhd" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>2.</b></td><td style="text-align: justify"><b><span id="xdx_825_zbf7sF9xh414">LIQUIDITY AND GOING CONCERN</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying condensed
financial statements have been prepared on the basis that the Company will continue as a going concern. As of July 31, 2022, the Company
had cash of $<span id="xdx_90B_eus-gaap--Cash_iI_dm_c20220731_zhy80yRdKLec" title="Cash">11.5 million</span> and an accumulated deficit of $<span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_dxL_c20220731_zGUbxu4sGi0h" title="Accumulated deficit::XDX::-32231569"><span style="-sec-ix-hidden: xdx2ixbrl0366">32.2</span></span> million. The Company incurred losses for the three months ended July 31,
2022 totaling $<span id="xdx_908_eus-gaap--NetIncomeLoss_dxL_c20220501__20220731_zdYObLJwvjU3" title="Net loss::XDX::-3037074"><span style="-sec-ix-hidden: xdx2ixbrl0368">3.0</span></span> million. Historically, the Company has financed its operations principally through issuances of equity and debt instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company expects to continue to incur losses for the foreseeable
future and needs to raise additional capital until it is able to generate revenues from operations sufficient to fund its development
and commercial operations. However, based on the Company&#8217;s current business plan, management believes that the Company&#8217;s cash
at July 31, 2022 is sufficient to meet the Company&#8217;s anticipated cash requirements during the twelve-month period subsequent to
the issuance of the financial statements included in this Quarterly Report.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI https://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146025563680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zEnl1wQwZMM9" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>3.</b></td><td style="text-align: justify"><b><span id="xdx_82A_zqNueUgRrBh4">SIGNIFICANT ACCOUNTING POLICIES</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zfwkyg0j68g6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_86D_zvEVSkVnw5ea">Basis of Presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying condensed
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#8220;U.S. GAAP&#8221;) and the rules of the Securities and Exchange Commission (&#8220;SEC&#8221;) applicable to interim
reports of companies filing as a smaller reporting company. These financial statements should be read in conjunction with the audited
financial statements and notes thereto contained in the Company&#8217;s Report on Form 10-K for the year ended April 30, 2022, filed with
the SEC on July 19, 2022. In the opinion of management, the accompanying condensed interim financial statements include all adjustments
necessary in order to make the financial statements not misleading. The results of operations for interim periods are not necessarily
indicative of the results to be expected for the full year or any other future period. Certain notes to the financial statements that
would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal year as reported
in the Company&#8217;s Report on Form 10-K have been omitted. The accompanying condensed balance sheet at April 30, 2022 has been derived
from the audited balance sheet at April 30, 2022 contained in such Form 10-K.</p>

<p id="xdx_85A_zqRVQUf3MaE1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_84C_eus-gaap--UseOfEstimates_zPjUqfNQfl64" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_86D_zuEq5qo7PVub">Accounting Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial
statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
expenses during the reporting period. The Company&#8217;s critical accounting policies that involve significant judgment and estimates
include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.</p>

<p id="xdx_854_zfVl8rBifcLk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z4s9nr151g07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_866_zzzEfTX9Y3R6">Cash and Cash Equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company considers all
highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of July 31, 2022
and April&#160;30, 2022, the Company had no cash equivalents.</p>

<p id="xdx_85F_zwAf77t1wJ8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zlFyaG6tVih4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_86A_zGVYruX2f5Qd">Fair Value of Financial
Instruments</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial Accounting Standards
Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820, <i>Fair Value Measurement</i>, defines fair value
as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques
used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy
is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last
is considered unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 1: Quoted prices in
active markets for identical assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 2: Inputs other than
Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in
markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the
full term of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 3 assumptions: Unobservable
inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including
liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of warrants
are determined using the Black-Scholes valuation model, a &#8220;Level 3&#8221; fair value measurement, based on the estimated fair value
of Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market
capitalization of such other entities, the expected life based on the remaining contractual term of the conversion option and warrants
and the risk free interest rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrants&#8217;
contractual life.</p>

<p id="xdx_858_z271fxl84CI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zZeFFfq2tm7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_862_zhRjIvqlH04l">Property and Equipment,
Net</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property and equipment are
stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life
of five years. Significant additions and improvements are capitalized, while repairs and maintenance are charged to expense as incurred.</p>

<p id="xdx_856_zXvaF1VSmu08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zXwRPdI1Zt27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_867_zFKQr73uXiSc">Research and Development
Expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development costs
are expensed as incurred. Research and development costs consist of scientific consulting fees and lab supplies, as well as fees paid
to other entities that conduct certain research and development activities on behalf of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has acquired and
may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire
license, products or rights, as well as any future milestone payments, are immediately recognized as research and development expense
provided that there is no alternative future use of the rights in other research and development projects.</p>

<p id="xdx_855_zDeOFLHJZkrg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p id="xdx_842_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z0ek2XiKgVIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_861_z8UkG0bAKQ4b">Stock-Based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognizes stock-based
compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they
occur. The Company&#8217;s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes
option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management
evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance
conditions as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognizes stock-based
compensation expense for restricted stocks on a straight-line basis over the requisite service period and account for forfeitures as they
occur. The Company&#8217;s stock-based compensation for restricted stocks is based upon the estimated fair value of the Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Black-Scholes option pricing
model utilizes inputs which are highly subjective assumptions and generally require significant judgment. Certain of such assumptions
involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the
Company uses significantly different assumptions or estimates, the Company&#8217;s stock-based compensation could be materially different.</p>

<p id="xdx_854_zV3YTiex39p4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p id="xdx_84A_ecustom--WarrantsPolicyTextBlock_zVILuVRGwGv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_86E_zTSh4yZKGKB9">Warrants</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts for stock
warrants as either equity instruments, derivative liabilities, or liabilities in accordance with ASC 480,&#160;<i>Distinguishing Liabilities
from Equity </i>(&#8220;ASC 480&#8221;)&#160;and ASC 815,&#160;<i>Derivatives and Hedging </i>(&#8220;ASC 815&#8221;)<i>,</i>&#160;depending
on the specific terms of the warrant agreement.</p>

<p id="xdx_854_zj2S6EKuo1Dg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z3ZnSefRZT7l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86C_zPJ5LMJzaIAf">Loss per Common Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company utilizes FASB
ASC 260,&#160;<i>Earnings per Share</i>. Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average
number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is
increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued
and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible
preferred stock, options and warrants were to be exercised or converted or otherwise resulted in the issuance of Common Stock that then
shared in the earnings of the entity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since the effects of outstanding
options, warrants, convertible preferred stock and convertible notes are anti-dilutive in the periods presented, shares of Common Stock
underlying these instruments have been excluded from the computation of loss per common share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zqAqwlq1ti7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_z2EGMMfrV5E3">The following sets forth the
number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have
been excluded from the computation of loss per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Series A convertible preferred stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuPhXO7Xn5k8" style="width: 15%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0391">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_d0_c20210501__20210731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zpZbSI0DZ5l4" style="width: 15%; text-align: right">15,000,000</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock options <sup id="xdx_F47_z7VLZN3QiKJ3">(1)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zDEFTaorQYA8" style="text-align: right">18,600,000</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210501__20210731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zP8r5yrCJpR4" style="text-align: right">17,500,000</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zXEgdLKzy3Ul" style="text-align: right">10,149,788</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210501__20210731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zBUP2jHaWtD4" style="text-align: right">8,830,785</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Convertible notes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_z7SL48dtsmcb" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">-</span></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210501__20210731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zdWVJZRS6Aqk" style="border-bottom: Black 1pt solid; text-align: right">232,049</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731_zfMhB8hOwJgl" style="border-bottom: Black 2.5pt double; text-align: right">28,749,788</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210501__20210731_zJlIX9UaCm7j" style="border-bottom: Black 2.5pt double; text-align: right">41,562,834</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_F06_zYnJiBoeeez5" style="font-size: 10pt">(1)
</span><span id="xdx_F19_zbxSgU7evvoa" style="font-size: 10pt">The Company has excluded
</span><span id="xdx_903_ecustom--NumberOfStockExcluded_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zLBewUqX7Aoi" style="font-size: 10pt">2,000,000
</span><span style="font-size: 10pt">stock options, with
an exercise price of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zMhijAxjDH57">0.0004</span></span><span style="font-size: 10pt">,
from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares
issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14.</span></p>

<p id="xdx_8A8_zZHtbKUQHxol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"/></p>

<p id="xdx_858_z1hrQlFg4g2e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zUdrSdjZia24" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;<b><span id="xdx_86F_zVXO0adZ8wAe">Recent Accounting Standards</span></b></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, new accounting
pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact
of recently issued standards that are not yet effective are not expected to have a material impact on the Company&#8217;s financial position
or results of operations upon adoption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has considered
all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on its
financial statements.</p>

<p id="xdx_852_zBKb6h1xHcq2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146030248464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_DisclosureNoteReceivableForCommonStockRelatedPartyAbstract', window );"><strong>Note Receivable For Common Stock Related Party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_MortgageNoteReceivableFromRelatedPartyTextBlock', window );">NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY</a></td>
<td class="text"><p id="xdx_80E_ecustom--MortgageNoteReceivableFromRelatedPartyTextBlock_zkdm7ezppFV3" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>4.</b></td><td style="text-align: justify"><b><span id="xdx_828_zx98wDGcdROf">NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 30, 2019, the Company
and Ault Life Sciences Fund, LLC (&#8220;ALSF&#8221;) entered into a securities purchase agreement for the purchase of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20190401__20190430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AultLifeSciencesFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z3nI7JwidrEa" title="Number of shares purchase (in shares)">10,000,000</span> shares
of Common Stock for a total purchase price of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20190401__20190430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AultLifeSciencesFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zPL1TiCoRA85" title="Number of shares purchase">15,000,000</span>, or $1.50 per share with <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_uShares_c20190401__20190430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AultLifeSciencesFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z60erB5NwzY9" title="Number of warrants granted">5,000,000</span> warrants with a <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20190401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AultLifeSciencesFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zy6UYJWv04fg" title="Warrant terms::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0415">5</span></span>-year life and an exercise
price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20190430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AultLifeSciencesFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zjsIZXTWgDoa" title="Exercise price (in dollars per share)">3.00</span> per share and vesting upon issuance. The total purchase price of $15,000,000 was in the form of a non-interest bearing
note receivable with a 12-month term from ALSF, a related party. In November 2019, the term of the note receivable was extended to December
31, 2021, and in May 2021, the term of the note receivable was extended to December 31, 2023. The note is secured by a pledge of the purchased
shares. As the note receivable from ALSF is related to the issuance of Common Stock, it is recorded as an offset to additional paid-in
capital. At July 31, 2022 and April 30, 2022, the outstanding balance of the note receivable was $<span id="xdx_903_ecustom--LongTermDebtAverageAmountOfOutstanding_iI_pid_uShares_c20220430_zbZk62Up5Awc" title="Outstanding receivable amount">14,883,295</span>. ALSF is wholly owned by
Ault Life Sciences, Inc. (&#8220;ALSI&#8221;). ALSI is majority owned by Ault &amp; Company, Inc. (&#8220;Ault &amp; Co.&#8221;). Messrs.
Horne and Nisser, directors of the Company, are also directors of Ault &amp; Co.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_DisclosureNoteReceivableForCommonStockRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_DisclosureNoteReceivableForCommonStockRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_MortgageNoteReceivableFromRelatedPartyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents mortgage note receivable from related party text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_MortgageNoteReceivableFromRelatedPartyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146030351936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_809_eus-gaap--OtherCurrentAssetsTextBlock_z13daPvwsyI1" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt; text-align: right"><b>5.</b></td><td style="width: 9pt"/><td style="text-align: justify"><b><span id="xdx_821_zyAIsiFeEDwb">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_89A_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zn2OLOQrCH2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B4_z51KuO4CVQqd">Prepaid expenses and other
current assets are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220731_zEEriKc63i12" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">July 31, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20210731_zRUzSlvEWXv9" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Prepaid consulting fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">116,667</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">186,667</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PrepaidInsurance_iI_zFyZnmAz1kL" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">451,885</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">155,880</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherPrepaidExpenseCurrent_iI_zv2YIVkopYw2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,577</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,176</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherReceivables_iI_zxv0Z4sdhiRi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other receivables</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,413</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0432">-</span></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssets_iTI_z51oCsa0bG91" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">587,542</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">349,723</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zS4qW0Pp78z9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 16, 2022, the
Company purchased D&amp;O insurance for 12 months in the amount of $<span id="xdx_902_ecustom--PrepaidInsurance1_iI_c20220616_zSGd7ckJK2jg" title="Purchase D&amp;O Insurance"><span style="-sec-ix-hidden: xdx2ixbrl0437">492,000.</span></span> Prepaid insurance at July 31, 2022 represented the unamortized
portion of annual premium paid for this policy of $<span id="xdx_901_ecustom--UnamortizedPrepaidExpense_iI_c20220731_zpQqgYHremza" title="Unamortized prepaid expense">452,000</span>. At July 31, 2022, prepaid consulting fees of $<span id="xdx_905_ecustom--PrepaidConsultingFees_iI_c20220731__us-gaap--RelatedPartyTransactionAxis__custom--SpartanCapitalSecuritiesMember_zo4Ndd27ZBfg" title="Prepaid consulting fees">117,000</span> consisted of payments
to Spartan Capital Securities, LLC (&#8220;Spartan Capital&#8221;).</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146025569840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_802_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zt9vFm3kLFja" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>6.</b></td><td style="text-align: justify"><b><span id="xdx_824_z1xyv6iqIWkd">STOCK-BASED COMPENSATION</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>2016 Stock Incentive
Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 30, 2016, the Company&#8217;s
stockholders approved the Company&#8217;s 2016 Stock Incentive Plan (the &#8220;Plan&#8221;). The Plan provides for the issuance of a
maximum of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_uShares_c20160430__us-gaap--PlanNameAxis__custom--StockIncentivePlan2016Member_z5YhwQ8NDZ5" title="Number of shares authorized for issuance">12,500,000</span> shares of Common Stock to be offered to the Company&#8217;s directors, officers, employees, and consultants. On
March 1, 2019, the Company&#8217;s stockholders approved an additional <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pid_uShares_c20160401__20160430__us-gaap--PlanNameAxis__custom--StockIncentivePlan2016Member_zzHsGB9bGQkf" title="Additional number of shares available for issuance">7,500,000</span> shares to be available for issuance under the Plan. Options
granted under the Plan have an exercise price equal to or greater than the fair value of the underlying Common Stock at the date of grant
and become exercisable based on a vesting schedule determined at the date of grant. The options expire between five and 10 years from
the date of grant. Restricted stock awards granted under the Plan are subject to a vesting period determined at the date of grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>2021 Stock Incentive
Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2021, the Company&#8217;s
board of directors (the &#8220;Board&#8221;) adopted, and the stockholders approved, the Alzamend Neuro, Inc. 2021 Stock Incentive Plan
(the &#8220;2021 Plan&#8221;). The 2021 Plan authorizes the grant to eligible individuals of (1) stock options (incentive and non-statutory),
(2) restricted stock, (3) stock appreciation rights, or SARs, (4) restricted stock units, and (5) other stock-based compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Stock Subject to the 2021
Plan.</i>&#160;The maximum number of shares of Common Stock that may be issued under the 2021 Plan is 10,000,000 shares, which number
will be increased to the extent that compensation granted under the 2021 Plan is forfeited, expires or is settled for cash (except as
otherwise provided in the 2021 Plan). Substitute awards (awards made or shares issued by the Company in assumption of, or in substitution
or exchange for, awards previously granted, or the right or obligation to make future awards, in each case by a company that the Company
acquires or any subsidiary of the Company or with which the Company or any subsidiary combines) will not reduce the shares authorized
for grant under the 2021 Plan, nor will shares subject to a substitute award be added to the shares available for issuance or transfer
under the 2021 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All options that the Company
grants are granted at the per share fair value on the grant date. Vesting of options differs based on the terms of each option. The Company
has valued the options at their date of grant utilizing the Black-Scholes option pricing model. As of the date of issuance of these options,
there was not an active public market for the Company&#8217;s shares. Accordingly, the fair value of the underlying options was determined
based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other
entities. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an
equivalent term approximating the expected life of the options as calculated using the simplified method. The expected life of the options
used was based on the contractual life of the option granted. Stock-based compensation is a non-cash expense because the Company settles
these obligations by issuing shares of Common Stock from its authorized shares instead of settling such obligations with cash payments.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zIIE8c15LYH3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zFzbIN2U4gFd">A summary of stock option
activity for the three months ended July 31, 2022 is presented below:</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>Outstanding Options</b></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: center; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>Shares <br/> Available <br/> for Grant</b></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>Number of <br/> Shares</b></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>Weighted <br/> Average <br/> Exercise <br/> Price</b></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Life (years)</b></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>Aggregate Intrinsic <br/> Value</b></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%">Balance at April 30, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pid_uShares_c20220501__20220731_z3FeV4uK1WI9" style="width: 12%; text-align: right" title="Balance at begining (in shares)">8,800,000</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220501__20220731_zYgncrLDXxs8" style="width: 12%; text-align: right" title="Balance at begining (in shares)">15,700,000</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220501__20220731_zyGkfNf3PXil" style="width: 12%; text-align: right" title="Balance at begining">1.20</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dxL_c20220501__20220731_zj0Rm6QuAx0b" style="width: 12%; text-align: right" title="::XDX::P6Y1M6D"><span style="-sec-ix-hidden: xdx2ixbrl0456">6.10</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220501__20220731_zGV3ZNgGvpY8" style="width: 12%; text-align: right" title="Balance at begining">2,219,700</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted_pid_uShares_c20220501__20220731_zNjyqkCRWKNa" style="text-align: right" title="Options granted"><span style="-sec-ix-hidden: xdx2ixbrl0460">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220501__20220731_zbvDvTrPGwV8" style="text-align: right" title="Options granted"><span style="-sec-ix-hidden: xdx2ixbrl0462">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220501__20220731_zj3TQqDY0wm6" style="text-align: right" title="Options granted"><span style="-sec-ix-hidden: xdx2ixbrl0464">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross_pid_uShares_c20220501__20220731_zvsY4c4MmtHd" style="text-align: right" title="Options exercised"><span style="-sec-ix-hidden: xdx2ixbrl0466">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220501__20220731_z6Cqz8rAzwr7" style="text-align: right" title="Options exercised"><span style="-sec-ix-hidden: xdx2ixbrl0468">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Options expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited_pid_uShares_c20220501__20220731_zgkev0eedOL" style="border-bottom: Black 1pt solid; text-align: right" title="Options expired"><span style="-sec-ix-hidden: xdx2ixbrl0470">-</span></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_uShares_c20220501__20220731_z9YvBOi4Kgj1" style="border-bottom: Black 1pt solid; text-align: right" title="Options expired">(1,100,000</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">)&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_pid_uUSDPShares_c20220501__20220731_zt1uBEgaOpS8" style="border-bottom: Black 1pt solid; text-align: right" title="Options expired">1.00</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at July 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_uShares_c20220501__20220731_z1iv2MSPzCb7" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end (in shares)">8,800,000</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20220501__20220731_z1IU0bYZqDef" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end (in shares)">14,600,000</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220501__20220731_zOhuHg3c1BHa" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end">1.22</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220501__20220731_zeFbb0VWsFX2" style="text-align: right" title="Balance at end (in shares)::XDX::P5Y9M14D"><span style="-sec-ix-hidden: xdx2ixbrl0482">5.79</span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20220501__20220731_zb8XrzbhPg66" style="text-align: right" title="Balance at end">1,777,200</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="4" style="text-align: left; padding-bottom: 2.5pt">Options vested and expected to vest at July 31, 2022</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_uShares_c20220731_zQqUROTgawa5" style="border-bottom: Black 2.5pt double; text-align: right" title="Options vested and expected to vest">13,700,000</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731_zJNA2VD2ZIh3" style="border-bottom: Black 2.5pt double; text-align: right" title="Options vested and expected to vest at end">1.23</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dxL_c20220501__20220731_zXZhGTWgVcad" style="text-align: right" title="Options vested and expected to vest at end::XDX::P6Y4M9D"><span style="-sec-ix-hidden: xdx2ixbrl0490">6.36</span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20220731_zqSBBt5xFNj9" style="text-align: right" title="Options vested and expected to vest at end">1,777,200</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options exercisable at July 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20220731_zawlo43xFvTa" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable at end">11,514,479</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731_zBlOVfebEIWj" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable at end">1.07</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dxL_c20220501__20220731_zBmnJxnHzWhi" style="text-align: right" title="Options exercisable at end::XDX::P5Y11M26D"><span style="-sec-ix-hidden: xdx2ixbrl0498">6.03</span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20220731_zRiEnO41IPKa" style="text-align: right" title="Options exercisable at end">1,777,200</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zcuaMwm16CP1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate intrinsic value
in the table above represents the total pretax intrinsic value (i.e., the difference between the estimated fair value on the respective
date and the exercise price, times the number of shares) that would have been received by the option holders had all option holders exercised
their options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in"><b><i>Stock Options Granted to Employees and Consultants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_892_ecustom--ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock_zY2YBlIAQC3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BF_zWYKRkfgDPY4">The estimated fair value of
stock options granted to employees and consultants during the three months ended July 31, 2021 were calculated using the Black-Scholes
option-pricing model using the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="4" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected term (in years)</td><td>&#160;</td>
    <td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c20220501__20220731__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zYlsYmHJjAuk" style="text-align: center" title="Expected Term (in years)"><span style="-sec-ix-hidden: xdx2ixbrl0504">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210501__20210731__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zeKpX0C9ilbl" title="Expected Term (in years)::XDX::P2Y6M0D"><span style="-sec-ix-hidden: xdx2ixbrl0506">2.50</span></span> &#8211; <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210501__20210731__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zLqA0imhsFR7" title="Expected Term (in years)::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0508">5.00</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 65%">Volatility</td><td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220501__20220731__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zNI3hfZY152" title="Volatility"><span style="-sec-ix-hidden: xdx2ixbrl0510">-</span></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 17%; text-align: center"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210501__20210731__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zWyYbNOLSX1a" title="Volatility">86.31</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220501__20220731__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zhWUcM51a0F9" title="Risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl0514">-</span></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210501__20210731__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_z4J6dY1Rvf57" title="Risk-free interest rate">1.01</span>%-<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210501__20210731__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zzdRAbMMziB8" title="Risk-free interest rate">1.07</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220501__20220731_zsUBZBVJvcMd" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0520">-</span></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210501__20210731_zKZGgQaEGZsf" title="Dividend yield">0.0</span>%</td></tr>
  </table>


<p id="xdx_8A2_z5NzlPecmGG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Expected Term:</i>&#160;The
expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method
(based on the mid-point between the vesting date and the end of the contractual term).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Expected Volatility:</i>&#160;The
Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry
that were deemed to be representative of future stock price trends as the Company did not have sufficient trading history for its Common
Stock at July 31, 2022. The Company will continue to apply this process until a sufficient amount of historical information regarding
the volatility of its own stock price becomes available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Risk-Free Interest Rate:</i>&#160;The
Company based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities
with similar maturities as of the date of the grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Expected Dividend:</i>&#160;The
Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock-based compensation to
employees and consultants from stock option grants for the three months ended July 31, 2022 and 2021 were $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20220501__20220731__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvtpRE4ZYyD3" title="Stock-based compensation to employees">867,000</span> and $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_c20210501__20210731__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAilxE5KcZlk">740,000</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Performance Contingent
Stock Options Granted to Employee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2018, the Board
granted <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20181101__20181130__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_z1Mc7egcDj71" title="Options granted">2,000,000</span> performance-contingent options under the Plan to the Chief Executive Officer. These options have an exercise price of
$<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20181101__20181130__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zsJWUEY6oUfi" title="Exercise price (in dollars per share)">1.00</span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These options have two separate
performance triggers for vesting based upon the therapies achieving certain Food and Drug Administration (&#8220;FDA&#8221;) approval
milestones within a specified timeframe. By definition, the performance condition in these options can only be achieved after the performance
condition of FDA approval has been achieved. As such, the requisite service period is based on the estimated period over which the market
condition can be achieved. When a performance goal is deemed to be probable of achievement, time-based vesting and recognition of stock-based
compensation expense commences. In the event any of the milestones are not achieved by the specified timelines, such vesting award will
terminate and no longer be exercisable with respect to that portion of the shares. The maximum potential expense associated with the performance-contingent
awards is $<span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_dm_c20220501__20220731__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zoiYgmGmWsK2" title="Maximum potential expense">1.2 million</span> of general and administrative expense if all of the performance conditions are achieved as stated in the option
agreement. Due to the significant risks and uncertainties associated with FDA approvals, as of July 31, 2022, the Company believes that
the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for
these awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 26, 2019, the
Board granted <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20191125__20191126__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KeyEmployeesAndDirectorMember_zEbE1pnPO9pi" title="Options granted">4,250,000</span> performance- and market-contingent awards to certain key employees and a director. These grants were made outside
of the Plan. These awards have an exercise price of $1.50 per share. These awards have multiple separate market triggers for vesting based
upon either (i) the successful achievement of stepped target closing prices on a national securities exchange for 90 consecutive trading
days later than 180 days after the Company&#8217;s initial public offering (&#8220;IPO&#8221;) for its Common Stock, or (ii) stepped target
prices for a change in control transaction. The target prices range from $15 per share to $40 per share. <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20191125__20191126__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KeyEmployeesAndDirectorMember_zHkKdCfjVF4c" title="Terms of warrent">In the event any of the stock
price milestones are not achieved within three years</span>, the unvested portion of the performance options will be reduced by 25%. Due to the
significant risks and uncertainties associated with achieving the market-contingent awards, as of July 31, 2022, the Company believes
that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized
for these awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Performance Contingent
Stock Options Granted to TAMM Net</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 23, 2021, the Company
issued performance-based stock options to the certain team members at TAMM Net, Inc. to purchase an aggregate of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20210322__20210323__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KeyEmployeesAndDirectorMember_zZGlKkR32XV2" title="Options granted">450,000</span> shares of Common
Stock at a per share exercise price of $1.50 per share, of which 50% vest upon the completion of Phase I of AL001 by March 31, 2022, and
the remaining 50% vest upon completion of Phase I of AL002 by December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The performance goal of completing
Phase I of AL001 was achieved on March 22, 2022, and the Company recognized stock compensation related to the completion of Phase I of
AL001 over the implied service period to complete this milestone. Due to the significant risks and uncertainties associated with achieving
the completion of Phase I for AL002, as of July 31, 2022, the Company believes that the achievement of the requisite performance conditions
is not probable and, as a result, no compensation cost has been recognized for these awards related to AL002.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Performance Contingent
Stock Options Granted to Consultants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 14, 2021, the Company
issued performance-based stock options to two consultants to purchase an aggregate of 200,000 shares of Common Stock with an exercise
price of $2.42 per share, of which 50,000 vest upon completion of each of the Phase II clinical trials of AL001 for a Bipolar indication,
AL001 for a PTSD indication, AL001 for a depression indication and AL002 for an Alzheimer&#8217;s indication.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of July 31, 2022, the Company
believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been
recognized for these awards related to Phase II of AL001 and AL002.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Stock-Based Compensation
Expense</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_891_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_z6eY9f1bMvgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B9_zf1t9hqjOdX4">The Company&#8217;s results
of operations include expenses relating to stock-based compensation for three months ended July 31, 2022 and 2021, that were comprised
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">&#160;Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20220501__20220731__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z9BR1zngADYj" style="width: 15%; text-align: right" title="Research and development"><span style="-sec-ix-hidden: xdx2ixbrl0541">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20210501__20210731__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zbo04MID9r19" style="width: 15%; text-align: right" title="Research and development">141,917</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20220501__20220731__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_znkayglINsj3" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative">867,338</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20210501__20210731__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z7UFSlnxxObj" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative">597,705</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: 10pt">&#160;Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220501__20220731_zXJ0mGBJlso6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">867,338</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210501__20210731_zHSrLAD7s2Mi" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">739,622</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zjzUxngSvDy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of July 31, 2022, total
unamortized stock-based compensation expense related to unvested employee and non-employee awards that are expected to vest was $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_dm_uShares_c20220731__us-gaap--IncomeStatementLocationAxis__custom--UnamortizedStockBasedCompensationMember_zjNQbjnzepF2" title="Options vested and expected to vest">3.7 million</span>.
The weighted-average period over which such stock-based compensation expense will be recognized is approximately <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtxL_c20220501__20220731__us-gaap--IncomeStatementLocationAxis__custom--UnamortizedStockBasedCompensationMember_zOfBUEh8k5B9" title="Weighted-average period vested and expected to vest at end::XDX::P2Y2M12D"><span style="-sec-ix-hidden: xdx2ixbrl0555">2.2</span></span> years.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146025469264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_DisclosureWarrantsAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_WarrantsDisclosureTextBlock', window );">WARRANTS</a></td>
<td class="text"><p id="xdx_805_ecustom--WarrantsDisclosureTextBlock_zX5kpIKJxDm4" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>7.</b></td><td style="text-align: justify"><b><span id="xdx_823_zGhtQHLZgSKe">WARRANTS</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_893_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zA8s07XDXMkl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BF_z1dJr0F8R55d">The following table summarizes
information about Common Stock warrants outstanding and exercisable at July 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="14" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Outstanding</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Exercisable</b></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Weighted</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Average</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Weighted</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Weighted</b></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Remaining</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Average</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Average</b></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Exercise</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Number</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Contractual</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Exercise</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Number</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Exercise</b></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Price</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Outstanding</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Life (years)</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Price</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Exercisable</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Price</b></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%">$</td>
    <td style="width: 14%; text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z6c3hqhOSxka" title="Exercse price (in dollars per share)">1.00</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zMfm1H51mBX" style="width: 14%; text-align: right" title="Number warrant outstanding">500,000</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z2K7DPB0wuea" style="width: 14%; text-align: right" title="Weighted average remaining contractual life (years)::XDX::P1Y7M6D"><span style="-sec-ix-hidden: xdx2ixbrl0565">1.6</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_98D_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_znMpTRBDE3bk" style="width: 14%; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">1.00</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_986_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_znyZMA6Qwlf" style="width: 14%; text-align: right" title="Number of warrant exercisable">500,000</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_988_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zIsqCau88ok3" style="width: 13%; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">1.00</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>$</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zJI72zHlPMvi" title="Exercse price (in dollars per share)">1.75</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zx0FfbvTHgX7" style="text-align: right" title="Number warrant outstanding">161,342</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zGawpNPyjy78" style="text-align: right" title="Weighted average remaining contractual life (years)::XDX::P2Y3M19D"><span style="-sec-ix-hidden: xdx2ixbrl0577">2.3</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zGsLhEt5oFp2" style="text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">1.75</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zERqgRVJ4Od" style="text-align: right" title="Number of warrant exercisable">161,342</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98D_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_z0gwdL3UTfW3" style="text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">1.75</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_zqvmMztnnAHh" title="Exercse price (in dollars per share)">3.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_z0ekQeMOm1he" style="text-align: right" title="Number warrant outstanding">9,427,196</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_z4djd98mNtwk" style="text-align: right" title="Weighted average remaining contractual life (years)::XDX::P2Y8M12D"><span style="-sec-ix-hidden: xdx2ixbrl0589">2.7</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_zCkGHj1FHXRc" style="text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">3.00</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_zsXrtR6EzwH4" style="text-align: right" title="Number of warrant exercisable">9,427,196</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_zz1f9yFngWXe" style="text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">3.00</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_zE4Tpmn5pHWd" title="Exercse price (in dollars per share)">6.25</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zQxgUdMpQly8" style="border-bottom: black 1pt solid; text-align: right" title="Number warrant outstanding">61,250</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zSJmIUBqhkce" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average remaining contractual life (years)::XDX::P3Y10M25D"><span style="-sec-ix-hidden: xdx2ixbrl0601">3.9</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td id="xdx_984_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zOyd1700VTk7" style="border-bottom: black 1pt solid; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">6.25</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_982_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zrOSbnjyCzu6" style="border-bottom: black 1pt solid; text-align: right" title="Number of warrant exercisable">61,250</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td id="xdx_981_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zjWEFKDoFzYf" style="border-bottom: black 1pt solid; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">6.25</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">$<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member__srt--RangeAxis__srt--MinimumMember_zMW0WoWiKWWf" title="Exercse price (in dollars per share)">1.00</span> - $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member__srt--RangeAxis__srt--MaximumMember_zm0S1G3iyfg6" title="Exercse price (in dollars per share)">6.25</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731_zTmFv0DmSME1" style="border-bottom: black 2.25pt double; text-align: right" title="Number warrant outstanding">10,149,788</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731_zhvPLCA1MJRl" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average remaining contractual life (years)::XDX::P2Y7M6D"><span style="-sec-ix-hidden: xdx2ixbrl0615">2.6</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_989_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731_zOQkaHdYgMna" style="border-bottom: black 2.25pt double; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">2.90</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_987_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731_zQcLHY4ZUaF5" style="border-bottom: black 2.25pt double; text-align: right" title="Number of warrant exercisable">10,149,788</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_981_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731_zh0MolRQFQgj" style="border-bottom: black 2.25pt double; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">2.90</td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8A4_zaXr8cONK36c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_89D_ecustom--ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock_zbbMtIAfu7d1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span id="xdx_8B3_zuejyHMYX3s5">The estimated fair value of warrants granted during
the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Expected term (in years)</td><td style="width: 1%">&#160;</td>
    <td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQImOIzcjzd2" style="width: 17%; text-align: center" title="Expected term (in years)"><span style="-sec-ix-hidden: xdx2ixbrl0625">-</span></td><td style="width: 1%">&#160;</td>
    <td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwjO06Eurs6c" style="width: 17%; text-align: center" title="::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0626">5.00</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&#160;</td>
    <td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zypgzgImH01k" style="text-align: center" title="Warrants measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0628">-</span></td><td>&#160;</td>
    <td id="xdx_987_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zhiVY4h4qVjg" style="text-align: center" title="Warrants measurement input">103.70%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zbAoT8ln8IM4" style="text-align: center" title="Warrants measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0632">-</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zV3jQ2XvrIh8" title="Warrants measurement input">0.27</span>% - <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_ziPVDHLdtEvf" title="Warrants measurement input">0.28</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zIGdub23qDb3" style="text-align: center" title="Warrants measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0638">-</span></td><td>&#160;</td>
    <td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--MinimumMember_zxnTvqD9M2Bf" style="text-align: center" title="Warrants measurement input">0.0%</td></tr>
  </table>

<p id="xdx_8A7_zrYzGKYkc0bd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Expected Term:</i>&#160;The
expected term represents the period that the warrants granted are expected to be outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Expected Volatility:</i>&#160;The
Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry
that were deemed to be representative of future stock price trends as the Company did not have sufficient trading history for its Common
Stock at July 31, 2021. The Company will continue to apply this process until a sufficient amount of historical information regarding
the volatility of its own stock price becomes available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Risk-Free Interest Rate:</i>&#160;The
Company based the risk-free interest rate over the expected term of the warrants based on the constant maturity rate of U.S. Treasury
securities with similar maturities as of the date of the grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Expected Dividend:</i>&#160;The
Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_DisclosureWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_DisclosureWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_WarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents warrants disclosure text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_WarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146030183280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">OTHER RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zeJtmtZyoMob" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>8.</b></td><td style="text-align: justify"><b><span id="xdx_821_ziQTb3OuL0la">OTHER RELATED PARTY TRANSACTIONS</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2021, the Company
entered into a securities purchase agreement with Digital Power Lending, LLC (&#8220;DPL&#8221;) pursuant to which the Company sold an
aggregate of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesOther_uShares_c20210331__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DigitalPowerLendingMember_z0rDBIwJc2nk" title="Number of shares sold (in shares)">6,666,667</span> shares of Common Stock for an aggregate of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueOther_pn6n6_c20210331__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DigitalPowerLendingMember_zKBJrKyqdRNe" title="Number of shares sold">10</span> million, or $1.50 per share, which sales were made in tranches.
On March 9, 2021, <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesOther_uShares_c20210308__20210309__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DigitalPowerLendingMember_zP7D71hzyXg6" title="Description of related party transaction">DPL paid $4 million, less the $1.8 million in prior advances and <span id="xdx_90E_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20210308__20210309__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DigitalPowerLendingMember_zNyOV3iXDwA8" title="Description of related party transaction">the surrender for cancellation of a $50,000 convertible
promissory note held by BitNile Holdings, Inc. (&#8220;BitNile&#8221;), the parent company of DPL, for an aggregate of 2,666,667 shares
of Common Stock. Under the terms of the securities purchase agreement, DPL (i) purchased an additional 1,333,333 shares of Common Stock
upon approval of the IND for Phase IA clinical trials for AL001 for a purchase price of $2 million, and (ii) purchased 2,666,667 shares
of Common Stock upon the completion of Phase IA clinical trials for AL001 for a purchase price of $4 million.</span></span> <span id="xdx_90D_eus-gaap--LongTermPurchaseCommitmentMilestones_c20210308__20210309__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DigitalPowerLendingMember_zdE6HV9yJ3Of" title="Description of milestones">The Company issued to DPL
warrants to purchase 3,333,333 shares of Common Stock at an exercise price of $3.00 per share. Finally, the Company agreed that for a
period of 18 months following the date of the payment of the final tranche of $4 million, DPL will have the right to invest an additional
$10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million as of
the date of this Quarterly Report.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146025461504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zkanNUh1xAQj" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>9.</b></td><td style="text-align: justify"><b><span id="xdx_820_zZ51ZDSEGj0a">COMMITMENTS AND CONTINGENCIES</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Contractual Obligations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 1, 2016, the Company
entered into a Standard Exclusive License Agreement for AL002 with Sublicensing Terms with Licensor, pursuant to which Licensor granted
the Company a royalty bearing exclusive worldwide license limited to the field of Alzheimer&#8217;s Immunotherapy and Diagnostics, under
United States Patent No. 8,188,046, entitled &#8220;Amyloid Beta Peptides and Methods of Use,&#8221; filed April&#160;7, 2009 and granted
May 29, 2012.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">There
are certain initial license fees and milestone payments required to be paid by the Company to the Licensor pursuant to the terms of license
agreements. The license agreements for AL002 require the Company to pay royalty payments of&#160;<span id="xdx_908_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._pid_dp_uPure_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember_zuYYu2jVdjH3" title="Percentage of royalty payments on net sales of product">4</span>% on net sales of products developed
from the licensed technology for AL002 while the license agreements for AL001 require that the Company pay combined royalty payments of&#160;<span id="xdx_90D_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._pid_dp_uPure_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zswzgyVAZn3c">4.5</span>%
on net sales of products developed from the licensed technology for AL001.&#160;<span id="xdx_904_ecustom--DescriptionOfLicensesAgreements_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zJdrqzHoMiTb" title="Description of licenses agreements">The Company has already paid an initial license fee of
$200,000 for AL002 and an initial license fee of $200,000 for AL001. As an additional licensing fee for the license of AL002, the Licensor
received 3,601,809 shares of common stock. As an additional licensing fee for the license of the AL001 technologies, the Licensor received
2,227,923 shares of common stock. Minimum royalties for AL001 are $25,000 in 2023, $45,000 in 2024 and $70,000 in 2025 and every year
thereafter, for the life of the agreement. Minimum royalties for AL002 are $20,000 in 2022, $40,000 in 2023 and $50,000 in 2024 and every
year thereafter, for the life of the respective agreement.</span>&#160;Additionally, the Company is required to pay milestone payments on the
due dates to the Licensor for the license of the AL001 technologies and for the AL002 technology, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_895_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zC4M9bZ7vk2f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><span id="xdx_8B9_zGw8l6J7Ii23">Original
AL001 License:</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid"><b>Payment</b></td>
    <td style="text-align: left; white-space: nowrap; vertical-align: middle"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><b>&#160;Due Date</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="border-bottom: black 1pt solid"><b>&#160;Event</b></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 1%">$</td>
    <td id="xdx_98F_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--PreINDMeetingMember_zjPksGXDXy2l" style="width: 11%; text-align: right" title="Payment">50,000</td>
    <td style="vertical-align: middle; width: 1%; text-align: left"><span id="xdx_F2F_zbSOF11wVTUd" style="font-size: 10pt">*</span></td>
    <td id="xdx_985_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--PreINDMeetingMember_zY1jktkhGQaj" style="width: 46%" title="Due Date">&#160;Completed September 2019</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 40%">&#160;Pre-IND meeting</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: middle; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_982_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zjJkpJxz5mze" style="text-align: right" title="Payment">65,000</td>
    <td style="vertical-align: middle; text-align: left"><span id="xdx_F2A_z7X0v1jlCYQb" style="font-size: 10pt">*</span></td>
    <td id="xdx_984_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_znf58gBDm5Gi" title="Due Date">&#160;Completed June 2021</td>
    <td>&#160;</td>
    <td>&#160;IND application filing</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: middle; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_98B_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zroqmNPrjqsj" style="text-align: right" title="Payment">190,000</td>
    <td style="vertical-align: middle; text-align: left"><span id="xdx_F21_za1ODzHwTgW2" style="font-size: 10pt">*</span></td>
    <td id="xdx_985_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zzCLYgSWciN" title="Due Date">&#160;Completed December 2021</td>
    <td>&#160;</td>
    <td>&#160;Upon first dosing of patient in a clinical trial</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: middle; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_98B_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPatientDosingMember_z0KUOaSBO4o" style="text-align: right" title="Payment">500,000</td>
    <td style="vertical-align: middle; text-align: left"><span id="xdx_F26_zxJOWjomOu2c" style="font-size: 10pt">*</span></td>
    <td id="xdx_98B_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPatientDosingMember_zrBkyfasuBsi" title="Due Date">&#160;Completed March 2022</td>
    <td>&#160;</td>
    <td>&#160;Upon Completion of first clinical trial</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; vertical-align: middle"><span style="font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_988_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_zCKSqqyXl998" style="text-align: right" title="Payment">1,250,000</td>
    <td style="text-align: left; vertical-align: middle"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_zF44zw4wFwuh" title="Due Date">&#160;12 months from completion of the first Phase II clinical trial</td>
    <td>&#160;</td>
    <td>&#160;Upon first patient treated in a Phase III clinical trial</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; vertical-align: middle"><span style="font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_986_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_z6Sh2hKlwVx" style="text-align: right" title="Payment">10,000,000</td>
    <td style="text-align: left; vertical-align: middle"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_z3CnLJGH3Dyh" title="Due Date">&#160;8 years from the effective date of the agreement</td>
    <td>&#160;</td>
    <td>&#160;Upon FDA approval</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td id="xdx_F02_zTGwSVr03vB3" style="width: 47px; text-align: right">*</td>
    <td style="width: 7px">&#160;</td>
    <td id="xdx_F19_zqQop9x9Ve8i" style="text-align: justify">Milestone met and completed</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>&#160;AL002
License:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"><b>Payment</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Due Date</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Event</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%">$</td>
    <td id="xdx_982_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--PreINDMeetingMember_zGzDlXyVxJ34" style="width: 11%; text-align: right" title="Payment">50,000</td>
    <td style="vertical-align: top; white-space: nowrap; width: 1%; text-align: left">*</td>
    <td id="xdx_98D_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--PreINDMeetingMember_zX6BlkE1pDaa" style="width: 46%" title="Due Date">Completed January 2022</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 40%; text-align: justify">&#160;Upon IND application filing</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_987_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zdltbFvp3WWh" style="text-align: right" title="Payment">50,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_988_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zTXfq8ACZeWj" title="Due Date">12 months from IND application filing date</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;Upon first dosing of patient in first Phase I clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_981_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zDILv2k8DQLf" style="text-align: right" title="Payment">175,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_98C_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zUfFSGpxKuL2" title="Due Date">12 months from first patient dosed in Phase I</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;Upon completion of first Phase I clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_982_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_zYjuxneHWsic" style="text-align: right" title="Payment">500,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_98C_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_z8A6Aqu6xTXe" title="Due Date">24 months from completion of first Phase I clinical trial</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;Upon completion of first Phase II clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_98C_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember_zkQDPeV7Vuu2" style="text-align: right" title="Payment">1,000,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_98F_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember_zhQzIoEWxNte" title="Due Date">12 months from completion of the first Phase II clinical trial</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;Upon first patient treated in a Phase III clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_989_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_zmbtq9N8w5Gf" style="text-align: right" title="Payment">10,000,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_989_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_zIwoWHKEmIU9" title="Due Date">7 years from the effective date of the agreement</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;Upon FDA BLA approval</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
Company has met the pre-IND meeting, IND application filing, and successfully completed the Phase I clinical trial milestones encompassing
AL001. If the Company fails to meet a milestone by its specified date, the Licensor may terminate the license agreement.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Licensor
was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by the Company
while Licensor remains the owner of any equity securities of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
June&#160;10, 2020, the Company obtained two (2) additional royalty-bearing exclusive worldwide licenses from the Licensor to a therapy
named AL001. One of the additional licenses is for the treatment of neurodegenerative diseases excluding Alzheimer&#8217;s and the other
license is for the treatment of psychiatric diseases and disorders. There are certain license fees and milestone payments required to
be paid pursuant to the terms of the Standard Exclusive License Agreements with Sublicensing Terms, both dated June&#160;10, 2020 and
effective&#160;as of November&#160;1, 2019, with the Licensor and the University of South Florida (the &#8220;June AL001 License Agreements&#8221;).
Under each of the June AL001 License Agreements, a royalty payment of&#160;<span id="xdx_902_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._pid_dp_uPure_c20200501__20200610__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zNNbAyQf2r5f" title="Percentage of royalty payments on net sales of product">3</span>% is required on net sales of products developed from the
licensed technology. For the two (2) additional AL001 licenses, in the aggregate, the Company has paid initial license fees of $<span id="xdx_907_ecustom--InitialLicenseFees_c20200501__20200610__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zC2q1CTKa5Xf" title="Initial license fees">20,000</span>.
Additionally, under each of the June AL001 License Agreements, the Company is required to pay milestone payments on the due dates to the
Licensor for the license of the technology, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Additional
AL001 Licenses:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"><b>Payment</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Due Date</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Event</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%">$</td>
    <td id="xdx_98E_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zSyt8NPBi1l8" style="width: 12%; text-align: right" title="Payment">50,000</td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td id="xdx_98E_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zPJNTq6CZuA" style="width: 47%" title="Due Date">Upon IND application filing</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 38%">&#160;IND application filing</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_98A_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zl1CyYvjPSY8" style="text-align: right" title="Payment">150,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_98D_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zcl1aoueDhsf" title="Due Date">12 months from IND filing date</td>
    <td>&#160;</td>
    <td>&#160;Upon first dosing of patient in a clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_980_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_z7zMeNxDQmzc" style="text-align: right" title="Payment">400,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_981_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_zIO8W0mRuTy6" title="Due Date">12 months from first patient dosing</td>
    <td>&#160;</td>
    <td>&#160;Upon Completion of first clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_985_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember_zOj7P1GfKvdf" style="text-align: right" title="Payment">1,000,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_980_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember_zxE8buiCBtYi" title="Due Date">36 months from completion of the first Phase II clinical trial</td>
    <td>&#160;</td>
    <td>&#160;Upon first patient treated in a Phase III clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_988_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_zqTtiPVGzRv8" style="text-align: right" title="Payment">8,000,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_984_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_zcQ256EItc9g" title="Due Date">8 years from the effective date of the agreement</td>
    <td>&#160;</td>
    <td>&#160;First commercial sale</td></tr>
  </table>
<p id="xdx_8AA_zpzXhmb8lA62" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146025556320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zK5UYkg4Cesc" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>10.</b></td><td style="text-align: justify"><b><span id="xdx_827_zbILYSsVVV0f">EQUITY TRANSACTIONS</span></b></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company is authorized to issue <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20220131_zb98q96lTl8f" title="Preferred stock, shares authorized">10,000,000</span> shares of Preferred Stock $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20220731_zdH8s9cCurY2" title="Preferred stock, par or stated value per share">0.0001</span> par value. The Board has designated <span id="xdx_90C_ecustom--PreferredStockSharesDesignated_iI_pid_uShares_c20220731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z4qJm3OkDB2f" title="Preferred stock shares designated">1,360,000</span> shares as the
Series A Preferred Shares. The rights, preferences, privileges and restrictions on the remaining authorized <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20220731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zicgMKvJeCRg" title="Preferred stock, shares authorized">8,640,000</span> shares of Preferred
Stock have not been determined. The Board is authorized to create a new series of preferred shares and determine the number of shares,
as well as the rights, preferences, privileges and restrictions granted to or imposed upon any series of preferred shares.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Series A Preferred Shares</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of July 31, 2022, there
were no Series A Preferred Shares or any other shares of Preferred Stock issued or outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 30, 2019, the Company
and ALSF entered into a SPA for the purchase of <span id="xdx_90B_ecustom--NumberOfSharesPurchase_pid_uShares_c20190430__20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_zUM4Aea5YzNb">10,000,000</span> shares of Common Stock for a total purchase price of $<span id="xdx_906_ecustom--SharesPurchasePrice_c20190430__20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_zwdHAmVT4Hfi" title="Shares purchase price">15,000,000</span>, or $<span id="xdx_90B_ecustom--SharesPurchasePricePerShares_pid_uUSDPShares_c20190430__20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_z9DDDN572Xsg" title="Shares purchase price (in dollars per share)">1.50</span>
per share with <span id="xdx_90E_ecustom--NumberOfSharesPurchase_pid_uShares_c20190430__20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVVz7zw2rOH7" title="Number of shares purchase">5,000,000</span> warrants with a <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlNqWrKjQWqi" title="Warrents terms::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0753">5</span></span>-year life and an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_zX1nN7yM4G64" title="Exercise price (in dollars per share)">3.00</span> per share and vesting upon issuance. The total purchase
price of $<span id="xdx_903_ecustom--SharesPurchasePrice_c20190430__20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_zAZlUunKjwe5" title="Shares purchase price">15,000,000</span> was in the form of a non-interest bearing note receivable with a <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20190430__dei--LegalEntityAxis__custom--ALSFMember_z18T6MJg4wF7" title="Warrant terms::XDX::P12M"><span style="-sec-ix-hidden: xdx2ixbrl0759">12</span></span>-month term from ALSF, a related party. The note
is secured by a pledge of the purchased shares. Pursuant to the SPA, ALSF is entitled to full ratchet anti-dilution protection, most-favored
nation status, denying the Company the right to enter into a variable rate transaction absent its consent, a right to participate in any
future financing the Company may consummate and to have all the shares of Common Stock to which it is entitled under the SPA registered
under the Securities Act within 180 days of the final closing of the IPO. In May 2021, the term of the note receivable was extended to
December 31, 2023. The note is secured by a pledge of the purchased shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2021, the Company
entered into a securities purchase agreement with DPL pursuant to which the Company agreed to sell an aggregate of <span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesNewIssuesOne_pid_uShares_c20210331__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_zy5DFZSu1ao7" title="Number of shares issued">6,666,667</span> shares of
Common Stock for an aggregate of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20210331__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_zNFKWj6VCPC5" title="Proceeds from sale of equity">10</span> million, or $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember_zCaXsWfxZ8oi" title="Shares issued price per share">1.50</span> per share, which sales will be made in tranches. On March 9, 2021, DPL paid $<span id="xdx_905_eus-gaap--ProceedsFromRelatedPartyDebt_pn6n6_c20210331__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember_z2aXmUMZrc0d" title="Proceeds from related party">4</span>
million, less the $<span id="xdx_905_ecustom--AdvanceFromRelatedParties_dm_c20210331__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember_zkteMakRiUf6" title="Advance from related parties">1.8 million</span> in prior advances and the surrender for cancellation of a $<span id="xdx_902_ecustom--SharesValueSurrenderForCancellation_c20210331__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--AultGlobalMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zGMITcUFeNcd" title="Shares value surrender for cancellation">50,000</span> convertible promissory note held by BitNile,
for an aggregate of <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesNewIssuesOne_pid_uShares_c20210301__20210309__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--AultGlobalMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zlfqwtjRc5w7" title="Number of shares issued">2,666,667</span> shares of Common Stock. Under the terms of the securities purchase agreement, <span id="xdx_907_ecustom--DescriptionOfPurchaseAgreementTerms_uShares_c20210301__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember_znJPG0EBILh6" title="Description of purchase agreement terms">DPL (i) purchased an additional
1,333,333 shares of Common Stock upon approval by the FDA of the Company&#8217;s IND for its Phase IA clinical trials for AL001 for a
purchase price of $2 million, and (ii) purchased 2,666,667 shares of Common Stock upon the completion of these Phase IA clinical trials
for AL001 for a purchase price of $4 million. The Company further agreed to issue to DPL warrants to purchase 3,333,333 shares of Common
Stock at an exercise price of $3.00 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finally, the Company
agreed that for a period of 18 months following the date of the payment of the final tranche of $4 million, on April 28, 2022, DPL
will have the right to invest an additional $<span id="xdx_903_ecustom--AdditionalRightToInvest_pn6n6_c20220426__20220428__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember__us-gaap--VestingAxis__custom--FinalTrancheMember_zipEB0892X61" title="Additional right to invest">10</span>
million on the same terms, except that no specific milestones have been determined with respect to the additional $<span id="xdx_903_ecustom--AdditionalRightToInvest_pn6n6_c20220426__20220428__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember__us-gaap--VestingAxis__custom--FinalTrancheMember_zMfUOG0sp2i8" title="Additional right to invest">10</span>
million as of the date of this Quarterly Report.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146030323504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zoyC9SVl1CS1" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>11.</b></td><td style="text-align: justify"><b><span id="xdx_82B_zPkfDZBlRNDi">SUBSEQUENT EVENTS</span></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has evaluated
subsequent events through the date the financial statements were issued. The Company has determined that there are no such events that
warrant disclosure or recognition in the condensed financial statements presented herein.&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146024658688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zfwkyg0j68g6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_86D_zvEVSkVnw5ea">Basis of Presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying condensed
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#8220;U.S. GAAP&#8221;) and the rules of the Securities and Exchange Commission (&#8220;SEC&#8221;) applicable to interim
reports of companies filing as a smaller reporting company. These financial statements should be read in conjunction with the audited
financial statements and notes thereto contained in the Company&#8217;s Report on Form 10-K for the year ended April 30, 2022, filed with
the SEC on July 19, 2022. In the opinion of management, the accompanying condensed interim financial statements include all adjustments
necessary in order to make the financial statements not misleading. The results of operations for interim periods are not necessarily
indicative of the results to be expected for the full year or any other future period. Certain notes to the financial statements that
would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal year as reported
in the Company&#8217;s Report on Form 10-K have been omitted. The accompanying condensed balance sheet at April 30, 2022 has been derived
from the audited balance sheet at April 30, 2022 contained in such Form 10-K.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--UseOfEstimates_zPjUqfNQfl64" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_86D_zuEq5qo7PVub">Accounting Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial
statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
expenses during the reporting period. The Company&#8217;s critical accounting policies that involve significant judgment and estimates
include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z4s9nr151g07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_866_zzzEfTX9Y3R6">Cash and Cash Equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company considers all
highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of July 31, 2022
and April&#160;30, 2022, the Company had no cash equivalents.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zlFyaG6tVih4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_86A_zGVYruX2f5Qd">Fair Value of Financial
Instruments</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial Accounting Standards
Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820, <i>Fair Value Measurement</i>, defines fair value
as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques
used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy
is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last
is considered unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 1: Quoted prices in
active markets for identical assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 2: Inputs other than
Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in
markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the
full term of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Level 3 assumptions: Unobservable
inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including
liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of warrants
are determined using the Black-Scholes valuation model, a &#8220;Level 3&#8221; fair value measurement, based on the estimated fair value
of Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market
capitalization of such other entities, the expected life based on the remaining contractual term of the conversion option and warrants
and the risk free interest rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrants&#8217;
contractual life.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zZeFFfq2tm7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_862_zhRjIvqlH04l">Property and Equipment,
Net</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Property and equipment are
stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life
of five years. Significant additions and improvements are capitalized, while repairs and maintenance are charged to expense as incurred.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zXwRPdI1Zt27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_867_zFKQr73uXiSc">Research and Development
Expenses</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development costs
are expensed as incurred. Research and development costs consist of scientific consulting fees and lab supplies, as well as fees paid
to other entities that conduct certain research and development activities on behalf of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has acquired and
may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire
license, products or rights, as well as any future milestone payments, are immediately recognized as research and development expense
provided that there is no alternative future use of the rights in other research and development projects.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_842_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z0ek2XiKgVIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_861_z8UkG0bAKQ4b">Stock-Based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognizes stock-based
compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they
occur. The Company&#8217;s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes
option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management
evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance
conditions as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recognizes stock-based
compensation expense for restricted stocks on a straight-line basis over the requisite service period and account for forfeitures as they
occur. The Company&#8217;s stock-based compensation for restricted stocks is based upon the estimated fair value of the Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Black-Scholes option pricing
model utilizes inputs which are highly subjective assumptions and generally require significant judgment. Certain of such assumptions
involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the
Company uses significantly different assumptions or estimates, the Company&#8217;s stock-based compensation could be materially different.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p id="xdx_84A_ecustom--WarrantsPolicyTextBlock_zVILuVRGwGv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i><span id="xdx_86E_zTSh4yZKGKB9">Warrants</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts for stock
warrants as either equity instruments, derivative liabilities, or liabilities in accordance with ASC 480,&#160;<i>Distinguishing Liabilities
from Equity </i>(&#8220;ASC 480&#8221;)&#160;and ASC 815,&#160;<i>Derivatives and Hedging </i>(&#8220;ASC 815&#8221;)<i>,</i>&#160;depending
on the specific terms of the warrant agreement.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per Common Share</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z3ZnSefRZT7l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86C_zPJ5LMJzaIAf">Loss per Common Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company utilizes FASB
ASC 260,&#160;<i>Earnings per Share</i>. Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average
number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is
increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued
and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible
preferred stock, options and warrants were to be exercised or converted or otherwise resulted in the issuance of Common Stock that then
shared in the earnings of the entity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since the effects of outstanding
options, warrants, convertible preferred stock and convertible notes are anti-dilutive in the periods presented, shares of Common Stock
underlying these instruments have been excluded from the computation of loss per common share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zqAqwlq1ti7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_z2EGMMfrV5E3">The following sets forth the
number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have
been excluded from the computation of loss per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Series A convertible preferred stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuPhXO7Xn5k8" style="width: 15%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0391">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_d0_c20210501__20210731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zpZbSI0DZ5l4" style="width: 15%; text-align: right">15,000,000</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock options <sup id="xdx_F47_z7VLZN3QiKJ3">(1)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zDEFTaorQYA8" style="text-align: right">18,600,000</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210501__20210731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zP8r5yrCJpR4" style="text-align: right">17,500,000</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zXEgdLKzy3Ul" style="text-align: right">10,149,788</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210501__20210731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zBUP2jHaWtD4" style="text-align: right">8,830,785</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Convertible notes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_z7SL48dtsmcb" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">-</span></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210501__20210731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zdWVJZRS6Aqk" style="border-bottom: Black 1pt solid; text-align: right">232,049</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731_zfMhB8hOwJgl" style="border-bottom: Black 2.5pt double; text-align: right">28,749,788</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210501__20210731_zJlIX9UaCm7j" style="border-bottom: Black 2.5pt double; text-align: right">41,562,834</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_F06_zYnJiBoeeez5" style="font-size: 10pt">(1)
</span><span id="xdx_F19_zbxSgU7evvoa" style="font-size: 10pt">The Company has excluded
</span><span id="xdx_903_ecustom--NumberOfStockExcluded_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zLBewUqX7Aoi" style="font-size: 10pt">2,000,000
</span><span style="font-size: 10pt">stock options, with
an exercise price of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zMhijAxjDH57">0.0004</span></span><span style="font-size: 10pt">,
from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares
issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14.</span></p>

<p id="xdx_8A8_zZHtbKUQHxol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"/></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zUdrSdjZia24" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;<b><span id="xdx_86F_zVXO0adZ8wAe">Recent Accounting Standards</span></b></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, new accounting
pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact
of recently issued standards that are not yet effective are not expected to have a material impact on the Company&#8217;s financial position
or results of operations upon adoption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has considered
all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on its
financial statements.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents warrants policy text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146025511024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">The following sets forth the number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have been excluded from the computation of loss per common share:</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zqAqwlq1ti7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_z2EGMMfrV5E3">The following sets forth the
number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have
been excluded from the computation of loss per common share:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Series A convertible preferred stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuPhXO7Xn5k8" style="width: 15%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0391">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_d0_c20210501__20210731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zpZbSI0DZ5l4" style="width: 15%; text-align: right">15,000,000</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock options <sup id="xdx_F47_z7VLZN3QiKJ3">(1)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zDEFTaorQYA8" style="text-align: right">18,600,000</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210501__20210731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zP8r5yrCJpR4" style="text-align: right">17,500,000</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zXEgdLKzy3Ul" style="text-align: right">10,149,788</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210501__20210731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zBUP2jHaWtD4" style="text-align: right">8,830,785</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Convertible notes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_z7SL48dtsmcb" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">-</span></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210501__20210731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zdWVJZRS6Aqk" style="border-bottom: Black 1pt solid; text-align: right">232,049</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731_zfMhB8hOwJgl" style="border-bottom: Black 2.5pt double; text-align: right">28,749,788</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210501__20210731_zJlIX9UaCm7j" style="border-bottom: Black 2.5pt double; text-align: right">41,562,834</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_F06_zYnJiBoeeez5" style="font-size: 10pt">(1)
</span><span id="xdx_F19_zbxSgU7evvoa" style="font-size: 10pt">The Company has excluded
</span><span id="xdx_903_ecustom--NumberOfStockExcluded_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zLBewUqX7Aoi" style="font-size: 10pt">2,000,000
</span><span style="font-size: 10pt">stock options, with
an exercise price of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zMhijAxjDH57">0.0004</span></span><span style="font-size: 10pt">,
from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares
issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146030345840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Prepaid expenses and other current assets are as follows:</a></td>
<td class="text"><p id="xdx_89A_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zn2OLOQrCH2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B4_z51KuO4CVQqd">Prepaid expenses and other
current assets are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220731_zEEriKc63i12" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">July 31, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20210731_zRUzSlvEWXv9" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Prepaid consulting fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">116,667</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">186,667</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PrepaidInsurance_iI_zFyZnmAz1kL" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">451,885</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">155,880</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherPrepaidExpenseCurrent_iI_zv2YIVkopYw2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,577</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,176</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherReceivables_iI_zxv0Z4sdhiRi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other receivables</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,413</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0432">-</span></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssets_iTI_z51oCsa0bG91" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">587,542</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">349,723</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents schedule of prepaid expenses and other current assets table text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146024590992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">A summary of stock option activity for the three months ended July 31, 2022 is presented below:</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zIIE8c15LYH3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zFzbIN2U4gFd">A summary of stock option
activity for the three months ended July 31, 2022 is presented below:</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>Outstanding Options</b></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: center; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>Shares <br/> Available <br/> for Grant</b></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>Number of <br/> Shares</b></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>Weighted <br/> Average <br/> Exercise <br/> Price</b></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Life (years)</b></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><b>Aggregate Intrinsic <br/> Value</b></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%">Balance at April 30, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pid_uShares_c20220501__20220731_z3FeV4uK1WI9" style="width: 12%; text-align: right" title="Balance at begining (in shares)">8,800,000</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220501__20220731_zYgncrLDXxs8" style="width: 12%; text-align: right" title="Balance at begining (in shares)">15,700,000</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220501__20220731_zyGkfNf3PXil" style="width: 12%; text-align: right" title="Balance at begining">1.20</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dxL_c20220501__20220731_zj0Rm6QuAx0b" style="width: 12%; text-align: right" title="::XDX::P6Y1M6D"><span style="-sec-ix-hidden: xdx2ixbrl0456">6.10</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220501__20220731_zGV3ZNgGvpY8" style="width: 12%; text-align: right" title="Balance at begining">2,219,700</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted_pid_uShares_c20220501__20220731_zNjyqkCRWKNa" style="text-align: right" title="Options granted"><span style="-sec-ix-hidden: xdx2ixbrl0460">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220501__20220731_zbvDvTrPGwV8" style="text-align: right" title="Options granted"><span style="-sec-ix-hidden: xdx2ixbrl0462">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220501__20220731_zj3TQqDY0wm6" style="text-align: right" title="Options granted"><span style="-sec-ix-hidden: xdx2ixbrl0464">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross_pid_uShares_c20220501__20220731_zvsY4c4MmtHd" style="text-align: right" title="Options exercised"><span style="-sec-ix-hidden: xdx2ixbrl0466">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220501__20220731_z6Cqz8rAzwr7" style="text-align: right" title="Options exercised"><span style="-sec-ix-hidden: xdx2ixbrl0468">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Options expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited_pid_uShares_c20220501__20220731_zgkev0eedOL" style="border-bottom: Black 1pt solid; text-align: right" title="Options expired"><span style="-sec-ix-hidden: xdx2ixbrl0470">-</span></td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_uShares_c20220501__20220731_z9YvBOi4Kgj1" style="border-bottom: Black 1pt solid; text-align: right" title="Options expired">(1,100,000</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">)&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_pid_uUSDPShares_c20220501__20220731_zt1uBEgaOpS8" style="border-bottom: Black 1pt solid; text-align: right" title="Options expired">1.00</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at July 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_uShares_c20220501__20220731_z1iv2MSPzCb7" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end (in shares)">8,800,000</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20220501__20220731_z1IU0bYZqDef" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end (in shares)">14,600,000</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220501__20220731_zOhuHg3c1BHa" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end">1.22</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220501__20220731_zeFbb0VWsFX2" style="text-align: right" title="Balance at end (in shares)::XDX::P5Y9M14D"><span style="-sec-ix-hidden: xdx2ixbrl0482">5.79</span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20220501__20220731_zb8XrzbhPg66" style="text-align: right" title="Balance at end">1,777,200</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td colspan="4" style="text-align: left; padding-bottom: 2.5pt">Options vested and expected to vest at July 31, 2022</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_uShares_c20220731_zQqUROTgawa5" style="border-bottom: Black 2.5pt double; text-align: right" title="Options vested and expected to vest">13,700,000</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731_zJNA2VD2ZIh3" style="border-bottom: Black 2.5pt double; text-align: right" title="Options vested and expected to vest at end">1.23</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dxL_c20220501__20220731_zXZhGTWgVcad" style="text-align: right" title="Options vested and expected to vest at end::XDX::P6Y4M9D"><span style="-sec-ix-hidden: xdx2ixbrl0490">6.36</span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20220731_zqSBBt5xFNj9" style="text-align: right" title="Options vested and expected to vest at end">1,777,200</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Options exercisable at July 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20220731_zawlo43xFvTa" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable at end">11,514,479</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731_zBlOVfebEIWj" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable at end">1.07</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dxL_c20220501__20220731_zBmnJxnHzWhi" style="text-align: right" title="Options exercisable at end::XDX::P5Y11M26D"><span style="-sec-ix-hidden: xdx2ixbrl0498">6.03</span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20220731_zRiEnO41IPKa" style="text-align: right" title="Options exercisable at end">1,777,200</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock', window );">The estimated fair value of stock options granted to employees and consultants during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions:</a></td>
<td class="text"><p id="xdx_892_ecustom--ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock_zY2YBlIAQC3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BF_zWYKRkfgDPY4">The estimated fair value of
stock options granted to employees and consultants during the three months ended July 31, 2021 were calculated using the Black-Scholes
option-pricing model using the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="4" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected term (in years)</td><td>&#160;</td>
    <td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c20220501__20220731__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zYlsYmHJjAuk" style="text-align: center" title="Expected Term (in years)"><span style="-sec-ix-hidden: xdx2ixbrl0504">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210501__20210731__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zeKpX0C9ilbl" title="Expected Term (in years)::XDX::P2Y6M0D"><span style="-sec-ix-hidden: xdx2ixbrl0506">2.50</span></span> &#8211; <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210501__20210731__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zLqA0imhsFR7" title="Expected Term (in years)::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0508">5.00</span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 65%">Volatility</td><td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220501__20220731__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zNI3hfZY152" title="Volatility"><span style="-sec-ix-hidden: xdx2ixbrl0510">-</span></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 17%; text-align: center"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210501__20210731__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zWyYbNOLSX1a" title="Volatility">86.31</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220501__20220731__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zhWUcM51a0F9" title="Risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl0514">-</span></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210501__20210731__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_z4J6dY1Rvf57" title="Risk-free interest rate">1.01</span>%-<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210501__20210731__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zzdRAbMMziB8" title="Risk-free interest rate">1.07</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220501__20220731_zsUBZBVJvcMd" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0520">-</span></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210501__20210731_zKZGgQaEGZsf" title="Dividend yield">0.0</span>%</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">The Company&#8217;s results of operations include expenses relating to stock-based compensation for three months ended July 31, 2022 and 2021, that were comprised as follows:</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_z6eY9f1bMvgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B9_zf1t9hqjOdX4">The Company&#8217;s results
of operations include expenses relating to stock-based compensation for three months ended July 31, 2022 and 2021, that were comprised
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">&#160;Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20220501__20220731__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z9BR1zngADYj" style="width: 15%; text-align: right" title="Research and development"><span style="-sec-ix-hidden: xdx2ixbrl0541">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20210501__20210731__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zbo04MID9r19" style="width: 15%; text-align: right" title="Research and development">141,917</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20220501__20220731__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_znkayglINsj3" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative">867,338</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20210501__20210731__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z7UFSlnxxObj" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative">597,705</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: 10pt">&#160;Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220501__20220731_zXJ0mGBJlso6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">867,338</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210501__20210731_zHSrLAD7s2Mi" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">739,622</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents schedule of stock options granted to employees and consultants table text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146030239456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_DisclosureWarrantsAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock', window );">The following table summarizes information about Common Stock warrants outstanding and exercisable at July 31, 2022:</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zA8s07XDXMkl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BF_z1dJr0F8R55d">The following table summarizes
information about Common Stock warrants outstanding and exercisable at July 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="14" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Outstanding</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Exercisable</b></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Weighted</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Average</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Weighted</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Weighted</b></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Remaining</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Average</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Average</b></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Exercise</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Number</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Contractual</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Exercise</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Number</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Exercise</b></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Price</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Outstanding</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Life (years)</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Price</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Exercisable</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><b>Price</b></td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%">$</td>
    <td style="width: 14%; text-align: right"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z6c3hqhOSxka" title="Exercse price (in dollars per share)">1.00</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zMfm1H51mBX" style="width: 14%; text-align: right" title="Number warrant outstanding">500,000</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z2K7DPB0wuea" style="width: 14%; text-align: right" title="Weighted average remaining contractual life (years)::XDX::P1Y7M6D"><span style="-sec-ix-hidden: xdx2ixbrl0565">1.6</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_98D_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_znMpTRBDE3bk" style="width: 14%; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">1.00</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_986_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_znyZMA6Qwlf" style="width: 14%; text-align: right" title="Number of warrant exercisable">500,000</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">$</td>
    <td id="xdx_988_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zIsqCau88ok3" style="width: 13%; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">1.00</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>$</td>
    <td style="text-align: right"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zJI72zHlPMvi" title="Exercse price (in dollars per share)">1.75</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zx0FfbvTHgX7" style="text-align: right" title="Number warrant outstanding">161,342</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zGawpNPyjy78" style="text-align: right" title="Weighted average remaining contractual life (years)::XDX::P2Y3M19D"><span style="-sec-ix-hidden: xdx2ixbrl0577">2.3</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_982_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zGsLhEt5oFp2" style="text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">1.75</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zERqgRVJ4Od" style="text-align: right" title="Number of warrant exercisable">161,342</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98D_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_z0gwdL3UTfW3" style="text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">1.75</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td style="text-align: right"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_zqvmMztnnAHh" title="Exercse price (in dollars per share)">3.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_z0ekQeMOm1he" style="text-align: right" title="Number warrant outstanding">9,427,196</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_z4djd98mNtwk" style="text-align: right" title="Weighted average remaining contractual life (years)::XDX::P2Y8M12D"><span style="-sec-ix-hidden: xdx2ixbrl0589">2.7</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_985_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_zCkGHj1FHXRc" style="text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">3.00</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_983_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_zsXrtR6EzwH4" style="text-align: right" title="Number of warrant exercisable">9,427,196</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td id="xdx_98C_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_zz1f9yFngWXe" style="text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">3.00</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid">$</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_zE4Tpmn5pHWd" title="Exercse price (in dollars per share)">6.25</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zQxgUdMpQly8" style="border-bottom: black 1pt solid; text-align: right" title="Number warrant outstanding">61,250</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zSJmIUBqhkce" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average remaining contractual life (years)::XDX::P3Y10M25D"><span style="-sec-ix-hidden: xdx2ixbrl0601">3.9</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td id="xdx_984_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zOyd1700VTk7" style="border-bottom: black 1pt solid; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">6.25</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_982_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zrOSbnjyCzu6" style="border-bottom: black 1pt solid; text-align: right" title="Number of warrant exercisable">61,250</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">$</td>
    <td id="xdx_981_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zjWEFKDoFzYf" style="border-bottom: black 1pt solid; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">6.25</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right">$<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member__srt--RangeAxis__srt--MinimumMember_zMW0WoWiKWWf" title="Exercse price (in dollars per share)">1.00</span> - $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member__srt--RangeAxis__srt--MaximumMember_zm0S1G3iyfg6" title="Exercse price (in dollars per share)">6.25</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731_zTmFv0DmSME1" style="border-bottom: black 2.25pt double; text-align: right" title="Number warrant outstanding">10,149,788</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731_zhvPLCA1MJRl" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average remaining contractual life (years)::XDX::P2Y7M6D"><span style="-sec-ix-hidden: xdx2ixbrl0615">2.6</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_989_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731_zOQkaHdYgMna" style="border-bottom: black 2.25pt double; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)">2.90</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_987_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731_zQcLHY4ZUaF5" style="border-bottom: black 2.25pt double; text-align: right" title="Number of warrant exercisable">10,149,788</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">$</td>
    <td id="xdx_981_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731_zh0MolRQFQgj" style="border-bottom: black 2.25pt double; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)">2.90</td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock', window );">The estimated fair value of warrants granted during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions:</a></td>
<td class="text"><p id="xdx_89D_ecustom--ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock_zbbMtIAfu7d1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span id="xdx_8B3_zuejyHMYX3s5">The estimated fair value of warrants granted during
the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Expected term (in years)</td><td style="width: 1%">&#160;</td>
    <td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQImOIzcjzd2" style="width: 17%; text-align: center" title="Expected term (in years)"><span style="-sec-ix-hidden: xdx2ixbrl0625">-</span></td><td style="width: 1%">&#160;</td>
    <td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwjO06Eurs6c" style="width: 17%; text-align: center" title="::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0626">5.00</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&#160;</td>
    <td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zypgzgImH01k" style="text-align: center" title="Warrants measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0628">-</span></td><td>&#160;</td>
    <td id="xdx_987_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zhiVY4h4qVjg" style="text-align: center" title="Warrants measurement input">103.70%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zbAoT8ln8IM4" style="text-align: center" title="Warrants measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0632">-</span></td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zV3jQ2XvrIh8" title="Warrants measurement input">0.27</span>% - <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_ziPVDHLdtEvf" title="Warrants measurement input">0.28</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zIGdub23qDb3" style="text-align: center" title="Warrants measurement input"><span style="-sec-ix-hidden: xdx2ixbrl0638">-</span></td><td>&#160;</td>
    <td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--MinimumMember_zxnTvqD9M2Bf" style="text-align: center" title="Warrants measurement input">0.0%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_DisclosureWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_DisclosureWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents schedule of estimated fair value of warrants granted table text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146030244176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Original AL001 License:</a></td>
<td class="text"><p id="xdx_895_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zC4M9bZ7vk2f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><span id="xdx_8B9_zGw8l6J7Ii23">Original
AL001 License:</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid"><b>Payment</b></td>
    <td style="text-align: left; white-space: nowrap; vertical-align: middle"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><b>&#160;Due Date</b></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="border-bottom: black 1pt solid"><b>&#160;Event</b></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 1%">$</td>
    <td id="xdx_98F_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--PreINDMeetingMember_zjPksGXDXy2l" style="width: 11%; text-align: right" title="Payment">50,000</td>
    <td style="vertical-align: middle; width: 1%; text-align: left"><span id="xdx_F2F_zbSOF11wVTUd" style="font-size: 10pt">*</span></td>
    <td id="xdx_985_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--PreINDMeetingMember_zY1jktkhGQaj" style="width: 46%" title="Due Date">&#160;Completed September 2019</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 40%">&#160;Pre-IND meeting</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: middle; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_982_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zjJkpJxz5mze" style="text-align: right" title="Payment">65,000</td>
    <td style="vertical-align: middle; text-align: left"><span id="xdx_F2A_z7X0v1jlCYQb" style="font-size: 10pt">*</span></td>
    <td id="xdx_984_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_znf58gBDm5Gi" title="Due Date">&#160;Completed June 2021</td>
    <td>&#160;</td>
    <td>&#160;IND application filing</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: middle; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_98B_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zroqmNPrjqsj" style="text-align: right" title="Payment">190,000</td>
    <td style="vertical-align: middle; text-align: left"><span id="xdx_F21_za1ODzHwTgW2" style="font-size: 10pt">*</span></td>
    <td id="xdx_985_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zzCLYgSWciN" title="Due Date">&#160;Completed December 2021</td>
    <td>&#160;</td>
    <td>&#160;Upon first dosing of patient in a clinical trial</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: middle; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_98B_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPatientDosingMember_z0KUOaSBO4o" style="text-align: right" title="Payment">500,000</td>
    <td style="vertical-align: middle; text-align: left"><span id="xdx_F26_zxJOWjomOu2c" style="font-size: 10pt">*</span></td>
    <td id="xdx_98B_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPatientDosingMember_zrBkyfasuBsi" title="Due Date">&#160;Completed March 2022</td>
    <td>&#160;</td>
    <td>&#160;Upon Completion of first clinical trial</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; vertical-align: middle"><span style="font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_988_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_zCKSqqyXl998" style="text-align: right" title="Payment">1,250,000</td>
    <td style="text-align: left; vertical-align: middle"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_zF44zw4wFwuh" title="Due Date">&#160;12 months from completion of the first Phase II clinical trial</td>
    <td>&#160;</td>
    <td>&#160;Upon first patient treated in a Phase III clinical trial</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left; vertical-align: middle"><span style="font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_986_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_z6Sh2hKlwVx" style="text-align: right" title="Payment">10,000,000</td>
    <td style="text-align: left; vertical-align: middle"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_z3CnLJGH3Dyh" title="Due Date">&#160;8 years from the effective date of the agreement</td>
    <td>&#160;</td>
    <td>&#160;Upon FDA approval</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td id="xdx_F02_zTGwSVr03vB3" style="width: 47px; text-align: right">*</td>
    <td style="width: 7px">&#160;</td>
    <td id="xdx_F19_zqQop9x9Ve8i" style="text-align: justify">Milestone met and completed</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>&#160;AL002
License:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"><b>Payment</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Due Date</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Event</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%">$</td>
    <td id="xdx_982_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--PreINDMeetingMember_zGzDlXyVxJ34" style="width: 11%; text-align: right" title="Payment">50,000</td>
    <td style="vertical-align: top; white-space: nowrap; width: 1%; text-align: left">*</td>
    <td id="xdx_98D_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--PreINDMeetingMember_zX6BlkE1pDaa" style="width: 46%" title="Due Date">Completed January 2022</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 40%; text-align: justify">&#160;Upon IND application filing</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_987_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zdltbFvp3WWh" style="text-align: right" title="Payment">50,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_988_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zTXfq8ACZeWj" title="Due Date">12 months from IND application filing date</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;Upon first dosing of patient in first Phase I clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_981_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zDILv2k8DQLf" style="text-align: right" title="Payment">175,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_98C_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zUfFSGpxKuL2" title="Due Date">12 months from first patient dosed in Phase I</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;Upon completion of first Phase I clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_982_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_zYjuxneHWsic" style="text-align: right" title="Payment">500,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_98C_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_z8A6Aqu6xTXe" title="Due Date">24 months from completion of first Phase I clinical trial</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;Upon completion of first Phase II clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_98C_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember_zkQDPeV7Vuu2" style="text-align: right" title="Payment">1,000,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_98F_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember_zhQzIoEWxNte" title="Due Date">12 months from completion of the first Phase II clinical trial</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;Upon first patient treated in a Phase III clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_989_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_zmbtq9N8w5Gf" style="text-align: right" title="Payment">10,000,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_989_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_zIwoWHKEmIU9" title="Due Date">7 years from the effective date of the agreement</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;Upon FDA BLA approval</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
Company has met the pre-IND meeting, IND application filing, and successfully completed the Phase I clinical trial milestones encompassing
AL001. If the Company fails to meet a milestone by its specified date, the Licensor may terminate the license agreement.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Licensor
was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by the Company
while Licensor remains the owner of any equity securities of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
June&#160;10, 2020, the Company obtained two (2) additional royalty-bearing exclusive worldwide licenses from the Licensor to a therapy
named AL001. One of the additional licenses is for the treatment of neurodegenerative diseases excluding Alzheimer&#8217;s and the other
license is for the treatment of psychiatric diseases and disorders. There are certain license fees and milestone payments required to
be paid pursuant to the terms of the Standard Exclusive License Agreements with Sublicensing Terms, both dated June&#160;10, 2020 and
effective&#160;as of November&#160;1, 2019, with the Licensor and the University of South Florida (the &#8220;June AL001 License Agreements&#8221;).
Under each of the June AL001 License Agreements, a royalty payment of&#160;<span id="xdx_902_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._pid_dp_uPure_c20200501__20200610__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zNNbAyQf2r5f" title="Percentage of royalty payments on net sales of product">3</span>% is required on net sales of products developed from the
licensed technology. For the two (2) additional AL001 licenses, in the aggregate, the Company has paid initial license fees of $<span id="xdx_907_ecustom--InitialLicenseFees_c20200501__20200610__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zC2q1CTKa5Xf" title="Initial license fees">20,000</span>.
Additionally, under each of the June AL001 License Agreements, the Company is required to pay milestone payments on the due dates to the
Licensor for the license of the technology, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Additional
AL001 Licenses:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"><b>Payment</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Due Date</b></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><b>Event</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%">$</td>
    <td id="xdx_98E_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zSyt8NPBi1l8" style="width: 12%; text-align: right" title="Payment">50,000</td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td id="xdx_98E_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zPJNTq6CZuA" style="width: 47%" title="Due Date">Upon IND application filing</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 38%">&#160;IND application filing</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_98A_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zl1CyYvjPSY8" style="text-align: right" title="Payment">150,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_98D_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zcl1aoueDhsf" title="Due Date">12 months from IND filing date</td>
    <td>&#160;</td>
    <td>&#160;Upon first dosing of patient in a clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_980_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_z7zMeNxDQmzc" style="text-align: right" title="Payment">400,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_981_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_zIO8W0mRuTy6" title="Due Date">12 months from first patient dosing</td>
    <td>&#160;</td>
    <td>&#160;Upon Completion of first clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_985_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember_zOj7P1GfKvdf" style="text-align: right" title="Payment">1,000,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_980_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember_zxE8buiCBtYi" title="Due Date">36 months from completion of the first Phase II clinical trial</td>
    <td>&#160;</td>
    <td>&#160;Upon first patient treated in a Phase III clinical trial</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>$</td>
    <td id="xdx_988_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_zqTtiPVGzRv8" style="text-align: right" title="Payment">8,000,000</td>
    <td style="white-space: nowrap">&#160;</td>
    <td id="xdx_984_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_zcQ256EItc9g" title="Due Date">8 years from the effective date of the agreement</td>
    <td>&#160;</td>
    <td>&#160;First commercial sale</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 303<br> -Paragraph (a)<br> -Subparagraph (5)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146025488608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146021695184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY AND GOING CONCERN (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(32,231,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (29,194,495)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,037,074)<span></span>
</td>
<td class="num">$ (2,319,867)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146026931392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following sets forth the number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have been excluded from the computation of loss per common share: (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">28,749,788<span></span>
</td>
<td class="nump">41,562,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">18,600,000<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">10,149,788<span></span>
</td>
<td class="nump">8,830,785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxneuro_ConvertibleNotesMember', window );">Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">232,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxneuro_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxneuro_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146024136720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_NumberOfStockExcluded', window );">Number Of Stock Excluded | shares</a></td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.0004<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_NumberOfStockExcluded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents number of stock excluded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_NumberOfStockExcluded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146027064960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Apr. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_LongTermDebtAverageAmountOfOutstanding', window );">Outstanding receivable amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,883,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alxneuro_AultLifeSciencesFundLLCMember', window );">Ault Life Sciences Fund L L C [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchase (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares purchase</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alxneuro_AultLifeSciencesFundLLCMember', window );">Ault Life Sciences Fund L L C [Member] | Securities Purchase Agreement [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of warrants granted</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_LongTermDebtAverageAmountOfOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents long term debt average amount of outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_LongTermDebtAverageAmountOfOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alxneuro_AultLifeSciencesFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alxneuro_AultLifeSciencesFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alxneuro_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alxneuro_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146020765536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid expenses and other current assets are as follows: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 451,885<span></span>
</td>
<td class="nump">$ 155,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">9,577<span></span>
</td>
<td class="nump">7,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">9,413<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 587,542<span></span>
</td>
<td class="nump">$ 349,723<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146024302064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Jun. 16, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_PrepaidInsurance1', window );">Purchase D&amp;O Insurance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 492,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_UnamortizedPrepaidExpense', window );">Unamortized prepaid expense</a></td>
<td class="nump">$ 452,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=alxneuro_SpartanCapitalSecuritiesMember', window );">Spartan Capital Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_PrepaidConsultingFees', window );">Prepaid consulting fees</a></td>
<td class="nump">$ 117,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_PrepaidConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents prepaid consulting fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_PrepaidConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_PrepaidInsurance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents prepaid insurance1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_PrepaidInsurance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_UnamortizedPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents unamortized prepaid expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_UnamortizedPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=alxneuro_SpartanCapitalSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=alxneuro_SpartanCapitalSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146026201104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>A summary of stock option activity for the three months ended July 31, 2022 is presented below: (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Balance at begining (in shares)</a></td>
<td class="nump">8,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at begining (in shares)</a></td>
<td class="nump">15,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at begining | $ / shares</a></td>
<td class="nump">$ 1.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1', window );">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance at begining | $</a></td>
<td class="nump">$ 2,219,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted', window );">Options granted</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross', window );">Options exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited', window );">Options expired</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options expired</a></td>
<td class="num">(1,100,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Options expired | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Balance at end (in shares)</a></td>
<td class="nump">8,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at end (in shares)</a></td>
<td class="nump">14,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at end | $ / shares</a></td>
<td class="nump">$ 1.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance at end (in shares)</a></td>
<td class="text">5 years 9 months 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance at end | $</a></td>
<td class="nump">$ 1,777,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest</a></td>
<td class="nump">13,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest at end | $ / shares</a></td>
<td class="nump">$ 1.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest at end</a></td>
<td class="text">6 years 4 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest at end | $</a></td>
<td class="nump">$ 1,777,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at end</a></td>
<td class="nump">11,514,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable at end | $ / shares</a></td>
<td class="nump">$ 1.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable at end</a></td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable at end | $</a></td>
<td class="nump">$ 1,777,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award number of shares available for grant options cancelled or forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award number of shares available for grant options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents share based compensation arrangement by share based payment award options exercised in period gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents sharebased compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in the weighted average exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146027157600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The estimated fair value of stock options granted to employees and consultants during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions: (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=alxneuro_EmployeesAndConsultantsMember', window );">Employees and Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">86.31%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Employees and Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term (in years)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.01%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Employees and Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.07%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=alxneuro_EmployeesAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=alxneuro_EmployeesAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146024300592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company&#8217;s results of operations include expenses relating to stock-based compensation for three months ended July 31, 2022 and 2021, that were comprised as follows: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 867,338<span></span>
</td>
<td class="nump">$ 739,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">141,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 867,338<span></span>
</td>
<td class="nump">$ 597,705<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146025698080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 23, 2021</div></th>
<th class="th"><div>Nov. 26, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Maximum potential expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 867,338<span></span>
</td>
<td class="nump">$ 739,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average period vested and expected to vest at end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 4 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Maximum potential expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 867,338<span></span>
</td>
<td class="nump">597,705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=alxneuro_UnamortizedStockBasedCompensationMember', window );">Unamortized Stock Based Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average period vested and expected to vest at end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Maximum potential expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 867,000<span></span>
</td>
<td class="nump">$ 740,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Minimum [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Maximum potential expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=alxneuro_PerformanceContingentStockOptionsMember', window );">Performance Contingent Stock Options [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=alxneuro_PerformanceContingentStockOptionsMember', window );">Performance Contingent Stock Options [Member] | Key Employees and Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">4,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Terms of warrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In the event any of the stock
price milestones are not achieved within three years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alxneuro_StockIncentivePlan2016Member', window );">Stock Incentive Plan2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=alxneuro_UnamortizedStockBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=alxneuro_UnamortizedStockBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=alxneuro_PerformanceContingentStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=alxneuro_PerformanceContingentStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alxneuro_KeyEmployeesAndDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alxneuro_KeyEmployeesAndDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alxneuro_StockIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alxneuro_StockIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146020879472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The following table summarizes information about Common Stock warrants outstanding and exercisable at July 31, 2022: (Details)<br></strong></div></th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number warrant outstanding | shares</a></td>
<td class="nump">10,149,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights', window );">Warrant outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_ClassOfWarrantOrRightExercisable', window );">Number of warrant exercisable | shares</a></td>
<td class="nump">10,149,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice', window );">Warrant exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alxneuro_ExercisePrice1Member', window );">Exercise Price1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercse price (in dollars per share)</a></td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number warrant outstanding | shares</a></td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights', window );">Warrant outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_ClassOfWarrantOrRightExercisable', window );">Number of warrant exercisable | shares</a></td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice', window );">Warrant exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alxneuro_ExercisePrice2Member', window );">Exercise Price 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercse price (in dollars per share)</a></td>
<td class="nump">$ 1.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number warrant outstanding | shares</a></td>
<td class="nump">161,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">2 years 3 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights', window );">Warrant outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_ClassOfWarrantOrRightExercisable', window );">Number of warrant exercisable | shares</a></td>
<td class="nump">161,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice', window );">Warrant exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alxneuro_ExercisePrice3Member', window );">Exercise Price 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercse price (in dollars per share)</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alxneuro_ExercisePriceFiftySixMember', window );">Exercise Price Fifty Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number warrant outstanding | shares</a></td>
<td class="nump">9,427,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights', window );">Warrant outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_ClassOfWarrantOrRightExercisable', window );">Number of warrant exercisable | shares</a></td>
<td class="nump">9,427,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice', window );">Warrant exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alxneuro_ExercisePrice4Member', window );">Exercise Price 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercse price (in dollars per share)</a></td>
<td class="nump">6.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alxneuro_ExercisePrice4Member', window );">Exercise Price 4 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercse price (in dollars per share)</a></td>
<td class="nump">1.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alxneuro_ExercisePrice4Member', window );">Exercise Price 4 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercse price (in dollars per share)</a></td>
<td class="nump">$ 6.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alxneuro_ExercisePriceFiftySevenMember', window );">Exercise Price Fifty Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number warrant outstanding | shares</a></td>
<td class="nump">61,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">3 years 10 months 25 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights', window );">Warrant outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_ClassOfWarrantOrRightExercisable', window );">Number of warrant exercisable | shares</a></td>
<td class="nump">61,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice', window );">Warrant exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_ClassOfWarrantOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents class of warrant or right exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_ClassOfWarrantOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents class of warrant or right exercisable weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents class of warrant or right weighted average exercise price of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alxneuro_ExercisePrice1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alxneuro_ExercisePrice1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alxneuro_ExercisePrice2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alxneuro_ExercisePrice2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alxneuro_ExercisePrice3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alxneuro_ExercisePrice3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alxneuro_ExercisePriceFiftySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alxneuro_ExercisePriceFiftySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alxneuro_ExercisePrice4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alxneuro_ExercisePrice4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alxneuro_ExercisePriceFiftySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=alxneuro_ExercisePriceFiftySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146024321712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The estimated fair value of warrants granted during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions: (Details) - Number<br></strong></div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term (in years)</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term (in years)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Measurement Input, Option Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">103.70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Measurement Input, Option Volatility [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Measurement Input, Expected Dividend Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146020768496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER RELATED PARTY TRANSACTIONS (Details Narrative) - Securities Purchase Agreement [Member] - Digital Power Lending [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Description of related party transaction</a></td>
<td class="nump">6,666,667<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Number of shares sold</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Description of related party transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the surrender for cancellation of a $50,000 convertible
promissory note held by BitNile Holdings, Inc. (&#8220;BitNile&#8221;), the parent company of DPL, for an aggregate of 2,666,667 shares
of Common Stock. Under the terms of the securities purchase agreement, DPL (i) purchased an additional 1,333,333 shares of Common Stock
upon approval of the IND for Phase IA clinical trials for AL001 for a purchase price of $2 million, and (ii) purchased 2,666,667 shares
of Common Stock upon the completion of Phase IA clinical trials for AL001 for a purchase price of $4 million.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentMilestones', window );">Description of milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company issued to DPL
warrants to purchase 3,333,333 shares of Common Stock at an exercise price of $3.00 per share. Finally, the Company agreed that for a
period of 18 months following the date of the payment of the final tranche of $4 million, DPL will have the right to invest an additional
$10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million as of
the date of this Quarterly Report.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the nature of achievements or target goals that are to be reached by specified dates to maintain the arrangement or extend it, generally without adjustment of the present financial terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123395306&amp;loc=d3e36975-112693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919370-209981<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918703-209980<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128295416&amp;loc=SL77919784-209982<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alxneuro_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alxneuro_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alxneuro_DigitalPowerLendingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alxneuro_DigitalPowerLendingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146025751584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Original AL001 License: (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alxneuro_AL001LicenseMember', window );">A L001 License [Member] | Pre I N D Meeting [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Payment</a></td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Due Date</a></td>
<td class="text">&#160;Completed September 2019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alxneuro_AL001LicenseMember', window );">A L001 License [Member] | Ind Application Filing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Payment</a></td>
<td class="nump">$ 65,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Due Date</a></td>
<td class="text">&#160;Completed June 2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alxneuro_AL001LicenseMember', window );">A L001 License [Member] | Upon First Dosing of Patient in Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Payment</a></td>
<td class="nump">$ 190,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Due Date</a></td>
<td class="text">&#160;Completed December 2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alxneuro_AL001LicenseMember', window );">A L001 License [Member] | Upon Completion of First Patient Dosing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Payment</a></td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Due Date</a></td>
<td class="text">&#160;Completed March 2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alxneuro_AL001LicenseMember', window );">A L001 License [Member] | Upon Completion of First Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Payment</a></td>
<td class="nump">$ 1,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Due Date</a></td>
<td class="text">&#160;12 months from completion of the first Phase II clinical trial<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alxneuro_AL001LicenseMember', window );">A L001 License [Member] | Upon Fda Approval [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Payment</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Due Date</a></td>
<td class="text">&#160;8 years from the effective date of the agreement<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alxneuro_AL002LicenseMember', window );">A L002 License [Member] | Pre I N D Meeting [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Payment</a></td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Due Date</a></td>
<td class="text">Completed January 2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alxneuro_AL002LicenseMember', window );">A L002 License [Member] | Ind Application Filing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Payment</a></td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Due Date</a></td>
<td class="text">12 months from IND application filing date<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alxneuro_AL002LicenseMember', window );">A L002 License [Member] | Upon First Dosing of Patient in Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Payment</a></td>
<td class="nump">$ 175,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Due Date</a></td>
<td class="text">12 months from first patient dosed in Phase I<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alxneuro_AL002LicenseMember', window );">A L002 License [Member] | Upon Completion of First Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Payment</a></td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Due Date</a></td>
<td class="text">24 months from completion of first Phase I clinical trial<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alxneuro_AL002LicenseMember', window );">A L002 License [Member] | Upon Fda Approval [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Payment</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Due Date</a></td>
<td class="text">7 years from the effective date of the agreement<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alxneuro_AL002LicenseMember', window );">A L002 License [Member] | Upon First Patient Treated In Phase3 Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Payment</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Due Date</a></td>
<td class="text">12 months from completion of the first Phase II clinical trial<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alxneuro_AdditionalAL001LicenseMember', window );">Additional A L001 License [Member] | Ind Application Filing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Payment</a></td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Due Date</a></td>
<td class="text">Upon IND application filing<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alxneuro_AdditionalAL001LicenseMember', window );">Additional A L001 License [Member] | Upon First Dosing of Patient in Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Payment</a></td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Due Date</a></td>
<td class="text">12 months from IND filing date<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alxneuro_AdditionalAL001LicenseMember', window );">Additional A L001 License [Member] | Upon Completion of First Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Payment</a></td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Due Date</a></td>
<td class="text">12 months from first patient dosing<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alxneuro_AdditionalAL001LicenseMember', window );">Additional A L001 License [Member] | Upon Fda Approval [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Payment</a></td>
<td class="nump">$ 8,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Due Date</a></td>
<td class="text">8 years from the effective date of the agreement<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alxneuro_AdditionalAL001LicenseMember', window );">Additional A L001 License [Member] | Upon First Patient Treated In Phase3 Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Payment</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Due Date</a></td>
<td class="text">36 months from completion of the first Phase II clinical trial<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the nature and terms of commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alxneuro_AL001LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alxneuro_AL001LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_LicenseEventsAxis=alxneuro_PreINDMeetingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_LicenseEventsAxis=alxneuro_PreINDMeetingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_LicenseEventsAxis=alxneuro_IndApplicationFilingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_LicenseEventsAxis=alxneuro_IndApplicationFilingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_LicenseEventsAxis=alxneuro_UponFirstDosingOfPatientInClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_LicenseEventsAxis=alxneuro_UponFirstDosingOfPatientInClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_LicenseEventsAxis=alxneuro_UponCompletionOfFirstPatientDosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_LicenseEventsAxis=alxneuro_UponCompletionOfFirstPatientDosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_LicenseEventsAxis=alxneuro_UponCompletionOfFirstClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_LicenseEventsAxis=alxneuro_UponCompletionOfFirstClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_LicenseEventsAxis=alxneuro_UponFdaApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_LicenseEventsAxis=alxneuro_UponFdaApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alxneuro_AL002LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alxneuro_AL002LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_LicenseEventsAxis=alxneuro_UponFirstPatientTreatedInPhase3ClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_LicenseEventsAxis=alxneuro_UponFirstPatientTreatedInPhase3ClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alxneuro_AdditionalAL001LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alxneuro_AdditionalAL001LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146021635264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 10, 2020</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alxneuro_AL002LicenseMember', window );">A L002 License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.', window );">Percentage of royalty payments on net sales of product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alxneuro_AL001LicenseMember', window );">A L001 License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.', window );">Percentage of royalty payments on net sales of product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=alxneuro_AdditionalAL001LicenseMember', window );">Additional A L001 License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.', window );">Percentage of royalty payments on net sales of product</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_DescriptionOfLicensesAgreements', window );">Description of licenses agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has already paid an initial license fee of
$200,000 for AL002 and an initial license fee of $200,000 for AL001. As an additional licensing fee for the license of AL002, the Licensor
received 3,601,809 shares of common stock. As an additional licensing fee for the license of the AL001 technologies, the Licensor received
2,227,923 shares of common stock. Minimum royalties for AL001 are $25,000 in 2023, $45,000 in 2024 and $70,000 in 2025 and every year
thereafter, for the life of the agreement. Minimum royalties for AL002 are $20,000 in 2022, $40,000 in 2023 and $50,000 in 2024 and every
year thereafter, for the life of the respective agreement.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_InitialLicenseFees', window );">Initial license fees</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_DescriptionOfLicensesAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents description of licenses agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_DescriptionOfLicensesAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_InitialLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents initial license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_InitialLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents percentage of royalty payments on net sales of product..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alxneuro_AL002LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alxneuro_AL002LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alxneuro_AL001LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alxneuro_AL001LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=alxneuro_AdditionalAL001LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=alxneuro_AdditionalAL001LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140146020639360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>EQUITY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Apr. 28, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 09, 2021</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=alxneuro_ALSFMember', window );">A L S F [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alxneuro_SecuritiesPurchaseAgreementsMember', window );">Securities Purchase Agreements [Member] | A L S F [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_NumberOfSharesPurchase', window );">Number of shares purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_SharesPurchasePrice', window );">Shares purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_SharesPurchasePricePerShares', window );">Shares purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_StockIssuedDuringPeriodSharesNewIssuesOne', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alxneuro_SecuritiesPurchaseAgreementsMember', window );">Securities Purchase Agreements [Member] | A L S F [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_NumberOfSharesPurchase', window );">Number of shares purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alxneuro_SecuritiesPurchaseAgreementsMember', window );">Securities Purchase Agreements [Member] | Digital Power Lending [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_AdvanceFromRelatedParties', window );">Advance from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alxneuro_SecuritiesPurchaseAgreementsMember', window );">Securities Purchase Agreements [Member] | Digital Power Lending [Member] | Final Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_AdditionalRightToInvest', window );">Additional right to invest</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alxneuro_SecuritiesPurchaseAgreementsMember', window );">Securities Purchase Agreements [Member] | Ault Global [Member] | Convertible Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_StockIssuedDuringPeriodSharesNewIssuesOne', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_SharesValueSurrenderForCancellation', window );">Shares value surrender for cancellation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alxneuro_PreferredStockSharesDesignated', window );">Preferred stock shares designated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,360,000<span></span>
</td>
<td class="nump">1,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_AdditionalRightToInvest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents additional right to invest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_AdditionalRightToInvest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_AdvanceFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents advance from related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_AdvanceFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_NumberOfSharesPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents number of shares purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_NumberOfSharesPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_PreferredStockSharesDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents preferred stock shares designated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_PreferredStockSharesDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_SharesPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents shares purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_SharesPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_SharesPurchasePricePerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents shares purchase price per shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_SharesPurchasePricePerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_SharesValueSurrenderForCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents shares value surrender for cancellation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_SharesValueSurrenderForCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxneuro_StockIssuedDuringPeriodSharesNewIssuesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents stock issued during period shares new issues one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxneuro_StockIssuedDuringPeriodSharesNewIssuesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxneuro_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alxneuro_ALSFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alxneuro_ALSFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alxneuro_SecuritiesPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alxneuro_SecuritiesPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alxneuro_DigitalPowerLendingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alxneuro_DigitalPowerLendingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=alxneuro_FinalTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=alxneuro_FinalTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alxneuro_AultGlobalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alxneuro_AultGlobalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alxneuro_ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alxneuro_ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>p9722010q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:alxneuro="http://alzamend.com/20220731"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="alxneuro-20220731.xsd" xlink:type="simple"/>
    <context id="From2022-05-01to2022-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
        </entity>
        <period>
            <instant>2022-09-13</instant>
        </period>
    </context>
    <context id="AsOf2022-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="AsOf2022-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="AsOf2022-07-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="AsOf2022-04-30_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="From2021-05-012021-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="AsOf2022-04-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="AsOf2022-04-30_custom_NoteRecievableForCommonStockRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alxneuro:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="AsOf2022-04-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="AsOf2021-04-30_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="AsOf2021-04-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="AsOf2021-04-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="AsOf2021-04-30_custom_NoteRecievableForCommonStockRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alxneuro:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="AsOf2021-04-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="AsOf2021-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alxneuro:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="From2021-05-012021-07-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="From2021-05-012021-07-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="From2021-05-012021-07-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="From2021-05-012021-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alxneuro:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="From2021-05-012021-07-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="AsOf2022-07-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alxneuro:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="AsOf2022-07-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="AsOf2021-07-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="AsOf2021-07-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="AsOf2021-07-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="AsOf2021-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alxneuro:NoteRecievableForCommonStockRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="AsOf2021-07-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="AsOf2021-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="From2021-05-012021-07-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="From2021-05-012021-07-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_ConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alxneuro:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="From2021-05-012021-07-31_custom_ConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alxneuro:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012019-04-30_custom_AultLifeSciencesFundLLCMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxneuro:AultLifeSciencesFundLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="From2019-04-012019-04-30_custom_AultLifeSciencesFundLLCMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxneuro:AultLifeSciencesFundLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-04-01_custom_AultLifeSciencesFundLLCMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxneuro:AultLifeSciencesFundLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-01</instant>
        </period>
    </context>
    <context id="AsOf2019-04-30_custom_AultLifeSciencesFundLLCMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxneuro:AultLifeSciencesFundLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
        </entity>
        <period>
            <instant>2022-06-16</instant>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_SpartanCapitalSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">alxneuro:SpartanCapitalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="AsOf2016-04-30_custom_StockIncentivePlan2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alxneuro:StockIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="From2016-04-012016-04-30_custom_StockIncentivePlan2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alxneuro:StockIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="From2021-05-012021-07-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="From2018-11-012018-11-30_custom_PerformanceContingentStockOptionsMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxneuro:PerformanceContingentStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="From2019-11-252019-11-26_custom_PerformanceContingentStockOptionsMember_custom_KeyEmployeesAndDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxneuro:PerformanceContingentStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxneuro:KeyEmployeesAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-25</startDate>
            <endDate>2019-11-26</endDate>
        </period>
    </context>
    <context id="From2021-03-222021-03-23_custom_PerformanceContingentStockOptionsMember_custom_KeyEmployeesAndDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxneuro:PerformanceContingentStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxneuro:KeyEmployeesAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-22</startDate>
            <endDate>2021-03-23</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_UnamortizedStockBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">alxneuro:UnamortizedStockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_UnamortizedStockBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">alxneuro:UnamortizedStockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_srt_MinimumMember_custom_EmployeesAndConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxneuro:EmployeesAndConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="From2021-05-012021-07-31_srt_MinimumMember_custom_EmployeesAndConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxneuro:EmployeesAndConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="From2021-05-012021-07-31_srt_MaximumMember_custom_EmployeesAndConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxneuro:EmployeesAndConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_EmployeesAndConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxneuro:EmployeesAndConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="From2021-05-012021-07-31_custom_EmployeesAndConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxneuro:EmployeesAndConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="From2021-05-012021-07-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="From2021-05-012021-07-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_ExercisePrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alxneuro:ExercisePrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_ExercisePrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alxneuro:ExercisePrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_ExercisePrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alxneuro:ExercisePrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_ExercisePriceFiftySixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alxneuro:ExercisePriceFiftySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_ExercisePrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alxneuro:ExercisePrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_ExercisePriceFiftySevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alxneuro:ExercisePriceFiftySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_ExercisePrice4Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alxneuro:ExercisePrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_ExercisePrice4Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">alxneuro:ExercisePrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="AsOf2022-07-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="AsOf2021-07-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="AsOf2022-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="AsOf2021-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="AsOf2022-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="AsOf2021-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="AsOf2021-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="AsOf2021-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementMember_custom_DigitalPowerLendingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxneuro:DigitalPowerLendingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-03-082021-03-09_custom_SecuritiesPurchaseAgreementMember_custom_DigitalPowerLendingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxneuro:DigitalPowerLendingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-08</startDate>
            <endDate>2021-03-09</endDate>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_AL002LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_AL001LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="From2020-05-012020-06-10_custom_AdditionalAL001LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-06-10</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_AL001LicenseMember_custom_PreINDMeetingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:PreINDMeetingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_PreINDMeetingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:PreINDMeetingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_AL001LicenseMember_custom_IndApplicationFilingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:IndApplicationFilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_IndApplicationFilingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:IndApplicationFilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_AL001LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFirstDosingOfPatientInClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFirstDosingOfPatientInClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_AL001LicenseMember_custom_UponCompletionOfFirstPatientDosingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponCompletionOfFirstPatientDosingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_UponCompletionOfFirstPatientDosingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponCompletionOfFirstPatientDosingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_AL001LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponCompletionOfFirstClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponCompletionOfFirstClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_AL001LicenseMember_custom_UponFdaApprovalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFdaApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_UponFdaApprovalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFdaApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_AL002LicenseMember_custom_PreINDMeetingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:PreINDMeetingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_PreINDMeetingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:PreINDMeetingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_AL002LicenseMember_custom_IndApplicationFilingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:IndApplicationFilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_IndApplicationFilingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:IndApplicationFilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_AL002LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFirstDosingOfPatientInClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFirstDosingOfPatientInClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_AL002LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponCompletionOfFirstClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponCompletionOfFirstClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_AL002LicenseMember_custom_UponFirstPatientTreatedInPhase3ClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFirstPatientTreatedInPhase3ClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_UponFirstPatientTreatedInPhase3ClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFirstPatientTreatedInPhase3ClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_AL002LicenseMember_custom_UponFdaApprovalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFdaApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_UponFdaApprovalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFdaApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AL002LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_AdditionalAL001LicenseMember_custom_IndApplicationFilingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:IndApplicationFilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember_custom_IndApplicationFilingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:IndApplicationFilingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFirstDosingOfPatientInClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFirstDosingOfPatientInClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_AdditionalAL001LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponCompletionOfFirstClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponCompletionOfFirstClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFirstPatientTreatedInPhase3ClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFirstPatientTreatedInPhase3ClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFirstPatientTreatedInPhase3ClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFirstPatientTreatedInPhase3ClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFdaApprovalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFdaApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFdaApprovalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="alxneuro:LicenseEventsAxis">alxneuro:UponFdaApprovalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">alxneuro:AdditionalAL001LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="From2019-04-302019-04-30_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxneuro:ALSFMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-30</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="From2019-04-302019-04-30_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxneuro:ALSFMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-30</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-04-30_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxneuro:ALSFMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="AsOf2019-04-30_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxneuro:ALSFMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="AsOf2019-04-30_custom_ALSFMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxneuro:ALSFMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxneuro:ALSFMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_SecuritiesPurchaseAgreementsMember_custom_DigitalPowerLendingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxneuro:DigitalPowerLendingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementsMember_custom_DigitalPowerLendingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxneuro:DigitalPowerLendingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementsMember_custom_AultGlobalMember_custom_ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxneuro:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxneuro:AultGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-03-012021-03-09_custom_SecuritiesPurchaseAgreementsMember_custom_AultGlobalMember_custom_ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxneuro:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxneuro:AultGlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-09</endDate>
        </period>
    </context>
    <context id="From2022-04-262022-04-28_custom_SecuritiesPurchaseAgreementsMember_custom_DigitalPowerLendingMember_custom_FinalTrancheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677077</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxneuro:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">alxneuro:FinalTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxneuro:DigitalPowerLendingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-26</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="N">
        <measure>alxneuro:Number</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-05-01to2022-07-31">0001677077</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-05-01to2022-07-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-05-01to2022-07-31">--04-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-05-01to2022-07-31">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-05-01to2022-07-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentQuarterlyReport contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0015">true</dei:DocumentQuarterlyReport>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="AsOf2022-07-31"
      id="xdx2ixbrl0072"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-07-31"
      id="xdx2ixbrl0087"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-04-30"
      id="xdx2ixbrl0088"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-07-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="xdx2ixbrl0105"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-07-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="xdx2ixbrl0107"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-04-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="xdx2ixbrl0109"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-04-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="xdx2ixbrl0111"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-04-30_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0180"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-04-30_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0187"
      unitRef="Shares"
      xsi:nil="true"/>
    <alxneuro:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2022-05-012022-07-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0191"
      unitRef="USD"
      xsi:nil="true"/>
    <alxneuro:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2022-05-012022-07-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0192"
      unitRef="USD"
      xsi:nil="true"/>
    <alxneuro:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2022-05-012022-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      id="xdx2ixbrl0194"
      unitRef="USD"
      xsi:nil="true"/>
    <alxneuro:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2022-05-012022-07-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0195"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-05-012022-07-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0198"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-05-012022-07-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0199"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-05-012022-07-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0200"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-05-012022-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      id="xdx2ixbrl0201"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-07-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0205"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-07-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0212"
      unitRef="Shares"
      xsi:nil="true"/>
    <alxneuro:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2021-05-012021-07-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0227"
      unitRef="USD"
      xsi:nil="true"/>
    <alxneuro:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2021-05-012021-07-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0228"
      unitRef="USD"
      xsi:nil="true"/>
    <alxneuro:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2021-05-012021-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      id="xdx2ixbrl0230"
      unitRef="USD"
      xsi:nil="true"/>
    <alxneuro:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2021-05-012021-07-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0231"
      unitRef="USD"
      xsi:nil="true"/>
    <alxneuro:StockIssuedDuringPeriodValueNewIssues2
      contextRef="From2021-05-012021-07-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0234"
      unitRef="USD"
      xsi:nil="true"/>
    <alxneuro:StockIssuedDuringPeriodValueNewIssues2
      contextRef="From2021-05-012021-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      id="xdx2ixbrl0237"
      unitRef="USD"
      xsi:nil="true"/>
    <alxneuro:StockIssuedDuringPeriodValueNewIssues2
      contextRef="From2021-05-012021-07-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0238"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-05-012021-07-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0243"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-05-012021-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      id="xdx2ixbrl0246"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-05-012021-07-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0247"
      unitRef="USD"
      xsi:nil="true"/>
    <alxneuro:StockIssuedDuringPeriodValueNewIssues3
      contextRef="From2021-05-012021-07-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <alxneuro:StockIssuedDuringPeriodValueNewIssues3
      contextRef="From2021-05-012021-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      id="xdx2ixbrl0255"
      unitRef="USD"
      xsi:nil="true"/>
    <alxneuro:StockIssuedDuringPeriodValueNewIssues3
      contextRef="From2021-05-012021-07-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0256"
      unitRef="USD"
      xsi:nil="true"/>
    <alxneuro:ConversionOfSeriesAConvertibleStock
      contextRef="From2021-05-012021-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <alxneuro:ConversionOfSeriesAConvertibleStock
      contextRef="From2021-05-012021-07-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <alxneuro:ConversionOfSeriesAConvertibleStock
      contextRef="From2021-05-012021-07-31"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-05-012021-07-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-05-012021-07-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-05-012021-07-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-05-012021-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-07-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-07-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0288"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:Depreciation
      contextRef="From2021-05-012021-07-31"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2022-05-01to2022-07-31"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-05-01to2022-07-31"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-05-01to2022-07-31"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <alxneuro:ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts
      contextRef="From2022-05-01to2022-07-31"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-05-01to2022-07-31"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <alxneuro:FairValueOfWarrantsIssuedInConnectionWithIpo
      contextRef="From2022-05-01to2022-07-31"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <alxneuro:FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty
      contextRef="From2022-05-01to2022-07-31"
      id="xdx2ixbrl0355"
      xsi:nil="true"/>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-07-31"
      decimals="0"
      id="xdx2ixbrl0366"
      unitRef="USD">-32231569</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-05-01to2022-07-31"
      decimals="0"
      id="xdx2ixbrl0368"
      unitRef="USD">-3037074</us-gaap:NetIncomeLoss>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-05-012022-07-31_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0391"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-05-012022-07-31_custom_ConvertibleNotesMember"
      id="xdx2ixbrl0397"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2019-04-01_custom_AultLifeSciencesFundLLCMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember"
      id="xdx2ixbrl0415">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:OtherReceivables
      contextRef="AsOf2021-07-31"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <alxneuro:PrepaidInsurance1
      contextRef="AsOf2022-06-16"
      decimals="0"
      id="xdx2ixbrl0437"
      unitRef="USD">492000</alxneuro:PrepaidInsurance1>
    <alxneuro:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0456">P6Y1M6D</alxneuro:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
    <alxneuro:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted
      contextRef="From2022-05-01to2022-07-31"
      id="xdx2ixbrl0460"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-05-01to2022-07-31"
      id="xdx2ixbrl0462"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-05-01to2022-07-31"
      id="xdx2ixbrl0464"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <alxneuro:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross
      contextRef="From2022-05-01to2022-07-31"
      id="xdx2ixbrl0466"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-05-01to2022-07-31"
      id="xdx2ixbrl0468"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <alxneuro:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited
      contextRef="From2022-05-01to2022-07-31"
      id="xdx2ixbrl0470"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0482">P5Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0490">P6Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-05-01to2022-07-31" id="xdx2ixbrl0498">P5Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2022-05-012022-07-31_srt_MinimumMember_custom_EmployeesAndConsultantsMember"
      id="xdx2ixbrl0504"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2021-05-012021-07-31_srt_MinimumMember_custom_EmployeesAndConsultantsMember"
      id="xdx2ixbrl0506">P2Y6M0D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2021-05-012021-07-31_srt_MaximumMember_custom_EmployeesAndConsultantsMember"
      id="xdx2ixbrl0508">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-05-012022-07-31_custom_EmployeesAndConsultantsMember"
      id="xdx2ixbrl0510"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-05-012022-07-31_custom_EmployeesAndConsultantsMember"
      id="xdx2ixbrl0514"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-05-01to2022-07-31"
      id="xdx2ixbrl0520"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-05-012022-07-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      id="xdx2ixbrl0541"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="From2022-05-012022-07-31_custom_UnamortizedStockBasedCompensationMember"
      id="xdx2ixbrl0555">P2Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-07-31_custom_ExercisePrice1Member"
      id="xdx2ixbrl0565">P1Y7M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-07-31_custom_ExercisePrice2Member"
      id="xdx2ixbrl0577">P2Y3M19D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-07-31_custom_ExercisePriceFiftySixMember"
      id="xdx2ixbrl0589">P2Y8M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-07-31_custom_ExercisePriceFiftySevenMember"
      id="xdx2ixbrl0601">P3Y10M25D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-07-31" id="xdx2ixbrl0615">P2Y7M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-07-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0625"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2021-07-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0626">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember"
      id="xdx2ixbrl0628"
      unitRef="N"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember_srt_MinimumMember"
      id="xdx2ixbrl0632"
      unitRef="N"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember_srt_MinimumMember"
      id="xdx2ixbrl0638"
      unitRef="N"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2019-04-30_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember_us-gaap_WarrantMember"
      id="xdx2ixbrl0753">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2019-04-30_custom_ALSFMember"
      id="xdx2ixbrl0759">P12M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <dei:DocumentType contextRef="From2022-05-01to2022-07-31">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-05-01to2022-07-31">2022-07-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2022-05-01to2022-07-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-05-01to2022-07-31">001-40483</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-05-01to2022-07-31">ALZAMEND NEURO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-05-01to2022-07-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-05-01to2022-07-31">81-1822909</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-05-01to2022-07-31">3500 Lenox Rd NE</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-05-01to2022-07-31">Suite 1500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-05-01to2022-07-31">Atlanta</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-05-01to2022-07-31">GA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-05-01to2022-07-31">30326</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-05-01to2022-07-31">844</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-05-01to2022-07-31">722-6303</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-05-01to2022-07-31">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-05-01to2022-07-31">ALZN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-05-01to2022-07-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2022-05-01to2022-07-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-05-01to2022-07-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-05-01to2022-07-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-05-01to2022-07-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-05-01to2022-07-31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2022-05-01to2022-07-31">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="From2022-05-01to2022-07-31">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2022-09-13" decimals="INF" unitRef="Shares">95481790</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">11527121</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-04-30" decimals="0" unitRef="USD">14063811</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">587542</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-04-30" decimals="0" unitRef="USD">349723</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">12114663</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-04-30" decimals="0" unitRef="USD">14413534</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">95812</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-04-30" decimals="0" unitRef="USD">102909</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">12210475</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2022-04-30" decimals="0" unitRef="USD">14516443</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">1028700</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-04-30" decimals="0" unitRef="USD">1162850</us-gaap:AccountsPayableCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2022-04-30" decimals="0" unitRef="USD">2082</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">1028700</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-04-30" decimals="0" unitRef="USD">1164932</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">1028700</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2022-04-30" decimals="0" unitRef="USD">1164932</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-07-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-04-30"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-07-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-04-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-07-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-04-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <alxneuro:PreferredStockSharesDesignated
      contextRef="AsOf2022-07-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1360000</alxneuro:PreferredStockSharesDesignated>
    <alxneuro:PreferredStockSharesDesignated
      contextRef="AsOf2022-04-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1360000</alxneuro:PreferredStockSharesDesignated>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-07-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-04-30"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-07-31" decimals="INF" unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-04-30" decimals="INF" unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-07-31" decimals="INF" unitRef="Shares">95481790</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-07-31" decimals="INF" unitRef="Shares">95481790</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-04-30" decimals="INF" unitRef="Shares">95481790</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-04-30" decimals="INF" unitRef="Shares">95481790</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">9548</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2022-04-30" decimals="0" unitRef="USD">9548</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">58287091</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-04-30" decimals="0" unitRef="USD">57419753</us-gaap:AdditionalPaidInCapital>
    <alxneuro:NoteReceivableForCommonStockRelatedParty contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">-14883295</alxneuro:NoteReceivableForCommonStockRelatedParty>
    <alxneuro:NoteReceivableForCommonStockRelatedParty contextRef="AsOf2022-04-30" decimals="0" unitRef="USD">-14883295</alxneuro:NoteReceivableForCommonStockRelatedParty>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">-32231569</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-04-30" decimals="0" unitRef="USD">-29194495</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">11181775</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-04-30" decimals="0" unitRef="USD">13351511</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">12210475</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-04-30" decimals="0" unitRef="USD">14516443</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-05-01to2022-07-31"
      decimals="0"
      unitRef="USD">1375953</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">916408</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-05-01to2022-07-31"
      decimals="0"
      unitRef="USD">1659589</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">1389831</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="From2022-05-01to2022-07-31"
      decimals="0"
      unitRef="USD">3035542</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">2306239</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-05-01to2022-07-31"
      decimals="0"
      unitRef="USD">-3035542</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">-2306239</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2022-05-01to2022-07-31"
      decimals="0"
      unitRef="USD">1532</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">13628</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-05-01to2022-07-31"
      decimals="0"
      unitRef="USD">-1532</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">-13628</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-05-01to2022-07-31"
      decimals="0"
      unitRef="USD">-3037074</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">-2319867</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-05-01to2022-07-31"
      decimals="INF"
      unitRef="USDPShares">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-05-012021-07-31"
      decimals="INF"
      unitRef="USDPShares">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-05-01to2022-07-31"
      decimals="INF"
      unitRef="Shares">97481790</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-05-012021-07-31"
      decimals="INF"
      unitRef="Shares">84588492</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-04-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">95481790</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-04-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">9548</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-04-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">57419753</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-04-30_custom_NoteRecievableForCommonStockRelatedPartyMember"
      decimals="0"
      unitRef="USD">-14883295</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-04-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-29194495</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-04-30" decimals="0" unitRef="USD">13351511</us-gaap:StockholdersEquity>
    <alxneuro:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2022-05-012022-07-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">867338</alxneuro:StockbasedCompensationToEmployeesAndConsultants>
    <alxneuro:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2022-05-01to2022-07-31"
      decimals="0"
      unitRef="USD">867338</alxneuro:StockbasedCompensationToEmployeesAndConsultants>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-05-012022-07-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-3037074</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-05-01to2022-07-31"
      decimals="0"
      unitRef="USD">-3037074</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-07-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">95481790</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-07-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">9548</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-07-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">58287091</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      decimals="0"
      unitRef="USD">-14883295</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-07-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-32231569</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">11181775</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-04-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">750000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-04-30_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      unitRef="USD">75</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-04-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">67429525</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-04-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">6743</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-04-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">33721859</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-04-30_custom_NoteRecievableForCommonStockRelatedPartyMember"
      decimals="0"
      unitRef="USD">-14883295</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-04-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-16832437</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-04-30" decimals="0" unitRef="USD">2012945</us-gaap:StockholdersEquity>
    <alxneuro:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2021-05-012021-07-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">739622</alxneuro:StockbasedCompensationToEmployeesAndConsultants>
    <alxneuro:StockbasedCompensationToEmployeesAndConsultants
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">739622</alxneuro:StockbasedCompensationToEmployeesAndConsultants>
    <alxneuro:StockIssuedDuringPeriodSharesNewIssues2
      contextRef="From2021-05-012021-07-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1333333</alxneuro:StockIssuedDuringPeriodSharesNewIssues2>
    <alxneuro:StockIssuedDuringPeriodValueNewIssues2
      contextRef="From2021-05-012021-07-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">133</alxneuro:StockIssuedDuringPeriodValueNewIssues2>
    <alxneuro:StockIssuedDuringPeriodValueNewIssues2
      contextRef="From2021-05-012021-07-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1999867</alxneuro:StockIssuedDuringPeriodValueNewIssues2>
    <alxneuro:StockIssuedDuringPeriodValueNewIssues2
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">2000000</alxneuro:StockIssuedDuringPeriodValueNewIssues2>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-05-012021-07-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">250000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-05-012021-07-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">25</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-05-012021-07-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">75</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">100</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">1500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <alxneuro:StockIssuedDuringPeriodSharesNewIssues3
      contextRef="From2021-05-012021-07-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2875000</alxneuro:StockIssuedDuringPeriodSharesNewIssues3>
    <alxneuro:StockIssuedDuringPeriodValueNewIssues3
      contextRef="From2021-05-012021-07-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">288</alxneuro:StockIssuedDuringPeriodValueNewIssues3>
    <alxneuro:StockIssuedDuringPeriodValueNewIssues3
      contextRef="From2021-05-012021-07-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">12911168</alxneuro:StockIssuedDuringPeriodValueNewIssues3>
    <alxneuro:StockIssuedDuringPeriodValueNewIssues3
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">12911456</alxneuro:StockIssuedDuringPeriodValueNewIssues3>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2021-05-012021-07-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">-750000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <alxneuro:ConversionOfSeriesAConvertibleStock
      contextRef="From2021-05-012021-07-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      unitRef="USD">-75</alxneuro:ConversionOfSeriesAConvertibleStock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2021-05-012021-07-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15000000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <alxneuro:ConversionOfSeriesAConvertibleStock
      contextRef="From2021-05-012021-07-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1500</alxneuro:ConversionOfSeriesAConvertibleStock>
    <alxneuro:ConversionOfSeriesAConvertibleStock
      contextRef="From2021-05-012021-07-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-1425</alxneuro:ConversionOfSeriesAConvertibleStock>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-05-012021-07-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2319867</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">-2319867</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-07-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">86887858</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-07-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">8689</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-07-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">49371166</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-07-31_custom_NoteRecievableForCommonStockRelatedPartyMember"
      decimals="0"
      unitRef="USD">-14883295</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-07-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-19152304</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-07-31" decimals="0" unitRef="USD">15344256</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-05-01to2022-07-31"
      decimals="0"
      unitRef="USD">-3037074</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">-2319867</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2022-05-01to2022-07-31"
      decimals="0"
      unitRef="USD">7097</us-gaap:Depreciation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">4795</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-05-01to2022-07-31"
      decimals="0"
      unitRef="USD">867338</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">739622</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-05-01to2022-07-31"
      decimals="0"
      unitRef="USD">237819</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">216169</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2022-05-01to2022-07-31"
      decimals="0"
      unitRef="USD">-136232</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">568955</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-05-01to2022-07-31"
      decimals="0"
      unitRef="USD">-2536690</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">-1222664</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">2000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">100</us-gaap:ProceedsFromStockOptionsExercised>
    <alxneuro:ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">12911456</alxneuro:ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">14911556</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-05-01to2022-07-31"
      decimals="0"
      unitRef="USD">-2536690</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">13688892</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-04-30" decimals="0" unitRef="USD">14063811</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-04-30" decimals="0" unitRef="USD">1929270</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">11527121</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-07-31" decimals="0" unitRef="USD">15618162</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <alxneuro:FairValueOfWarrantsIssuedInConnectionWithIpo
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">461877</alxneuro:FairValueOfWarrantsIssuedInConnectionWithIpo>
    <alxneuro:FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty contextRef="From2021-05-012021-07-31">4,799,742</alxneuro:FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_806_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zAYDEQTG8lal" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_82A_zUe5PEn8xtX"&gt;DESCRIPTION OF BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;Organization&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Alzamend Neuro, Inc. (the
&#x201c;Company&#x201d; or &#x201c;Alzamend&#x201d;), is an early clinical-stage biopharmaceutical company focused on developing novel products
for the treatment of neurodegenerative diseases and psychiatric disorders. The Company&#x2019;s primary focus is Alzheimer&#x2019;s disease.
With two current and future product candidates, Alzamend aims to bring treatments or cures to market at a reasonable cost as quickly as
possible. The Company&#x2019;s current pipeline consists of two novel therapeutic drug candidates (collectively, the &#x201c;Technology&#x201d;):
(i) a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001, through
two royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., as licensor (the &#x201c;Licensor&#x201d;);
and (ii) a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability
of a patient&#x2019;s immunological system to combat Alzheimer&#x2019;s, known as AL002 or CA022W, through a royalty-bearing exclusive worldwide
license from the same Licensor.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company is devoting substantially
all its efforts towards research and development of its Technology and raising capital. The Company has not generated any product revenue
to date. The Company has financed its operations to date primarily through debt financings and through the sale of its common stock, par
value $&lt;span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20220731_zAc6sOZXZyOd" title="Common stock, par value (in dollars per share)"&gt;0.0001&lt;/span&gt; per share (&#x201c;Common Stock&#x201d;). The Company expects to continue to incur net losses in the foreseeable future.&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-07-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_80E_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zeVPtDNzUBhd" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_825_zbf7sF9xh414"&gt;LIQUIDITY AND GOING CONCERN&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The accompanying condensed
financial statements have been prepared on the basis that the Company will continue as a going concern. As of July 31, 2022, the Company
had cash of $&lt;span id="xdx_90B_eus-gaap--Cash_iI_dm_c20220731_zhy80yRdKLec" title="Cash"&gt;11.5 million&lt;/span&gt; and an accumulated deficit of $&lt;span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_dxL_c20220731_zGUbxu4sGi0h" title="Accumulated deficit::XDX::-32231569"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0366"&gt;32.2&lt;/span&gt;&lt;/span&gt; million. The Company incurred losses for the three months ended July 31,
2022 totaling $&lt;span id="xdx_908_eus-gaap--NetIncomeLoss_dxL_c20220501__20220731_zdYObLJwvjU3" title="Net loss::XDX::-3037074"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0368"&gt;3.0&lt;/span&gt;&lt;/span&gt; million. Historically, the Company has financed its operations principally through issuances of equity and debt instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company expects to continue to incur losses for the foreseeable
future and needs to raise additional capital until it is able to generate revenues from operations sufficient to fund its development
and commercial operations. However, based on the Company&#x2019;s current business plan, management believes that the Company&#x2019;s cash
at July 31, 2022 is sufficient to meet the Company&#x2019;s anticipated cash requirements during the twelve-month period subsequent to
the issuance of the financial statements included in this Quarterly Report.&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:Cash contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">11500000</us-gaap:Cash>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zEnl1wQwZMM9" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_82A_zqNueUgRrBh4"&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zfwkyg0j68g6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zvEVSkVnw5ea"&gt;Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The accompanying condensed
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#x201c;U.S. GAAP&#x201d;) and the rules of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) applicable to interim
reports of companies filing as a smaller reporting company. These financial statements should be read in conjunction with the audited
financial statements and notes thereto contained in the Company&#x2019;s Report on Form 10-K for the year ended April 30, 2022, filed with
the SEC on July 19, 2022. In the opinion of management, the accompanying condensed interim financial statements include all adjustments
necessary in order to make the financial statements not misleading. The results of operations for interim periods are not necessarily
indicative of the results to be expected for the full year or any other future period. Certain notes to the financial statements that
would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal year as reported
in the Company&#x2019;s Report on Form 10-K have been omitted. The accompanying condensed balance sheet at April 30, 2022 has been derived
from the audited balance sheet at April 30, 2022 contained in such Form 10-K.&lt;/p&gt;

&lt;p id="xdx_85A_zqRVQUf3MaE1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zPjUqfNQfl64" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zuEq5qo7PVub"&gt;Accounting Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The preparation of financial
statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
expenses during the reporting period. The Company&#x2019;s critical accounting policies that involve significant judgment and estimates
include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.&lt;/p&gt;

&lt;p id="xdx_854_zfVl8rBifcLk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z4s9nr151g07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zzzEfTX9Y3R6"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company considers all
highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of July 31, 2022
and April&#160;30, 2022, the Company had no cash equivalents.&lt;/p&gt;

&lt;p id="xdx_85F_zwAf77t1wJ8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zlFyaG6tVih4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zGVYruX2f5Qd"&gt;Fair Value of Financial
Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Financial Accounting Standards
Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820, &lt;i&gt;Fair Value Measurement&lt;/i&gt;, defines fair value
as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques
used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy
is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last
is considered unobservable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Level 1: Quoted prices in
active markets for identical assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Level 2: Inputs other than
Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in
markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the
full term of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Level 3 assumptions: Unobservable
inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including
liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair values of warrants
are determined using the Black-Scholes valuation model, a &#x201c;Level 3&#x201d; fair value measurement, based on the estimated fair value
of Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market
capitalization of such other entities, the expected life based on the remaining contractual term of the conversion option and warrants
and the risk free interest rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrants&#x2019;
contractual life.&lt;/p&gt;

&lt;p id="xdx_858_z271fxl84CI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zZeFFfq2tm7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zhRjIvqlH04l"&gt;Property and Equipment,
Net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Property and equipment are
stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life
of five years. Significant additions and improvements are capitalized, while repairs and maintenance are charged to expense as incurred.&lt;/p&gt;

&lt;p id="xdx_856_zXvaF1VSmu08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zXwRPdI1Zt27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zFKQr73uXiSc"&gt;Research and Development
Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Research and development costs
are expensed as incurred. Research and development costs consist of scientific consulting fees and lab supplies, as well as fees paid
to other entities that conduct certain research and development activities on behalf of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has acquired and
may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire
license, products or rights, as well as any future milestone payments, are immediately recognized as research and development expense
provided that there is no alternative future use of the rights in other research and development projects.&lt;/p&gt;

&lt;p id="xdx_855_zDeOFLHJZkrg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z0ek2XiKgVIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_z8UkG0bAKQ4b"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company recognizes stock-based
compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they
occur. The Company&#x2019;s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes
option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management
evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance
conditions as of the reporting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company recognizes stock-based
compensation expense for restricted stocks on a straight-line basis over the requisite service period and account for forfeitures as they
occur. The Company&#x2019;s stock-based compensation for restricted stocks is based upon the estimated fair value of the Common Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Black-Scholes option pricing
model utilizes inputs which are highly subjective assumptions and generally require significant judgment. Certain of such assumptions
involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the
Company uses significantly different assumptions or estimates, the Company&#x2019;s stock-based compensation could be materially different.&lt;/p&gt;

&lt;p id="xdx_854_zV3YTiex39p4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--WarrantsPolicyTextBlock_zVILuVRGwGv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zTSh4yZKGKB9"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company accounts for stock
warrants as either equity instruments, derivative liabilities, or liabilities in accordance with ASC 480,&#160;&lt;i&gt;Distinguishing Liabilities
from Equity &lt;/i&gt;(&#x201c;ASC 480&#x201d;)&#160;and ASC 815,&#160;&lt;i&gt;Derivatives and Hedging &lt;/i&gt;(&#x201c;ASC 815&#x201d;)&lt;i&gt;,&lt;/i&gt;&#160;depending
on the specific terms of the warrant agreement.&lt;/p&gt;

&lt;p id="xdx_854_zj2S6EKuo1Dg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z3ZnSefRZT7l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zPJ5LMJzaIAf"&gt;Loss per Common Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company utilizes FASB
ASC 260,&#160;&lt;i&gt;Earnings per Share&lt;/i&gt;. Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average
number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is
increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued
and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible
preferred stock, options and warrants were to be exercised or converted or otherwise resulted in the issuance of Common Stock that then
shared in the earnings of the entity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Since the effects of outstanding
options, warrants, convertible preferred stock and convertible notes are anti-dilutive in the periods presented, shares of Common Stock
underlying these instruments have been excluded from the computation of loss per common share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zqAqwlq1ti7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BA_z2EGMMfrV5E3"&gt;The following sets forth the
number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have
been excluded from the computation of loss per common share:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;For the Three Months Ended July 31,&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Series A convertible preferred stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuPhXO7Xn5k8" style="width: 15%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0391"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_d0_c20210501__20210731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zpZbSI0DZ5l4" style="width: 15%; text-align: right"&gt;15,000,000&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock options &lt;sup id="xdx_F47_z7VLZN3QiKJ3"&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zDEFTaorQYA8" style="text-align: right"&gt;18,600,000&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210501__20210731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zP8r5yrCJpR4" style="text-align: right"&gt;17,500,000&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zXEgdLKzy3Ul" style="text-align: right"&gt;10,149,788&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210501__20210731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zBUP2jHaWtD4" style="text-align: right"&gt;8,830,785&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Convertible notes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_z7SL48dtsmcb" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0397"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210501__20210731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zdWVJZRS6Aqk" style="border-bottom: Black 1pt solid; text-align: right"&gt;232,049&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731_zfMhB8hOwJgl" style="border-bottom: Black 2.5pt double; text-align: right"&gt;28,749,788&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210501__20210731_zJlIX9UaCm7j" style="border-bottom: Black 2.5pt double; text-align: right"&gt;41,562,834&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_F06_zYnJiBoeeez5" style="font-size: 10pt"&gt;(1)
&lt;/span&gt;&lt;span id="xdx_F19_zbxSgU7evvoa" style="font-size: 10pt"&gt;The Company has excluded
&lt;/span&gt;&lt;span id="xdx_903_ecustom--NumberOfStockExcluded_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zLBewUqX7Aoi" style="font-size: 10pt"&gt;2,000,000
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;stock options, with
an exercise price of $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zMhijAxjDH57"&gt;0.0004&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;,
from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares
issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A8_zZHtbKUQHxol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p id="xdx_858_z1hrQlFg4g2e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zUdrSdjZia24" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;b&gt;&lt;span id="xdx_86F_zVXO0adZ8wAe"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;From time to time, new accounting
pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact
of recently issued standards that are not yet effective are not expected to have a material impact on the Company&#x2019;s financial position
or results of operations upon adoption.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has considered
all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on its
financial statements.&lt;/p&gt;

&lt;p id="xdx_852_zBKb6h1xHcq2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zfwkyg0j68g6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zvEVSkVnw5ea"&gt;Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The accompanying condensed
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#x201c;U.S. GAAP&#x201d;) and the rules of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) applicable to interim
reports of companies filing as a smaller reporting company. These financial statements should be read in conjunction with the audited
financial statements and notes thereto contained in the Company&#x2019;s Report on Form 10-K for the year ended April 30, 2022, filed with
the SEC on July 19, 2022. In the opinion of management, the accompanying condensed interim financial statements include all adjustments
necessary in order to make the financial statements not misleading. The results of operations for interim periods are not necessarily
indicative of the results to be expected for the full year or any other future period. Certain notes to the financial statements that
would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal year as reported
in the Company&#x2019;s Report on Form 10-K have been omitted. The accompanying condensed balance sheet at April 30, 2022 has been derived
from the audited balance sheet at April 30, 2022 contained in such Form 10-K.&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zPjUqfNQfl64" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zuEq5qo7PVub"&gt;Accounting Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The preparation of financial
statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
expenses during the reporting period. The Company&#x2019;s critical accounting policies that involve significant judgment and estimates
include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z4s9nr151g07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zzzEfTX9Y3R6"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company considers all
highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of July 31, 2022
and April&#160;30, 2022, the Company had no cash equivalents.&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zlFyaG6tVih4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zGVYruX2f5Qd"&gt;Fair Value of Financial
Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Financial Accounting Standards
Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820, &lt;i&gt;Fair Value Measurement&lt;/i&gt;, defines fair value
as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques
used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy
is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last
is considered unobservable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Level 1: Quoted prices in
active markets for identical assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Level 2: Inputs other than
Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in
markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the
full term of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Level 3 assumptions: Unobservable
inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including
liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair values of warrants
are determined using the Black-Scholes valuation model, a &#x201c;Level 3&#x201d; fair value measurement, based on the estimated fair value
of Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market
capitalization of such other entities, the expected life based on the remaining contractual term of the conversion option and warrants
and the risk free interest rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrants&#x2019;
contractual life.&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zZeFFfq2tm7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zhRjIvqlH04l"&gt;Property and Equipment,
Net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Property and equipment are
stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life
of five years. Significant additions and improvements are capitalized, while repairs and maintenance are charged to expense as incurred.&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zXwRPdI1Zt27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zFKQr73uXiSc"&gt;Research and Development
Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Research and development costs
are expensed as incurred. Research and development costs consist of scientific consulting fees and lab supplies, as well as fees paid
to other entities that conduct certain research and development activities on behalf of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has acquired and
may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire
license, products or rights, as well as any future milestone payments, are immediately recognized as research and development expense
provided that there is no alternative future use of the rights in other research and development projects.&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_842_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z0ek2XiKgVIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_z8UkG0bAKQ4b"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company recognizes stock-based
compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they
occur. The Company&#x2019;s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes
option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management
evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance
conditions as of the reporting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company recognizes stock-based
compensation expense for restricted stocks on a straight-line basis over the requisite service period and account for forfeitures as they
occur. The Company&#x2019;s stock-based compensation for restricted stocks is based upon the estimated fair value of the Common Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Black-Scholes option pricing
model utilizes inputs which are highly subjective assumptions and generally require significant judgment. Certain of such assumptions
involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the
Company uses significantly different assumptions or estimates, the Company&#x2019;s stock-based compensation could be materially different.&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <alxneuro:WarrantsPolicyTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_84A_ecustom--WarrantsPolicyTextBlock_zVILuVRGwGv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zTSh4yZKGKB9"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company accounts for stock
warrants as either equity instruments, derivative liabilities, or liabilities in accordance with ASC 480,&#160;&lt;i&gt;Distinguishing Liabilities
from Equity &lt;/i&gt;(&#x201c;ASC 480&#x201d;)&#160;and ASC 815,&#160;&lt;i&gt;Derivatives and Hedging &lt;/i&gt;(&#x201c;ASC 815&#x201d;)&lt;i&gt;,&lt;/i&gt;&#160;depending
on the specific terms of the warrant agreement.&lt;/p&gt;

</alxneuro:WarrantsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z3ZnSefRZT7l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zPJ5LMJzaIAf"&gt;Loss per Common Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company utilizes FASB
ASC 260,&#160;&lt;i&gt;Earnings per Share&lt;/i&gt;. Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average
number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is
increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued
and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible
preferred stock, options and warrants were to be exercised or converted or otherwise resulted in the issuance of Common Stock that then
shared in the earnings of the entity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Since the effects of outstanding
options, warrants, convertible preferred stock and convertible notes are anti-dilutive in the periods presented, shares of Common Stock
underlying these instruments have been excluded from the computation of loss per common share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zqAqwlq1ti7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BA_z2EGMMfrV5E3"&gt;The following sets forth the
number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have
been excluded from the computation of loss per common share:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;For the Three Months Ended July 31,&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Series A convertible preferred stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuPhXO7Xn5k8" style="width: 15%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0391"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_d0_c20210501__20210731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zpZbSI0DZ5l4" style="width: 15%; text-align: right"&gt;15,000,000&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock options &lt;sup id="xdx_F47_z7VLZN3QiKJ3"&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zDEFTaorQYA8" style="text-align: right"&gt;18,600,000&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210501__20210731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zP8r5yrCJpR4" style="text-align: right"&gt;17,500,000&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zXEgdLKzy3Ul" style="text-align: right"&gt;10,149,788&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210501__20210731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zBUP2jHaWtD4" style="text-align: right"&gt;8,830,785&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Convertible notes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_z7SL48dtsmcb" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0397"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210501__20210731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zdWVJZRS6Aqk" style="border-bottom: Black 1pt solid; text-align: right"&gt;232,049&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731_zfMhB8hOwJgl" style="border-bottom: Black 2.5pt double; text-align: right"&gt;28,749,788&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210501__20210731_zJlIX9UaCm7j" style="border-bottom: Black 2.5pt double; text-align: right"&gt;41,562,834&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_F06_zYnJiBoeeez5" style="font-size: 10pt"&gt;(1)
&lt;/span&gt;&lt;span id="xdx_F19_zbxSgU7evvoa" style="font-size: 10pt"&gt;The Company has excluded
&lt;/span&gt;&lt;span id="xdx_903_ecustom--NumberOfStockExcluded_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zLBewUqX7Aoi" style="font-size: 10pt"&gt;2,000,000
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;stock options, with
an exercise price of $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zMhijAxjDH57"&gt;0.0004&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;,
from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares
issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A8_zZHtbKUQHxol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zqAqwlq1ti7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BA_z2EGMMfrV5E3"&gt;The following sets forth the
number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have
been excluded from the computation of loss per common share:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;For the Three Months Ended July 31,&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Series A convertible preferred stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zuPhXO7Xn5k8" style="width: 15%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0391"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_d0_c20210501__20210731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zpZbSI0DZ5l4" style="width: 15%; text-align: right"&gt;15,000,000&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock options &lt;sup id="xdx_F47_z7VLZN3QiKJ3"&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zDEFTaorQYA8" style="text-align: right"&gt;18,600,000&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210501__20210731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_fKDEp_zP8r5yrCJpR4" style="text-align: right"&gt;17,500,000&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zXEgdLKzy3Ul" style="text-align: right"&gt;10,149,788&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210501__20210731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zBUP2jHaWtD4" style="text-align: right"&gt;8,830,785&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Convertible notes&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_z7SL48dtsmcb" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0397"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210501__20210731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleNotesMember_zdWVJZRS6Aqk" style="border-bottom: Black 1pt solid; text-align: right"&gt;232,049&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220501__20220731_zfMhB8hOwJgl" style="border-bottom: Black 2.5pt double; text-align: right"&gt;28,749,788&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210501__20210731_zJlIX9UaCm7j" style="border-bottom: Black 2.5pt double; text-align: right"&gt;41,562,834&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_F06_zYnJiBoeeez5" style="font-size: 10pt"&gt;(1)
&lt;/span&gt;&lt;span id="xdx_F19_zbxSgU7evvoa" style="font-size: 10pt"&gt;The Company has excluded
&lt;/span&gt;&lt;span id="xdx_903_ecustom--NumberOfStockExcluded_pid_uShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zLBewUqX7Aoi" style="font-size: 10pt"&gt;2,000,000
&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;stock options, with
an exercise price of $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220501__20220731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zMhijAxjDH57"&gt;0.0004&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;,
from its anti-dilutive securities as these shares have been included in our determination of basic loss per share as they represent shares
issuable for little or no cash consideration upon the satisfaction of certain conditions pursuant to ASC 260-10-45-14.&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-05-012021-07-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">15000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-05-012022-07-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">18600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-05-012021-07-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">17500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-05-012022-07-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">10149788</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-05-012021-07-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">8830785</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-05-012021-07-31_custom_ConvertibleNotesMember"
      decimals="INF"
      unitRef="Shares">232049</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-05-01to2022-07-31"
      decimals="INF"
      unitRef="Shares">28749788</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-05-012021-07-31"
      decimals="INF"
      unitRef="Shares">41562834</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <alxneuro:NumberOfStockExcluded
      contextRef="From2022-05-012022-07-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">2000000</alxneuro:NumberOfStockExcluded>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-05-012022-07-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">0.0004</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zUdrSdjZia24" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;b&gt;&lt;span id="xdx_86F_zVXO0adZ8wAe"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;From time to time, new accounting
pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact
of recently issued standards that are not yet effective are not expected to have a material impact on the Company&#x2019;s financial position
or results of operations upon adoption.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has considered
all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on its
financial statements.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <alxneuro:MortgageNoteReceivableFromRelatedPartyTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_80E_ecustom--MortgageNoteReceivableFromRelatedPartyTextBlock_zkdm7ezppFV3" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_828_zx98wDGcdROf"&gt;NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On April 30, 2019, the Company
and Ault Life Sciences Fund, LLC (&#x201c;ALSF&#x201d;) entered into a securities purchase agreement for the purchase of &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20190401__20190430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AultLifeSciencesFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z3nI7JwidrEa" title="Number of shares purchase (in shares)"&gt;10,000,000&lt;/span&gt; shares
of Common Stock for a total purchase price of $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20190401__20190430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AultLifeSciencesFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zPL1TiCoRA85" title="Number of shares purchase"&gt;15,000,000&lt;/span&gt;, or $1.50 per share with &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_uShares_c20190401__20190430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AultLifeSciencesFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z60erB5NwzY9" title="Number of warrants granted"&gt;5,000,000&lt;/span&gt; warrants with a &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20190401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AultLifeSciencesFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zy6UYJWv04fg" title="Warrant terms::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0415"&gt;5&lt;/span&gt;&lt;/span&gt;-year life and an exercise
price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20190430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AultLifeSciencesFundLLCMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zjsIZXTWgDoa" title="Exercise price (in dollars per share)"&gt;3.00&lt;/span&gt; per share and vesting upon issuance. The total purchase price of $15,000,000 was in the form of a non-interest bearing
note receivable with a 12-month term from ALSF, a related party. In November 2019, the term of the note receivable was extended to December
31, 2021, and in May 2021, the term of the note receivable was extended to December 31, 2023. The note is secured by a pledge of the purchased
shares. As the note receivable from ALSF is related to the issuance of Common Stock, it is recorded as an offset to additional paid-in
capital. At July 31, 2022 and April 30, 2022, the outstanding balance of the note receivable was $&lt;span id="xdx_903_ecustom--LongTermDebtAverageAmountOfOutstanding_iI_pid_uShares_c20220430_zbZk62Up5Awc" title="Outstanding receivable amount"&gt;14,883,295&lt;/span&gt;. ALSF is wholly owned by
Ault Life Sciences, Inc. (&#x201c;ALSI&#x201d;). ALSI is majority owned by Ault &amp;amp; Company, Inc. (&#x201c;Ault &amp;amp; Co.&#x201d;). Messrs.
Horne and Nisser, directors of the Company, are also directors of Ault &amp;amp; Co.&lt;/p&gt;

</alxneuro:MortgageNoteReceivableFromRelatedPartyTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-04-012019-04-30_custom_AultLifeSciencesFundLLCMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="Shares">10000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-04-012019-04-30_custom_AultLifeSciencesFundLLCMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">15000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2019-04-012019-04-30_custom_AultLifeSciencesFundLLCMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-04-30_custom_AultLifeSciencesFundLLCMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <alxneuro:LongTermDebtAverageAmountOfOutstanding contextRef="AsOf2022-04-30" decimals="INF" unitRef="Shares">14883295</alxneuro:LongTermDebtAverageAmountOfOutstanding>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_809_eus-gaap--OtherCurrentAssetsTextBlock_z13daPvwsyI1" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0pt; text-align: right"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 9pt"/&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_821_zyAIsiFeEDwb"&gt;PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zn2OLOQrCH2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B4_z51KuO4CVQqd"&gt;Prepaid expenses and other
current assets are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220731_zEEriKc63i12" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;July 31, 2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20210731_zRUzSlvEWXv9" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;April 30, 2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Prepaid consulting fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;116,667&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;186,667&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PrepaidInsurance_iI_zFyZnmAz1kL" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;451,885&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;155,880&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherPrepaidExpenseCurrent_iI_zv2YIVkopYw2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,577&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,176&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherReceivables_iI_zxv0Z4sdhiRi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other receivables&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,413&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0432"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssets_iTI_z51oCsa0bG91" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;587,542&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;349,723&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zS4qW0Pp78z9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On June 16, 2022, the
Company purchased D&amp;amp;O insurance for 12 months in the amount of $&lt;span id="xdx_902_ecustom--PrepaidInsurance1_iI_c20220616_zSGd7ckJK2jg" title="Purchase D&amp;amp;O Insurance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0437"&gt;492,000.&lt;/span&gt;&lt;/span&gt; Prepaid insurance at July 31, 2022 represented the unamortized
portion of annual premium paid for this policy of $&lt;span id="xdx_901_ecustom--UnamortizedPrepaidExpense_iI_c20220731_zpQqgYHremza" title="Unamortized prepaid expense"&gt;452,000&lt;/span&gt;. At July 31, 2022, prepaid consulting fees of $&lt;span id="xdx_905_ecustom--PrepaidConsultingFees_iI_c20220731__us-gaap--RelatedPartyTransactionAxis__custom--SpartanCapitalSecuritiesMember_zo4Ndd27ZBfg" title="Prepaid consulting fees"&gt;117,000&lt;/span&gt; consisted of payments
to Spartan Capital Securities, LLC (&#x201c;Spartan Capital&#x201d;).&lt;/p&gt;

</us-gaap:OtherCurrentAssetsTextBlock>
    <alxneuro:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_89A_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zn2OLOQrCH2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B4_z51KuO4CVQqd"&gt;Prepaid expenses and other
current assets are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220731_zEEriKc63i12" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;July 31, 2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20210731_zRUzSlvEWXv9" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;April 30, 2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Prepaid consulting fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;116,667&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;186,667&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PrepaidInsurance_iI_zFyZnmAz1kL" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;451,885&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;155,880&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherPrepaidExpenseCurrent_iI_zv2YIVkopYw2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,577&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,176&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherReceivables_iI_zxv0Z4sdhiRi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other receivables&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,413&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0432"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssets_iTI_z51oCsa0bG91" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;587,542&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;349,723&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</alxneuro:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidInsurance contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">451885</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2021-07-31" decimals="0" unitRef="USD">155880</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">9577</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2021-07-31" decimals="0" unitRef="USD">7176</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherReceivables contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">9413</us-gaap:OtherReceivables>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">587542</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="AsOf2021-07-31" decimals="0" unitRef="USD">349723</us-gaap:PrepaidExpenseAndOtherAssets>
    <alxneuro:UnamortizedPrepaidExpense contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">452000</alxneuro:UnamortizedPrepaidExpense>
    <alxneuro:PrepaidConsultingFees
      contextRef="AsOf2022-07-31_custom_SpartanCapitalSecuritiesMember"
      decimals="0"
      unitRef="USD">117000</alxneuro:PrepaidConsultingFees>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_802_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zt9vFm3kLFja" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_824_z1xyv6iqIWkd"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;2016 Stock Incentive
Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On April 30, 2016, the Company&#x2019;s
stockholders approved the Company&#x2019;s 2016 Stock Incentive Plan (the &#x201c;Plan&#x201d;). The Plan provides for the issuance of a
maximum of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_uShares_c20160430__us-gaap--PlanNameAxis__custom--StockIncentivePlan2016Member_z5YhwQ8NDZ5" title="Number of shares authorized for issuance"&gt;12,500,000&lt;/span&gt; shares of Common Stock to be offered to the Company&#x2019;s directors, officers, employees, and consultants. On
March 1, 2019, the Company&#x2019;s stockholders approved an additional &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pid_uShares_c20160401__20160430__us-gaap--PlanNameAxis__custom--StockIncentivePlan2016Member_zzHsGB9bGQkf" title="Additional number of shares available for issuance"&gt;7,500,000&lt;/span&gt; shares to be available for issuance under the Plan. Options
granted under the Plan have an exercise price equal to or greater than the fair value of the underlying Common Stock at the date of grant
and become exercisable based on a vesting schedule determined at the date of grant. The options expire between five and 10 years from
the date of grant. Restricted stock awards granted under the Plan are subject to a vesting period determined at the date of grant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;2021 Stock Incentive
Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In February 2021, the Company&#x2019;s
board of directors (the &#x201c;Board&#x201d;) adopted, and the stockholders approved, the Alzamend Neuro, Inc. 2021 Stock Incentive Plan
(the &#x201c;2021 Plan&#x201d;). The 2021 Plan authorizes the grant to eligible individuals of (1) stock options (incentive and non-statutory),
(2) restricted stock, (3) stock appreciation rights, or SARs, (4) restricted stock units, and (5) other stock-based compensation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Stock Subject to the 2021
Plan.&lt;/i&gt;&#160;The maximum number of shares of Common Stock that may be issued under the 2021 Plan is 10,000,000 shares, which number
will be increased to the extent that compensation granted under the 2021 Plan is forfeited, expires or is settled for cash (except as
otherwise provided in the 2021 Plan). Substitute awards (awards made or shares issued by the Company in assumption of, or in substitution
or exchange for, awards previously granted, or the right or obligation to make future awards, in each case by a company that the Company
acquires or any subsidiary of the Company or with which the Company or any subsidiary combines) will not reduce the shares authorized
for grant under the 2021 Plan, nor will shares subject to a substitute award be added to the shares available for issuance or transfer
under the 2021 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;All options that the Company
grants are granted at the per share fair value on the grant date. Vesting of options differs based on the terms of each option. The Company
has valued the options at their date of grant utilizing the Black-Scholes option pricing model. As of the date of issuance of these options,
there was not an active public market for the Company&#x2019;s shares. Accordingly, the fair value of the underlying options was determined
based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other
entities. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an
equivalent term approximating the expected life of the options as calculated using the simplified method. The expected life of the options
used was based on the contractual life of the option granted. Stock-based compensation is a non-cash expense because the Company settles
these obligations by issuing shares of Common Stock from its authorized shares instead of settling such obligations with cash payments.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zIIE8c15LYH3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BE_zFzbIN2U4gFd"&gt;A summary of stock option
activity for the three months ended July 31, 2022 is presented below:&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;b&gt;Outstanding Options&lt;/b&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;b&gt;Shares &lt;br/&gt; Available &lt;br/&gt; for Grant&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;b&gt;Number of &lt;br/&gt; Shares&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;b&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;b&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Life (years)&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;b&gt;Aggregate Intrinsic &lt;br/&gt; Value&lt;/b&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 25%"&gt;Balance at April 30, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pid_uShares_c20220501__20220731_z3FeV4uK1WI9" style="width: 12%; text-align: right" title="Balance at begining (in shares)"&gt;8,800,000&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220501__20220731_zYgncrLDXxs8" style="width: 12%; text-align: right" title="Balance at begining (in shares)"&gt;15,700,000&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220501__20220731_zyGkfNf3PXil" style="width: 12%; text-align: right" title="Balance at begining"&gt;1.20&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dxL_c20220501__20220731_zj0Rm6QuAx0b" style="width: 12%; text-align: right" title="::XDX::P6Y1M6D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0456"&gt;6.10&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220501__20220731_zGV3ZNgGvpY8" style="width: 12%; text-align: right" title="Balance at begining"&gt;2,219,700&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted_pid_uShares_c20220501__20220731_zNjyqkCRWKNa" style="text-align: right" title="Options granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0460"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220501__20220731_zbvDvTrPGwV8" style="text-align: right" title="Options granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0462"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220501__20220731_zj3TQqDY0wm6" style="text-align: right" title="Options granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0464"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross_pid_uShares_c20220501__20220731_zvsY4c4MmtHd" style="text-align: right" title="Options exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0466"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220501__20220731_z6Cqz8rAzwr7" style="text-align: right" title="Options exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0468"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Options expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited_pid_uShares_c20220501__20220731_zgkev0eedOL" style="border-bottom: Black 1pt solid; text-align: right" title="Options expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0470"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_uShares_c20220501__20220731_z9YvBOi4Kgj1" style="border-bottom: Black 1pt solid; text-align: right" title="Options expired"&gt;(1,100,000&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;)&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_pid_uUSDPShares_c20220501__20220731_zt1uBEgaOpS8" style="border-bottom: Black 1pt solid; text-align: right" title="Options expired"&gt;1.00&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at July 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_uShares_c20220501__20220731_z1iv2MSPzCb7" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end (in shares)"&gt;8,800,000&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20220501__20220731_z1IU0bYZqDef" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end (in shares)"&gt;14,600,000&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220501__20220731_zOhuHg3c1BHa" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end"&gt;1.22&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220501__20220731_zeFbb0VWsFX2" style="text-align: right" title="Balance at end (in shares)::XDX::P5Y9M14D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0482"&gt;5.79&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20220501__20220731_zb8XrzbhPg66" style="text-align: right" title="Balance at end"&gt;1,777,200&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td colspan="4" style="text-align: left; padding-bottom: 2.5pt"&gt;Options vested and expected to vest at July 31, 2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_uShares_c20220731_zQqUROTgawa5" style="border-bottom: Black 2.5pt double; text-align: right" title="Options vested and expected to vest"&gt;13,700,000&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731_zJNA2VD2ZIh3" style="border-bottom: Black 2.5pt double; text-align: right" title="Options vested and expected to vest at end"&gt;1.23&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dxL_c20220501__20220731_zXZhGTWgVcad" style="text-align: right" title="Options vested and expected to vest at end::XDX::P6Y4M9D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0490"&gt;6.36&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20220731_zqSBBt5xFNj9" style="text-align: right" title="Options vested and expected to vest at end"&gt;1,777,200&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options exercisable at July 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20220731_zawlo43xFvTa" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable at end"&gt;11,514,479&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731_zBlOVfebEIWj" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable at end"&gt;1.07&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dxL_c20220501__20220731_zBmnJxnHzWhi" style="text-align: right" title="Options exercisable at end::XDX::P5Y11M26D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0498"&gt;6.03&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20220731_zRiEnO41IPKa" style="text-align: right" title="Options exercisable at end"&gt;1,777,200&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zcuaMwm16CP1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The aggregate intrinsic value
in the table above represents the total pretax intrinsic value (i.e., the difference between the estimated fair value on the respective
date and the exercise price, times the number of shares) that would have been received by the option holders had all option holders exercised
their options.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;Stock Options Granted to Employees and Consultants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock_zY2YBlIAQC3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BF_zWYKRkfgDPY4"&gt;The estimated fair value of
stock options granted to employees and consultants during the three months ended July 31, 2021 were calculated using the Black-Scholes
option-pricing model using the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;For the Three Months Ended July 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c20220501__20220731__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zYlsYmHJjAuk" style="text-align: center" title="Expected Term (in years)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0504"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210501__20210731__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zeKpX0C9ilbl" title="Expected Term (in years)::XDX::P2Y6M0D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0506"&gt;2.50&lt;/span&gt;&lt;/span&gt; &#x2013; &lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210501__20210731__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zLqA0imhsFR7" title="Expected Term (in years)::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0508"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 65%"&gt;Volatility&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220501__20220731__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zNI3hfZY152" title="Volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0510"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 17%; text-align: center"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210501__20210731__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zWyYbNOLSX1a" title="Volatility"&gt;86.31&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220501__20220731__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zhWUcM51a0F9" title="Risk-free interest rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0514"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210501__20210731__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_z4J6dY1Rvf57" title="Risk-free interest rate"&gt;1.01&lt;/span&gt;%-&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210501__20210731__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zzdRAbMMziB8" title="Risk-free interest rate"&gt;1.07&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220501__20220731_zsUBZBVJvcMd" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0520"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210501__20210731_zKZGgQaEGZsf" title="Dividend yield"&gt;0.0&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A2_z5NzlPecmGG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Expected Term:&lt;/i&gt;&#160;The
expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method
(based on the mid-point between the vesting date and the end of the contractual term).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Expected Volatility:&lt;/i&gt;&#160;The
Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry
that were deemed to be representative of future stock price trends as the Company did not have sufficient trading history for its Common
Stock at July 31, 2022. The Company will continue to apply this process until a sufficient amount of historical information regarding
the volatility of its own stock price becomes available.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Risk-Free Interest Rate:&lt;/i&gt;&#160;The
Company based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities
with similar maturities as of the date of the grant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Expected Dividend:&lt;/i&gt;&#160;The
Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Stock-based compensation to
employees and consultants from stock option grants for the three months ended July 31, 2022 and 2021 were $&lt;span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20220501__20220731__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zvtpRE4ZYyD3" title="Stock-based compensation to employees"&gt;867,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_c20210501__20210731__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAilxE5KcZlk"&gt;740,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;Performance Contingent
Stock Options Granted to Employee&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In November 2018, the Board
granted &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20181101__20181130__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_z1Mc7egcDj71" title="Options granted"&gt;2,000,000&lt;/span&gt; performance-contingent options under the Plan to the Chief Executive Officer. These options have an exercise price of
$&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20181101__20181130__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zsJWUEY6oUfi" title="Exercise price (in dollars per share)"&gt;1.00&lt;/span&gt; per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;These options have two separate
performance triggers for vesting based upon the therapies achieving certain Food and Drug Administration (&#x201c;FDA&#x201d;) approval
milestones within a specified timeframe. By definition, the performance condition in these options can only be achieved after the performance
condition of FDA approval has been achieved. As such, the requisite service period is based on the estimated period over which the market
condition can be achieved. When a performance goal is deemed to be probable of achievement, time-based vesting and recognition of stock-based
compensation expense commences. In the event any of the milestones are not achieved by the specified timelines, such vesting award will
terminate and no longer be exercisable with respect to that portion of the shares. The maximum potential expense associated with the performance-contingent
awards is $&lt;span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_dm_c20220501__20220731__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zoiYgmGmWsK2" title="Maximum potential expense"&gt;1.2 million&lt;/span&gt; of general and administrative expense if all of the performance conditions are achieved as stated in the option
agreement. Due to the significant risks and uncertainties associated with FDA approvals, as of July 31, 2022, the Company believes that
the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for
these awards.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On November 26, 2019, the
Board granted &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20191125__20191126__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KeyEmployeesAndDirectorMember_zEbE1pnPO9pi" title="Options granted"&gt;4,250,000&lt;/span&gt; performance- and market-contingent awards to certain key employees and a director. These grants were made outside
of the Plan. These awards have an exercise price of $1.50 per share. These awards have multiple separate market triggers for vesting based
upon either (i) the successful achievement of stepped target closing prices on a national securities exchange for 90 consecutive trading
days later than 180 days after the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;) for its Common Stock, or (ii) stepped target
prices for a change in control transaction. The target prices range from $15 per share to $40 per share. &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20191125__20191126__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KeyEmployeesAndDirectorMember_zHkKdCfjVF4c" title="Terms of warrent"&gt;In the event any of the stock
price milestones are not achieved within three years&lt;/span&gt;, the unvested portion of the performance options will be reduced by 25%. Due to the
significant risks and uncertainties associated with achieving the market-contingent awards, as of July 31, 2022, the Company believes
that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized
for these awards.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;Performance Contingent
Stock Options Granted to TAMM Net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On March 23, 2021, the Company
issued performance-based stock options to the certain team members at TAMM Net, Inc. to purchase an aggregate of &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20210322__20210323__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KeyEmployeesAndDirectorMember_zZGlKkR32XV2" title="Options granted"&gt;450,000&lt;/span&gt; shares of Common
Stock at a per share exercise price of $1.50 per share, of which 50% vest upon the completion of Phase I of AL001 by March 31, 2022, and
the remaining 50% vest upon completion of Phase I of AL002 by December 31, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The performance goal of completing
Phase I of AL001 was achieved on March 22, 2022, and the Company recognized stock compensation related to the completion of Phase I of
AL001 over the implied service period to complete this milestone. Due to the significant risks and uncertainties associated with achieving
the completion of Phase I for AL002, as of July 31, 2022, the Company believes that the achievement of the requisite performance conditions
is not probable and, as a result, no compensation cost has been recognized for these awards related to AL002.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;Performance Contingent
Stock Options Granted to Consultants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On October 14, 2021, the Company
issued performance-based stock options to two consultants to purchase an aggregate of 200,000 shares of Common Stock with an exercise
price of $2.42 per share, of which 50,000 vest upon completion of each of the Phase II clinical trials of AL001 for a Bipolar indication,
AL001 for a PTSD indication, AL001 for a depression indication and AL002 for an Alzheimer&#x2019;s indication.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of July 31, 2022, the Company
believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been
recognized for these awards related to Phase II of AL001 and AL002.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation
Expense&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_z6eY9f1bMvgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B9_zf1t9hqjOdX4"&gt;The Company&#x2019;s results
of operations include expenses relating to stock-based compensation for three months ended July 31, 2022 and 2021, that were comprised
as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;For the Three Months Ended July 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&#160;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20220501__20220731__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z9BR1zngADYj" style="width: 15%; text-align: right" title="Research and development"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0541"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20210501__20210731__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zbo04MID9r19" style="width: 15%; text-align: right" title="Research and development"&gt;141,917&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20220501__20220731__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_znkayglINsj3" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative"&gt;867,338&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20210501__20210731__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z7UFSlnxxObj" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative"&gt;597,705&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: 10pt"&gt;&#160;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220501__20220731_zXJ0mGBJlso6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;867,338&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210501__20210731_zHSrLAD7s2Mi" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;739,622&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zjzUxngSvDy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of July 31, 2022, total
unamortized stock-based compensation expense related to unvested employee and non-employee awards that are expected to vest was $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_dm_uShares_c20220731__us-gaap--IncomeStatementLocationAxis__custom--UnamortizedStockBasedCompensationMember_zjNQbjnzepF2" title="Options vested and expected to vest"&gt;3.7 million&lt;/span&gt;.
The weighted-average period over which such stock-based compensation expense will be recognized is approximately &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtxL_c20220501__20220731__us-gaap--IncomeStatementLocationAxis__custom--UnamortizedStockBasedCompensationMember_zOfBUEh8k5B9" title="Weighted-average period vested and expected to vest at end::XDX::P2Y2M12D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0555"&gt;2.2&lt;/span&gt;&lt;/span&gt; years.&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2016-04-30_custom_StockIncentivePlan2016Member"
      decimals="INF"
      unitRef="Shares">12500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2016-04-012016-04-30_custom_StockIncentivePlan2016Member"
      decimals="INF"
      unitRef="Shares">7500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zIIE8c15LYH3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BE_zFzbIN2U4gFd"&gt;A summary of stock option
activity for the three months ended July 31, 2022 is presented below:&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;b&gt;Outstanding Options&lt;/b&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;b&gt;Shares &lt;br/&gt; Available &lt;br/&gt; for Grant&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;b&gt;Number of &lt;br/&gt; Shares&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;b&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;b&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Life (years)&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;b&gt;Aggregate Intrinsic &lt;br/&gt; Value&lt;/b&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 25%"&gt;Balance at April 30, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pid_uShares_c20220501__20220731_z3FeV4uK1WI9" style="width: 12%; text-align: right" title="Balance at begining (in shares)"&gt;8,800,000&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220501__20220731_zYgncrLDXxs8" style="width: 12%; text-align: right" title="Balance at begining (in shares)"&gt;15,700,000&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220501__20220731_zyGkfNf3PXil" style="width: 12%; text-align: right" title="Balance at begining"&gt;1.20&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dxL_c20220501__20220731_zj0Rm6QuAx0b" style="width: 12%; text-align: right" title="::XDX::P6Y1M6D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0456"&gt;6.10&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220501__20220731_zGV3ZNgGvpY8" style="width: 12%; text-align: right" title="Balance at begining"&gt;2,219,700&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted_pid_uShares_c20220501__20220731_zNjyqkCRWKNa" style="text-align: right" title="Options granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0460"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220501__20220731_zbvDvTrPGwV8" style="text-align: right" title="Options granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0462"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220501__20220731_zj3TQqDY0wm6" style="text-align: right" title="Options granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0464"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross_pid_uShares_c20220501__20220731_zvsY4c4MmtHd" style="text-align: right" title="Options exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0466"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220501__20220731_z6Cqz8rAzwr7" style="text-align: right" title="Options exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0468"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Options expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited_pid_uShares_c20220501__20220731_zgkev0eedOL" style="border-bottom: Black 1pt solid; text-align: right" title="Options expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0470"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_uShares_c20220501__20220731_z9YvBOi4Kgj1" style="border-bottom: Black 1pt solid; text-align: right" title="Options expired"&gt;(1,100,000&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;)&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_pid_uUSDPShares_c20220501__20220731_zt1uBEgaOpS8" style="border-bottom: Black 1pt solid; text-align: right" title="Options expired"&gt;1.00&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at July 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_uShares_c20220501__20220731_z1iv2MSPzCb7" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end (in shares)"&gt;8,800,000&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20220501__20220731_z1IU0bYZqDef" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end (in shares)"&gt;14,600,000&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220501__20220731_zOhuHg3c1BHa" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end"&gt;1.22&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220501__20220731_zeFbb0VWsFX2" style="text-align: right" title="Balance at end (in shares)::XDX::P5Y9M14D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0482"&gt;5.79&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20220501__20220731_zb8XrzbhPg66" style="text-align: right" title="Balance at end"&gt;1,777,200&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td colspan="4" style="text-align: left; padding-bottom: 2.5pt"&gt;Options vested and expected to vest at July 31, 2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_uShares_c20220731_zQqUROTgawa5" style="border-bottom: Black 2.5pt double; text-align: right" title="Options vested and expected to vest"&gt;13,700,000&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731_zJNA2VD2ZIh3" style="border-bottom: Black 2.5pt double; text-align: right" title="Options vested and expected to vest at end"&gt;1.23&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dxL_c20220501__20220731_zXZhGTWgVcad" style="text-align: right" title="Options vested and expected to vest at end::XDX::P6Y4M9D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0490"&gt;6.36&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20220731_zqSBBt5xFNj9" style="text-align: right" title="Options vested and expected to vest at end"&gt;1,777,200&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Options exercisable at July 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20220731_zawlo43xFvTa" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable at end"&gt;11,514,479&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731_zBlOVfebEIWj" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable at end"&gt;1.07&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dxL_c20220501__20220731_zBmnJxnHzWhi" style="text-align: right" title="Options exercisable at end::XDX::P5Y11M26D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0498"&gt;6.03&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20220731_zRiEnO41IPKa" style="text-align: right" title="Options exercisable at end"&gt;1,777,200&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2022-04-30" decimals="INF" unitRef="Shares">8800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-04-30" decimals="INF" unitRef="Shares">15700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-04-30"
      decimals="INF"
      unitRef="USDPShares">1.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2022-04-30" decimals="0" unitRef="USD">2219700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-05-01to2022-07-31"
      decimals="INF"
      unitRef="Shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="From2022-05-01to2022-07-31"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2022-07-31" decimals="INF" unitRef="Shares">8800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-07-31" decimals="INF" unitRef="Shares">14600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-07-31"
      decimals="INF"
      unitRef="USDPShares">1.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">1777200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2022-07-31" decimals="INF" unitRef="Shares">13700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-07-31"
      decimals="INF"
      unitRef="USDPShares">1.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">1777200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2022-07-31" decimals="INF" unitRef="Shares">11514479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-07-31"
      decimals="INF"
      unitRef="USDPShares">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2022-07-31" decimals="0" unitRef="USD">1777200</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <alxneuro:ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_892_ecustom--ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock_zY2YBlIAQC3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BF_zWYKRkfgDPY4"&gt;The estimated fair value of
stock options granted to employees and consultants during the three months ended July 31, 2021 were calculated using the Black-Scholes
option-pricing model using the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="4" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;For the Three Months Ended July 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c20220501__20220731__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zYlsYmHJjAuk" style="text-align: center" title="Expected Term (in years)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0504"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210501__20210731__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zeKpX0C9ilbl" title="Expected Term (in years)::XDX::P2Y6M0D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0506"&gt;2.50&lt;/span&gt;&lt;/span&gt; &#x2013; &lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210501__20210731__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zLqA0imhsFR7" title="Expected Term (in years)::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0508"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 65%"&gt;Volatility&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220501__20220731__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zNI3hfZY152" title="Volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0510"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 17%; text-align: center"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210501__20210731__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zWyYbNOLSX1a" title="Volatility"&gt;86.31&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220501__20220731__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zhWUcM51a0F9" title="Risk-free interest rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0514"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210501__20210731__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_z4J6dY1Rvf57" title="Risk-free interest rate"&gt;1.01&lt;/span&gt;%-&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210501__20210731__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--EmployeesAndConsultantsMember_zzdRAbMMziB8" title="Risk-free interest rate"&gt;1.07&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220501__20220731_zsUBZBVJvcMd" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0520"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210501__20210731_zKZGgQaEGZsf" title="Dividend yield"&gt;0.0&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</alxneuro:ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-05-012021-07-31_custom_EmployeesAndConsultantsMember"
      decimals="INF"
      unitRef="Pure">0.8631</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-05-012021-07-31_srt_MinimumMember_custom_EmployeesAndConsultantsMember"
      decimals="INF"
      unitRef="Pure">0.0101</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-05-012021-07-31_srt_MaximumMember_custom_EmployeesAndConsultantsMember"
      decimals="INF"
      unitRef="Pure">0.0107</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-05-012021-07-31"
      decimals="INF"
      unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-05-012022-07-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">867000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-05-012021-07-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">740000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2018-11-012018-11-30_custom_PerformanceContingentStockOptionsMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2018-11-012018-11-30_custom_PerformanceContingentStockOptionsMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-05-012022-07-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2019-11-252019-11-26_custom_PerformanceContingentStockOptionsMember_custom_KeyEmployeesAndDirectorMember"
      decimals="INF"
      unitRef="Shares">4250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward contextRef="From2019-11-252019-11-26_custom_PerformanceContingentStockOptionsMember_custom_KeyEmployeesAndDirectorMember">In the event any of the stock
price milestones are not achieved within three years</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-03-222021-03-23_custom_PerformanceContingentStockOptionsMember_custom_KeyEmployeesAndDirectorMember"
      decimals="INF"
      unitRef="Shares">450000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_z6eY9f1bMvgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B9_zf1t9hqjOdX4"&gt;The Company&#x2019;s results
of operations include expenses relating to stock-based compensation for three months ended July 31, 2022 and 2021, that were comprised
as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;For the Three Months Ended July 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&#160;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20220501__20220731__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z9BR1zngADYj" style="width: 15%; text-align: right" title="Research and development"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0541"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20210501__20210731__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zbo04MID9r19" style="width: 15%; text-align: right" title="Research and development"&gt;141,917&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20220501__20220731__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_znkayglINsj3" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative"&gt;867,338&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20210501__20210731__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z7UFSlnxxObj" style="border-bottom: Black 1pt solid; text-align: right" title="General and administrative"&gt;597,705&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: 10pt"&gt;&#160;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220501__20220731_zXJ0mGBJlso6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;867,338&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210501__20210731_zHSrLAD7s2Mi" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;739,622&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-05-012021-07-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">141917</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-05-012022-07-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">867338</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-05-012021-07-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">597705</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-05-01to2022-07-31"
      decimals="0"
      unitRef="USD">867338</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-05-012021-07-31"
      decimals="0"
      unitRef="USD">739622</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2022-07-31_custom_UnamortizedStockBasedCompensationMember"
      decimals="INF"
      unitRef="Shares">3700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <alxneuro:WarrantsDisclosureTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_805_ecustom--WarrantsDisclosureTextBlock_zX5kpIKJxDm4" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_823_zGhtQHLZgSKe"&gt;WARRANTS&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zA8s07XDXMkl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BF_z1dJr0F8R55d"&gt;The following table summarizes
information about Common Stock warrants outstanding and exercisable at July 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="14" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;b&gt;Life (years)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z6c3hqhOSxka" title="Exercse price (in dollars per share)"&gt;1.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zMfm1H51mBX" style="width: 14%; text-align: right" title="Number warrant outstanding"&gt;500,000&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z2K7DPB0wuea" style="width: 14%; text-align: right" title="Weighted average remaining contractual life (years)::XDX::P1Y7M6D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0565"&gt;1.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_znMpTRBDE3bk" style="width: 14%; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)"&gt;1.00&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_znyZMA6Qwlf" style="width: 14%; text-align: right" title="Number of warrant exercisable"&gt;500,000&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zIsqCau88ok3" style="width: 13%; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)"&gt;1.00&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zJI72zHlPMvi" title="Exercse price (in dollars per share)"&gt;1.75&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zx0FfbvTHgX7" style="text-align: right" title="Number warrant outstanding"&gt;161,342&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zGawpNPyjy78" style="text-align: right" title="Weighted average remaining contractual life (years)::XDX::P2Y3M19D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0577"&gt;2.3&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zGsLhEt5oFp2" style="text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)"&gt;1.75&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zERqgRVJ4Od" style="text-align: right" title="Number of warrant exercisable"&gt;161,342&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_z0gwdL3UTfW3" style="text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)"&gt;1.75&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_zqvmMztnnAHh" title="Exercse price (in dollars per share)"&gt;3.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_z0ekQeMOm1he" style="text-align: right" title="Number warrant outstanding"&gt;9,427,196&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_z4djd98mNtwk" style="text-align: right" title="Weighted average remaining contractual life (years)::XDX::P2Y8M12D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0589"&gt;2.7&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_zCkGHj1FHXRc" style="text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)"&gt;3.00&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_zsXrtR6EzwH4" style="text-align: right" title="Number of warrant exercisable"&gt;9,427,196&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_zz1f9yFngWXe" style="text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)"&gt;3.00&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_zE4Tpmn5pHWd" title="Exercse price (in dollars per share)"&gt;6.25&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zQxgUdMpQly8" style="border-bottom: black 1pt solid; text-align: right" title="Number warrant outstanding"&gt;61,250&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zSJmIUBqhkce" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average remaining contractual life (years)::XDX::P3Y10M25D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0601"&gt;3.9&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zOyd1700VTk7" style="border-bottom: black 1pt solid; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)"&gt;6.25&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zrOSbnjyCzu6" style="border-bottom: black 1pt solid; text-align: right" title="Number of warrant exercisable"&gt;61,250&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zjWEFKDoFzYf" style="border-bottom: black 1pt solid; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)"&gt;6.25&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;$&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member__srt--RangeAxis__srt--MinimumMember_zMW0WoWiKWWf" title="Exercse price (in dollars per share)"&gt;1.00&lt;/span&gt; - $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member__srt--RangeAxis__srt--MaximumMember_zm0S1G3iyfg6" title="Exercse price (in dollars per share)"&gt;6.25&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731_zTmFv0DmSME1" style="border-bottom: black 2.25pt double; text-align: right" title="Number warrant outstanding"&gt;10,149,788&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731_zhvPLCA1MJRl" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average remaining contractual life (years)::XDX::P2Y7M6D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0615"&gt;2.6&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731_zOQkaHdYgMna" style="border-bottom: black 2.25pt double; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)"&gt;2.90&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731_zQcLHY4ZUaF5" style="border-bottom: black 2.25pt double; text-align: right" title="Number of warrant exercisable"&gt;10,149,788&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731_zh0MolRQFQgj" style="border-bottom: black 2.25pt double; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)"&gt;2.90&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_zaXr8cONK36c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock_zbbMtIAfu7d1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span id="xdx_8B3_zuejyHMYX3s5"&gt;The estimated fair value of warrants granted during
the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;For the Three Months Ended July 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQImOIzcjzd2" style="width: 17%; text-align: center" title="Expected term (in years)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0625"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwjO06Eurs6c" style="width: 17%; text-align: center" title="::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0626"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zypgzgImH01k" style="text-align: center" title="Warrants measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0628"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zhiVY4h4qVjg" style="text-align: center" title="Warrants measurement input"&gt;103.70%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zbAoT8ln8IM4" style="text-align: center" title="Warrants measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0632"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zV3jQ2XvrIh8" title="Warrants measurement input"&gt;0.27&lt;/span&gt;% - &lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_ziPVDHLdtEvf" title="Warrants measurement input"&gt;0.28&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zIGdub23qDb3" style="text-align: center" title="Warrants measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0638"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--MinimumMember_zxnTvqD9M2Bf" style="text-align: center" title="Warrants measurement input"&gt;0.0%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zrYzGKYkc0bd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Expected Term:&lt;/i&gt;&#160;The
expected term represents the period that the warrants granted are expected to be outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Expected Volatility:&lt;/i&gt;&#160;The
Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry
that were deemed to be representative of future stock price trends as the Company did not have sufficient trading history for its Common
Stock at July 31, 2021. The Company will continue to apply this process until a sufficient amount of historical information regarding
the volatility of its own stock price becomes available.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Risk-Free Interest Rate:&lt;/i&gt;&#160;The
Company based the risk-free interest rate over the expected term of the warrants based on the constant maturity rate of U.S. Treasury
securities with similar maturities as of the date of the grant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Expected Dividend:&lt;/i&gt;&#160;The
Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.&lt;/p&gt;

</alxneuro:WarrantsDisclosureTextBlock>
    <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_893_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zA8s07XDXMkl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BF_z1dJr0F8R55d"&gt;The following table summarizes
information about Common Stock warrants outstanding and exercisable at July 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="14" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;b&gt;Life (years)&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z6c3hqhOSxka" title="Exercse price (in dollars per share)"&gt;1.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zMfm1H51mBX" style="width: 14%; text-align: right" title="Number warrant outstanding"&gt;500,000&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z2K7DPB0wuea" style="width: 14%; text-align: right" title="Weighted average remaining contractual life (years)::XDX::P1Y7M6D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0565"&gt;1.6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_znMpTRBDE3bk" style="width: 14%; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)"&gt;1.00&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_znyZMA6Qwlf" style="width: 14%; text-align: right" title="Number of warrant exercisable"&gt;500,000&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_zIsqCau88ok3" style="width: 13%; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)"&gt;1.00&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zJI72zHlPMvi" title="Exercse price (in dollars per share)"&gt;1.75&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zx0FfbvTHgX7" style="text-align: right" title="Number warrant outstanding"&gt;161,342&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zGawpNPyjy78" style="text-align: right" title="Weighted average remaining contractual life (years)::XDX::P2Y3M19D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0577"&gt;2.3&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zGsLhEt5oFp2" style="text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)"&gt;1.75&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zERqgRVJ4Od" style="text-align: right" title="Number of warrant exercisable"&gt;161,342&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_z0gwdL3UTfW3" style="text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)"&gt;1.75&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_zqvmMztnnAHh" title="Exercse price (in dollars per share)"&gt;3.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_z0ekQeMOm1he" style="text-align: right" title="Number warrant outstanding"&gt;9,427,196&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_z4djd98mNtwk" style="text-align: right" title="Weighted average remaining contractual life (years)::XDX::P2Y8M12D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0589"&gt;2.7&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_zCkGHj1FHXRc" style="text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)"&gt;3.00&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_zsXrtR6EzwH4" style="text-align: right" title="Number of warrant exercisable"&gt;9,427,196&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySixMember_zz1f9yFngWXe" style="text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)"&gt;3.00&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member_zE4Tpmn5pHWd" title="Exercse price (in dollars per share)"&gt;6.25&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zQxgUdMpQly8" style="border-bottom: black 1pt solid; text-align: right" title="Number warrant outstanding"&gt;61,250&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zSJmIUBqhkce" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average remaining contractual life (years)::XDX::P3Y10M25D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0601"&gt;3.9&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zOyd1700VTk7" style="border-bottom: black 1pt solid; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)"&gt;6.25&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zrOSbnjyCzu6" style="border-bottom: black 1pt solid; text-align: right" title="Number of warrant exercisable"&gt;61,250&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiftySevenMember_zjWEFKDoFzYf" style="border-bottom: black 1pt solid; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)"&gt;6.25&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;$&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member__srt--RangeAxis__srt--MinimumMember_zMW0WoWiKWWf" title="Exercse price (in dollars per share)"&gt;1.00&lt;/span&gt; - $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice4Member__srt--RangeAxis__srt--MaximumMember_zm0S1G3iyfg6" title="Exercse price (in dollars per share)"&gt;6.25&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_uShares_c20220731_zTmFv0DmSME1" style="border-bottom: black 2.25pt double; text-align: right" title="Number warrant outstanding"&gt;10,149,788&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20220731_zhvPLCA1MJRl" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average remaining contractual life (years)::XDX::P2Y7M6D"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0615"&gt;2.6&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_iI_pid_uUSDPShares_c20220731_zOQkaHdYgMna" style="border-bottom: black 2.25pt double; text-align: right" title="Warrant outstanding, weighted average exercise price (in dollars per share)"&gt;2.90&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ClassOfWarrantOrRightExercisable_iI_pid_uShares_c20220731_zQcLHY4ZUaF5" style="border-bottom: black 2.25pt double; text-align: right" title="Number of warrant exercisable"&gt;10,149,788&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20220731_zh0MolRQFQgj" style="border-bottom: black 2.25pt double; text-align: right" title="Warrant exercisable, weighted average exercise price (in dollars per share)"&gt;2.90&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-07-31_custom_ExercisePrice1Member"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-07-31_custom_ExercisePrice1Member"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <alxneuro:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
      contextRef="AsOf2022-07-31_custom_ExercisePrice1Member"
      decimals="INF"
      unitRef="USDPShares">1.00</alxneuro:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights>
    <alxneuro:ClassOfWarrantOrRightExercisable
      contextRef="AsOf2022-07-31_custom_ExercisePrice1Member"
      decimals="INF"
      unitRef="Shares">500000</alxneuro:ClassOfWarrantOrRightExercisable>
    <alxneuro:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-07-31_custom_ExercisePrice1Member"
      decimals="INF"
      unitRef="USDPShares">1.00</alxneuro:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-07-31_custom_ExercisePrice2Member"
      decimals="INF"
      unitRef="USDPShares">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-07-31_custom_ExercisePrice2Member"
      decimals="INF"
      unitRef="Shares">161342</us-gaap:ClassOfWarrantOrRightOutstanding>
    <alxneuro:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
      contextRef="AsOf2022-07-31_custom_ExercisePrice2Member"
      decimals="INF"
      unitRef="USDPShares">1.75</alxneuro:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights>
    <alxneuro:ClassOfWarrantOrRightExercisable
      contextRef="AsOf2022-07-31_custom_ExercisePrice2Member"
      decimals="INF"
      unitRef="Shares">161342</alxneuro:ClassOfWarrantOrRightExercisable>
    <alxneuro:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-07-31_custom_ExercisePrice2Member"
      decimals="INF"
      unitRef="USDPShares">1.75</alxneuro:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-07-31_custom_ExercisePrice3Member"
      decimals="INF"
      unitRef="USDPShares">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-07-31_custom_ExercisePriceFiftySixMember"
      decimals="INF"
      unitRef="Shares">9427196</us-gaap:ClassOfWarrantOrRightOutstanding>
    <alxneuro:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
      contextRef="AsOf2022-07-31_custom_ExercisePriceFiftySixMember"
      decimals="INF"
      unitRef="USDPShares">3.00</alxneuro:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights>
    <alxneuro:ClassOfWarrantOrRightExercisable
      contextRef="AsOf2022-07-31_custom_ExercisePriceFiftySixMember"
      decimals="INF"
      unitRef="Shares">9427196</alxneuro:ClassOfWarrantOrRightExercisable>
    <alxneuro:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-07-31_custom_ExercisePriceFiftySixMember"
      decimals="INF"
      unitRef="USDPShares">3.00</alxneuro:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-07-31_custom_ExercisePrice4Member"
      decimals="INF"
      unitRef="USDPShares">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-07-31_custom_ExercisePriceFiftySevenMember"
      decimals="INF"
      unitRef="Shares">61250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <alxneuro:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
      contextRef="AsOf2022-07-31_custom_ExercisePriceFiftySevenMember"
      decimals="INF"
      unitRef="USDPShares">6.25</alxneuro:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights>
    <alxneuro:ClassOfWarrantOrRightExercisable
      contextRef="AsOf2022-07-31_custom_ExercisePriceFiftySevenMember"
      decimals="INF"
      unitRef="Shares">61250</alxneuro:ClassOfWarrantOrRightExercisable>
    <alxneuro:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-07-31_custom_ExercisePriceFiftySevenMember"
      decimals="INF"
      unitRef="USDPShares">6.25</alxneuro:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-07-31_custom_ExercisePrice4Member_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-07-31_custom_ExercisePrice4Member_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2022-07-31" decimals="INF" unitRef="Shares">10149788</us-gaap:ClassOfWarrantOrRightOutstanding>
    <alxneuro:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
      contextRef="AsOf2022-07-31"
      decimals="INF"
      unitRef="USDPShares">2.90</alxneuro:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights>
    <alxneuro:ClassOfWarrantOrRightExercisable contextRef="AsOf2022-07-31" decimals="INF" unitRef="Shares">10149788</alxneuro:ClassOfWarrantOrRightExercisable>
    <alxneuro:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-07-31"
      decimals="INF"
      unitRef="USDPShares">2.90</alxneuro:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice>
    <alxneuro:ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_89D_ecustom--ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock_zbbMtIAfu7d1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span id="xdx_8B3_zuejyHMYX3s5"&gt;The estimated fair value of warrants granted during
the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;For the Three Months Ended July 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQImOIzcjzd2" style="width: 17%; text-align: center" title="Expected term (in years)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0625"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwjO06Eurs6c" style="width: 17%; text-align: center" title="::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0626"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zypgzgImH01k" style="text-align: center" title="Warrants measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0628"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zhiVY4h4qVjg" style="text-align: center" title="Warrants measurement input"&gt;103.70%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zbAoT8ln8IM4" style="text-align: center" title="Warrants measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0632"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zV3jQ2XvrIh8" title="Warrants measurement input"&gt;0.27&lt;/span&gt;% - &lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_ziPVDHLdtEvf" title="Warrants measurement input"&gt;0.28&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zIGdub23qDb3" style="text-align: center" title="Warrants measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0638"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uN_c20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--MinimumMember_zxnTvqD9M2Bf" style="text-align: center" title="Warrants measurement input"&gt;0.0%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</alxneuro:ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="INF"
      unitRef="N">103.70</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember"
      decimals="INF"
      unitRef="N">0.27</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember"
      decimals="INF"
      unitRef="N">0.28</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember_srt_MinimumMember"
      decimals="INF"
      unitRef="N">0.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zeJtmtZyoMob" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_821_ziQTb3OuL0la"&gt;OTHER RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In March 2021, the Company
entered into a securities purchase agreement with Digital Power Lending, LLC (&#x201c;DPL&#x201d;) pursuant to which the Company sold an
aggregate of &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesOther_uShares_c20210331__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DigitalPowerLendingMember_z0rDBIwJc2nk" title="Number of shares sold (in shares)"&gt;6,666,667&lt;/span&gt; shares of Common Stock for an aggregate of $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueOther_pn6n6_c20210331__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DigitalPowerLendingMember_zKBJrKyqdRNe" title="Number of shares sold"&gt;10&lt;/span&gt; million, or $1.50 per share, which sales were made in tranches.
On March 9, 2021, &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesOther_uShares_c20210308__20210309__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DigitalPowerLendingMember_zP7D71hzyXg6" title="Description of related party transaction"&gt;DPL paid $4 million, less the $1.8 million in prior advances and &lt;span id="xdx_90E_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20210308__20210309__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DigitalPowerLendingMember_zNyOV3iXDwA8" title="Description of related party transaction"&gt;the surrender for cancellation of a $50,000 convertible
promissory note held by BitNile Holdings, Inc. (&#x201c;BitNile&#x201d;), the parent company of DPL, for an aggregate of 2,666,667 shares
of Common Stock. Under the terms of the securities purchase agreement, DPL (i) purchased an additional 1,333,333 shares of Common Stock
upon approval of the IND for Phase IA clinical trials for AL001 for a purchase price of $2 million, and (ii) purchased 2,666,667 shares
of Common Stock upon the completion of Phase IA clinical trials for AL001 for a purchase price of $4 million.&lt;/span&gt;&lt;/span&gt; &lt;span id="xdx_90D_eus-gaap--LongTermPurchaseCommitmentMilestones_c20210308__20210309__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DigitalPowerLendingMember_zdE6HV9yJ3Of" title="Description of milestones"&gt;The Company issued to DPL
warrants to purchase 3,333,333 shares of Common Stock at an exercise price of $3.00 per share. Finally, the Company agreed that for a
period of 18 months following the date of the payment of the final tranche of $4 million, DPL will have the right to invest an additional
$10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million as of
the date of this Quarterly Report.&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementMember_custom_DigitalPowerLendingMember"
      decimals="INF"
      unitRef="Shares">6666667</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementMember_custom_DigitalPowerLendingMember"
      decimals="-6"
      unitRef="USD">10000000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2021-03-082021-03-09_custom_SecuritiesPurchaseAgreementMember_custom_DigitalPowerLendingMember"
      decimals="INF"
      unitRef="Shares">4</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="From2021-03-082021-03-09_custom_SecuritiesPurchaseAgreementMember_custom_DigitalPowerLendingMember">the surrender for cancellation of a $50,000 convertible
promissory note held by BitNile Holdings, Inc. (&#x201c;BitNile&#x201d;), the parent company of DPL, for an aggregate of 2,666,667 shares
of Common Stock. Under the terms of the securities purchase agreement, DPL (i) purchased an additional 1,333,333 shares of Common Stock
upon approval of the IND for Phase IA clinical trials for AL001 for a purchase price of $2 million, and (ii) purchased 2,666,667 shares
of Common Stock upon the completion of Phase IA clinical trials for AL001 for a purchase price of $4 million.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:LongTermPurchaseCommitmentMilestones contextRef="From2021-03-082021-03-09_custom_SecuritiesPurchaseAgreementMember_custom_DigitalPowerLendingMember">The Company issued to DPL
warrants to purchase 3,333,333 shares of Common Stock at an exercise price of $3.00 per share. Finally, the Company agreed that for a
period of 18 months following the date of the payment of the final tranche of $4 million, DPL will have the right to invest an additional
$10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million as of
the date of this Quarterly Report.</us-gaap:LongTermPurchaseCommitmentMilestones>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zkanNUh1xAQj" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_820_zZ51ZDSEGj0a"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;Contractual Obligations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On May 1, 2016, the Company
entered into a Standard Exclusive License Agreement for AL002 with Sublicensing Terms with Licensor, pursuant to which Licensor granted
the Company a royalty bearing exclusive worldwide license limited to the field of Alzheimer&#x2019;s Immunotherapy and Diagnostics, under
United States Patent No. 8,188,046, entitled &#x201c;Amyloid Beta Peptides and Methods of Use,&#x201d; filed April&#160;7, 2009 and granted
May 29, 2012.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;There
are certain initial license fees and milestone payments required to be paid by the Company to the Licensor pursuant to the terms of license
agreements. The license agreements for AL002 require the Company to pay royalty payments of&#160;&lt;span id="xdx_908_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._pid_dp_uPure_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember_zuYYu2jVdjH3" title="Percentage of royalty payments on net sales of product"&gt;4&lt;/span&gt;% on net sales of products developed
from the licensed technology for AL002 while the license agreements for AL001 require that the Company pay combined royalty payments of&#160;&lt;span id="xdx_90D_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._pid_dp_uPure_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zswzgyVAZn3c"&gt;4.5&lt;/span&gt;%
on net sales of products developed from the licensed technology for AL001.&#160;&lt;span id="xdx_904_ecustom--DescriptionOfLicensesAgreements_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zJdrqzHoMiTb" title="Description of licenses agreements"&gt;The Company has already paid an initial license fee of
$200,000 for AL002 and an initial license fee of $200,000 for AL001. As an additional licensing fee for the license of AL002, the Licensor
received 3,601,809 shares of common stock. As an additional licensing fee for the license of the AL001 technologies, the Licensor received
2,227,923 shares of common stock. Minimum royalties for AL001 are $25,000 in 2023, $45,000 in 2024 and $70,000 in 2025 and every year
thereafter, for the life of the agreement. Minimum royalties for AL002 are $20,000 in 2022, $40,000 in 2023 and $50,000 in 2024 and every
year thereafter, for the life of the respective agreement.&lt;/span&gt;&#160;Additionally, the Company is required to pay milestone payments on the
due dates to the Licensor for the license of the AL001 technologies and for the AL002 technology, as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zC4M9bZ7vk2f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_8B9_zGw8l6J7Ii23"&gt;Original
AL001 License:&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&lt;b&gt;Payment&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; vertical-align: middle"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;b&gt;&#160;Due Date&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;b&gt;&#160;Event&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--PreINDMeetingMember_zjPksGXDXy2l" style="width: 11%; text-align: right" title="Payment"&gt;50,000&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 1%; text-align: left"&gt;&lt;span id="xdx_F2F_zbSOF11wVTUd" style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--PreINDMeetingMember_zY1jktkhGQaj" style="width: 46%" title="Due Date"&gt;&#160;Completed September 2019&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 40%"&gt;&#160;Pre-IND meeting&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zjJkpJxz5mze" style="text-align: right" title="Payment"&gt;65,000&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;span id="xdx_F2A_z7X0v1jlCYQb" style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_znf58gBDm5Gi" title="Due Date"&gt;&#160;Completed June 2021&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;IND application filing&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zroqmNPrjqsj" style="text-align: right" title="Payment"&gt;190,000&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;span id="xdx_F21_za1ODzHwTgW2" style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zzCLYgSWciN" title="Due Date"&gt;&#160;Completed December 2021&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;Upon first dosing of patient in a clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPatientDosingMember_z0KUOaSBO4o" style="text-align: right" title="Payment"&gt;500,000&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;span id="xdx_F26_zxJOWjomOu2c" style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPatientDosingMember_zrBkyfasuBsi" title="Due Date"&gt;&#160;Completed March 2022&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;Upon Completion of first clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; vertical-align: middle"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_zCKSqqyXl998" style="text-align: right" title="Payment"&gt;1,250,000&lt;/td&gt;
    &lt;td style="text-align: left; vertical-align: middle"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_zF44zw4wFwuh" title="Due Date"&gt;&#160;12 months from completion of the first Phase II clinical trial&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;Upon first patient treated in a Phase III clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; vertical-align: middle"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_z6Sh2hKlwVx" style="text-align: right" title="Payment"&gt;10,000,000&lt;/td&gt;
    &lt;td style="text-align: left; vertical-align: middle"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_z3CnLJGH3Dyh" title="Due Date"&gt;&#160;8 years from the effective date of the agreement&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;Upon FDA approval&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td id="xdx_F02_zTGwSVr03vB3" style="width: 47px; text-align: right"&gt;*&lt;/td&gt;
    &lt;td style="width: 7px"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_F19_zqQop9x9Ve8i" style="text-align: justify"&gt;Milestone met and completed&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&#160;AL002
License:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Payment&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Due Date&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Event&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--PreINDMeetingMember_zGzDlXyVxJ34" style="width: 11%; text-align: right" title="Payment"&gt;50,000&lt;/td&gt;
    &lt;td style="vertical-align: top; white-space: nowrap; width: 1%; text-align: left"&gt;*&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--PreINDMeetingMember_zX6BlkE1pDaa" style="width: 46%" title="Due Date"&gt;Completed January 2022&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;&#160;Upon IND application filing&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zdltbFvp3WWh" style="text-align: right" title="Payment"&gt;50,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zTXfq8ACZeWj" title="Due Date"&gt;12 months from IND application filing date&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;Upon first dosing of patient in first Phase I clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zDILv2k8DQLf" style="text-align: right" title="Payment"&gt;175,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zUfFSGpxKuL2" title="Due Date"&gt;12 months from first patient dosed in Phase I&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;Upon completion of first Phase I clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_zYjuxneHWsic" style="text-align: right" title="Payment"&gt;500,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_z8A6Aqu6xTXe" title="Due Date"&gt;24 months from completion of first Phase I clinical trial&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;Upon completion of first Phase II clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember_zkQDPeV7Vuu2" style="text-align: right" title="Payment"&gt;1,000,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember_zhQzIoEWxNte" title="Due Date"&gt;12 months from completion of the first Phase II clinical trial&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;Upon first patient treated in a Phase III clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_zmbtq9N8w5Gf" style="text-align: right" title="Payment"&gt;10,000,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_zIwoWHKEmIU9" title="Due Date"&gt;7 years from the effective date of the agreement&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;Upon FDA BLA approval&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;The
Company has met the pre-IND meeting, IND application filing, and successfully completed the Phase I clinical trial milestones encompassing
AL001. If the Company fails to meet a milestone by its specified date, the Licensor may terminate the license agreement.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;Licensor
was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by the Company
while Licensor remains the owner of any equity securities of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;On
June&#160;10, 2020, the Company obtained two (2) additional royalty-bearing exclusive worldwide licenses from the Licensor to a therapy
named AL001. One of the additional licenses is for the treatment of neurodegenerative diseases excluding Alzheimer&#x2019;s and the other
license is for the treatment of psychiatric diseases and disorders. There are certain license fees and milestone payments required to
be paid pursuant to the terms of the Standard Exclusive License Agreements with Sublicensing Terms, both dated June&#160;10, 2020 and
effective&#160;as of November&#160;1, 2019, with the Licensor and the University of South Florida (the &#x201c;June AL001 License Agreements&#x201d;).
Under each of the June AL001 License Agreements, a royalty payment of&#160;&lt;span id="xdx_902_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._pid_dp_uPure_c20200501__20200610__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zNNbAyQf2r5f" title="Percentage of royalty payments on net sales of product"&gt;3&lt;/span&gt;% is required on net sales of products developed from the
licensed technology. For the two (2) additional AL001 licenses, in the aggregate, the Company has paid initial license fees of $&lt;span id="xdx_907_ecustom--InitialLicenseFees_c20200501__20200610__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zC2q1CTKa5Xf" title="Initial license fees"&gt;20,000&lt;/span&gt;.
Additionally, under each of the June AL001 License Agreements, the Company is required to pay milestone payments on the due dates to the
Licensor for the license of the technology, as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;Additional
AL001 Licenses:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Payment&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Due Date&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Event&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zSyt8NPBi1l8" style="width: 12%; text-align: right" title="Payment"&gt;50,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zPJNTq6CZuA" style="width: 47%" title="Due Date"&gt;Upon IND application filing&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 38%"&gt;&#160;IND application filing&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zl1CyYvjPSY8" style="text-align: right" title="Payment"&gt;150,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zcl1aoueDhsf" title="Due Date"&gt;12 months from IND filing date&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;Upon first dosing of patient in a clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_z7zMeNxDQmzc" style="text-align: right" title="Payment"&gt;400,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_zIO8W0mRuTy6" title="Due Date"&gt;12 months from first patient dosing&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;Upon Completion of first clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember_zOj7P1GfKvdf" style="text-align: right" title="Payment"&gt;1,000,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember_zxE8buiCBtYi" title="Due Date"&gt;36 months from completion of the first Phase II clinical trial&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;Upon first patient treated in a Phase III clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_zqTtiPVGzRv8" style="text-align: right" title="Payment"&gt;8,000,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_zcQ256EItc9g" title="Due Date"&gt;8 years from the effective date of the agreement&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;First commercial sale&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AA_zpzXhmb8lA62" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <alxneuro:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.
      contextRef="From2022-05-012022-07-31_custom_AL002LicenseMember"
      decimals="INF"
      unitRef="Pure">0.04</alxneuro:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.>
    <alxneuro:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.
      contextRef="From2022-05-012022-07-31_custom_AL001LicenseMember"
      decimals="INF"
      unitRef="Pure">0.045</alxneuro:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.>
    <alxneuro:DescriptionOfLicensesAgreements contextRef="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember">The Company has already paid an initial license fee of
$200,000 for AL002 and an initial license fee of $200,000 for AL001. As an additional licensing fee for the license of AL002, the Licensor
received 3,601,809 shares of common stock. As an additional licensing fee for the license of the AL001 technologies, the Licensor received
2,227,923 shares of common stock. Minimum royalties for AL001 are $25,000 in 2023, $45,000 in 2024 and $70,000 in 2025 and every year
thereafter, for the life of the agreement. Minimum royalties for AL002 are $20,000 in 2022, $40,000 in 2023 and $50,000 in 2024 and every
year thereafter, for the life of the respective agreement.</alxneuro:DescriptionOfLicensesAgreements>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_895_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zC4M9bZ7vk2f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_8B9_zGw8l6J7Ii23"&gt;Original
AL001 License:&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid"&gt;&lt;b&gt;Payment&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left; white-space: nowrap; vertical-align: middle"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;b&gt;&#160;Due Date&lt;/b&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;b&gt;&#160;Event&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--PreINDMeetingMember_zjPksGXDXy2l" style="width: 11%; text-align: right" title="Payment"&gt;50,000&lt;/td&gt;
    &lt;td style="vertical-align: middle; width: 1%; text-align: left"&gt;&lt;span id="xdx_F2F_zbSOF11wVTUd" style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--PreINDMeetingMember_zY1jktkhGQaj" style="width: 46%" title="Due Date"&gt;&#160;Completed September 2019&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 40%"&gt;&#160;Pre-IND meeting&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zjJkpJxz5mze" style="text-align: right" title="Payment"&gt;65,000&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;span id="xdx_F2A_z7X0v1jlCYQb" style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_znf58gBDm5Gi" title="Due Date"&gt;&#160;Completed June 2021&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;IND application filing&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zroqmNPrjqsj" style="text-align: right" title="Payment"&gt;190,000&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;span id="xdx_F21_za1ODzHwTgW2" style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zzCLYgSWciN" title="Due Date"&gt;&#160;Completed December 2021&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;Upon first dosing of patient in a clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPatientDosingMember_z0KUOaSBO4o" style="text-align: right" title="Payment"&gt;500,000&lt;/td&gt;
    &lt;td style="vertical-align: middle; text-align: left"&gt;&lt;span id="xdx_F26_zxJOWjomOu2c" style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPatientDosingMember_zrBkyfasuBsi" title="Due Date"&gt;&#160;Completed March 2022&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;Upon Completion of first clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; vertical-align: middle"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_zCKSqqyXl998" style="text-align: right" title="Payment"&gt;1,250,000&lt;/td&gt;
    &lt;td style="text-align: left; vertical-align: middle"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_zF44zw4wFwuh" title="Due Date"&gt;&#160;12 months from completion of the first Phase II clinical trial&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;Upon first patient treated in a Phase III clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; vertical-align: middle"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_z6Sh2hKlwVx" style="text-align: right" title="Payment"&gt;10,000,000&lt;/td&gt;
    &lt;td style="text-align: left; vertical-align: middle"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL001LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_z3CnLJGH3Dyh" title="Due Date"&gt;&#160;8 years from the effective date of the agreement&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;Upon FDA approval&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td id="xdx_F02_zTGwSVr03vB3" style="width: 47px; text-align: right"&gt;*&lt;/td&gt;
    &lt;td style="width: 7px"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_F19_zqQop9x9Ve8i" style="text-align: justify"&gt;Milestone met and completed&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&#160;AL002
License:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Payment&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Due Date&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Event&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--PreINDMeetingMember_zGzDlXyVxJ34" style="width: 11%; text-align: right" title="Payment"&gt;50,000&lt;/td&gt;
    &lt;td style="vertical-align: top; white-space: nowrap; width: 1%; text-align: left"&gt;*&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--PreINDMeetingMember_zX6BlkE1pDaa" style="width: 46%" title="Due Date"&gt;Completed January 2022&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;&#160;Upon IND application filing&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zdltbFvp3WWh" style="text-align: right" title="Payment"&gt;50,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zTXfq8ACZeWj" title="Due Date"&gt;12 months from IND application filing date&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;Upon first dosing of patient in first Phase I clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zDILv2k8DQLf" style="text-align: right" title="Payment"&gt;175,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zUfFSGpxKuL2" title="Due Date"&gt;12 months from first patient dosed in Phase I&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;Upon completion of first Phase I clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_zYjuxneHWsic" style="text-align: right" title="Payment"&gt;500,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_z8A6Aqu6xTXe" title="Due Date"&gt;24 months from completion of first Phase I clinical trial&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;Upon completion of first Phase II clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember_zkQDPeV7Vuu2" style="text-align: right" title="Payment"&gt;1,000,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember_zhQzIoEWxNte" title="Due Date"&gt;12 months from completion of the first Phase II clinical trial&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;Upon first patient treated in a Phase III clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_zmbtq9N8w5Gf" style="text-align: right" title="Payment"&gt;10,000,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AL002LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_zIwoWHKEmIU9" title="Due Date"&gt;7 years from the effective date of the agreement&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;Upon FDA BLA approval&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;The
Company has met the pre-IND meeting, IND application filing, and successfully completed the Phase I clinical trial milestones encompassing
AL001. If the Company fails to meet a milestone by its specified date, the Licensor may terminate the license agreement.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;Licensor
was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by the Company
while Licensor remains the owner of any equity securities of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;On
June&#160;10, 2020, the Company obtained two (2) additional royalty-bearing exclusive worldwide licenses from the Licensor to a therapy
named AL001. One of the additional licenses is for the treatment of neurodegenerative diseases excluding Alzheimer&#x2019;s and the other
license is for the treatment of psychiatric diseases and disorders. There are certain license fees and milestone payments required to
be paid pursuant to the terms of the Standard Exclusive License Agreements with Sublicensing Terms, both dated June&#160;10, 2020 and
effective&#160;as of November&#160;1, 2019, with the Licensor and the University of South Florida (the &#x201c;June AL001 License Agreements&#x201d;).
Under each of the June AL001 License Agreements, a royalty payment of&#160;&lt;span id="xdx_902_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._pid_dp_uPure_c20200501__20200610__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zNNbAyQf2r5f" title="Percentage of royalty payments on net sales of product"&gt;3&lt;/span&gt;% is required on net sales of products developed from the
licensed technology. For the two (2) additional AL001 licenses, in the aggregate, the Company has paid initial license fees of $&lt;span id="xdx_907_ecustom--InitialLicenseFees_c20200501__20200610__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zC2q1CTKa5Xf" title="Initial license fees"&gt;20,000&lt;/span&gt;.
Additionally, under each of the June AL001 License Agreements, the Company is required to pay milestone payments on the due dates to the
Licensor for the license of the technology, as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;Additional
AL001 Licenses:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Payment&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Due Date&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; white-space: nowrap"&gt;&lt;b&gt;Event&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 1%"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zSyt8NPBi1l8" style="width: 12%; text-align: right" title="Payment"&gt;50,000&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--IndApplicationFilingMember_zPJNTq6CZuA" style="width: 47%" title="Due Date"&gt;Upon IND application filing&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 38%"&gt;&#160;IND application filing&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zl1CyYvjPSY8" style="text-align: right" title="Payment"&gt;150,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember_zcl1aoueDhsf" title="Due Date"&gt;12 months from IND filing date&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;Upon first dosing of patient in a clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_z7zMeNxDQmzc" style="text-align: right" title="Payment"&gt;400,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember_zIO8W0mRuTy6" title="Due Date"&gt;12 months from first patient dosing&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;Upon Completion of first clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember_zOj7P1GfKvdf" style="text-align: right" title="Payment"&gt;1,000,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhase3ClinicalTrialMember_zxE8buiCBtYi" title="Due Date"&gt;36 months from completion of the first Phase II clinical trial&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;Upon first patient treated in a Phase III clinical trial&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ContractualObligation_iI_pp0p0_c20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_zqTtiPVGzRv8" style="text-align: right" title="Payment"&gt;8,000,000&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--OtherCommitmentsDescription_c20220501__20220731__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__custom--LicenseEventsAxis__custom--UponFdaApprovalMember_zcQ256EItc9g" title="Due Date"&gt;8 years from the effective date of the agreement&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;First commercial sale&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:ContractualObligation
      contextRef="AsOf2022-07-31_custom_AL001LicenseMember_custom_PreINDMeetingMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription contextRef="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_PreINDMeetingMember">&#160;Completed September 2019</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2022-07-31_custom_AL001LicenseMember_custom_IndApplicationFilingMember"
      decimals="0"
      unitRef="USD">65000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription contextRef="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_IndApplicationFilingMember">&#160;Completed June 2021</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2022-07-31_custom_AL001LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember"
      decimals="0"
      unitRef="USD">190000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription contextRef="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember">&#160;Completed December 2021</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2022-07-31_custom_AL001LicenseMember_custom_UponCompletionOfFirstPatientDosingMember"
      decimals="0"
      unitRef="USD">500000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription contextRef="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_UponCompletionOfFirstPatientDosingMember">&#160;Completed March 2022</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2022-07-31_custom_AL001LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember"
      decimals="0"
      unitRef="USD">1250000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription contextRef="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember">&#160;12 months from completion of the first Phase II clinical trial</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2022-07-31_custom_AL001LicenseMember_custom_UponFdaApprovalMember"
      decimals="0"
      unitRef="USD">10000000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription contextRef="From2022-05-012022-07-31_custom_AL001LicenseMember_custom_UponFdaApprovalMember">&#160;8 years from the effective date of the agreement</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2022-07-31_custom_AL002LicenseMember_custom_PreINDMeetingMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription contextRef="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_PreINDMeetingMember">Completed January 2022</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2022-07-31_custom_AL002LicenseMember_custom_IndApplicationFilingMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription contextRef="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_IndApplicationFilingMember">12 months from IND application filing date</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2022-07-31_custom_AL002LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember"
      decimals="0"
      unitRef="USD">175000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription contextRef="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember">12 months from first patient dosed in Phase I</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2022-07-31_custom_AL002LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember"
      decimals="0"
      unitRef="USD">500000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription contextRef="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember">24 months from completion of first Phase I clinical trial</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2022-07-31_custom_AL002LicenseMember_custom_UponFirstPatientTreatedInPhase3ClinicalTrialMember"
      decimals="0"
      unitRef="USD">1000000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription contextRef="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_UponFirstPatientTreatedInPhase3ClinicalTrialMember">12 months from completion of the first Phase II clinical trial</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2022-07-31_custom_AL002LicenseMember_custom_UponFdaApprovalMember"
      decimals="0"
      unitRef="USD">10000000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription contextRef="From2022-05-012022-07-31_custom_AL002LicenseMember_custom_UponFdaApprovalMember">7 years from the effective date of the agreement</us-gaap:OtherCommitmentsDescription>
    <alxneuro:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.
      contextRef="From2020-05-012020-06-10_custom_AdditionalAL001LicenseMember"
      decimals="INF"
      unitRef="Pure">0.03</alxneuro:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.>
    <alxneuro:InitialLicenseFees
      contextRef="From2020-05-012020-06-10_custom_AdditionalAL001LicenseMember"
      decimals="0"
      unitRef="USD">20000</alxneuro:InitialLicenseFees>
    <us-gaap:ContractualObligation
      contextRef="AsOf2022-07-31_custom_AdditionalAL001LicenseMember_custom_IndApplicationFilingMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription contextRef="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember_custom_IndApplicationFilingMember">Upon IND application filing</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember"
      decimals="0"
      unitRef="USD">150000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription contextRef="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFirstDosingOfPatientInClinicalTrialMember">12 months from IND filing date</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2022-07-31_custom_AdditionalAL001LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember"
      decimals="0"
      unitRef="USD">400000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription contextRef="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember_custom_UponCompletionOfFirstClinicalTrialMember">12 months from first patient dosing</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFirstPatientTreatedInPhase3ClinicalTrialMember"
      decimals="0"
      unitRef="USD">1000000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription contextRef="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFirstPatientTreatedInPhase3ClinicalTrialMember">36 months from completion of the first Phase II clinical trial</us-gaap:OtherCommitmentsDescription>
    <us-gaap:ContractualObligation
      contextRef="AsOf2022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFdaApprovalMember"
      decimals="0"
      unitRef="USD">8000000</us-gaap:ContractualObligation>
    <us-gaap:OtherCommitmentsDescription contextRef="From2022-05-012022-07-31_custom_AdditionalAL001LicenseMember_custom_UponFdaApprovalMember">8 years from the effective date of the agreement</us-gaap:OtherCommitmentsDescription>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zK5UYkg4Cesc" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_827_zbILYSsVVV0f"&gt;EQUITY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;The
Company is authorized to issue &lt;span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20220131_zb98q96lTl8f" title="Preferred stock, shares authorized"&gt;10,000,000&lt;/span&gt; shares of Preferred Stock $&lt;span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20220731_zdH8s9cCurY2" title="Preferred stock, par or stated value per share"&gt;0.0001&lt;/span&gt; par value. The Board has designated &lt;span id="xdx_90C_ecustom--PreferredStockSharesDesignated_iI_pid_uShares_c20220731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z4qJm3OkDB2f" title="Preferred stock shares designated"&gt;1,360,000&lt;/span&gt; shares as the
Series A Preferred Shares. The rights, preferences, privileges and restrictions on the remaining authorized &lt;span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20220731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zicgMKvJeCRg" title="Preferred stock, shares authorized"&gt;8,640,000&lt;/span&gt; shares of Preferred
Stock have not been determined. The Board is authorized to create a new series of preferred shares and determine the number of shares,
as well as the rights, preferences, privileges and restrictions granted to or imposed upon any series of preferred shares.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;Series A Preferred Shares&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of July 31, 2022, there
were no Series A Preferred Shares or any other shares of Preferred Stock issued or outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On April 30, 2019, the Company
and ALSF entered into a SPA for the purchase of &lt;span id="xdx_90B_ecustom--NumberOfSharesPurchase_pid_uShares_c20190430__20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_zUM4Aea5YzNb"&gt;10,000,000&lt;/span&gt; shares of Common Stock for a total purchase price of $&lt;span id="xdx_906_ecustom--SharesPurchasePrice_c20190430__20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_zwdHAmVT4Hfi" title="Shares purchase price"&gt;15,000,000&lt;/span&gt;, or $&lt;span id="xdx_90B_ecustom--SharesPurchasePricePerShares_pid_uUSDPShares_c20190430__20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_z9DDDN572Xsg" title="Shares purchase price (in dollars per share)"&gt;1.50&lt;/span&gt;
per share with &lt;span id="xdx_90E_ecustom--NumberOfSharesPurchase_pid_uShares_c20190430__20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVVz7zw2rOH7" title="Number of shares purchase"&gt;5,000,000&lt;/span&gt; warrants with a &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlNqWrKjQWqi" title="Warrents terms::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0753"&gt;5&lt;/span&gt;&lt;/span&gt;-year life and an exercise price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_zX1nN7yM4G64" title="Exercise price (in dollars per share)"&gt;3.00&lt;/span&gt; per share and vesting upon issuance. The total purchase
price of $&lt;span id="xdx_903_ecustom--SharesPurchasePrice_c20190430__20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_zAZlUunKjwe5" title="Shares purchase price"&gt;15,000,000&lt;/span&gt; was in the form of a non-interest bearing note receivable with a &lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20190430__dei--LegalEntityAxis__custom--ALSFMember_z18T6MJg4wF7" title="Warrant terms::XDX::P12M"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0759"&gt;12&lt;/span&gt;&lt;/span&gt;-month term from ALSF, a related party. The note
is secured by a pledge of the purchased shares. Pursuant to the SPA, ALSF is entitled to full ratchet anti-dilution protection, most-favored
nation status, denying the Company the right to enter into a variable rate transaction absent its consent, a right to participate in any
future financing the Company may consummate and to have all the shares of Common Stock to which it is entitled under the SPA registered
under the Securities Act within 180 days of the final closing of the IPO. In May 2021, the term of the note receivable was extended to
December 31, 2023. The note is secured by a pledge of the purchased shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In March 2021, the Company
entered into a securities purchase agreement with DPL pursuant to which the Company agreed to sell an aggregate of &lt;span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesNewIssuesOne_pid_uShares_c20210331__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_zy5DFZSu1ao7" title="Number of shares issued"&gt;6,666,667&lt;/span&gt; shares of
Common Stock for an aggregate of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20210331__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--ALSFMember_zNFKWj6VCPC5" title="Proceeds from sale of equity"&gt;10&lt;/span&gt; million, or $&lt;span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember_zCaXsWfxZ8oi" title="Shares issued price per share"&gt;1.50&lt;/span&gt; per share, which sales will be made in tranches. On March 9, 2021, DPL paid $&lt;span id="xdx_905_eus-gaap--ProceedsFromRelatedPartyDebt_pn6n6_c20210331__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember_z2aXmUMZrc0d" title="Proceeds from related party"&gt;4&lt;/span&gt;
million, less the $&lt;span id="xdx_905_ecustom--AdvanceFromRelatedParties_dm_c20210331__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember_zkteMakRiUf6" title="Advance from related parties"&gt;1.8 million&lt;/span&gt; in prior advances and the surrender for cancellation of a $&lt;span id="xdx_902_ecustom--SharesValueSurrenderForCancellation_c20210331__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--AultGlobalMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zGMITcUFeNcd" title="Shares value surrender for cancellation"&gt;50,000&lt;/span&gt; convertible promissory note held by BitNile,
for an aggregate of &lt;span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesNewIssuesOne_pid_uShares_c20210301__20210309__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--AultGlobalMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zlfqwtjRc5w7" title="Number of shares issued"&gt;2,666,667&lt;/span&gt; shares of Common Stock. Under the terms of the securities purchase agreement, &lt;span id="xdx_907_ecustom--DescriptionOfPurchaseAgreementTerms_uShares_c20210301__20210331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember_znJPG0EBILh6" title="Description of purchase agreement terms"&gt;DPL (i) purchased an additional
1,333,333 shares of Common Stock upon approval by the FDA of the Company&#x2019;s IND for its Phase IA clinical trials for AL001 for a
purchase price of $2 million, and (ii) purchased 2,666,667 shares of Common Stock upon the completion of these Phase IA clinical trials
for AL001 for a purchase price of $4 million. The Company further agreed to issue to DPL warrants to purchase 3,333,333 shares of Common
Stock at an exercise price of $3.00 per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Finally, the Company
agreed that for a period of 18 months following the date of the payment of the final tranche of $4 million, on April 28, 2022, DPL
will have the right to invest an additional $&lt;span id="xdx_903_ecustom--AdditionalRightToInvest_pn6n6_c20220426__20220428__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember__us-gaap--VestingAxis__custom--FinalTrancheMember_zipEB0892X61" title="Additional right to invest"&gt;10&lt;/span&gt;
million on the same terms, except that no specific milestones have been determined with respect to the additional $&lt;span id="xdx_903_ecustom--AdditionalRightToInvest_pn6n6_c20220426__20220428__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--DigitalPowerLendingMember__us-gaap--VestingAxis__custom--FinalTrancheMember_zMfUOG0sp2i8" title="Additional right to invest"&gt;10&lt;/span&gt;
million as of the date of this Quarterly Report.&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-01-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-07-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <alxneuro:PreferredStockSharesDesignated
      contextRef="AsOf2022-07-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1360000</alxneuro:PreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-07-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">8640000</us-gaap:PreferredStockSharesAuthorized>
    <alxneuro:NumberOfSharesPurchase
      contextRef="From2019-04-302019-04-30_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember"
      decimals="INF"
      unitRef="Shares">10000000</alxneuro:NumberOfSharesPurchase>
    <alxneuro:SharesPurchasePrice
      contextRef="From2019-04-302019-04-30_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember"
      decimals="0"
      unitRef="USD">15000000</alxneuro:SharesPurchasePrice>
    <alxneuro:SharesPurchasePricePerShares
      contextRef="From2019-04-302019-04-30_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember"
      decimals="INF"
      unitRef="USDPShares">1.50</alxneuro:SharesPurchasePricePerShares>
    <alxneuro:NumberOfSharesPurchase
      contextRef="From2019-04-302019-04-30_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">5000000</alxneuro:NumberOfSharesPurchase>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-04-30_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember"
      decimals="INF"
      unitRef="USDPShares">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <alxneuro:SharesPurchasePrice
      contextRef="From2019-04-302019-04-30_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember"
      decimals="0"
      unitRef="USD">15000000</alxneuro:SharesPurchasePrice>
    <alxneuro:StockIssuedDuringPeriodSharesNewIssuesOne
      contextRef="From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember"
      decimals="INF"
      unitRef="Shares">6666667</alxneuro:StockIssuedDuringPeriodSharesNewIssuesOne>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementsMember_custom_ALSFMember"
      decimals="-6"
      unitRef="USD">10000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-03-31_custom_SecuritiesPurchaseAgreementsMember_custom_DigitalPowerLendingMember"
      decimals="INF"
      unitRef="USDPShares">1.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementsMember_custom_DigitalPowerLendingMember"
      decimals="-6"
      unitRef="USD">4000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <alxneuro:AdvanceFromRelatedParties
      contextRef="From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementsMember_custom_DigitalPowerLendingMember"
      decimals="0"
      unitRef="USD">1800000</alxneuro:AdvanceFromRelatedParties>
    <alxneuro:SharesValueSurrenderForCancellation
      contextRef="From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementsMember_custom_AultGlobalMember_custom_ConvertiblePromissoryNoteMember"
      decimals="0"
      unitRef="USD">50000</alxneuro:SharesValueSurrenderForCancellation>
    <alxneuro:StockIssuedDuringPeriodSharesNewIssuesOne
      contextRef="From2021-03-012021-03-09_custom_SecuritiesPurchaseAgreementsMember_custom_AultGlobalMember_custom_ConvertiblePromissoryNoteMember"
      decimals="INF"
      unitRef="Shares">2666667</alxneuro:StockIssuedDuringPeriodSharesNewIssuesOne>
    <alxneuro:AdditionalRightToInvest
      contextRef="From2022-04-262022-04-28_custom_SecuritiesPurchaseAgreementsMember_custom_DigitalPowerLendingMember_custom_FinalTrancheMember"
      decimals="-6"
      unitRef="USD">10000000</alxneuro:AdditionalRightToInvest>
    <alxneuro:AdditionalRightToInvest
      contextRef="From2022-04-262022-04-28_custom_SecuritiesPurchaseAgreementsMember_custom_DigitalPowerLendingMember_custom_FinalTrancheMember"
      decimals="-6"
      unitRef="USD">10000000</alxneuro:AdditionalRightToInvest>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-05-01to2022-07-31">&lt;p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zoyC9SVl1CS1" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 0.25in"&gt;&lt;b&gt;11.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_82B_zPkfDZBlRNDi"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has evaluated
subsequent events through the date the financial statements were issued. The Company has determined that there are no such events that
warrant disclosure or recognition in the condensed financial statements presented herein.&#160;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>52
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M2\%]H<P!\/U<2KW;,#]0_ ^%P7]02P,$%     @ V8,M58C].5$6!0  #14
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M6D(.)R*P)((2[ ;>3N060]<CONL>6$QA&WOXJ[7MZG)\=GEU.;N\L%((7[/
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M;4_@6B.2SB)QG, I$T[T+$5&Q7\4.8I9(31+K2SV=9\7FI(8[1Y$;):!2Z+
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MM5CDI]M\H'B2'1 ?N-+'S>PRTK\(0)@ _7S!N=H,S)FS_(TQ^0M02P,$%
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MPP2>-Y0K ?B^84P>)LI ]V":_ -02P,$%     @ V8,M54OF$:OD!@  6BL
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MVS_(N;_@=-T\1WA/.:=%\W)%<$I8;2 ^7U+*GR[J1Q,/C]-._P%02P,$%
M  @ V8,M57CP38A4 @  [@0  !@   !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q]5%%OVC 0_BLG;]I::6I"H'3J0J32=AJ3JJ$BMH=I#R:Y$*N.G=H7:/_]
M; <R)A7RD/CL^[[[[G+G=*O-DZT0"5YJJ>R$543-=139O,*:VPO=H'(GI38U
M)V>:=60;@[P(H%I&21R/HYH+Q;(T[,U-ENJ6I% X-V#;NN;F=8I2;R=LP/8;
MCV)=D=^(LK3A:UP@+9NY<5;4LQ2B1F6%5F"PG+";P?5TY/V#PT^!6WNP!I_)
M2NLG;\R*"8N]()28DV?@[K/!6Y32$SD9SSM.UH?TP,/UGOUKR-WELN(6;[7\
M)0JJ)NPS@P)+WDIZU-MON,OGTO/E6MKPAFWG>S5DD+>6=+T#.P6U4-V7O^SJ
M< !(DB. 9 =(@NXN4%!YQXEGJ=%;,-[;L?E%2#6@G3BA_$]9D'&GPN$HN]6J
M<"7& A;$"5VYR8(NG:7SITK+ HW]"/?/K:!7.%LJWA:"L#B'LSDWSKE"$CF7
MYVE$3HWGC/)=Y&D7.3D2>0@/VN$MW#L%Q?_XR&71IY+L4YDF)PF_M_("AH-/
MD,3) ):+.SA[?WZ"=]B7:!AXAT=X^\(<K<OOFY4EXQKLSUMEZ-A';[/[H;NV
M#<]QPMQ4630;9-F'=X-Q_.6$]E&O?72*/9L;G2,6%DJC:YA9VW*5(\R4(,$E
MS-N5%#G\*$LT0JW?4M_QCP._G_!--KB,_9-&FT-AT4$/UFC68=(LY+I5U+5C
MO]L/\TW7P__<NYO@@9NU4!8DE@X:7UQ=,C#=='4&Z29T]$J3FX^PK-R%A,8[
MN/-2:]H;/D!_Q65_ 5!+ P04    " #9@RU5IW( =;,%  ">%@  &    'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;*U8VV[;.!#]%<)=%"V0U")EW5+'0.)N
MT2[0(FB0W6=:HFUN)5%+TG'S]SN49,D7BDEVG8=8%W(XY\QPYHC3K9 _U9HQ
MC7X5>:FN1VNMJZOQ6*5K5E#U052LA#=+(0NJX5:NQJJ2C&;UI"(?$\\+QP7E
MY6@VK9_=R=E4;'3.2W8GD=H4!95/MRP7V^L1'NT>_."KM38/QK-I15?LGNF'
MZD["W;BSDO&"E8J+$DFVO![=X*LY\<V$>L2?G&W5WC4R4!9"_#0W7[/KD6<\
M8CE+M3%!X>>1S5F>&TO@QS^MT5&WIIFX?[VS_KD&#V 65+&YR/_BF5Y?C^(1
MRMB2;G+]0VR_L!908.RE(E?U?[1MQWHCE&Z4%D4[&3PH>-G\TE\M$7L3P(Y]
M FDGD.,)DX$)?CNA9F[<>%;#^D0UG4VEV")I1H,U<U%S4\\&-+PT8;S7$MYR
MF*=G<U%F$!26H7M--8, :87$$LVI6J//$&2%WCV4=)-QS;+WZ!(]W']"[WY[
M/QUK6-W8&*?M2K?-2F1@)1]]$Z5>*_0[K)@=SA^#UYWK9.?Z+7$:_&.3?T ^
MOD#$(\3BS_SET['#';]CTJ_M^4-,&L:6-6-+*0H$.TU2S<M5DZI<<Z:N;+0U
M9B=VLV8;7ZF*INQZ!/M4,?G(1K.W;W#H?;1A/I.Q P8F'0,3E_79=Z@ZN5#*
M!K*9&=8S36EYG%WZGA]YT60Z?MP'8!E(?)S$8=0-/' NZ)P+G.&YR?Z&W=3D
MMQ90@5)1ICQGJ&R]-D_-=6KBN#$[@I<O#V)PSB">R=@!3V''4^@,XB<&1E-.
MZR++?E6F.-@ -U:"O3A%7A(=!=.YE!T(<F"(.@R1$\/74C,PJ'?^0]G*V$*C
MC*M4;$IMP^.T^")7&\C1"2^3* GLN1MW>&(GGGLMTI^7IEME*!6%P=3$!U*6
M%54NGAA3B);F;:F@@5'(<AO(^,0YV%>^'Q^%[718Y">A*;(V%$F'(G$7R#4M
M5^#GX;92BNG&]YS3!<^'MUARSBUV)F,'1&"O;[J>,Z!WDE649[O\;/ +O682
M>KZ44*1:8JQMUCL)#Y3(*,;)41BM W&(P\0>2+PG&K#3_YNTWD<*5?2)+J"(
M&O]IFLH-.XBCU7U\ZA7V0^*38_=/!P9AG 0#FPF3WGOR;)]ZMLI;72<60@,_
M#!/OV'?+2$P("</)@/>]S,"OTQE+7E+H9,^W*'Q6H7$N:X<L]%(#N[7&G10I
M8UG+ >P<Q)7: !',J%<HD@641V7J9IV;6RJE*8K0"23+0>AFD+I2/UV8EF\E
MR[G\*_I!:V@_$^ 3R_P-)$(O:+!3!QQ1T& 55=NWF4RYO7&[K;X&67""# ^B
MZN4'=NN/0U2\A'RF.:HVBYRG$-HEDY#J==A,H#?P+2&W$CY.I'K[)B8X^MAU
M^5U'+ I(#6"EN>_2)!5JH+[^?]72$G2JD3!),)X$X0!+O<#!;H73E;!*BD<.
MWU-H\62M!%: Y](Z^%3LX D # 8!]HH'NR6/ ?@N8ZEDH'K>0QXT5Z9:&]Q6
M6*>R9:@ZGXZ$#A3'<3(@<7"O<;!3.335F6JT8"M>EB86D*707KC(K#XG%@:]
MT(\Q/O;9,C(A"8D&=ASIQ0AQBY&=R\QH$)>SY%1/0*Q)A,FQL[:108AC' X0
M3'KI0;"S_7T7Y66=^2_N>\2I95[;]\YE[1!^KUV(6[M\IERB1YIOZC[7M353
MU1HM U\ 97M$MN5Z/51!K40YEWY%76@-[7_$3R#ZT< G/.FU#W&JBM>C_T9E
MNJY/>)!B(*WK+ $NX*FI)G0E67WF=7$H"ZSL_ ?!8V?'C7%R$27)130AMGP9
M[YWT%4RNZ@-0A>I^UYR<=4^[0]:;^FCQZ/DMOIHW1Z6]F>;D%BB#TJ50SI9@
MTOL0P2Z6S6%H<Z-%59\G+H36HJ@OUXQ"'S8#X/U2"+V[,0MT1]*S?P%02P,$
M%     @ V8,M5:]I9%D !0  K@H  !@   !X;"]W;W)K<VAE971S+W-H965T
M."YX;6R55FEO&S<0_:Y?,5"*P $4778.^! @.S'J(H=A)<V'HA\H[DA+:)?<
MD%PKRJ_O&^Y*EAO;10%#7A[S^.;-09ZNG5^%G#G2C[*PX:R;QU@=#P9!YURJ
MT'<56ZPLG"]5Q- O!Z'RK+)D5!:#\7#X>E J8[N3TS1W[2>GKHZ%L7SM*=1E
MJ?SFG NW/NN.NMN)&[/,HTP,)J>56O*,X]?JVF,TV*%DIF0;C+/D>7'6G8Z.
MSX]D?]KPI^%UV/LF\63NW$H&5]E9=RB$N& =!4'AWRU?<%$($&A\;S&[NR/%
M</][BWZ9?(<O<Q7XPA7?3!;SL^[;+F6\4'41;]SZ=V[]>25XVA4A_=*ZV7N(
M$W4=HBM;8XQ+8YO_ZD>KPY[!V^$C!N/68)QX-P<EEN]45)-3[];D93?0Y".Y
MFJQ!SE@)RBQZK!K8Q<F[][.+FZOK+U>?/]'G2SK_.KOZ]'XV.QU$@,N6@6Z!
MSAN@\2- A_31V9@'>F\SSN[;#T!JQVR\978^?A+PC[KHT^&H1^/A>/P$WN'.
MT\.$=_@(WE1K5]MH[)*N76&TX4!_3><A>F3&WP\YW. =/8PGU7(<*J7YK(MR
M".QON3MY_FST>GCR!-NC'=NCI]#_3UR>!AKUZ1$L^NR7RIJ?*I7'M/BI4&P9
M?>+:NQY=6=VG@YASY_FSM^/Q\.3"E96RFS0:G9#SU"YL+=N5%STR@90E5K[8
MD 8AHU7Q,D04.<V-JW*%<M)<1YDGW>#2PB'=.2-PR?@6W:*24%F'3ZJ\RVH=
M0P==B,")(AI0Q*&1W(*L,,YXR9:]DB*GS 1&J0J-C*JPT;E1T1LM"\YG[$.?
MO@!FSZ?1FY. <XRTIH:+N '?<D83\KLM+72_\\W$G.+:H4J]%R9RUJ*.M><M
M7]*8,YF*''IW BM3!HJ.YEX<W'D21%)@<5H$C15:LL(?>I\*SJIYP1 K8";0
M]]KH%=15H5.Y$ S6'O9H2ZXR%4MJ  $--<AIB\2^$1B:>E6ED%#FZ^4><SI
MCTE-%!LWO21_&_DOK'/K"K?<9L6+X\Z!>0'*%2QM1#216H#43OL-$@ '[4P0
MY0*0201UCP R8FYLDY9@64!H4Y<]436Y($('A1+>%#BF1ROKUE94F7X8#D?"
MT+MZF7?$/>\VJHB;EW-DHYS$/W11!\D1W!9%AF;+.$#CEH&G"^_*Y-]7*\R"
MB1LA,,-EEM-EX3P4H1O4NO(:$V@G66+95$M/*#18B.3!GDX?VLFM2B<=<>'
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M&^,Q$.*RP@1F&P1P7QKC[S>!8)CIRW\ 4$L#!!0    ( -F#+54I-ZP&G T
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M6F25^\B9$0R;F>\>Y\UI:DD\,(?D:'Q-O@/\FD71JM\9KZ*-'&J:+[S,J7
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M1L/2^6"10$H9SE/2-XHSH9U <F.STXY8K_,7A3QUAKZ/]C;UP0;[(S\RXMG
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MK61UR]R7VG&"B13G5Y<=K?4:3B$7A1*U 4\U#B\3R&>LUX!7%Y%=ZH*DDCA
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M%J)\:O);UB8QU6HRB7D-D"_[?$A(,^?" =[8CJFXE]82@3M9-.$1D6A_D@8
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MR=DD!-V-OFYA5>/'S599&EY>+.EK ;53H/V=HA+I%^Z X?MC\1=02P,$%
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M&T@B'^(PCJ_@)>TE) XON8 WQ0TJA05,I#;:APFKN6&"?\?"A[G"FG$R6%7
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M\:AL )UOI#0GQQ*T?QJC'U!+ P04    " #9@RU5!3'2J)\$  "(#   &0
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6S-5VUOXC@0_IY?866KU58*D!<@
MM M(T';O>J>^J'"['T[WP20#6'7BK.V4\N]O[(24WE%V;W4?5E7!+^.99\;/
MC(?A1LA'M0;0Y#GCN1JY:ZV+\TY')6O(J&J+ G+<60J948U3N>JH0@)-[:&,
M=T+?[W<RRG)W/+1K]W(\%*7F+(=[2529951NI\#%9N0&[F[A@:W6VBQTQL."
MKF &^H_B7N*LTVA)60:Y8B(G$I8C=Q*<3_M&W@I\9K!1>V-B/%D(\6@FU^G(
M]0T@X)!HHX'BUQ-< .=&$<+X6NMT&Y/FX/YXI_V3]1U]65 %%X)_8:E>C]R!
M2U)8TI+K!['Y%6I_>D9?(KBRGV13R_HN24JE158?1@09RZMO^ES'X7L.A/6!
MT.*N#%F4EU33\5"*#9%&&K69@775GD9P+#>7,M,2=QF>T^/9_.[B]]9T,KNZ
M)!=W-_=7M[/)_/KNEGR8TP4'=3KL:#1CA#M)K7):J0S?4!F1&Y'KM2)7>0KI
MZ_,=A-=@#'<8I^%1A;^5O$VBP".A'X9']$6-SY'5%[WE\YI*:$WQ+E-R3[=(
M,4TF4M)\!7;\YV2AM$2^_'7(^4IW][!NDT/GJJ )C%Q,$@7R"=SQ^W=!W_]X
M!'FW0=X]IGT\V24/$4N"W$@>B2A>V,WTEF">$KT&_)< )*MN LQ-$(SCMHDC
M88I8A+G&K87)SO-#[AX%=-C=-U$Z_PM*YZ[42M,\9?F*W%G%RK%WJLAMF2U
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M_7:,54A6?6\UT:*PO>9":.Q<[7"-/Q5 &@'<7PJA=Q-CH/GQ,?X;4$L#!!0
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MA8;4=SZH>MK7@I%;-V%7TM"\=MN<?I!060>R9U*:HV!?T/YRS?X$4$L#!!0
M   ( -F#+54/I/^XUP4  #H0   9    >&PO=V]R:W-H965T<R]S:&5E=#(T
M+GAM;,U8VY+;-@Q]]U=@G$XFR3BVK+UFL^L9[ZUU)GN9>+=]Z/2!EF"+$TI4
M2&H=]^L+4!?;6=MI\M*^9"V).#@ #@DPIW-M/ML$T<'75&7VK)TXEY_T>C9*
M,!6VJW/,Z,M4FU0X>C2SGLT-BM@;I:H7!L%A+Q4R:P]._;M[,SC5A5,RPWL#
MMDA381;GJ/3\K-UOUR\^R5GB^$5O<)J+&8[1/>;WAIYZ#4HL4\RLU!D8G)ZU
MA_V3\WU>[Q?\+G%N5WX#1S+1^C,_C.*S=L"$4&'D&$'0GR>\0*48B&A\J3#;
MC4LV7/U=HU_[V"F6B;!XH=4?,G;)6?NX#3%.1:'<)SW_#:MX#A@OTLKZ?V%>
MKCT(VQ 5UNFT,B8&J<S*O^)KE8<5@^-@BT%8&82>=^G(L[P43@Q.C9Z#X=6$
MQC]\J-Z:R,F,BS)VAKY*LG.#B[N;F]'#S=7MPQB&MY=P<7?[,+K]]>KV8G0U
MAE</8J+0OC[M.?+%%KVHPCTO<<,MN'MPHS.76+C*8HS7[7O$L2$:UD3/PYV
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M&"KG8.\W4IJCX9JDF8GQ;U!+ P04    " #9@RU5I.$9RO@"  #>"   &0
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MFX^HJL?7?#$CHO@&F\K7,D"<"\G2"JPR2#$M?^%#I<,.0/$T YP*X!P"O"<
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MQZ,YO#]#PWBB8<*48E;!#UW?4&+K[D=EDD&1)'@E20LNI3!K#2,18_RKOT^
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MQF@<MN7$N"(8.PG*8&Y4[.5K><H].PTTKV-PQ 8%5M.#_\KFMG %7*W@H+?
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M4[(22BLF9@GA#T9CO$TI5E17I2!A/A)&D;"@A(T+F%GZ;*8'XXGGZ;RVV=7
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MM-(XX?HX,S.FY"03^LKY,M8Q$;F/U3(V#,EY^0?KUN0!=9JAM !*"U&TYM>
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MVWW8Z8,  9[XPLH"0F<__$JVL)Q@A..)2QYB&UM'YQS]=7[R9;A-^&.Z9$R
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M2KO S"^%T+N!/>$V_V@L_@=02P,$%     @ V8,M5=N<_1F?!   &0P  !D
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MAN2BKH%+V-AP0,(3$6[F65S&8$0N[D0],FY2ES.M%G$MZHV4&W&C^D63FTH
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MIQ%', ?@ 4.2Q+T'#]Y'\>8]%6]_XQK_!E!+ P04    " #9@RU5EXJ[',
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M7TA=7N&F6FG[ZH_#8=?TW.Q,-UW31+HL8TN.Z^-KJ>,KM2_? 5!+ P04
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M2=9WK5=__0F_79-:E<W1GW7_2>:?4$L! A0#%     @ V8,M50=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " #9@RU5AU6=<.X    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " #9@RU5F5R<(Q &  "<)P  $P
M        @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( -F#
M+56@-<0+#@8  *T@   8              " @0T(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " #9@RU5B/TY418%   -%0  &
M        @(%1#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ V8,M50(9-9 M P  ;PP  !@              ("!G1,  'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( -F#+570KKI[PP,  #P-   8
M              " @0 7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    " #9@RU52^81J^0&  !:*P  &               @('Y&@  >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ V8,M57CP38A4 @
M[@0  !@              ("!$R(  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    ( -F#+56G<@!ULP4  )X6   8              " @9TD
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #9@RU5KVED
M60 %  "N"@  &               @(&&*@  >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ V8,M561Z=4FG P  WP<  !@
M ("!O"\  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( -F#
M+54I-ZP&G T  !PD   9              " @9DS  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ V8,M5=?PXS"K @  U 4  !D
M         ("!;$$  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    " #9@RU59EC]I!P#  "R!@  &0              @(%.1   >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( -F#+54N5NW<I L  '$>
M   9              " @:%'  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ V8,M51>G(N&G P  )0@  !D              ("!?%,
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #9@RU5C?>R
MJ6P$  #F"0  &0              @(%:5P  >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    ( -F#+56P8L0OD@<  +P5   9
M  " @?U;  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
MV8,M52ZS[H$?!   @0D  !D              ("!QF,  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    " #9@RU51O29F(@"  "R!0  &0
M            @($<:   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    ( -F#+56H<%5!0 X   TI   9              " @=MJ  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ V8,M5:U1A(O% P
MBP@  !D              ("!4GD  'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    " #9@RU5GD"BBMT"  ! !@  &0              @(%.
M?0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( -F#+54%
M,=*HGP0  (@,   9              " @6*   !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ V8,M5<872UNG P  ?@D  !D
M     ("!.(4  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -F#+55X(6&>_P(  '\(   9              "
M@9J8  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ V8,M
M56E/P[E.!   KA<  !D              ("!T)L  'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6Q02P$"% ,4    " #9@RU5^3I9-;8"  !I!P  &0
M        @(%5H   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0
M   ( -F#+54_CYL/V (  /<(   9              " @4*C  !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ V8,M53E98:J(!   %Q0
M !D              ("!4:8  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q0
M2P$"% ,4    " #9@RU5XOYIP@<$  !J$@  &0              @($0JP
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( -F#+56P]"LF
M; ,   H,   9              " @4ZO  !X;"]W;W)K<VAE971S+W-H965T
M,S0N>&UL4$L! A0#%     @ V8,M5?X4Q'SE!P  "TL  !D
M ("!\;(  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #9
M@RU5&S9US'H%  !R)   &0              @($-NP  >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( -F#+56+=]/]H@,  -T0   9
M          " @;[   !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#
M%     @ V8,M5=N<_1F?!   &0P  !D              ("!E\0  'AL+W=O
M<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " #9@RU5[X[[9IP&  #6
M,0  &0              @(%MR0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM
M;%!+ 0(4 Q0    ( -F#+54.@,0,6P0  $D1   9              " @4#0
M  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ V8,M5>N_
MWP40"0  U'   !D              ("!TM0  'AL+W=O<FMS:&5E=',O<VAE
M970T,2YX;6Q02P$"% ,4    " #9@RU5X ,WA2\#  #P$@  #0
M    @ $9W@  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( -F#+567BKL<P
M !,"   +              "  7/A  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M -F#+57,S!>W/ 0  -8;   /              "  5SB  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " #9@RU5*5V(H),!  #B&   &@
M@ '%Y@  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #9
M@RU5B(RI-Z4!   O&0  $P              @ &0Z   6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     ,0 Q $X-  !FZ@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>136</ContextCount>
  <ElementCount>188</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/BalanceSheets</Role>
      <ShortName>Condensed Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>Condensed Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Statements of Stockholders' Equity (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/StatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Statements of Stockholders' Equity (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Condensed Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/DescriptionOfBusiness</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - LIQUIDITY AND GOING CONCERN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/LiquidityAndGoingConcern</Role>
      <ShortName>LIQUIDITY AND GOING CONCERN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/NoteReceivableForCommonStockRelatedParty</Role>
      <ShortName>NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/Stock-basedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - WARRANTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/Warrants</Role>
      <ShortName>WARRANTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - OTHER RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/OtherRelatedPartyTransactions</Role>
      <ShortName>OTHER RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - EQUITY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/EquityTransactions</Role>
      <ShortName>EQUITY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alzamend.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/Stock-basedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alzamend.com/role/Stock-basedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - WARRANTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/WarrantsTables</Role>
      <ShortName>WARRANTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alzamend.com/role/Warrants</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alzamend.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - DESCRIPTION OF BUSINESS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/DescriptionOfBusinessDetailsNarrative</Role>
      <ShortName>DESCRIPTION OF BUSINESS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://alzamend.com/role/DescriptionOfBusiness</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative</Role>
      <ShortName>LIQUIDITY AND GOING CONCERN (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://alzamend.com/role/LiquidityAndGoingConcern</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - The following sets forth the number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have been excluded from the computation of loss per common share: (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://alzamend.com/role/FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails</Role>
      <ShortName>The following sets forth the number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have been excluded from the computation of loss per common share: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/SignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://alzamend.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative</Role>
      <ShortName>NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://alzamend.com/role/NoteReceivableForCommonStockRelatedParty</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Prepaid expenses and other current assets are as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsAreAsFollowsDetails</Role>
      <ShortName>Prepaid expenses and other current assets are as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - A summary of stock option activity for the three months ended July 31, 2022 is presented below: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails</Role>
      <ShortName>A summary of stock option activity for the three months ended July 31, 2022 is presented below: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - The estimated fair value of stock options granted to employees and consultants during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails</Role>
      <ShortName>The estimated fair value of stock options granted to employees and consultants during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - The Company???s results of operations include expenses relating to stock-based compensation for three months ended July 31, 2022 and 2021, that were comprised as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/CompanysResultsOfOperationsIncludeExpensesRelatingToStock-basedCompensationForThreeMonthsEndedJuly312022And2021ThatWereComprisedAsFollowsDetails</Role>
      <ShortName>The Company???s results of operations include expenses relating to stock-based compensation for three months ended July 31, 2022 and 2021, that were comprised as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://alzamend.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - The following table summarizes information about Common Stock warrants outstanding and exercisable at July 31, 2022: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details</Role>
      <ShortName>The following table summarizes information about Common Stock warrants outstanding and exercisable at July 31, 2022: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - The estimated fair value of warrants granted during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails</Role>
      <ShortName>The estimated fair value of warrants granted during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - OTHER RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>OTHER RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://alzamend.com/role/OtherRelatedPartyTransactions</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Original AL001 License: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/OriginalAl001LicenseDetails</Role>
      <ShortName>Original AL001 License: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://alzamend.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="p9722010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - EQUITY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alzamend.com/role/EquityTransactionsDetailsNarrative</Role>
      <ShortName>EQUITY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://alzamend.com/role/EquityTransactions</ParentRole>
      <Position>41</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 24 fact(s) appearing in ix:hidden were eligible for transformation: alxneuro:PrepaidInsurance1, alxneuro:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1, dei:DocumentQuarterlyReport, us-gaap:NetIncomeLoss, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding, us-gaap:RetainedEarningsAccumulatedDeficit, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1, us-gaap:WarrantsAndRightsOutstandingTerm -  p9722010q.htm 30, 34, 35, 36, 37, 80, 81, 84, 86, 87, 94, 95, 96, 98, 99, 104, 105, 106, 107, 108, 109, 111, 115, 116</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="p9722010q.htm">p9722010q.htm</File>
    <File>alxneuro-20220731.xsd</File>
    <File>alxneuro-20220731_cal.xml</File>
    <File>alxneuro-20220731_def.xml</File>
    <File>alxneuro-20220731_lab.xml</File>
    <File>alxneuro-20220731_pre.xml</File>
    <File>ex31_1.htm</File>
    <File>ex31_2.htm</File>
    <File>ex32_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="319">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>58
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "p9722010q.htm": {
   "axisCustom": 1,
   "axisStandard": 16,
   "contextCount": 136,
   "dts": {
    "calculationLink": {
     "local": [
      "alxneuro-20220731_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "alxneuro-20220731_def.xml"
     ]
    },
    "inline": {
     "local": [
      "p9722010q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "alxneuro-20220731_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "alxneuro-20220731_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "alxneuro-20220731.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 344,
   "entityCount": 1,
   "hidden": {
    "http://alzamend.com/20220731": 25,
    "http://fasb.org/us-gaap/2022": 61,
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 92
   },
   "keyCustom": 39,
   "keyStandard": 149,
   "memberCustom": 32,
   "memberStandard": 15,
   "nsprefix": "alxneuro",
   "nsuri": "http://alzamend.com/20220731",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://alzamend.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://alzamend.com/role/SignificantAccountingPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alxneuro:MortgageNoteReceivableFromRelatedPartyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY",
     "role": "http://alzamend.com/role/NoteReceivableForCommonStockRelatedParty",
     "shortName": "NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alxneuro:MortgageNoteReceivableFromRelatedPartyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "role": "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssets",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://alzamend.com/role/Stock-basedCompensation",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alxneuro:WarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - WARRANTS",
     "role": "http://alzamend.com/role/Warrants",
     "shortName": "WARRANTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alxneuro:WarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - OTHER RELATED PARTY TRANSACTIONS",
     "role": "http://alzamend.com/role/OtherRelatedPartyTransactions",
     "shortName": "OTHER RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://alzamend.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - EQUITY TRANSACTIONS",
     "role": "http://alzamend.com/role/EquityTransactions",
     "shortName": "EQUITY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://alzamend.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://alzamend.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2022-07-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Condensed Balance Sheets (Unaudited)",
     "role": "http://alzamend.com/role/BalanceSheets",
     "shortName": "Condensed Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2022-07-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://alzamend.com/role/SignificantAccountingPoliciesTables",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alxneuro:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "role": "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "alxneuro:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "role": "http://alzamend.com/role/Stock-basedCompensationTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "alxneuro:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - WARRANTS (Tables)",
     "role": "http://alzamend.com/role/WarrantsTables",
     "shortName": "WARRANTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "alxneuro:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "role": "http://alzamend.com/role/CommitmentsAndContingenciesTables",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2022-07-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - DESCRIPTION OF BUSINESS (Details Narrative)",
     "role": "http://alzamend.com/role/DescriptionOfBusinessDetailsNarrative",
     "shortName": "DESCRIPTION OF BUSINESS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2022-07-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)",
     "role": "http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative",
     "shortName": "LIQUIDITY AND GOING CONCERN (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2022-07-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - The following sets forth the number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have been excluded from the computation of loss per common share: (Details)",
     "role": "http://alzamend.com/role/FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails",
     "shortName": "The following sets forth the number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have been excluded from the computation of loss per common share: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-012022-07-31_us-gaap_StockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "alxneuro:NumberOfStockExcluded",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "role": "http://alzamend.com/role/SignificantAccountingPoliciesDetailsNarrative",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-012022-07-31_us-gaap_StockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "alxneuro:NumberOfStockExcluded",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "alxneuro:MortgageNoteReceivableFromRelatedPartyTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2022-04-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "alxneuro:LongTermDebtAverageAmountOfOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY (Details Narrative)",
     "role": "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative",
     "shortName": "NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "alxneuro:MortgageNoteReceivableFromRelatedPartyTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2022-04-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "alxneuro:LongTermDebtAverageAmountOfOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2022-07-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://alzamend.com/role/BalanceSheetsParenthetical",
     "shortName": "Condensed Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2022-07-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "alxneuro:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2022-07-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - Prepaid expenses and other current assets are as follows: (Details)",
     "role": "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsAreAsFollowsDetails",
     "shortName": "Prepaid expenses and other current assets are as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "alxneuro:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2022-07-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2022-07-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "alxneuro:UnamortizedPrepaidExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details Narrative)",
     "role": "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2022-07-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "alxneuro:UnamortizedPrepaidExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2022-04-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - A summary of stock option activity for the three months ended July 31, 2022 is presented below: (Details)",
     "role": "http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails",
     "shortName": "A summary of stock option activity for the three months ended July 31, 2022 is presented below: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2022-04-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "alxneuro:ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2021-05-012021-07-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - The estimated fair value of stock options granted to employees and consultants during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions: (Details)",
     "role": "http://alzamend.com/role/EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails",
     "shortName": "The estimated fair value of stock options granted to employees and consultants during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "alxneuro:ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2021-05-012021-07-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - The Company\u2019s results of operations include expenses relating to stock-based compensation for three months ended July 31, 2022 and 2021, that were comprised as follows: (Details)",
     "role": "http://alzamend.com/role/CompanysResultsOfOperationsIncludeExpensesRelatingToStock-basedCompensationForThreeMonthsEndedJuly312022And2021ThatWereComprisedAsFollowsDetails",
     "shortName": "The Company\u2019s results of operations include expenses relating to stock-based compensation for three months ended July 31, 2022 and 2021, that were comprised as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2021-05-012021-07-31_us-gaap_ResearchAndDevelopmentExpenseMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)",
     "role": "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative",
     "shortName": "STOCK-BASED COMPENSATION (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2022-07-31_custom_UnamortizedStockBasedCompensationMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "alxneuro:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2022-07-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - The following table summarizes information about Common Stock warrants outstanding and exercisable at July 31, 2022: (Details)",
     "role": "http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details",
     "shortName": "The following table summarizes information about Common Stock warrants outstanding and exercisable at July 31, 2022: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "alxneuro:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2022-07-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "alxneuro:ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock",
       "alxneuro:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2021-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "N",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - The estimated fair value of warrants granted during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions: (Details)",
     "role": "http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails",
     "shortName": "The estimated fair value of warrants granted during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "alxneuro:ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock",
       "alxneuro:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2021-07-31_us-gaap_WarrantMember_us-gaap_MeasurementInputOptionVolatilityMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "N",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementMember_custom_DigitalPowerLendingMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - OTHER RELATED PARTY TRANSACTIONS (Details Narrative)",
     "role": "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative",
     "shortName": "OTHER RELATED PARTY TRANSACTIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2021-03-312021-03-31_custom_SecuritiesPurchaseAgreementMember_custom_DigitalPowerLendingMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2022-07-31_custom_AL001LicenseMember_custom_PreINDMeetingMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - Original AL001 License: (Details)",
     "role": "http://alzamend.com/role/OriginalAl001LicenseDetails",
     "shortName": "Original AL001 License: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2022-07-31_custom_AL001LicenseMember_custom_PreINDMeetingMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Condensed Statements of Operations (Unaudited)",
     "role": "http://alzamend.com/role/StatementsOfOperations",
     "shortName": "Condensed Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-012022-07-31_custom_AL002LicenseMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "alxneuro:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "role": "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-012022-07-31_custom_AL002LicenseMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "alxneuro:PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2022-07-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - EQUITY TRANSACTIONS (Details Narrative)",
     "role": "http://alzamend.com/role/EquityTransactionsDetailsNarrative",
     "shortName": "EQUITY TRANSACTIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2022-01-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2021-04-30_us-gaap_SeriesAPreferredStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Condensed Statements of Stockholders' Equity (Unaudited)",
     "role": "http://alzamend.com/role/StatementsOfStockholdersEquity",
     "shortName": "Condensed Statements of Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "AsOf2021-04-30_us-gaap_SeriesAPreferredStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2021-05-012021-07-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Condensed Statements of Stockholders' Equity (Unaudited) (Parenthetical)",
     "role": "http://alzamend.com/role/StatementsOfStockholdersEquityParenthetical",
     "shortName": "Condensed Statements of Stockholders' Equity (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2021-05-012021-07-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2021-05-012021-07-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000007 - Statement - Condensed Statements of Cash Flows (Unaudited)",
     "role": "http://alzamend.com/role/StatementsOfCashFlows",
     "shortName": "Condensed Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - DESCRIPTION OF BUSINESS",
     "role": "http://alzamend.com/role/DescriptionOfBusiness",
     "shortName": "DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - LIQUIDITY AND GOING CONCERN",
     "role": "http://alzamend.com/role/LiquidityAndGoingConcern",
     "shortName": "LIQUIDITY AND GOING CONCERN",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "p9722010q.htm",
      "contextRef": "From2022-05-01to2022-07-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 49,
   "tag": {
    "alxneuro_AL001LicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents a l001 license member.",
        "label": "A L001 License [Member]"
       }
      }
     },
     "localname": "AL001LicenseMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://alzamend.com/role/OriginalAl001LicenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_AL002LicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents a l002 license member.",
        "label": "A L002 License [Member]"
       }
      }
     },
     "localname": "AL002LicenseMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://alzamend.com/role/OriginalAl001LicenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_ALSFMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents a l s f member.",
        "label": "A L S F [Member]"
       }
      }
     },
     "localname": "ALSFMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_AdditionalAL001LicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents additional a l001 license member.",
        "label": "Additional A L001 License [Member]"
       }
      }
     },
     "localname": "AdditionalAL001LicenseMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://alzamend.com/role/OriginalAl001LicenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_AdditionalRightToInvest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents additional right to invest.",
        "label": "Additional right to invest"
       }
      }
     },
     "localname": "AdditionalRightToInvest",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alxneuro_AdvanceFromRelatedParties": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents advance from related parties.",
        "label": "Advance from related parties"
       }
      }
     },
     "localname": "AdvanceFromRelatedParties",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alxneuro_AultGlobalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents ault global member.",
        "label": "Ault Global [Member]"
       }
      }
     },
     "localname": "AultGlobalMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_AultLifeSciencesFundLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ault Life Sciences Fund L L C [Member]"
       }
      }
     },
     "localname": "AultLifeSciencesFundLLCMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_ClassOfWarrantOrRightExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents class of warrant or right exercisable.",
        "label": "Number of warrant exercisable"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisable",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "alxneuro_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents class of warrant or right exercisable weighted average exercise price.",
        "label": "Warrant exercisable, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "alxneuro_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents class of warrant or right weighted average exercise price of warrants or rights.",
        "label": "Warrant outstanding, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "alxneuro_ConversionOfSeriesAConvertibleStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents conversion of series a convertible stock.",
        "label": "Conversion of Series A convertible stock"
       }
      }
     },
     "localname": "ConversionOfSeriesAConvertibleStock",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alxneuro_ConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents convertible notes member.",
        "label": "Convertible Notes [Member]"
       }
      }
     },
     "localname": "ConvertibleNotesMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_ConvertiblePromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents convertible promissory note member.",
        "label": "Convertible Promissory Note [Member]"
       }
      }
     },
     "localname": "ConvertiblePromissoryNoteMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_DescriptionOfLicensesAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents description of licenses agreements.",
        "label": "Description of licenses agreements"
       }
      }
     },
     "localname": "DescriptionOfLicensesAgreements",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "alxneuro_DescriptionOfPurchaseAgreementTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents description of purchase agreement terms.",
        "label": "Description of purchase agreement terms"
       }
      }
     },
     "localname": "DescriptionOfPurchaseAgreementTerms",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "alxneuro_DigitalPowerLendingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents digital power lending member.",
        "label": "Digital Power Lending [Member]"
       }
      }
     },
     "localname": "DigitalPowerLendingMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative",
      "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_DisclosureNoteReceivableForCommonStockRelatedPartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Receivable For Common Stock Related Party"
       }
      }
     },
     "localname": "DisclosureNoteReceivableForCommonStockRelatedPartyAbstract",
     "nsuri": "http://alzamend.com/20220731",
     "xbrltype": "stringItemType"
    },
    "alxneuro_DisclosureWarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants"
       }
      }
     },
     "localname": "DisclosureWarrantsAbstract",
     "nsuri": "http://alzamend.com/20220731",
     "xbrltype": "stringItemType"
    },
    "alxneuro_EmployeesAndConsultantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents employees and consultants member.",
        "label": "Employees and Consultants [Member]"
       }
      }
     },
     "localname": "EmployeesAndConsultantsMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_ExercisePrice1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents exercise price1 member.",
        "label": "Exercise Price1 [Member]"
       }
      }
     },
     "localname": "ExercisePrice1Member",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_ExercisePrice2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents exercise price2 member.",
        "label": "Exercise Price 2 [Member]"
       }
      }
     },
     "localname": "ExercisePrice2Member",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_ExercisePrice3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents exercise price3 member.",
        "label": "Exercise Price 3 [Member]"
       }
      }
     },
     "localname": "ExercisePrice3Member",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_ExercisePrice4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents exercise price4 member.",
        "label": "Exercise Price 4 [Member]"
       }
      }
     },
     "localname": "ExercisePrice4Member",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_ExercisePriceFiftySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents exercise price fifty seven member.",
        "label": "Exercise Price Fifty Seven [Member]"
       }
      }
     },
     "localname": "ExercisePriceFiftySevenMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_ExercisePriceFiftySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents exercise price fifty six member.",
        "label": "Exercise Price Fifty Six [Member]"
       }
      }
     },
     "localname": "ExercisePriceFiftySixMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_FairValueOfWarrantsIssuedInConnectionWithIpo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents fair value of warrants issued in connection with ipo.",
        "label": "Fair value of warrants issued in connection with initial public offering"
       }
      }
     },
     "localname": "FairValueOfWarrantsIssuedInConnectionWithIpo",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alxneuro_FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents fair value of warrants issued in connection with march2021 securities purchase agreement related party.",
        "label": "Fair value of warrants issued in connection with March 2021 securities purchase agreement, related party"
       }
      }
     },
     "localname": "FairValueOfWarrantsIssuedInConnectionWithMarch2021SecuritiesPurchaseAgreementRelatedParty",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "alxneuro_FinalTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents final tranche member.",
        "label": "Final Tranche [Member]"
       }
      }
     },
     "localname": "FinalTrancheMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_IndApplicationFilingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents ind application filing member.",
        "label": "Ind Application Filing [Member]"
       }
      }
     },
     "localname": "IndApplicationFilingMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/OriginalAl001LicenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_InitialLicenseFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents initial license fees.",
        "label": "Initial license fees"
       }
      }
     },
     "localname": "InitialLicenseFees",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alxneuro_KeyEmployeesAndDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents key employees and director member.",
        "label": "Key Employees and Director [Member]"
       }
      }
     },
     "localname": "KeyEmployeesAndDirectorMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_LicenseEventsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents license events axis.",
        "label": "License Events [Axis]"
       }
      }
     },
     "localname": "LicenseEventsAxis",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/OriginalAl001LicenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "alxneuro_LicenseEventsDomain": {
     "auth_ref": [],
     "localname": "LicenseEventsDomain",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/OriginalAl001LicenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_LongTermDebtAverageAmountOfOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents long term debt average amount of outstanding.",
        "label": "Outstanding receivable amount"
       }
      }
     },
     "localname": "LongTermDebtAverageAmountOfOutstanding",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "alxneuro_MortgageNoteReceivableFromRelatedPartyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents mortgage note receivable from related party text block.",
        "label": "NOTE RECEIVABLE FOR COMMON STOCK, RELATED PARTY"
       }
      }
     },
     "localname": "MortgageNoteReceivableFromRelatedPartyTextBlock",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/NoteReceivableForCommonStockRelatedParty"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alxneuro_NoteReceivableForCommonStockRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://alzamend.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents note receivable for common stock related party.",
        "label": "Note receivable for common stock \u2013 related party"
       }
      }
     },
     "localname": "NoteReceivableForCommonStockRelatedParty",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alxneuro_NoteRecievableForCommonStockRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents note recievable for common stock related party member.",
        "label": "Note Recievable For Common Stock Related Party [Member]"
       }
      }
     },
     "localname": "NoteRecievableForCommonStockRelatedPartyMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_NumberOfSharesPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents number of shares purchase.",
        "label": "Number Of Shares Purchase",
        "verboseLabel": "Number of shares purchase"
       }
      }
     },
     "localname": "NumberOfSharesPurchase",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "alxneuro_NumberOfStockExcluded": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents number of stock excluded.",
        "label": "Number Of Stock Excluded"
       }
      }
     },
     "localname": "NumberOfStockExcluded",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "alxneuro_PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents percentage of royalty payments on net sales of product..",
        "label": "Percentage of royalty payments on net sales of product"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentsOnNetSalesOfProduct.",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "alxneuro_PerformanceContingentStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents performance contingent stock options member.",
        "label": "Performance Contingent Stock Options [Member]"
       }
      }
     },
     "localname": "PerformanceContingentStockOptionsMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_PreINDMeetingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents pre i n d meeting member.",
        "label": "Pre I N D Meeting [Member]"
       }
      }
     },
     "localname": "PreINDMeetingMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/OriginalAl001LicenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_PreferredStockSharesDesignated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents preferred stock shares designated.",
        "label": "Preferred stock shares designated"
       }
      }
     },
     "localname": "PreferredStockSharesDesignated",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/BalanceSheetsParenthetical",
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "alxneuro_PrepaidConsultingFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents prepaid consulting fees.",
        "label": "Prepaid consulting fees"
       }
      }
     },
     "localname": "PrepaidConsultingFees",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alxneuro_PrepaidInsurance1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents prepaid insurance1.",
        "label": "Purchase D&amp;O Insurance"
       }
      }
     },
     "localname": "PrepaidInsurance1",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alxneuro_ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://alzamend.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents proceeds from initial public offering net of underwriters discounts and commissions and issuance costs.",
        "label": "Proceeds from initial public offering, net of underwriters\u2019 discounts and commissions and issuance costs"
       }
      }
     },
     "localname": "ProceedsFromInitialPublicOfferingNetOfUnderwritersDiscountsAndCommissionsAndIssuanceCosts",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alxneuro_ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents schedule of estimated fair value of warrants granted table text block.",
        "label": "The estimated fair value of warrants granted during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions:"
       }
      }
     },
     "localname": "ScheduleOfEstimatedFairValueOfWarrantsGrantedTableTextBlock",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/WarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alxneuro_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents schedule of prepaid expenses and other current assets table text block.",
        "label": "Prepaid expenses and other current assets are as follows:"
       }
      }
     },
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alxneuro_ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents schedule of stock options granted to employees and consultants table text block.",
        "label": "The estimated fair value of stock options granted to employees and consultants during the three months ended July 31, 2021 were calculated using the Black-Scholes option-pricing model using the following assumptions:"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsGrantedToEmployeesAndConsultantsTableTextBlock",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alxneuro_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents securities purchase agreement member.",
        "label": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative",
      "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_SecuritiesPurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents securities purchase agreements member.",
        "label": "Securities Purchase Agreements [Member]"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementsMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangement by share based payment award number of shares available for grant options cancelled or forfeited.",
        "label": "Options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsCancelledOrForfeited",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangement by share based payment award number of shares available for grant options granted.",
        "label": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsGranted",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "alxneuro_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents share based compensation arrangement by share based payment award options exercised in period gross.",
        "label": "Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodGross",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "alxneuro_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents sharebased compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term1.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "alxneuro_SharesPurchasePrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents shares purchase price.",
        "label": "Shares purchase price"
       }
      }
     },
     "localname": "SharesPurchasePrice",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alxneuro_SharesPurchasePricePerShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents shares purchase price per shares.",
        "label": "Shares purchase price (in dollars per share)"
       }
      }
     },
     "localname": "SharesPurchasePricePerShares",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "alxneuro_SharesValueSurrenderForCancellation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents shares value surrender for cancellation.",
        "label": "Shares value surrender for cancellation"
       }
      }
     },
     "localname": "SharesValueSurrenderForCancellation",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alxneuro_SpartanCapitalSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents spartan capital securities member.",
        "label": "Spartan Capital Securities [Member]"
       }
      }
     },
     "localname": "SpartanCapitalSecuritiesMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_StockIncentivePlan2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents stock incentive plan2016 member.",
        "label": "Stock Incentive Plan2016 [Member]"
       }
      }
     },
     "localname": "StockIncentivePlan2016Member",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_StockIssuedDuringPeriodSharesNewIssues2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents stock issued during period shares new issues2.",
        "label": "Proceeds from sale of common stocks and warrants-related party (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues2",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "alxneuro_StockIssuedDuringPeriodSharesNewIssues3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents stock issued during period shares new issues3.",
        "label": "Proceeds from initial public offering, net of underwriters' discounts and commissions and issuance costs of $1.5 million (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues3",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "alxneuro_StockIssuedDuringPeriodSharesNewIssuesOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents stock issued during period shares new issues one.",
        "label": "Number of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssuesOne",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "alxneuro_StockIssuedDuringPeriodValueNewIssues2": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents stock issued during period value new issues2.",
        "label": "Proceeds from sale of common stocks and warrants-related party"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues2",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alxneuro_StockIssuedDuringPeriodValueNewIssues3": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents stock issued during period value new issues3.",
        "label": "Proceeds from initial public offering, net of underwriters' discounts and commissions and issuance costs of $1.5 million"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues3",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alxneuro_StockbasedCompensationToEmployeesAndConsultants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents stockbased compensation to employees and consultants.",
        "label": "Stock-based compensation to employees and consultants"
       }
      }
     },
     "localname": "StockbasedCompensationToEmployeesAndConsultants",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alxneuro_UnamortizedPrepaidExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents unamortized prepaid expense.",
        "label": "Unamortized prepaid expense"
       }
      }
     },
     "localname": "UnamortizedPrepaidExpense",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alxneuro_UnamortizedStockBasedCompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents unamortized stock based compensation member.",
        "label": "Unamortized Stock Based Compensation [Member]"
       }
      }
     },
     "localname": "UnamortizedStockBasedCompensationMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_UponCompletionOfFirstClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents upon completion of first clinical trial member.",
        "label": "Upon Completion of First Clinical Trial [Member]"
       }
      }
     },
     "localname": "UponCompletionOfFirstClinicalTrialMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/OriginalAl001LicenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_UponCompletionOfFirstPatientDosingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents upon completion of first patient dosing member.",
        "label": "Upon Completion of First Patient Dosing [Member]"
       }
      }
     },
     "localname": "UponCompletionOfFirstPatientDosingMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/OriginalAl001LicenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_UponFdaApprovalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents upon fda approval member.",
        "label": "Upon Fda Approval [Member]"
       }
      }
     },
     "localname": "UponFdaApprovalMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/OriginalAl001LicenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_UponFirstDosingOfPatientInClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents upon first dosing of patient in clinical trial member.",
        "label": "Upon First Dosing of Patient in Clinical Trial [Member]"
       }
      }
     },
     "localname": "UponFirstDosingOfPatientInClinicalTrialMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/OriginalAl001LicenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_UponFirstPatientTreatedInPhase3ClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents upon first patient treated in phase3 clinical trial member.",
        "label": "Upon First Patient Treated In Phase3 Clinical Trial [Member]"
       }
      }
     },
     "localname": "UponFirstPatientTreatedInPhase3ClinicalTrialMember",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/OriginalAl001LicenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alxneuro_WarrantsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents warrants disclosure text block.",
        "label": "WARRANTS"
       }
      }
     },
     "localname": "WarrantsDisclosureTextBlock",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/Warrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "alxneuro_WarrantsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents warrants policy text block.",
        "label": "Warrants Policy [Text Block]",
        "verboseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsPolicyTextBlock",
     "nsuri": "http://alzamend.com/20220731",
     "presentation": [
      "http://alzamend.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r366",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alzamend.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of chief executive officer.",
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.",
        "label": "Original AL001 License:"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alzamend.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r146",
      "r169",
      "r201",
      "r202",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r339",
      "r341",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alzamend.com/role/EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails",
      "http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails",
      "http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r146",
      "r169",
      "r201",
      "r202",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r339",
      "r341",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alzamend.com/role/EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails",
      "http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails",
      "http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details",
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r109",
      "r126",
      "r127",
      "r192",
      "r193",
      "r308",
      "r338",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://alzamend.com/role/OriginalAl001LicenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r109",
      "r126",
      "r127",
      "r192",
      "r193",
      "r308",
      "r338",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://alzamend.com/role/OriginalAl001LicenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r119",
      "r125",
      "r126",
      "r127",
      "r128",
      "r146",
      "r169",
      "r194",
      "r201",
      "r202",
      "r236",
      "r237",
      "r238",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r339",
      "r341",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alzamend.com/role/EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails",
      "http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails",
      "http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details",
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r119",
      "r125",
      "r126",
      "r127",
      "r128",
      "r146",
      "r169",
      "r194",
      "r201",
      "r202",
      "r236",
      "r237",
      "r238",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r339",
      "r341",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alzamend.com/role/EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails",
      "http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails",
      "http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details",
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r25",
      "r297"
     ],
     "calculation": {
      "http://alzamend.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r18",
      "r297"
     ],
     "calculation": {
      "http://alzamend.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r248",
      "r249",
      "r250",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Total",
        "verboseLabel": "Maximum potential expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/CompanysResultsOfOperationsIncludeExpensesRelatingToStock-basedCompensationForThreeMonthsEndedJuly312022And2021ThatWereComprisedAsFollowsDetails",
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r44",
      "r50",
      "r159",
      "r279"
     ],
     "calculation": {
      "http://alzamend.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Interest expense - debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails",
      "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative",
      "http://alzamend.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails",
      "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative",
      "http://alzamend.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative",
      "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative",
      "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r9",
      "r58",
      "r101",
      "r103",
      "r107",
      "r112",
      "r130",
      "r131",
      "r132",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r141",
      "r142",
      "r258",
      "r260",
      "r270",
      "r295",
      "r297",
      "r321",
      "r331"
     ],
     "calculation": {
      "http://alzamend.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r24",
      "r58",
      "r112",
      "r130",
      "r131",
      "r132",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r141",
      "r142",
      "r258",
      "r260",
      "r270",
      "r295",
      "r297"
     ],
     "calculation": {
      "http://alzamend.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "TOTAL CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r230",
      "r231",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails",
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r3",
      "r61",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/DescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r8",
      "r297",
      "r347",
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r8",
      "r52"
     ],
     "calculation": {
      "http://alzamend.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "periodEndLabel": "Cash at end of period",
        "periodStartLabel": "Cash at beginning of period"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheets",
      "http://alzamend.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r47",
      "r271"
     ],
     "calculation": {
      "http://alzamend.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r55",
      "r58",
      "r77",
      "r78",
      "r79",
      "r81",
      "r83",
      "r89",
      "r90",
      "r91",
      "r112",
      "r130",
      "r135",
      "r136",
      "r137",
      "r141",
      "r142",
      "r167",
      "r168",
      "r172",
      "r176",
      "r183",
      "r270",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheetsParenthetical",
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative",
      "http://alzamend.com/role/FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails",
      "http://alzamend.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Exercise price (in dollars per share)",
        "verboseLabel": "Exercse price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative",
      "http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details",
      "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Number warrant outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r29",
      "r325",
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r129",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r62",
      "r63",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheetsParenthetical",
      "http://alzamend.com/role/DescriptionOfBusinessDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16",
      "r297"
     ],
     "calculation": {
      "http://alzamend.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.0001 par value: 300,000,000 shares authorized; 95,481,790 \u00a0shares issued and outstanding as of July 31, 2022 and April 30, 2022"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Payment"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/OriginalAl001LicenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://alzamend.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r57",
      "r60",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r281",
      "r322",
      "r323",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r28",
      "r57",
      "r60",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative",
      "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r50",
      "r116"
     ],
     "calculation": {
      "http://alzamend.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r205",
      "r206",
      "r243",
      "r244",
      "r245",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/Stock-basedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r25",
      "r59",
      "r133",
      "r135",
      "r136",
      "r140",
      "r141",
      "r142",
      "r290"
     ],
     "calculation": {
      "http://alzamend.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Related party payable"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r39",
      "r67",
      "r68",
      "r69",
      "r70",
      "r71",
      "r75",
      "r77",
      "r81",
      "r82",
      "r83",
      "r86",
      "r87",
      "r264",
      "r265",
      "r327",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic and diluted net loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/CompanysResultsOfOperationsIncludeExpensesRelatingToStock-basedCompensationForThreeMonthsEndedJuly312022And2021ThatWereComprisedAsFollowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r34",
      "r35",
      "r36",
      "r62",
      "r63",
      "r64",
      "r66",
      "r72",
      "r74",
      "r88",
      "r113",
      "r183",
      "r190",
      "r248",
      "r249",
      "r250",
      "r255",
      "r256",
      "r263",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r286",
      "r342",
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative",
      "http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails",
      "http://alzamend.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://alzamend.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/CompanysResultsOfOperationsIncludeExpensesRelatingToStock-basedCompensationForThreeMonthsEndedJuly312022And2021ThatWereComprisedAsFollowsDetails",
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r118",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/CompanysResultsOfOperationsIncludeExpensesRelatingToStock-basedCompensationForThreeMonthsEndedJuly312022And2021ThatWereComprisedAsFollowsDetails",
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/CompanysResultsOfOperationsIncludeExpensesRelatingToStock-basedCompensationForThreeMonthsEndedJuly312022And2021ThatWereComprisedAsFollowsDetails",
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://alzamend.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://alzamend.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r37",
      "r100",
      "r278",
      "r280",
      "r328"
     ],
     "calculation": {
      "http://alzamend.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r26",
      "r58",
      "r104",
      "r112",
      "r130",
      "r131",
      "r132",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r141",
      "r142",
      "r259",
      "r260",
      "r261",
      "r270",
      "r295",
      "r296"
     ],
     "calculation": {
      "http://alzamend.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r58",
      "r112",
      "r270",
      "r297",
      "r324",
      "r333"
     ],
     "calculation": {
      "http://alzamend.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r27",
      "r58",
      "r112",
      "r130",
      "r131",
      "r132",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r141",
      "r142",
      "r259",
      "r260",
      "r261",
      "r270",
      "r295",
      "r296",
      "r297"
     ],
     "calculation": {
      "http://alzamend.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "TOTAL CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the nature of achievements or target goals that are to be reached by specified dates to maintain the arrangement or extend it, generally without adjustment of the present financial terms of the arrangement.",
        "label": "Description of milestones"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentMilestones",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns.",
        "label": "Measurement Input, Option Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputOptionVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://alzamend.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r47",
      "r48",
      "r51"
     ],
     "calculation": {
      "http://alzamend.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r32",
      "r33",
      "r36",
      "r38",
      "r51",
      "r58",
      "r65",
      "r67",
      "r68",
      "r69",
      "r70",
      "r73",
      "r74",
      "r80",
      "r101",
      "r102",
      "r105",
      "r106",
      "r108",
      "r112",
      "r130",
      "r131",
      "r132",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r141",
      "r142",
      "r265",
      "r270",
      "r326",
      "r336"
     ],
     "calculation": {
      "http://alzamend.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://alzamend.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "NET LOSS",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative",
      "http://alzamend.com/role/StatementsOfCashFlows",
      "http://alzamend.com/role/StatementsOfOperations",
      "http://alzamend.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://alzamend.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER EXPENSE, NET"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r101",
      "r102",
      "r105",
      "r106",
      "r108"
     ],
     "calculation": {
      "http://alzamend.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the nature and terms of commitment.",
        "label": "Due Date"
       }
      }
     },
     "localname": "OtherCommitmentsDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/OriginalAl001LicenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "PREPAID EXPENSES AND OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r23",
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsAreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivables": {
     "auth_ref": [
      "r17"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from parties in nontrade transactions, classified as other.",
        "label": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsAreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r230",
      "r231",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r230",
      "r231",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value (in dollars per share)",
        "verboseLabel": "Preferred stock, par or stated value per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheetsParenthetical",
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheetsParenthetical",
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r15",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15",
      "r297"
     ],
     "calculation": {
      "http://alzamend.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Convertible Preferred stock, $0.0001 par value: 10,000,000 shares authorized; \u00a0Series A Convertible Preferred Stock, $0.0001 stated value per share, 1,360,000 shares designated; \u00a0nil issued and outstanding as of July 31, 2022 and April 30, 2022"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsAreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://alzamend.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r5",
      "r114",
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsAreAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://alzamend.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from the issuance of common stock and warrants - related party, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from sale of equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Proceeds from related party"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r45",
      "r247"
     ],
     "calculation": {
      "http://alzamend.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Proceeds from stock option exercise"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductLiabilityContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Liability Contingency [Line Items]"
       }
      }
     },
     "localname": "ProductLiabilityContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://alzamend.com/role/OriginalAl001LicenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductLiabilityContingencyTable": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information and financial data about the reasonably possible loss or the recognized and additional reasonably possible loss from product liability related to an individual product.",
        "label": "Product Liability Contingency [Table]"
       }
      }
     },
     "localname": "ProductLiabilityContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://alzamend.com/role/OriginalAl001LicenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r117",
      "r297",
      "r329",
      "r334"
     ],
     "calculation": {
      "http://alzamend.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r117",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r195",
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative",
      "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative",
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r195",
      "r289",
      "r290",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": {
     "auth_ref": [
      "r13",
      "r282",
      "r283",
      "r284",
      "r285",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.",
        "label": "Related Party Transaction, Description of Transaction",
        "verboseLabel": "Description of related party transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDescriptionOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r195",
      "r289",
      "r292",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative",
      "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative",
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r287",
      "r288",
      "r290",
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "OTHER RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/OtherRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r254",
      "r307",
      "r354"
     ],
     "calculation": {
      "http://alzamend.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/CompanysResultsOfOperationsIncludeExpensesRelatingToStock-basedCompensationForThreeMonthsEndedJuly312022And2021ThatWereComprisedAsFollowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r190",
      "r297",
      "r332",
      "r345",
      "r346"
     ],
     "calculation": {
      "http://alzamend.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheets",
      "http://alzamend.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r62",
      "r63",
      "r64",
      "r66",
      "r72",
      "r74",
      "r113",
      "r248",
      "r249",
      "r250",
      "r255",
      "r256",
      "r263",
      "r342",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "The following sets forth the number of shares of Common Stock underlying outstanding convertible preferred stock, options, warrants, and convertible notes that have been excluded from the computation of loss per common share:"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in common stock outstanding.",
        "label": "The following table summarizes information about Common Stock warrants outstanding and exercisable at July 31, 2022:"
       }
      }
     },
     "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/WarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "The Company\u2019s results of operations include expenses relating to stock-based compensation for three months ended July 31, 2022 and 2021, that were comprised as follows:"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative",
      "http://alzamend.com/role/PrepaidExpensesAndOtherCurrentAssetsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r241",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/CompanysResultsOfOperationsIncludeExpensesRelatingToStock-basedCompensationForThreeMonthsEndedJuly312022And2021ThatWereComprisedAsFollowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r203",
      "r204",
      "r206",
      "r207",
      "r208",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r230",
      "r231",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails",
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r210",
      "r226",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "A summary of stock option activity for the three months ended July 31, 2022 is presented below:"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r55",
      "r89",
      "r90",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r172",
      "r176",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r14",
      "r15",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheetsParenthetical",
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative",
      "http://alzamend.com/role/FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails",
      "http://alzamend.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://alzamend.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation to employees and consultants"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails",
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Number of warrants granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Additional number of shares available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Number of shares authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Balance at end (in shares)",
        "periodStartLabel": "Balance at begining (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Options exercisable at end"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Options exercisable at end"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative",
      "http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Balance at end",
        "periodStartLabel": "Balance at begining"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance at end (in shares)",
        "periodStartLabel": "Balance at begining (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in the weighted average exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price",
        "verboseLabel": "Options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance at end",
        "periodStartLabel": "Balance at begining"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "verboseLabel": "Options vested and expected to vest at end"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative",
      "http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Options vested and expected to vest at end"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of award under share-based payment arrangement.",
        "label": "Terms of warrent"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r230",
      "r231",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails",
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercise price (in dollars per share)",
        "verboseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative",
      "http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r209",
      "r233",
      "r234",
      "r235",
      "r236",
      "r239",
      "r251",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected Term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EstimatedFairValueOfStockOptionsGrantedToEmployeesAndConsultantsDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Options exercisable at end"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Options exercisable at end"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Balance at end (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Weighted-average period vested and expected to vest at end",
        "verboseLabel": "Options vested and expected to vest at end"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/Stock-basedCompensationDetailsNarrative",
      "http://alzamend.com/role/SummaryOfStockOptionActivityForThreeMonthsEndedJuly312022IsPresentedBelowDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares issued price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r54",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r55",
      "r58",
      "r77",
      "r78",
      "r79",
      "r81",
      "r83",
      "r89",
      "r90",
      "r91",
      "r112",
      "r130",
      "r135",
      "r136",
      "r137",
      "r141",
      "r142",
      "r167",
      "r168",
      "r172",
      "r176",
      "r183",
      "r270",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheetsParenthetical",
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative",
      "http://alzamend.com/role/FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails",
      "http://alzamend.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r31",
      "r34",
      "r35",
      "r36",
      "r62",
      "r63",
      "r64",
      "r66",
      "r72",
      "r74",
      "r88",
      "r113",
      "r183",
      "r190",
      "r248",
      "r249",
      "r250",
      "r255",
      "r256",
      "r263",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r286",
      "r342",
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative",
      "http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails",
      "http://alzamend.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheetsParenthetical",
      "http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails",
      "http://alzamend.com/role/FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails",
      "http://alzamend.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r88",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheetsParenthetical",
      "http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails",
      "http://alzamend.com/role/FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails",
      "http://alzamend.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r30",
      "r154",
      "r183",
      "r184",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Conversion of Series A convertible stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r183",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Number of shares purchase (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Description of related party transaction"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r183",
      "r190",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Proceeds from stock option exercise (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r183",
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Number of shares purchase"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Number of shares sold"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r31",
      "r183",
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Proceeds from stock option exercise"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails",
      "http://alzamend.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r20",
      "r21",
      "r58",
      "r111",
      "r112",
      "r270",
      "r297"
     ],
     "calculation": {
      "http://alzamend.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheets",
      "http://alzamend.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r56",
      "r168",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r190",
      "r191",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "EQUITY TRANSACTIONS"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EquityTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
        "label": "LIQUIDITY AND GOING CONCERN"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/LiquidityAndGoingConcern"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative",
      "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative",
      "http://alzamend.com/role/OtherRelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Accounting Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r230",
      "r231",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r230",
      "r231",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative",
      "http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails",
      "http://alzamend.com/role/FollowingSetsForthNumberOfSharesOfCommonStockUnderlyingOutstandingConvertiblePreferredStockOptionsWarrantsAndConvertibleNotesThatHaveBeenExcludedFromComputationOfLossPerCommonShareDetails",
      "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants measurement input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrant terms",
        "terseLabel": "Expected term (in years)",
        "verboseLabel": "Weighted average remaining contractual life (years)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/EquityTransactionsDetailsNarrative",
      "http://alzamend.com/role/EstimatedFairValueOfWarrantsGrantedDuringThreeMonthsEndedJuly312021WereCalculatedUsingBlack-scholesOption-pricingModelUsingFollowingAssumptionsDetails",
      "http://alzamend.com/role/FollowingTableSummarizesInformationAboutCommonStockWarrantsOutstandingAndExercisableAtJuly312022Details",
      "http://alzamend.com/role/NoteReceivableForCommonStockRelatedPartyDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r76",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Basic and diluted weighted average common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alzamend.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=51888271"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123395306&loc=d3e36975-112693"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918703-209980"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919370-209981"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128295416&loc=SL77919784-209982"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r355": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r356": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r357": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r358": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r359": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r360": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r361": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r362": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r363": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r364": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r365": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r366": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r367": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r368": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r369": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r370": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r371": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r372": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "303",
   "Subparagraph": "(5)"
  },
  "r373": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r374": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r375": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r376": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>59
<FILENAME>0001214659-22-011092-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001214659-22-011092-xbrl.zip
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M5@66T1VUTW%#[$EEV(35][7M3M(FE?.\*BPG;GEP%UQ*5ZPPM;TU[[V%K"J
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MBE&AZ=CM.'=,>AL3W%9<90,L<!XFZ13+5/AB*Y,/)\&](?#Q?U!+ P04
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M!:[ 5TBEUB,[]E.RJ<0'%>1_<C:$;_X+4$L#!!0    ( -F#+56U:^=I_"(
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MZ'3P^@DYKQ*<J+ #Z($YN#/(_V.@MU^UO#\P8KY#L#TF?SP>0JR[F%+:;16
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M)/.9F-SKY)UO BZ=_?(U0ZHF+O^ :;'\H?7@AI:W<T2+@_+<CJKN@LC-F?T
MO)@5YF1KZ"98O&,=^WA%MWP;%)V?D\:YMJJ* AUTL"KFHFXON$#LU[ZUAD'H
M_H%5*'-FX(B?V:>3,/"YJ7N'(#<+XE?A\;GZ A2&&/9T*-N^DS"P.9%PZ;9:
MBV>S7EO!<WPM,W))FWC-?73#YPL8+#'.X K;U14:D5'_OO&>3P<$[3'"/")
M7-5GP(,_N.Z&W(,>IH&B#]-"^K1N?E0#W[#BCY.2^[2B?4A(,-:4!H.R9A J
MC-/!KP8AQ' 1*:@?D6+<$EI:<4J,4.BNB;&ZL-R 1HLR0DS\^$LX6C]X\!F
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M4JA[<RXX"A?J(B][.[],<0[,-8S^PG6C=DDQ-\8MZD\JJZVL<J2Z_LS(Y\3
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M8U,S@;ZU^TV:=9%3I_1 :D(A?%S@82SI%QQ1!:^69_'F54!)B9L%L#<!%BM
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M39,HJGM0U%;QXTI,"1<^DES I4XU* [#0DMO3&UX:?J:!3X0NGBW.<.C@2
M#J585&:+TTG5NQ6<"0)+T5[[T;:O5UC6_)2L2J@L,Z&O2MA7)>RK$K[4JH1L
M6"7J]B4\*:I T7QAPC2#3-!J,9D(V*_OX>.Q ]QHUN)_["8K_N'F$MQ;WL@/
M76:Y0=PJUZ@+!K&(;J:TVQ%V1 IS=X^;9%NT;*HX$H,,"INU/'5+5$OK4%KJ
MBB+4BPN)B&G2J/7%FZ69N>!HAD*F%!M*OZZWC&';#UQ(RIA/,$ODGQH2N8DG
MY1</WDKDL^\WO1FT'>^7U>)"0IGNQ8'"TI 23VES/,'%W;JP^Y#CA 796U6
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MQ_XC0$56)%^E*M.C&SAPB6?*/N6B8%6=B7]/_G.+H<6_^7]02P,$%     @
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MPWQ#YQEDQA+GF8G'$NLX\5HJ^$+/)5* PS0#E&VN<5&TE87BQ BB91+K79=
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MTGM^5PGQ>@1&G-?*HHF/C=6MCF@]"]48W QUG?-O(.!.J+351EOUXA!88>#
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M)F-:0H"8(D8F84@EC+BTFPO:/'M$%611AR=, :,6MWQ=6PFZ=6M;* N(,TJ
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ML<H3 _ -HBCDX3!%#[)#E=']_>@.0-S96/X@A<@\=KQ(%UGJU6R.CZ:%J ^
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M_>AMPA<P9J0JG[T,7R7+99C3>=^G,,)9GL18%E>:J=ID;Y_"U"EKH@?&I_8
MJV'ELI)W3L-9F@1K/[\-O2>6]XT>QB7#!8Y]Y41>KV:3?J:%J%-/IP.&=H9
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MO/7GX53'XLUTX35L/^#F-RI+H[2!"ZNM9^\<M_;?\*9.ZNLPQ7Z>I(HV5FK
M:UD3N(;M^0O>M+IM4%ASW8J?8X\^^!K^6KP;W!GC5*>'S'3AM6P_X*;GA+9&
MBXXJ&*H=MW:YMCI+HM#7O)(LD877FFJ@?=^;7#$K$!Y:J^6PH9EK5*.G6!1>
M4REQ#LC&0U/P.!\(:]ZD^<:RSFDVI>&UE@[J ,?8>AC:]9'F(A(GX97TC)U0
M$EY;J6#V/-[L5S;<'K9[H'D)O?C*6]$\D]NLP:ISK$H5>*UFA-=T>8#;0CXW
M5L^+[/HX,EV0>-(OGCQ)%D]JMRM:FT#W>.F%,?D[G7JEGI^OO8A>T1#?4'"
M R#EG%5"GV4NPU4NU2)7[>9,=R\O+;&RZ74!EEW$<7>G@TU%.BWSF$B6CL04
M[V<#(#T'%:#/<7\!M?)$OJ@&_YWER2H1<J&/ 7A$&(#^4 \<AZO$-@O6V>G"
M\U8_C[(,Y]D5R^K;R/LH%/CY_.?H*;+6C@W<1?NI<;5;B$N=H$+.:27+:Q=<
MM6KJTU$UWH;>4QBQB%-!V*X4H.I5@&M7=4W4-7]K4#0U#K.J3>K84=6R<.0Y
MB0*<9N-_KL-\(ZKAKM3/WX"I: 6X=GW71?\5<6$TRO,T?%KG[.P#B91F'@RJ
MDT#0K'5T.C [A1JJHJ>P ):+.VJDJR3+*?YBM5#HE-HR@!I!"JU=Z4R05W<A
MZJC"IRLRJZ4+=I.8S&OP;>NTCD(,4+6KT+5KOI)%7!A]2<7_X*CZ)W&.26WD
M@F5_B0B@:I<A:U=Y*5=RW5%=WR5QTB2*HM:EPH#J7X^QW1)UC8K_A9*K+L /
M=$HR_TB%?KX TPQR;)T@B4F>H)JLRTKOG%V0UGQ'$E OT  4ML$IDT?%&C6J
M+6&?(-)'?"][=NRL2.=,,0%YC?G_G<3%-MTUGF,R8RQ##!)L3/-GG,H7(H99
M M3 .Q:@.QIQ,^C+TN ?Z,I=8;-L=A:;,7/(Z<K('<ZO"!MG:?(2!CBXW'QF
M)X&K*&;DY^&+=/YNK@VHO0> [HQS.$?4!BJ-T&V?+S_S8\M_0-L8<&O+4?L2
M@#[&049?YZL?_:Q.?8N:5:L$J#7-L;8;L=3D+PXR750HHTH;5K>DK]_$_M!N
M*= &U) #0/?LEI4I]]V2HJ3_0Q=#7KR(;O[<DQE,&OHYB3/(#V2P:?ZA)LFO
M:;2'K?&;'ZUIR$?^\4S#C7LOQ^/Y'/O"Q6Z[" #QS%'!.RLTQ/ )9VO-_@G:
M?AIQ$1HHM/[8U."8D"#N.$$5,E1"0Q0;XN".^:RO^_F9,<1VTY?RB"N@GZ@*
M8CK_XRQ,J!^BU ?]*GE ?=T(9C<N !FI'^IFJ_FD?/=O >BUUHJH6ABH?[*^
M.D#C%>$" OWP";JK;O[RCZ-1X^8O^_ZQL;-[=H^7<J^TE'WD/?!16[8#$+'X
M9F.EL:3G\1/0--N-Y4^_3[(:E=@:A4LTJ(!3+00@!NCXN3V)R40BSD*?'6 \
M,)N;'WN?_)64T1ICJ^\C!N!(&?J1GZ*5)?4XX&< S58.6;I#\O%C<4HY+I8B
MZ%_(MZ%2,>M5C7L/!O;W^6-RJ <H]1!*9\,Y_3Y#@R*+U9H0HJS\0SA>P6?>
MD>-5E>Z0CK?VW2U3CY2(M:!&O,CN<%;6'] [(O=^ZL%:/*S:#7F?+OP'G-':
MYZ>"Z1[18T+_5*N5T6*1XH67X\//_@:#>4<]9O<Z.&1OX>BJL^%L4S%/V)];
M7:E"^4XFF0,26EO^]#OJ!'U+?$C*U[" '@1VR'T@KVZC1!0.84#CO*/2N^-_
MA0W5P"&*[OC[0G-\/33E6U][G\R6%=(:@6$$(_<XH@^MSKPTWSR2 F4>2\MP
MC3,_#1GNZ;SV=Q'S>IH 1*>AR-L<*>P@9@C5-$Y0S18]\%#[S=6IM>;!CQFI
M3_K KO#0FE@4P'JM*<+.R5I^\F1:G3PI-02-4?_3+?D7^7/Y)_*_J(<A?_G_
M4$L#!!0    ( -F#+56\9>.2>34  /AH P 9    86QX;F5U<F\M,C R,C W
M,S%?<')E+GAM;.U];7/C.)+F]XO8_\"KC=B8BVAWE<O5KS-S&[(EUVC'EC26
MJGMGOW30)"3QFB(U?/%+__H#0%*B2 )(4B03<FDC=MIE V#FDXD$D)E(_.4_
M7S:N\42"T/&]O[Z[_/;#.X-XEF\[WNJO[[[,+P;SF_'XG1%&IF>;KN^1O[[S
M_'?_^7__[7\9]/_^\K\O+HQ;A[CVS\;0MR[&WM+_LS$Q-^1GXS/Q2&!&?O!G
MXQ?3C=EO_%O')8%QXV^V+HD(_4/RX9^-[[Z]_,XR+BX X_Y"/-L/OCR,=^.N
MHV@;_OS^_?/S\[>>_V0^^\'OX;>6OX$-.(_,* YWHWUX^9#^7]+]+Z[C_?XS
M^Y]',R0&Q<L+?WX)G;^^8]]-/_M\]:T?K-Y__/#A\OU_W]_-K379F!>.QW"S
MR+NL%QNEJM_E3S_]])[_-6M::OGR&+C9-Z[>9^3L1J9_=23M<Y2$SL\A)^_.
MM\R(BUWY&4/8@OWK(FMVP7YU<?GQXNKRVY?0?I>!SQ$,?)<\D*7!_DNEM_NJ
MZ?Y!Q>#93&#OV1_?W_A4(2FEO-LZ(,N_OC/=%X_$@4^_\/'CAQ^2\?_]H&'T
MNJ7*&3I,M]X9[QM^^]IT&4[S-2%1"*&ALD,'M,S,@'C1FD2.9;JU":OLW0Z5
M;/H0^JLHG"ZG6S;EJ4Z!H)/W;)^Z>>1;OZ]]UZ969_2OV(E>ZU(I'J$/:FNK
M0(/AVN?CQ@S7MZ[_7%LE2AW;H6U(0BMPMDS7ILOK.'0\$H)HDW9LA[8[ATK&
MIK(9>/9GGZ[!-SZ=PH$'(4_5MR7).BO/65*-\:*!9?FQ%]$OS7S7L1P"DS!D
M@'9HG?@1;6D1Y\E\=,FM']"-Q\;W^$QX("[5-)O. 9@5J#M6.QS, K(U'7OT
MLB5>2$(JV2F=L,%-'+"I.PA#X")59YRV+  %YH)M"FRVW:.?Y=8=9@.D7=NA
M[U<S"*@*@M KMFV' BZ!O.HLZ$="TP(OGZ !VJ&5*;L3<;M,=8<:%C9IZ3D!
M..<!W=NA,UG8Z@(I[M727(@?0_*OF+(_>B) G1/UZ<&*MV;-N['JTD\NF'4^
MGO+#8?JSY7#RZX_6J5VO@3MD@'9M/)RXZAZ=VU X@>!!.MPK#TED.FXX85A%
MSA-IO'<6#=3M7KH)^77':H>#6]^EQQ_ZM3F=S'3+&:TG\>:1!/0PMZ9G-W9$
MVF]"OWCT9.>^TM;3..+NNH3,)Q)$#M4,:C"6A!H'F[>><E&$F;XGNI0U97O=
M<+$VH[^93^2:$&_T8KFQ3>S;P-^P21M'9B+).S\,9R3;"S.B4D0@H+X!]GI8
MT9JH:Z,!^SUS-6'KV+'[6\<' 1F$B7Z'-6;$D4/WQU\3Z1TS;EO[\,W&#%Y3
M7UAB(P9TP_]$#3O5I@6EGMS3)74=CJBUL?\K=E^O+AD/XY 2'U(JB7U-*/ U
M1-K5-ULZ+X61LV'SYM9T A[_." T_,S,)[$7_HA^QW\E)#6E8>Q&S+ .XX!:
M%B$3E[^2@-R8KA7SR?F%+ONK:]>D^[_06M/OA\EG+K8!M4S>ZMZWB<L;[98&
MJA;Q)J&E!N@GS%9K>\VMZ;V&#X2Q=.!>'WM\L<NF(;>;C%E?L#&7*BF%C>'!
M%E..">T7.'2 )L9/5YH[/3<U6MWK#=7R7I0?,Q*KYOQ!0A9(#3:<@,&C'T>Y
M)3G;?>4V;!3[T0L)+"=DHPRBO52:[!O[(:4[2YM1E9JC$S*F^E#>@R^VR1QM
M-&!+O 3.RO%,=^!^^'!YYUC,9-80-Z![Y_Z0)H@W&*XKGW,3\N&CR*C>)EM&
M;@/OZ"\.NI"7B+!YF0W$J(=F841.Q!JGB3&7Q@7+HHD9VO3'I&5*2$:*ZUL'
M7W=9MHE?2.O(,G=X3DE(K&]7_M-[FSCO&3;L!PX2!XC^XS?^H<%C& 44HVPD
MUWPD+A__-]JFT.1]#U1E2"SHB-5$';8HTI07VB"P##^P24"QSL8R ^M 5.4D
MG+3%^RV/Z%]8:\?=27D9^!L1.BD2OH#0/%#T$_V@.6!:R&BX=<U5-9R%)D \
M+S$ K>0&"]&<$U8![$%+(+X?4?&MX*UGF+.Y\T!6#J.7D;)+9Y';!4$7(/!7
MF)9"RBV2! :>%YON ]GZ@0+XPY9 O#]AXEW%&Q+,_XCIQI8YY2%(EQH#P?X.
M$VP!ATAX\\VAP_"! %YN#43\>]2-AX!'),CG:^*ZJ6,* GI5>R#L/V#"+N93
M ^!Y LR0+BUP['-=@/#_J O\)6Z1)# C@>/;=$D/ -B7&@-1_PD3=0&'J'B/
M/!N*]JXI^/R##W:!/22H;YW0,MV$HEOZNU .=T5S*.0H9TXEFZBP_Y.8 1CT
M7&,HY"C'4 6+/0.>AM3WQ$BMBK@U%'*4 ZB*R9XQ'WD1B^@[+DF2F*JQ+K>"
M8HQRZ!0QA8)MYFGP(G9M4X9OL2448Y2SIHPY%)QO*#^!Z8X]F[S\G;S*@"XU
MA2*-<L:4LH<"]2QP6'+0W+'41J/<%@HVRLE2SB *V@OS96Q3KGAF) -)#;JP
M"Q1[E&,EB%T4$8P]RP^V?LY=?,.R4X/7&]^6FG1%1Z@X4,Z;-5A'$<K MBE<
M8?J?.\<CES)15#8'QXCP!"!A4Q/8/]:#_2,<=I1SJ))-36"_J@?[%1QVE+.H
MDDU,V&_HC]-@X3\+(M#"QE#(4<ZB"A8Q ><KS328!?Z3D]1_4:%>Z@&%'O&(
M*F<65>&311ZB[5E+*-Z(Q]5JYC!QGOEA9+K_XVQ5.\GJ]E#,$0^N,D;[=C F
M<F=."U$J4:$)%%^4LVHE.WU#RB0<$%.LOH<MH("B'$"KF.D9SSN?Q3[6OB?U
MQY9;07%%.4F*F.K;\+)$XE X]7-_!F>PH9C5(AL]P_AKX$24 I:X'GNICT80
M%1,TA<*+<OR3LM<SU'-^]YG="+BG.\3 V=<[.\2YJAT49)3#GIBQGA&>\9MT
M&T*WW3R/B]TT"*;+I<CRRMI#$4<YZZD9Q45^'(8Q">KB7]$+*@648Q^4Z;[M
M#+%B:O9>+S\^+MB-&8&5*;6"8HURY!,QU3.V$W\1F.SFYOQU\^B[XNLAE0VA
M"*,<\"2L]0SR 1W5\!::0(%%.=E5LH-D$T8OUMKT5D2<O5#=$@HPRDE/QAR:
M[5V!;.^JINU%.?&)F$+"-LD-9T68'EUG=5"6LQKFR@[@>S:8B$M8[?O^'K_R
MDZMN<$M_J(9=T!0*.,X521E[?4,=VTY$[(2D6\<S/8L>J?9%J06H*WM!!8!S
MAQ+(-(I[_U?BNG_W_&=O3LS0]XB=;/5E'GYA%Z@4$&.("G911/"+[\84I8 G
M@@:".2!H"H4<,78H8 \G]S)):MZM/<G3)#+$13V@P",&$>7,(N6G1831[#R1
MH1F9*84R_$4]H/@C!A3ES*+ESP<W=.%9^?*8>:$A%&W$5-A*UE! GF],URV^
M7U$%<J$A%&3$G-=*UE! 'FU(L*)&[7/@/T?K]&ZG#&Q!!RCHB)FM4E9QP'_9
MWR-/[K])D:]H#:Y.@ B[D$FLLAN[4L-S_EI<($!=UAZ*.^K%2C&C/2.?5IG;
M[Y\X,6-Z;I,E/:A[0:6 <ER%,HVSMN9N\DN7UH-V4+P1#Z95C.'<F8H?7<>Z
M=7U3NB\_: ;%%_$46L$6"KS7IO=[$&\CZW46^!8A+'P2[F8;X$ $'  J$L3S
M:2TH<-P%^PJWZ9,)^_JV4J>!M!]4-)B7. &,(^V"POU%+V)?OSZP9RE8FL*"
MO$37]$._RS=%@.Y0^:!6% +#4"&FO[PO\75'?]%9I=/J)UP/*IY^-"Z,G4><
MESREXWLAL8VTLY'T-O[TQ3,3?_K_.;XBZM(,'[F,XO!B99K;1/6(&X79;_8Z
MF/[BMQV5T^7.ES_SDV."I'1JVAW6^_CYU(2S]/T+)0_%=ECU5FM!>CB1!)QT
M8-B:"R)[N ,HCU)SM+*M<G"K)"!@%5T0[(5<5NR:_H?5CWXR769Y!]&-&03L
MJ21>K5TL&&!WM/JO(!GX35C21'Z'3^)D+^(<\"N6'J@S6@G9!K*K@0:ZY( R
M:B:-]H^A#:2APGV;/;AVEW MI)"3%_F1Z?*6>'/-WY* 'K1=]BJ:9S/SL&7+
M\H1()YFL%UH-VT:S2\V_)M-*-9\02]G6WSN\@:ESYYB/CDLWK/R=+'[J7OLN
M13A,7JU0;P'A(Z!5RSU^MUX7)O39EB,8O)F7]4$KM=M4 $+YZ;KA3R-/X<Q\
M9:]6J?<?@O9HY7GA4/L@1C21RS F"S_WW-.>+[%L9'WP2OHV%9 : 70AE7FJ
M8^8PB_XV%8J8X[>Q&P')#[-T< N">P,2DSS-)G%.R3KA529N9ZL!0 3=7#;9
MY[>PL^^@TG$[,CN!#?TL,PR<5H7WM[(Q7JED.,HEKZ&(9W1YY,+4*E=\J25>
M*>6FDA!QBRZ&@6WS\SL]R9N./?9NS*T3598 R4X;H@YX)9>;"D7!^[&RJ7[,
M-/OM;Q,_(@_$(LX3.[7=^D%.1_*OXU:((AL#/@1>3>;:PJG/G"93Z8$]2NL1
M>V0&'DN'HN?R>),\ZSPD2U:*1CRK('WQ"CDWG6!P1-"%5^:MSDX.L\AS4^&(
M.3[AXY1J']O<#8]94+IU'ZX4FU;%CYJO-N.HKDGD6+EE_2!Y[:I!\IKQIX.!
MS\EL77&V8"L_@(>TG6J"EM1;MRA9D:&\*QM9%'1>$G:/1.*5JFJKF4@.%$H$
M?H[\_*J-+( ;UPS#Z9*;[<&+ Y%#N<LIBJ/,12[[$<EWD2-IZ&_H'E?BO:AH
MJYD81*I5]&%4<++/#T::'B1@VYE#1]<]$5SPRQB7=<+."A3K5G&"J%E'/U4=
M$D=W3=. :YW-G6 S$O ;*E _K+B_+FGLI552ZI!5X:&9^)+;1(,X6ON!\\=^
M1ZX26[D?=GI[0WF) .C845A%Q)"$SLICFB-Q#ZHZ8B>OJ\4 Y43C^<*+5-6<
M*UD?[+7HJ'ERR+B6LI%?"97PUN1.:&>QVZ.DU/7ET"-#@_6W#*#.V,GI8)'5
M@$(GL<&W"M).V*GL3<34U2:A??&H5B9A!VWRT&N+1;,UJ6:- A%735:C#@.]
M384#6XKZ#BCL:[U.E],M"0IOM1P$$SX)@PG[40Q_:>S'P;\3SVH1;,B./G7D
M0-@!:PZ%/%$PO1H)N ,O[H'L1E"(HC1_Y(RC6[<'"A[]/+MS/"1/Q/7YE;J4
M7%DJA+0;MN] "7LQ!0(  KJH/A./6B27$CFP-X[G,)98[5.EL)0=L7T,-<4%
M! )=8$6VX-8.WZM04R0B5D\X2R5=_[U58O'O_,I:LVGKRL;8/H=Z2Y6$WQ.6
MXL3W_$/&LO(,RBT(H"NVBZ*>A,%8H%M.7MF;A.I]2*DAMC>BGD0$?-:?;S\E
M\\TC*^9ZTG/&-9AI^&Z,EF;86["D)(*LA(5FV)Z.FO*KXO&$99;E=&=NZ&LS
M="RQ[ 3-L2_;UY.AE&?TE>U7XJS6[+&B)VHF5NDSV-/ET'%C^ML:#L;: Z%?
MR:\GQH9 :>:,E"1P'S@EOP,Z)?/C_8>Y]<,_&\FP^#[*7$IMLYNWH.[G9.>C
MDIT;7$ Y9SMW*I-SMO/IB>.<[=RU&([/=O[^ZTMW[CX5$RB64\AZWO&4+(/L
M91#?8]LLH"6K[J;9- )9LVI.<C$?I+/K(5DJHR9HKIE 9,I6/,=6,X1NWG(I
M(2JC5M$4.]381!)"CM&-F* XADHNBF[8L<<F,@(AT4^Q$(<HBF$(Q5.HJ@$>
M"#O06$M@39G49,H5RV6HYIJH/7;HL,DDD_..+IJ>RH/@WWCJH"S$EC_ 22D(
M(M2(10T/>',?-^)E*3'M>@A0L<1QS7LT0V(S@T&\D$.[\$>;K>N_$I)6@PQC
ME_)560@_&ZKV2-KL2H2R;<R:)O:STP@O_LTJ57"WL_F27&@8Q@&=Y\E#Q_QN
MT(0\\[^$'U73!#" -ML)V.P 0X(CG\0\'R.@\@C8F4E'2T@$"KK=DFD4_]MT
MR^]QC%Y(8#FA[#I5@Z&P,Y3J[1J;P*2K@!.%;$?"TK&PDYB.%3$ *!W6P:MC
MU\$K_%REEM?!*ZW6P08"*H^ GH?4]D+8EXSHD>&)'O@I3--E&F%+?A4YCVYB
MP27R ?5&?R$$+IL::.B]?N49R7- +-I4_DC(L>.BORO2SL(&1E /16CLH?P-
M?HKH[N&0(YR4OU4=&9IXN48>[A6'8YR4=82([S.I)+\C&>J5IPLH2_Q]FTF[
MVM4K?G-)O+/ MPBQPULZ&]A2P@I'CSVZ0)CN+'YT'6NZI%JL*#,%'D*7:H<-
M<GYK Z59TCU[//W6]9\%!4!^ $Y;-HS!Q]$JN7['7:WI6-$++<C :*$Z]N10
M\5Z_?J'(C[W=[>.!%3E/2?U[]0W=!F/I,R^%@BS'+1HBAK[?[32BU-DA] C
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MF59>$U;T]3H]G<_,('I=4$!">A9G9%Z_YO\B7\SKC*&'O>YZI:^#2,ZFX:N
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M>7I-)Q\[JV6[>*+?FFUULC6[F7;DQS11R>ZF=I?FL:=7-/+?O50_GE'97,]
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MV3SAS/ /6*,C4MYRC?=YFN:>Q7,V)2A7(ZNEH,I^++0[V6S% A\:9!?NJED
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M-%=2QFO=N$[_PO[GD0J2_N;_ U!+ P04    " #9@RU58&]EOS$'  !$'P
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M:^Z&_+R^6YG-9^)0;VMOVKDKM2X9^<M+90,3ELU'>K ?>(=JJ"W.<:(5+K2
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M(3GB!\@XB2.^SX[X 3%4XH@?AR-^0"R7..+[Z8CO'POY7!9(O*;=EQQLZ7)
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M6%:T+O]ZY<T9PJ7\]"#2JIXOG5#@<>*7GI[>5^]/3R'R1'/@I"$*20NOZ:'
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MSY\LEYTP<9@OI.5VNX;MF(&"I:&9O]?@;T ]_-@089O76_8>Q$CCZ$/;_ &
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M&A!MG%9D,U'F%1<8L+*,\F[_VH/YONO/O1\_I[QTG5M.=<-=6F2\PK+7>_C
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MD&84//>@H*%8*N"ARQ+6/VXJ.IJZVV-O<[7Z>;$SS$N/V]_N&@T>7!BHAL:
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M!3I5*I52Q?R:)Y=[;SH.)4T8>$/'E(B+2$(V.%'.;%#2F206#CD,24!,0$Q
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M@V0[]HOPO']G#SYRI*]FWK?E/WG6]>"X 'LMSN#$3+,8N!"D9UD$IT2=962
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M9LU:\2=L%+NJ? &[QD6^.!NNU_)I]U47]:W_3/1VIZ)CG)<J[^VD<^2ELD]
M37YB-9XL_**)DYXWTR8YS9CVM^\N#E>Y45<>$& NFD:"HLFQE[W)3$G]@P*>
MW&0^/#^1K_0#ZZ)<RD_FPS?R7I1<:\QZZ6A(94)R.W$=P8'\)>_FTZ%0!H&
MC.6K22&II(C4F4 F98 AH2YA1Y@V-!HOWE3&?.?\L4):L_?S9R^#N[V8;>$7
M]K<9T>>.0+YYN=]C,RTA5VWB-@MA*;#N&L.[*YR&+C)\RZ9Z0<C)]:"X^4JS
MN_=Z[5Y]/0EOC\]-,<6FZ!>N[W[>/J=SK;:_*?@E#"?HV[??E=_?OIWG[Z9.
MY,K)>5C^:'!Z!WLNL-XO%+4)CDPPV#.-WN:57GQP=9O8(!*F]W]T^*^.C&P1
M<_KQ*3=G8)$'I_;G]]5MNV(%9FTU>MZ%MJR*M?!V*/H_T:Q]TXI&I6,9[M\
MF1@^R\GNCA&)H:,3[ ZM$<08B^P)Q!B&7YEH^@;F#<A71P"<X)@9>#.\=<=O
MCM2 34GQ5CH;M_W@B)#(<F:'VN6R9DQT?H3>8XIP$%GG%@3L[^]*-5,ZPXXI
MJ$T#YS3<PVGD%72P[FJ$$P#.9P5^PMNWMWB#79FA4, ,3I4^_^*M#Q5->[.,
M>BP5P&'N+@L>*U+/T-2VC]GIMP3F.#RL!W#<.WVRX!,%63AV=A+,3TK2778Y
MHLRQ7@/8X+/5PM:?Z(H'6$C8P6('6_[Q)C0P$#?:B5CR&Q%+T1[$8020AF*(
MD211;D3^AC(93BRF:"M:P^5GI"P)I]X*J6)?WD9.FE'6#AI_'@N9ZUZ^_-+T
MQ4CHSO!86(OWB?D%TPTI3F!@"!(%QGSN:RY5*F53F;VX;'S:SKL^6[QT+ 3A
MM%Y,XK;MK=%(30KV4',W'*6IB2@-/:>&S^DJ#Q9K9\V?Q$(^_U?I]OX5H:#A
M!X4OV T>>:HYCNWL;F_]L&R3R9LS8%?-3O'VE01M&FEQPKIE $FLZ"715TP5
MA\[=#TZT'X^G=^WC@Q]OQP]<'_#D!2*NCT%9E].?,.OO +,NIS]QUM\%9WT]
M]N02$AWJ>')Y@*VPP!^@-JY))UEA'VC,7?<#.:LJY\\O3K\F?_1CJX3#F=BS
MK.&%%>G)C>_YV!,L?M\>2\!YV^F6#(YUN>;HAUJU\M+X\OW\HGI>KE6DZN_S
MZMEE]5(JGU6D^M6/ZH5T<'UQ43V[DLJ7E]6KR^%S+=2BBS[96F(:CV^:!7!]
MY]0G414]\,JF&L/$.+DD%, 0*O<\3[T?F)GZ2?V7?? C\_".<']@^.3E8Z^>
M.[CY]:1BXTR:B>B,P!(5**\!#'XV'='GF6?4,7! YQ-%;]VQWL2BY_8RH3*?
M:M76CYN%K"ZO!N8LXBEN/"Y<0-/]4-7*Q?7@TGBNWOY^WEL)3:.^]@<%D1.2
M::CGYC+@Q?Y*>F@"%)<L%U*%0G&=$=-FGE)I"5,*,Y"_<]*E2.]M6N0:++&-
MX2$,X P.^W_,;GD@/YY\F9WOIH?E$@RFBY<O!B+CK= 0PZ1("AS-4%,V<OB<
MR\NITG+@&]::;+.5XL6<V>>!;$O') JV2'[8Z8H:G-S.I,WRG+FKW3Q:O;N7
MS!MVRQ12>G3\-"+$\XQ8CN_+!LE46L8^VDOEB\6/M(MF)-^<^ZF8DHN%U>VF
MZO!N"M)P'=I#K\_I/SE'[>@7^A(U3H+-6?>3R/F0WA\I9%G(&,/$7\[6S,G9
ME:%6;.@J39E(D<TL'Q$G?LONC]J(7"R)6 L+LMSK5S6,:%@'CI)N'.W)J]&!
M"87U7[Y?L7/QQ*"*%(VIO!?DPXAWL R,A7'KMHR=GR\54_E<YD-C=:SGPLUI
M#F019"6S(*']=H2+<=6X!_>#R]S3;?J\5RP-]N:O6WK7.HZ?GJE)<B&4J1'T
M!_7S3J0*G:C7 _>8LM[EC-1E'39X:@]+EHA-G\L$H?-A+XTRXUAV1D$N '&/
MU&+S\>=QYB'( Q1Y4?Y( A]O>@U6!*=WCW 7=J,9@=*(^R\IPWDM?MVXQMJT
M>K!/L&7[ --RJ'D[J]M33--C8K^K>UW*F.'%*M@[GNI\8PDD!P2Z#AX=W7X!
MH2C4V/OUU+[[ 2\:!-EPH7N'5<_$));$]RXG_) 9EY$[FEF4\N<S% 6,)6=^
MA-\._+L.-6;K!Z2<F'TYE">)F6:*><"2H(+L/9&F:.7.5#53_+,?RF1-"&%.
M7)38T8];$#^I<.P@WQS^D(MC$ZFI+-:AGG,M8'[*-7>VMUQ+XN.1^("D8$31
MFK"AZ_PLH6EK2KW^Q>FKF]F[>UH6],#23N(KNM,T+!!!6KT53N7G3'E@.:XS
MDLF?>%H?SEF?\\GW W?O^;";?3PY?% ^^HG^'(6HA;D*47/W _FU_US0GVJW
MC^J7[U1MNK-?OJQ6L  5S^O+5[7ZV?(K3M_)* DUF,ZDY0(OL*N9>-:E8Z>W
M<T,Q%]XW=NW+:PNQ/=>WMR*M7I5>S[:>N7$R#-X01TT)B2E]Q<NYY,4O@J1,
M3$ZF2_"YNJHY?LUM.)-8V=[J*J]ZU^O&5> >+J0H36!W4;)KV7,[EHTV2DR"
M+ZQ8M)@")X 9=$/ZFPH)!2'P&KQ5:._\7>?E5^FL\F=,R:+BCX*H(BBRO$JM
M!!K$EB 4HB4(XV8[7]9Q9DR'AG#1[&AG66I6:[5:5/#-$]2'F=;/ZTWAE7I3
MPT]:MV=8?4T+^D*B681E&;M2W=S>.E7 49#DF+)T_[GQVT8QPXGNPXQ<7B0C
ME_WWC+!T##_S\LI%</;@AW.TO]<X^O78\ED[&$RHY[+@<K^_]$J9/)D^L?6(
M!;\><56,/ZXS283O&9_'DY&U1R4.Q:$!^S(XN.TM7O8Y= %'?QD!^-.>T-^$
M-\&SV[:&V#"(!,2+;13=EIZQ0%KDSX>:LD:VI&C0#??CI30&AN30T)I6UV\M
M3?-H4%0 ,7[\PB"')\3Y<&RXIV*>R12+:( %KBGL<GB%^X+0;BW"*H)WRFD)
MJ_0<JF@!]V'T*1?P7IB_&_19?B&@G 3B8<*:XS4>0*)038L_;M9O>>*H-QW#
M*&):9>05F5;O:4753.E0:]B>8H<KMD:,J(8%;(/K')21A&VB??S9ARCA"%],
M]Q"B5YPN86\J&P,0BUC*@GX\KX2)HSTQZ/96^*UTV:@YYG\=V!^L#JQM<YA!
M#0A#G2N &#I8;2 :2/M^E?^1(H"A6"<IWH^3P5H\1(WR@ +]?U(PG,P_".X5
MV6,IZ6M6/ <G"V*2H2)2*-DAL(++\@5\^)H;O9OD*-?;7_/_\$,0^FF'"91F
M2%]L_(YC/J'.._Y=!K+'Y2O)]MPN;CHV0%QB84Q/;*Y-8&]=I8\*AH.-!2(O
M8!3=D0)L$_ZL%"8<@I7$WK&]1=AB^!BS"?K#"2PR*E]TV:O":Q,C9"-O!#77
MTG3:*$S .Q(I/FPA#D8'LYD)7/.K]MK4>G@$MKT5@-]QCT,5<67_X; /@)!
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M=^I#7*&#UXVPI7VLB0MM5/CY>O<27H)ZP[,Y[*5 40%!"LZ)#E34.(0',Y%
MPRFNF*6/2$J ')S6/D\Y_KA0VSCB)H<&1$BJ70VDE,KF.>Y9(#MP0KADD:FA
M0XG>&SI1H[>)[;;+M&Z,G8*T8E &I-#X61LZ30J\,"*'F?9SB&>1AWU%X: 6
M0-*1(Q6O[P/$["#T)#2=Z;B:0D8LO8*>0LP0>@,M"0U1G,KL+EC:+5Q\ANJ0
MP<WFG0^^CZU)EC]KDM^C)EG^K$E^EYIDBC^)C;'H/;?&Q9U^J-&OPHP/.H;:
M'SAEM M !8^M\(QTQIC[X?>#6JU::LKYD[L?V7<L]*S>#PX'C=I9YCK7/E3!
MV 3UT.UR'R(<%D!_@TW$MYC<#MH-/,^'@=E$$V-T<HMX9DQ#,ZP740ZZ;/VR
M"46ALR2)3YM&.U.YX\RYR&^J5)CZYA@YO\Q,["56@,JYE=1W_K?Q/0Q-Q.5-
M+%K .G1?G(FW1^<[/[_'/7.N!5_!&K\MF7].KF*'6=)_&[;TG^]2V??I^!<H
M_PD%-([5WC2TZ<J.ETZA3P:9DD&"I ?.$HQC/OGA?Y0?1%NR0&00SIWXT\?A
MY'\3:N8GLWPR2QRS7&A=14= 6/'%02@,Q[\B2,*OE ;PSR<?_8_R4;G=MK4V
M!JMKP""ZB9W].'\0[O]\AO ;9KXB()1,'CS,?8Z3JKC2!)B7!:"$3-7Z>5$)
MC,+:/+1L,C+O]<O)7<FSA]I-SCN6;VL!:GZ(1 VMS41*N)W)\-0S\7''U:1M
M#L]Z:7BPI50I,4%M?7%J$CFPM @.Y)YSR)EFJS,5Z]VUS:9]4OG]ZI0VA/62
MIKL\#.)\JKB!3/=7#+\M)&U]= '&-D867#BA-_*@?_38.FMESW_KQCA.7#ON
MF[ZI\0)X,@QR+^]F-HLC$\5@J)$@3:XQ>6$:,R^,;YF'+')$-I=%3Y-1EGQ(
M7W0+O[SR:[KALZ3HU5&XDT\+E:FY<<I2WGSAR_?"KIR>!8]BC>1+;CGRQ;>0
MR3(FB=)+]]+QBW9TD_USUCYZ[MV-U6AK)T>BDUR Y, C(C#>M9ABUTPJ(^^A
M5ENR_%A*Q#T&JXMGU?"<EL6@3 5<71D23TLPF/D,$IJ1C3+YV4/_Z?'@XO;X
M+*B0'Z+"E[B9SBB."ND9L7&6"_P5+,G^ @4-$=VIF:SIWI%M.2/M,D<7H/%<
M>;ZRSX]>;DI+78!9P8D6O !Q0GZFDC%G)N*/-22GLB(?LE>_GBIWZ9=N8:GK
MDENKC9$\H9VU'MT;CS\7K&C>A@_I%WHQ'EV0UEGOE0R$0'$!.I&34.QR=481
M_.S<Y9JYTZ[[0QW9ZOZJ+&2S%]9/".<7*83%"BQ0#A<.G@8ENSQXL8M+7IS2
MIR3^,))X7I312/&M.CR;U:-7!OOU8&4^Q %ZNH:AJ77[4)2K31:F[4?M.:W!
M32<QVY6H.752V!R;N3BKO[%A:*81GW)A#@Q?9L\.!/B]?D9KKNKCEWWO[GF_
MKN>.VP_R,M;]ZW*C)S$3CP-2B$^_GN=$("7/<R P)=/^\VY<&V=PR,L)[;%5
MJ_$"W8K&_C^__>'*WGZUK=1[EZ/^^2($VJJB@K/39ZD[('K^L.0-L"#^7[K-
MMC'366YR^K)]\ 3XX5!L?VP;IE6A%X\S 5>0;E*=;.O)^G/F]/)\<- HQIV0
M(+1'W''_,E"85YV ,K?JGS,!94,0N%<2=X])6)F&>6O7Z<;=GZ>*UMI8YITU
MA65^@S67*OP/L.T*CZ3'I[Q4IS-2ZQWO1SO;E/=_* F\O"G\^Y8DF 49H9F-
M:88PCYQ=:4I,)CDE1CML--(WM\[A[\P4XE<DR^3O]D[E7&41\=Y2YLOW_&YQ
M;YXHT7LL]=PGJ6]/EZF.2Y=IE'[;@T;GO%TH3))!ZY\=,QMN?U)VC)PJ%HNI
MS$J5Y6+#YGXM;RYV\<9V]Q%1$L21)/A8-8"?<2WZ>J*OM2:[<+&V[R)#MC=$
MW+))C2B0M%<6?A5C$H] 08N-^^OI^J)^U59>E/Q(A&O,VJVU13$M699G*&?G
MR_7>$!Z/4T:+K$68O([C[>=:@OU,C/_SK)RYJ63^U#K961A_$RSJ^>BV;$-[
ME<VK5F5HCW#]'(;VS*OWAI3TWW\Z1U>W[9NF,IKT,IGY@^3UW.G>0LSQO30F
MK&<+'\$<7V2H8#(O^ 6@P^9ZI!76T^7^OIM_/3Q[V)M'V*VA)$N8_S):<FV<
M0?_VTY"A'"L"/EG"R<C['$*MJ36U$H^A&BSH1-= >3&L7/;U\/EJM#I@B#'6
MW2(:F?;R3'\YE9=SJ1R&EC;#S%F8Z;^00OC1!9O#QM\WZC<MK5&MW3Y\( Y^
M1^,]7=P4KIY!OH[D),UAO"<OTQNL]/VN^?/5_#&X[>A3L&\0)9?ETTQA,79Y
M">WR=/8CV.4CXFDQRQRU.ZE9;SA.3@MYH5?->DZNG1_/I$G?)F26,JT/'"J?
MMJ]U]7[0])33EZY<.#B7-[FO-6+!*SYPD.X#!Q&>__861[QG\+%*PWK6@N[.
MK)^.:[FLA[.KO [?+WW5=[5=UB6 M5 @K&O1PHHP[6%L78*L'VW* *]!3X]Z
M+E%_ ]%**-K6"YY/M,%?AGO!_,,Z1+Q8GJ&RKF -?+.M-37].6AYPA'L17>B
MC@(^L-]EPO_:KS(A6'H8+<?+7_^V&K'-K1A8OI ]O% 8W?VJ:!Q(!#\(^@8N
MO^G5XG"O_:[0(6SJ$ HUG^Z5Y4^V;*JAJ8Z%O@YU:%_$T^\'=YF[?:-6_G60
M;;PC]O7A_>#V[OCBL=6NG-_EF&R(WY\MWE'5[S[1#KA'BW!/J.NDI'I^PXX)
M4-FR](*M2F(;6D3ZHFQOL1'L1!JCA*YN689AO>!?02\CYYMOPWPXO.V]J>&V
MIT,>G@\M>A(P='"8/ _VW2''7[\BICIE3%6-,-6,$;15T&;-( O??.@>CP[X
MT6@COU=5>-6/PV-3(,R$$C"?X\HW%^SJ'(+L)^._' A1/PQ/CFN<TWKOV.[.
MS@4^G+7>I;]/P?/M>EW>:#?HTDLOPN8IT3:]"1I4].F],YR[[H^?#V7OT7>G
M?))=14D6ZTSY )K3N<'Y]+OA-$1'&C1<'BG<7LX*B]"$[*^RO+)5UHY[O],'
M>[K1,":NLHA]9.X*I^G*# M;@(V^FP^ LEA[8NI_)O\[TN9ZY&AO+:C.6F(N
MB.HG3^6TWNTXAQ?%J:F>OYN!XB5,O$P/47R)1=_<1BH@8.R-WVAN9!?/!F66
M3^H.-8EAWA(!'L<PP8PNP&1FQ;J]>^_<L[5X\3PG>YS5LIW6GSLY'^3M!D.8
MG@OD2(7V.H'4%3=E94>$PYPK>]N_:YS53RY_RTK\TB[G>&-Z$L16I,HL-, ^
M86! -+<?.]M93D)XS'(G$PI:XB)\^5XJ[&;EI!;W?[^7[7@1W\QR89;'WK(8
M'P=^"..N\6&O1J!U;J^;IWE921\&F3$)))Q!O.7>)MZ6;C8NI/#N[8OW'F9D
M[F=!O9,OGEOYXA0+O#HA%T>Q*44<4.D^2J35"3UY-YTL\W:&^6TAJ2M+Y[>%
M&M #]:+<.#T=Z/NE#\5O$2*ME-_B<@X6IF.GAX>MZ,^ZBI5IU.5Y>9[\HJTH
M,>[I].G N=[_LW_S\[EY&J0&1Z<^O1[,O-',7[H>7$B5PMN)/BR7!L=_CMJ_
ME.K1'Z>53/35&^#A64PG*Q:SZ=.[<9D L7L^='H_X?P^<S_(GPV,<ZW9/3HJ
M+N7([3T/]?^K?X_$:;[AP2T;SE5'V][2(C'EH0/]'N$#L7/S<(-Y<<0'C!-)
M#F_ ):&NFWCHISNPOOALW1S?BWY[ZVNDPWQ75W=Z%BC&2(X II_C(Z(Y *8J
M^L^'^]+C6_]9_P/Y65<Q<'^'UQ*WN&+V@<ITXBHIO'M81P>U;*/BD]A1+>5*
M2,_^@Y!Z3;S9IK/*GM<PZ,@='Z?#LUYTM\/3/QJZY6K-C@EJLMVG%>B!_.B"
MG/9(M8(IH\),[#XF1F"Z!1[>JAK(&L$A/H\IF,Z!KVYYB+(6&9MKPZ+")!@?
MBHFIN@K*P&79&X[7:NE-'1X$5RO$<&RBK NS#CP,]W6Q/3-+;QC.5-^5KD+/
M?M$-@]A'-SU,99&47L_ E!#JU&PU-<<!>03TDI3PJY4NF TNSB)$9=UDX@[E
M,:;3V#@ZRA09(CH.TGHQ(U-O:$!X7$ !._-A6)CL730V)6%M2JA"DMB8B0/*
M_HDWE"4+&)QG 86E&)<%0EI%Q HF(: U"O, IL-E8$]J2=>[E\ 1B(#F 0N!
M]8(_ZYA7@.R/ @N6PQ;WX;8 [N2O4ODS\#,)QP^S9K[8$4H_:;4Z0 W<FSU%
M9U5#JJ6Q;X <L%EZ2**>TF>* ?<R>YXC<<EB:D!=)@IH9]H:;"(M%5U?-6+]
M2"_PTH%F6Q^#W"2F=AB[-D/F&D@C4-2)N30M,+JD< X.8T%G^F;T^,0@U>:O
M8;,X?&Y<-@RKB6DX\98ELHOIS!B3\[\7CF,H?TKXS\]N[Z*:^W/7KP1UN6/H
M%:0>3;*0IYO0.-S#(/U,S.0^<2)O+3(K%8H)=>/L:!)7<&3=BF];MZF/$*99
MM[)NO%;SQ\T_QN,25V(T.+&TE2CFDBKX:252H515H[_Q<BF4(WJNV40Q3-L]
M(#NI#1<)XVI,[NCR4T57**-KIG0&9@>E%F?2<HGIIWT+-L;VEO"+EA)7&--0
MIHDCD66V:_%3-CTY8!E:SV YPYFK(Y'/"XT2,,\5V^U?P3 <QOK.?C_\2RB$
M>M#1M5;U%4PIW YU-)HU6T@&^;19U-K-RD-Q%!U:-%-9<O54#"WCQ(M<VI%E
M$B_L$U"71SJGI2&&2L<08Z[2P@R*H['*H1>,<J?I#].WCSW@<&8HG!L**4_R
MN7"XDC]>B0^83#,G,*[)%8.[HGGXE!8\HH]FV@;+[>VS>=O%^7E[7;TK6-<M
M/92!$R$ZIN"HF 5L.[CFK.[AG[DWT>)68G,VUQ10U/[>8G3>>%4O:H"&-[?[
M8H$WC+$A%]R]D"R17%MOM[$:!AT-$9ECYKC7X_XV_+.5'GG+35BC9[P$EL95
M@%</+8NYBA7;:TMEM:N;NN/:S(;_BMEVF?2_AY4R?9+__0=#,K;UK!C;6^"+
MP_LL,PA.*1*:72RBB$5 +1NX?%?:!T]3:\&#\:$I$=7TIP#\J-)/W L-3;X)
MLLLRP4UJ:'SL&/%LN5Q6AIZRO14\QFI),&)_I.064YV1>,2N5'8DQVMV4KRP
MZ<G3'1U\8T>SGW$7\Z"K/A2X"*HO^ 44_'CIZ,T.BY<J]J/FAH>"$PB-?5>Z
M[> X(O-O6QBN<J(1.AAZ@P*!,!E^-^YY5ES%_2VQW+A\MM:TVJ8_?R=PRW X
M(;],8R8\.FM=+/]R=J4:G]TS!=/,OHBBA!88H\P41Q"+P"NUHNMMZ";R/U(V
M&!Q**8KL;6^Q&+0(&YN69%@@4&R<;[C6DF(]W(1GJE!QI9YEB\G1BTDPL/!A
MEQV PB4NS$ ':HI)*HYC-75:,7KH$-.$-/'V%@W4P84849KYV9TXM;MP_WNV
ME(R:B2',2Q>&BHQS@H-&G1)]VY%F@FPPRJ8:WOK/&I^&4'R6?M?N'G5OG>,@
MN? TB>KKY>W'I&2(>Z::_,PEM(61$MK=40!;W%L&?! J#+BZS49#6T.)C,=G
M9[W%ZB!;R3*4;=5 5H*<<XG_>82/25;@]K:M$6/L2A46:V<G0B!#0&]C<!8#
MOBS0Y9E<6_"(:W1/A44M;'X6D(W$ME*1 X0&B D8FT/;F@7D0P).3"Z0R0G3
MU'FH4\A)&"B]7$')X1D@*4&^1"1?TW+<0!=P@3G 4CK+IG&@P" AL,9VQ)?O
MX>),[;5I>*KV_;__9V='.L1P[#?I'"R^?^'>)P_%._8]EG9VQ%F\JC^/A]+H
MO8H*'?;:'=?J?9-*6%3$OQ W%+ $:+;*NLGU<G(Z_3>O W)@;1B!\#6)^2,P
MOKBLA-'\X6SV[PF)R-E<4H9QB+R"L/]**+R_265;:>C-?Z4SD'&,^&<6$ES.
MA._ZC[@-?TIZ?3:^0?5P:;PX6/_O?V UXQ;6UA30_12Z_R;UB!W"BUF(6<S2
M[(L96C%:H"14*(9%&[TZG*026NQ2N*ILJ/H@=M9A"B/I&75#&V,]-_$,SD ]
M'.LJH#R5]TB>;F]1P$M*BG<5EQSO&D*FDO=D.9,G9QX_%=[;F1=O.=;ZX52X
MB@YRW[5\C[[:J,H]\[R^UQO%<5FS -@>>N:9O/^I,*N/SB\?2Y&YHF"Y5"8_
M?12,3 OF,84C8MP,!X-$N*B/6G^HBEV15#YJ$0KCIVUT=M955)8#HZNP2[@]
M@6$U<3%_16+83/I+WLVG0V&%F/NZ8&+H/4/SW7(^E3$.^?86>>2:COZX]%7_
MAYE<7A/S&EJ>,6P&.:[6ZZ%G!:(#'MPT+,K<H5$ZZ)(JP(E(7LPI\8_*83K-
M#K(>#6 O3<>4(H#(DS00OZ/O2+AGT)$&&LBEM$3?!<XUM]>HX*[X+QX1ZV3E
M\\P4"_%#<#PB2% [K_M!@FCRAT3,F)(LG#5,.SJQ[2T^([Q)D?C@=9/E$5D&
M#EIL=>;O<8+PVVPV63R _4O.!ZN&+/17+K*,2TGPQ(PNI]ZBSQLL"7\\'JL'
MK8>;PUS3EX0T-61%&+<-8_)%83(BR*K$U()D<'CQZ& I-A!"T13.IV.C(GZ2
M%A[V4R7F2-ZC.*+$YWHF1W@="FZ$71X1"J/<*$K=4KTF"\!D\G^'O;?MK;>X
M;T%(,(A@C<KC&?PZGG3V_G[=]A9/OM@$OV[Y1\%7Y=-3&(S[H8Z"P3P^5>QF
M1\ID&5)-A">WMW3'\5BXUK<[6.PTBI?#PQ_"XG UI2MU2=(XF+(H2)>2:F9S
M%Z_N>?!2Q2'[(<#K AX?5C&+[*HZA1F>D=/93(8GCF0SV0U1/G^.C./'BVSF
M]TUFS<UP3&[)[F0R_J?L^IGA$XQP%CI'9AW)S55"YM-$LSA%E@$=?N33?S-4
M<O_,"26TH0FE=DY[I88?RR?IM(S:B^W;0)> H&?10%O <0X]=NPC,_C(BM9D
MGK*?7OPAA-S5D$E !T8\71P)@@;]"(4Q+=.W2RQ?3&9"Y(ZH[U \E,G&B(ZU
MV<[V!67"4FQOL9?[2<%488"/C!ZLN99XA,:RNWVC:NYPM&_/,&:*'RD:!L0U
ML\:KWVK6H"9:9+PZ8M:$5X=FM?%L/X^=LUR 1#8H090%/WXVPZ<.^@*%G9R;
MU_1YL2+)S./LFPS+<QI1(LS'YULPB*D(IPFU1V8WETG0'O3()$FOP7X3^XQO
MX)K4-$!%8)V':^N@"P.YQZ((^WK/PDH!H)K.#CY30C:Q"\ZO+BOA7R-WJU0>
MX["4!'$)R1ZF:N@J4RH;@XX&JVF'8B3BZHW?@L1EY0G"<7MK(=)Q7J=O>VM*
MZ>BSC\\N_J)N_((-0\GND*4KA:WA[2U^M+U)R+&^@>]#NX:G= !\<&C9HZ9]
M*'>.)QS U;R=^(B;@$\!_P6#Q&.19B/>W'N,YWY0T.[V6G+C]+G=>D=LVKW[
M04MV]SI/#W7U-\>F'0X8LZWK4 C>@HVO\+UNTM&<2&K@^Y,"4%8X;RFZW]FN
MGK*&)B4%=8_X%)NA1"L.QY_]R(BSI14ASLX,+EM8+;CLM"-=%0KM7*"J/A$S
MXSNA+!%\=CZ<V0V;O;R(V2\;8$S )PYGK81A.2[ #B+'GZI!P2PSK![JH#FA
M^&+?&-?98W_198O3I36*:6-@+9CT4%+CWOZ%/##;Y<I=T((HB5XC62_#,).S
M=6_)Y^0986N7#Z\X]9IF%UW2N, U;5CIW&FMLF?+>XM;T]573$XQUS>W2LS)
MJ3WYC<VBIN;"E0 _C=4A1XGIM%/(]OFPS=_8X&J%\G'*M&_S4>FWC=J9\Q 4
M?"?3=6KEO,H]EIPQON#L[]%:\6RVM)BF2?(\3;I6R<U[[Z,9IN3FXO7AI6&^
MOM8;#YO*S<D:8ZG<G-\KIHKI_,JX^5U:ZPX%/ECB.0=9P:9:Z]3/,S?[1@MW
MOAMN.?XSW3W:_VDX5B%(_<(I+[7MYOQ"/1H[G+?3W4)%]@;UAJW.PTLC<(D_
M+NV3<J7H9$[US>"EM^(DCN&D8G8O5<B,%GVM4<?$@_O!P^#ZU6Q?/E?ZI4WN
MF!A_1(4<M[WE 9=@9J6?U! 761;%=:%C(C\O4Z2=\WI5<R?X@J>I8YQY&(*1
M#C(Q_V*DD#2SP&RP&QHB*'R_0XF%7]4#\,=H&W&U&]-)?$I32Z1Q70<$I3.F
MD>$+6^OA[%?CP1QHO</1A"Y.6R3I,-66G>0U+<W&]505"5Q3TN(-L*N%F*2N
M[.ZHRSY41+J[O87',"\<_&%'0$^.UJI3@?;$#1%D'/MGJ[K#2CU?J0P>MMQ$
M5/$Y6MY.7JSI^SB["8V<E\7_]=;^=;53>LSO!W&HVX2%&;,?AOI'9^XRIW)F
MAB9*^3PV4<H,]5"BQ/3@O'N,GI#3V.RI5+:M4L.^+:R=G@A5PXZK@,U^5L"^
M1P5L]K,"]ETJ8!>]M>9]%/OO;@;LM6D,NQUV*4MF\9-4EM&+^%:Q*>N[HCM8
M7>?928D?6"DF=,"8F\"5SC_V:L<_7RO=H)=JF//2(WRWLM2!B'R)C"EF-TPA
M<S"N,KJ%B6]B-W=H58N[;%VCU\6BMB,/1'-/,MG[P5''_?7CY$_[\EC[\OVV
M?'%1/KNZ]#=,(V;3+,\M677J4]<R655!8 ==@!(YM&PJ\!B7OI1-2E^:Y9GW
M@W+)21?!(CE]--ZW/;:L_K33AZ6+?%YE*4A!>VFVB1RO"Z\#R8H)V"% <*5A
M>>Y0YBK?UB/H^6%DHF'X\H7G$8WEL$0Y$98+PW)C/CF1:*^\(<?(3^.0<TG!
MH,94>1RQ!DKC>XAY?1DP<\;.'#?$9#HM<GK5@ _?/KVW93O%). LD8YO)_PF
M#R]QW87;^+X\O<FD_=##^]S1ZSJ\Q!W-PU5KO*$_A=$FDO93%*SK\!(7W0]9
MK_&&VF YMJEL,3=EERD*)GDHZ\P0B6-GYWZ;./+08=<F#O^3:3:3Z@N3,(N,
MD5"'@W59CP\9VUK.]$[TEB9]I7/I?S[B_#XL7RXD*+F^TYMSW>9+9/[_#@ZJ
MU</#Y,H_K.SZ*V%D_(KA\_Q(F5J0ME,.'0P=&(KCU%O\F+-N7^ MD18R_H\.
M_]6119+94(N?D2R;^ 0N=D/9<SL6'M:HU]@-*02=A77PSGX_,HA0'P1Q,AOY
M71:I.(5FMO/4J5^^/BK1ICUS]NQY$YVF22R+F\92&^B,9Z%IRP?GNRS(1\Y/
MXL60+O39;KU8[K35E7_DY>[^;Y_CF*DH3AG#AXPCZ21)>W9V;JR'W[)"QA-,
MET]LBK9.#%<(,9S8L&5393LV1$),)42&4_U<PG=GM,QQL7*^GW[Q-&4DS=!O
M/1[@Z84[LQLADTOD%\IWQ=-"96J&=*9+0BSD4?P4WD?8#.O'8-DK04I/[.89
MUT1M5+*OL0(T3WM7%_N5:K;Q&##)J!Q*^9G#/N=H4_6VFTM^^;E8"UB#=5.N
M:R;DQG)[R)!?4Z5J]O^<E@N_7HS6L%+E .7(SZ%DG67R937\FO]=Q9HL7$O3
ML]O8MJ'K*U5KSM.!XI5*UF-V1*J&N'!A4C4A-7I.[IV^4^@FB=/Y_.Z7(?B)
M)!]["K]Z_^/YU1FQ 7[6BIG!#^/\]%G?0+\ZLS!>+<;5Q<>8NK%"=?HOHY;K
MAGK(/O.\I@];C>>K'^W?Q5E<Y/=WB^?A&Y]G"G(JFTNH#UX"OZ0WSL'U^>1(
M>>F=G?<?^L72(AS<S%WV5-ZKC.6G*;W:8A%+Z[+S;O5D$RKSP?W38(V=DT[5
MS5N'O<Q2_=/-\$F7K)B6(V$.-M6[])FP>O'4OKCYF:NK,WJ7:^!1KJ5.>GO@
M;6-]0Y^9TNT7]21[?=6Z7:YON.;^X#N)LD6?NL[A_TVTU#?/_\L*)G]Z[IX.
M7-,L_^ALH/^771!O9J<^5UV./;]9_M^AWG+[E_JK+RBUQU_::;TK=[3-<@.C
M$YE+\^ZE<IEB2MXK?/J#4_--3GU0]TK=,_?E<3%N88EP51;@%I;VT"TL+L\M
MS']PMW!XJ0\>CWX\R(<_?E\T/[W#1<B=*;37<L1.=E.=Q&&6='[;[D6A.GCY
MD=L\9W&]-5>RW)LAQ+!97N,P=PWDUE[_T&S?_M;^EYW']Y5TBSU!G"XU.3&9
M=U)&\_^F(YKS0W>YJU[7S/=^W*H;Z(CF%L3@A=W,P@\BI^7;#WM>R820]JSY
MP(Z_7MO7ZFGOE]$OS>*QOF4+OX='&TQU+LN@(*<R^<59EDO@PTWR>\/\=_FS
M6[O>?^H\-K5%>+[9.SE]FLE7YF+4Z5SC0EI&-;RW(IF4;$GF_B<\Z##3U/NJ
M7$RG;ZX>BTOUH1<FY=; QYY3$DZAFM]5%D[*+EAS9SS,W7;]LF$^] \&7F%&
M=WQ%_#J_N[[9:CE9%,L?VZD/<^G#;?7PN&(=#NY:2W7K5\_32W#[WT_X+JMD
M-W99,C VO^W)3.U>8NZ/7=J1#A35CQL(N'=L=V<G=#7]?0J&<-?K^J69M^E;
MZU8_OKUM;6ZP &=V'YG84NN#I9W13B:Y_SD^4E[#?-1-7\I'6;W?:A<VG8_"
M$]N\,-0T,C1RBK" 4-3@JGOXG*YT+T^K\MQ1H,E"?'F1H/E2!M,I.;>7*I82
M>J:][TIGY@KV##K/YR<'9?GTYX6QF R#2&7U6QEARDB+3&U?XBNNE[,8R2;^
MW@JC+8/ZKT?EAWK7/C65U0<ZWKJ15Q7LF%NV9W;W5N0\SK;5BXN(90Q^-4]^
MW.7^7"N'^46$$9;##5.&$C99KK]SM&#029]:QL6OPU_MA]4[ZDOGFK<ZZZL6
M'O\=;6DYMJ%E[GZ@_+9+S?K9<;;07'BCLB4T'PH:L%0=E_KIJ8>*;M\HAA<2
M[$?X7VU\6Y=00<4<#[T?-!JG;JW<\HJJO*"^+A-:N&3O!Y[VT/]Q>O<[Z^19
M"Q=-C%MJP<"E9QQY2  [4IL-7E(]&U3Y]I8+-[D=6].D+HRUXV##//@YW*=%
MAKUJ:U)3,9H>:_+I.=0D!FZEKF](-\N V5GD/>[@!L8+NI:J&:&+@_XRL,N\
M+NM3N*PF,$/$&^+()76)FMR@KH3]RZ:*D,4AUTU"S LNI:YH3,;B XVD,PT?
M C ['@EUY'GQJ'^'EDU+?44L=<I8JAIAJ1D#A0LF0VQ']3?TBIX$B3@EO5#>
M;>"8Y05$>Z?H-,_W3&$8>X:U:*SZ[3[!"25[04"@NG$=U*: ^9%G]'IC(VZB
M!VKUR=/=/H;=+%/#!U$T;/CY?F9,K5NO#9H/ S43BHC%3W $W:28U'=R2H\W
M ]IC)](Q\2W4.WACS$!># 5?'NKI0M6SG4*0ZBX""/F[Q=.L\.5[GL*^(;+-
MM2%NAY%3;BQ0M[H!-!"+LJ@<G5--P=:+2.2:V?-<WZ@_6R!/!]\/OPX[GP[=
M.GP)"T0'%!"KW.^U!^U:]T=:'H%C<Z1N\!!)QZ?$INO.O-*ET=TQA5.]B(58
MS-98RD)T])N[7"?W=//0GGLAQD9H9R%?K \F\U ^?^!]E#CBV^GF/>+(H;?&
M'3@P,Q-]N3,,#&1WBZ-.W-^K4:6CZO-"=QYW6FBFZ;@,V"_;!NZ:EL.GU94;
M*VJF.A!ME*VKDF&6:J>Y58FC;&9:<33Q9<&!Y+0HKNLOKY"M#X&K:YRI+V $
MLZSH3?;A5^;WLUWKE*99T?447F.(L)C#;Y!GZ=U,,>FL\F]I1QIFL8^C$F=G
ML>CIMWY^4_EQHKK5YY%DIH_#8G.?BS,6BXNB,Q9;@L6=K"PK^K,.@EB5^M@M
M_E-'SB)1:T>JU\ADGRJ-$3R7I>G(-YCL'T<%BKB!8-I95>"K>?7\5-D[S>Q/
M)9\VSK0?0Y_)VG%Z@S^].]G:]X]G)AS0%.\']MW@Z/CNL9ENJ$OI&S\2(U]*
M-_:$HPT]B.9A>.@;$(,/YZJC;6]ID4B8K?5 X^ >HEAS#]YMP4\=Q:6_1\XZ
M%!M/%\43+*FAA=,9=A<VX76A8""FA^F(TD<Q^Y+GP!A DHJSUX[NN):-2A-&
M;#4?^1GLL_\@/$-JXLTV'9STO(9!)WGX.!V>]:*['=TD\C=TR]6:'1-4;+L/
M+U&E7D>!+=34/%++(#54F(G=Q\,G6#(Z7%(UV)YB<?SUA9<_T_%5RW-A T?&
MYMJP<V$2C ?$Q%1=E4S+E3HP,\GQ6BV]J:.D<FT%UYI/M(^;6M*!1>"^KF5N
M;U'RHP2CB1Q\[4I7H6>_Z(9!0D@W/0V'JO1Z<#%,W($Q64W-<6#_ [TD)?QJ
MI0LFAXNS"%%9-YE809EH:VW%5OW3N"C1<9#6BQF9>D,#PN,"/BNZ@>NQ.!9>
M1\E @0HT-25A:THHL9-XNX'9KL04=GR$0[* Z^F"J%@!:D?$!WN0Q;@:UAT%
MA@L3 5;$Q6&/:DG7NY? )S;I&.!I,$KP=[$I)$?OPB+9XC[\'GB6OTOES\#/
M)*T^GC 22C9IN3I #=RQ/06V+DH+U=+8-T .V$(])%%/Z=.Q,>UP]CQ'XO+&
MU("Z3$#0?K4UV%I:*KK :L1^AS5VI(%F6P&YQRA?.7<_,([SAS_=PT%579;R
M92-98*J$,+(N-#JT/U=LMW\%/.8P4\2IZ$[3L- P2LB,B&2IS_"4^X'VT^VZ
M?_K6J=7PJ<5HL.-:O6]( _ZG.* <9=<EG="+XY]T^F]_$&Q,/7=T5'C,.L:S
MA!O1>QP]+4M_23I' Y>6;9'&]]*NWQLOP?<,F*,QG/V1D>\'^J^K1K;NG:0-
MY<OW^M6/ZH5T43TI7U4KTGGYXNI.NKHHGUV6#ZYJ];-+WQMJA,ZJ(O;G)DN<
MFBF=*G:S0VH[%38)P'@DX:^B$K!0-0<"NN?!+2#E):5M:\RE(9E=T=NZ"UKZ
MW +C1#K1>-KKR<F!]/7__G\E<,C_K9R?T"?YWW_P,8Z'N@&>_]+1811AD\2Q
M#!1LVUM*NXVJGDG\<14A9(S4',<#%X72=,[)PF6Y8'5XMAW)P)336?0X@T_^
M@]!7K+?*J,_:-+UH_<:E3XES3HBRH,.(&YJT__?[X5^BS^=D)"IR(OK0A79E
MO_;RLYDQ'V/212G7SV&4PV-O]O?$ZH_)=/L2)U'!B<R"% T^B:*/R?3A%R9.
M=+YZTU2A@/\2HZR"3D Q9L=*S(Q%XQ:-^S"_C90@R9,9CN6]$;_US()9V%AN
M.][_:1_WG]2+LQ&@S"BWO9'# D*M*8/M%$!5@N*"J12B&:9X+IG(7V"Y&O!W
M2@*&^DO>S:>#3-P4EW2.@HE_Y,-U%54CHPP6K-G1G-WMK;H0RWLI+IG'553.
M+O?2)<&)Z;V-X,3S8J4H=P;]WZ'"MPI8;[9. 59D1YL]%VQ>># 1D[_SRW=0
M.LQ._FMY@C!=\C_MK8D@S(TP:,"9!GK=J&Z!/TOB:^1"<)51#*K/P(P4[%#'
M\E[".H?6IMX*?;^Q#'C6K]]D]=^5EW+I#0PXV3U9*@]-Y=@D+=F7[\@FX*E@
MX C$&&K))C*'82ABZHKT5YYZP^'4R-H'ZWA[JP=STQT' T?@F&I2!WW(1E_:
MU]TS';R4'Z Z8)A@QM;,YJYO(_*?A9W(S%*@*MJ936X=PDMA5Z=B=79&& !<
M16UO#6GZ78DJ=^FY&,+PXPIC;=P4OA'LJG_\WU1Z-7A92 >P>^54-IO%?PD6
MQO:6UX//2@\(\PS7\[?6SBHTCW-Z7ZTL-0W=I'"7:^NPO^G'\DDZ+;/I!F-C
M<2TT4S+!UL8M^U6/#',B120:& O8='N&)A9VGB'EQ)!V1Z($PJ=BZG(<;.")
MQ1(?!?/CH'67N!]8!!C?W&"MIE8+/V[V^C^S]5:24.GZLUPS*3+-PK#:"N'0
MZ:18T=F#?;2]Y<<+X0N?>[(3=A"&FH%7AFJ>D-L0:C,PLW:E0QUVI-&/^+1L
M+_,C#^);D%'L% 0>(9=$+4=0<#$<;.PI?7)W^9\M?(DPW*),SZ0%Q;XIJ,X"
MJ^T.>;LZ"$G'C4J/[:V_Y+2OB?EN=(#F3$2E8-)-K>>RP9N6Y/1 _;> #P(6
M86]J:)H)M@'>I9LP6W+-@988TL.7XW-#0BO\5HJPLG!Z,&O=D7YYP->:;?2E
M"ZUGV6[RCIXB+%@ QO\#ALOQ7JU\55QXT=3_V=F!Q0=-\TTZ5]K:OW#7DZ>9
MF+ OYZ2='7&(K>K/8[/^,[U7D?4?CG>58N)=!1;OFB7R-KGBA87:J+; T0<:
M(\VDL%I<OO]H,"V;_3NI\$-<,5PZX!],A\@K"/NOA"+VFU2VE8;>_%<Z Z9E
MQ#^SD.!R+GS7?\1M^%/2ZQ/ZC@Z7ZHDXW'__ ZL9M["VICSN-"BR_0TV+[)#
M>#$+,8M9FGTQ0RM&"Y04E\3UB*SO4&9&:+%+X4J5H4SYV%F'*8RD9YR^D/#D
MP@*3[+\4R9TF1KD3"OJR^.N20OV![L*4B@,ZJFP#BX*ZG!SM#P>$9GO0_>!1
M,<^N._)K^=?#9\ _,>"_-U? /WT_^).7_U0NJT</:>7+]X/ZZ6GMZK1Z=G4I
ME<'R/JB?7=7.CJIG![7J"J+]2<=8#7]=&XO;<-.=!&3%'M._'X001>H-N(U<
M/ ?/()<_L/<\"*&(6U^B! :Y,/XDY!(S8!1;E:JO3<-S,-?B!,Q0$^Q1WZKV
M':0,L[\N*?,#KD&K\HI\3OJ>W6C9J9C3$/&;2,AAAIEORTJVU5<,MP\&GX+!
M*C00^7!>+-M082-IDL$'9N@@F)CUS0Q7=,7!O"L;@XX&%+31VY:+_SI2K=OU
MP%OO:+;28WDH%5UIFQ80KPET]M!SWMZZ-NEQE*7G@*YW<<YGUJY42LFE4BJ=
M QK"5^C3J!+WZ\O=OF'IJK2ON8IT#K8L#)!%F$XUMV.I9.U?.UJ*>_XP2KR[
M#$:^P3BCB,N3WJ-[?*+@NF4H4"IG/D@>0-@H2 3ZIS/[[2W,TFJ"O%5TC-^!
M54]@0&S56QHGL.\C" _& 8_@R=-M/WF(XJ.-?L1=XLSB\V&812.Q$_X^/*OC
M_.^P'" QD.#[T,;@(QA^)8S09VU_M%:++\=0K* 4H!"<@T^(R4]M\/8OV/WG
M_/:Z>::YEQARK[?.;4OUFNXN)9^JO7L//%B-YPOGT^R(AF<.4Y(GO[YNPZ(^
MPW2BWCW-A.]^X=9[=W=>YN%&??@1).X&@Z-0X<CT3,G47'XJ !?TV$LG F_,
M..?8\#4WET;!VT;G-DLXFI^;[&1"D6DD=5Q<VB]_2*"# P]_U@RKA_N]!<,F
MGN',A6E(?MY<2.QV,,3HCF=".<2$/ U2<"*R8=/J-LB'GIH?*VO C_(0/SHO
M@W;_IOS'S#;?GZ'D93#4;B+ZW]_;6Y-Y2IJ*I>3=^"4/(;M'8NA\HHYO$SAO
M7U4_7!.WOC]5^VGPPSK5KQI)840^+R>T!Z:))R:OY)@!C6#.3*!*-$J(>6V*
M 7Z[VA>Y;7%JC>)4?X$Q0*<.P:Y'99=XAS1R@[PKE9VA*'Y@I^%=+8[,(9Z$
M-A.^*151C=M;MM;4P/12I6RJD)93);!2@A!FDX4P'7;X,/L;\4\FKGR^U-'.
MB&AG,8+MK4PJDRFF]C+9Q"'P7'TNU_"\(Y"(:%#\E<D3G<"F@,7/IJ2_<N$O
M<D3GOXKIT'=Y^@ZVE-TGO 6R5F$=6V EI$*3:ODS\GEQW'@R?#SA5V5P/.$O
MLFP\^?3(&&D\VULX(&G2>'B,% WH8&@)D4XF"H)M,!QIUJ,&%BJ3&!N,17FW
MMU2/!5R=$9-K:F:@V8JK&>$"&9;"R"Z+:B\>.&B)L%4@&K^%7-+ (SW441O<
MP:J>\KQB@4$U%K,J?Z^1M)WKF?>#@]SI7N-/\?DQTUI65NM4'L!HM&-_[WYP
M]%(R"C^+-3V3!;_6UMLZG2XPEN'B]ULDT+%D?@@B5.&(U'#$:KX(56(\_0VH
M43ZV4V9*?'M:"6XF^:&CB=61"6A"P^/KZJJ*"(5)D6)V+# :*IZY88(?@JJ
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MY'6[%*,U:<84YE5@UGAI@A,,E[UT]&8'QA(A&$-TX 2%U6KK#@5.MK="OP1
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MNMM/A?F-0'V:'5Q\-@A@-DH!AJ'J>/0KJ7J+T*3 M*"T1G; 3AP\\A)[RI?
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M=12#"5BBG$'5NR^@>S1A.5)X'':WXH0LF*#G/59TPV>6O 8R<7N+"G*%C4/
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M8W>7.X:R\N+$E!ZWNPSLO^,\H20=2= #86X1)($;I)Q11,KKMP"]+K'07>]
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MO"N$[-2J3&03;2%M:-J0U-F9@F]>Y&)WH8TP;;UM-G='C]T9KMVM9=DDV[Y
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M@0'@>*(1J\1JN'7C,(UZ:">MD*UW$DC'[HG<=(*ER)+WXP1VFXTD:AS;==U
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M2 ],(*77Q!+.Q8N<8X9%@H5*\?C!>8WX#E>[%*?#(0CZ<;FF=!+883BQK!6
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MSNYO;O>^LE1G@25$!H66O?A/RMSJ15X7_3[8.@G.O7%E&E>).Q @<!U3H8+
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M975R;RTR,#(R,#<S,2YX<V102P$"% ,4    " #9@RU5I]45FI\-   4@P
M&0              @ $%$0  86QX;F5U<F\M,C R,C W,S%?8V%L+GAM;%!+
M 0(4 Q0    ( -F#+56U:^=I_"(  &PI @ 9              "  =L>  !A
M;'AN975R;RTR,#(R,#<S,5]D968N>&UL4$L! A0#%     @ V8,M5>N.M<S#
M2P  ODX$ !D              ( !#D(  &%L>&YE=7)O+3(P,C(P-S,Q7VQA
M8BYX;6Q02P$"% ,4    " #9@RU5O&7CDGDU  #X: , &0
M@ $(C@  86QX;F5U<F\M,C R,C W,S%?<')E+GAM;%!+ 0(4 Q0    ( -F#
M+55@;V6_,0<  $0?   *              "  ;C#  !E>#,Q7S$N:'1M4$L!
M A0#%     @ V8,M543&.I Y!P  E!\   H              ( !$<L  &5X
M,S%?,BYH=&U02P$"% ,4    " #9@RU5#5F8BH4$  # %P  "@
M    @ %RT@  97@S,E\Q+FAT;5!+ 0(4 Q0    ( -F#+54@A+FTWP<! %G.
M"0 -              "  1_7  !P.3<R,C Q,'$N:'1M4$L%!@     )  D
*0@(  "G? 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
